{"bb5b40ece48b81368300cada06ebe4e91c9d757c": [["Unstructured AbstractHospital staff testing is critical to identify and isolate SARS-CoV-2 infected individuals while reducing unnecessary workforce depletion.", [["SARS-CoV-2 infected", "DISEASE", 80, 99], ["SARS-CoV-2", "ORGANISM", 80, 90], ["individuals", "ORGANISM", 100, 111], ["SARS-CoV", "SPECIES", 80, 88], ["infected individuals", "PROBLEM", 91, 111], ["unnecessary workforce depletion", "TREATMENT", 127, 158]]], ["Tygerberg Hospital implemented an online preregistration system to expedite staff testing.", [["staff testing", "TEST", 76, 89]]], ["In a retrospective descriptive study of all clients registering during May 2020 (N=799), we found rapid and sustained uptake of the system.", [["rapid and sustained uptake of the system", "PROBLEM", 98, 138], ["rapid", "OBSERVATION_MODIFIER", 98, 103], ["sustained", "OBSERVATION_MODIFIER", 108, 117], ["uptake", "OBSERVATION", 118, 124], ["system", "ANATOMY", 132, 138]]], ["The most frequent presenting symptoms were headache, sore throat, cough and myalgia.", [["headache", "DISEASE", 43, 51], ["sore throat", "DISEASE", 53, 64], ["cough", "DISEASE", 66, 71], ["myalgia", "DISEASE", 76, 83], ["The most frequent presenting symptoms", "PROBLEM", 0, 37], ["headache", "PROBLEM", 43, 51], ["sore throat", "PROBLEM", 53, 64], ["cough", "PROBLEM", 66, 71], ["myalgia", "PROBLEM", 76, 83], ["sore throat", "ANATOMY", 53, 64], ["cough", "OBSERVATION", 66, 71], ["myalgia", "OBSERVATION", 76, 83]]], ["Amongst those testing positive (n=105), fever, altered smell, altered taste sensation and chills were the most likely symptoms, but 12/145 asymptomatic clients also tested positive.", [["fever", "DISEASE", 40, 45], ["taste sensation", "DISEASE", 70, 85], ["chills", "DISEASE", 90, 96], ["taste", "ORGANISM_SUBDIVISION", 70, 75], ["those testing", "TEST", 8, 21], ["fever", "PROBLEM", 40, 45], ["altered smell", "PROBLEM", 47, 60], ["altered taste sensation", "PROBLEM", 62, 85], ["chills", "PROBLEM", 90, 96], ["symptoms", "PROBLEM", 118, 126], ["asymptomatic clients", "PROBLEM", 139, 159]]], ["Staff testing should form part of a bundle of strategies to protect staff.Unstructured Abstract.", [["Staff testing", "TEST", 0, 13]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprintIntroductionThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed severe pressure on an already overburdened healthcare system in South Africa.", [["CC", "CHEMICAL", 0, 2], ["acute respiratory syndrome coronavirus", "DISEASE", 372, 410], ["SARS-CoV-2", "CHEMICAL", 414, 424], ["severe acute respiratory syndrome coronavirus", "SPECIES", 365, 410], ["SARS-CoV-2", "SPECIES", 414, 424], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 320, 327], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 365, 410], ["SARS", "TEST", 414, 418], ["CoV", "TEST", 419, 422], ["severe pressure", "PROBLEM", 437, 452], ["med", "ANATOMY", 99, 102], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["acute", "OBSERVATION_MODIFIER", 372, 377], ["respiratory syndrome", "OBSERVATION", 378, 398], ["severe", "OBSERVATION_MODIFIER", 437, 443], ["pressure", "OBSERVATION", 444, 452]]], ["At Tygerberg Hospital (TBH), initially the designated coronavirus disease 2019 (COVID-19) hospital in the Western Cape, South Africa, mitigation strategies have included the establishment of separately staffed high risk COVID-19 areas with clear signage, guidelines on the use of Personal Protective Equipment (PPE), staff education and training, and the construction of new infrastructure for triage, testing and treatment with multi-departmental involvement.", [["coronavirus disease", "DISEASE", 54, 73], ["coronavirus", "ORGANISM", 54, 65], ["the designated coronavirus disease", "PROBLEM", 39, 73], ["mitigation strategies", "TREATMENT", 134, 155], ["triage, testing", "TEST", 394, 409], ["treatment", "TREATMENT", 414, 423], ["coronavirus disease", "OBSERVATION", 54, 73]]], ["[1] These measures aimed to meet the challenge of COVID-19 while protecting staff, but healthcare workers remain at increased risk of contracting SARS-CoV-2, potentially causing institutional outbreaks and spreading infection back to their communities.", [["SARS", "DISEASE", 146, 150], ["infection", "DISEASE", 216, 225], ["SARS-CoV-2", "ORGANISM", 146, 156], ["SARS-CoV", "SPECIES", 146, 154], ["COVID", "TEST", 50, 55], ["contracting SARS", "PROBLEM", 134, 150], ["institutional outbreaks", "PROBLEM", 178, 201], ["spreading infection", "PROBLEM", 206, 225], ["spreading", "OBSERVATION_MODIFIER", 206, 215], ["infection", "OBSERVATION", 216, 225]]], ["[2] This can result in the closure of entire departments or hospitals as has been reported in the media.", [["closure", "OBSERVATION", 27, 34]]], ["TBH has not been immune, with numerous confirmed positive cases and COVID-19-related deaths reported amongst staff.IntroductionIsolation of potentially SARS-CoV-2 infected healthcare workers is critical in preventing nosocomial spread.", [["TBH", "CHEMICAL", 0, 3], ["deaths", "DISEASE", 85, 91], ["SARS-CoV-2 infected", "DISEASE", 152, 171], ["SARS-CoV-2", "ORGANISM", 152, 162], ["CoV-", "SPECIES", 157, 161], ["TBH", "TEST", 0, 3], ["COVID", "TEST", 68, 73], ["nosocomial spread", "PROBLEM", 217, 234], ["nosocomial spread", "OBSERVATION", 217, 234]]], ["However, workforce depletion in the context of existing staff shortages weakens the fight against COVID-19.", [["workforce depletion", "PROBLEM", 9, 28], ["COVID", "TEST", 98, 103], ["depletion", "OBSERVATION", 19, 28]]], ["A balanced approach is required.", [["A balanced approach", "TREATMENT", 0, 19]]], ["[3] The Occupational Health Department (OHD) developed a risk assessment tool to identify individuals at risk for severe disease and place staff in the most appropriate areas to work.", [["a risk assessment", "TEST", 55, 72], ["severe disease", "PROBLEM", 114, 128], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["disease", "OBSERVATION", 121, 128]]], ["A system was also implemented to screen and test staff members, both symptomatic or contacts of confirmed cases, that would allow for early return to work according to current national guidelines, mitigating against staff shortages while at the same time identifying and isolating infected individuals.", [["isolating infected individuals", "PROBLEM", 271, 301], ["infected", "OBSERVATION", 281, 289]]], ["[4] The necessity of staff testing created additional workload for the Triage and Testing Centre (TATC) which, by late April 2020 was routinely processing over 200 tests per day.", [["staff testing", "TEST", 21, 34], ["the Triage", "TEST", 67, 77]]], ["Smoothly processing staff members rapidly became more difficult as the number presenting increased.", [["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["To minimize waiting time and decrease the risk of cross infection from traditional paper-based formats, an online pre-registration system for staff and clusters was implemented.", [["infection", "DISEASE", 56, 65], ["cross infection", "PROBLEM", 50, 65], ["infection", "OBSERVATION", 56, 65]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint relevant screening information.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 208, 228], ["med", "ANATOMY", 99, 102]]], ["Once submitted, it generated an email to the clerks in the TATC allowing a folder to be opened.", [["the TATC", "TREATMENT", 55, 63]]], ["On arrival, staff in the TATC could retrieve the folder and test the individual in as little as 10 minutes.IntroductionWe aimed to determine reasons for testing and specific presentations associated with positive or negative results.", [["TATC", "DNA", 25, 29], ["testing", "TEST", 153, 160]]], ["This information could be used to refine future healthcare worker testing and isolation guidelines.", [["isolation guidelines", "TREATMENT", 78, 98]]], ["We also aimed to identify specific sectors of staff where testing was delayed or deficient and for whom more targeted interventions may be required.MethodsWe conducted a single-centre retrospective descriptive study involving all cases created via the pre-registration system from 1 to 31 May 2020.", [["testing", "TEST", 58, 65], ["the pre-registration system", "TEST", 248, 275]]], ["All cases were included as there were no exclusion criteria.MethodsWe collected self-reported information from all emails received over the study period including date of registration, demographic information, symptoms, contact history, comorbidities and employment information.", [["the study", "TEST", 136, 145], ["symptoms", "PROBLEM", 210, 218]]], ["This data was exported from the inbox and algorithmically extracted before being checked for completeness and coded for statistical analysis.", [["statistical analysis", "TEST", 120, 140]]], ["At our institution reverse transcriptase polymerase chain reaction for SARS-CoV-2 is performed on nasopharyngeal specimens.", [["nasopharyngeal specimens", "ANATOMY", 98, 122], ["nasopharyngeal specimens", "CANCER", 98, 122], ["reverse transcriptase", "PROTEIN", 19, 40], ["SARS-CoV", "SPECIES", 71, 79], ["transcriptase polymerase chain reaction", "PROBLEM", 27, 66], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["nasopharyngeal specimens", "TEST", 98, 122], ["nasopharyngeal", "ANATOMY", 98, 112]]], ["Test results were obtained from the National Health Laboratory Service (NHLS) TrakCare Web Results Viewer.MethodsData analysis was performed using VassarStats (available at http://vassarstats.net).", [["MethodsData analysis", "TEST", 106, 126], ["VassarStats", "TREATMENT", 147, 158]]], ["Statistical significance was set at p < 0.05 and a 95% confidence interval (95% CI) was used.MethodsEthics approval for this article was obtained from the Health Research Ethics Committee ofResultsThis study included 799 cases.", [["This study", "TEST", 197, 207]]], ["The mean (standard deviation (SD)) age of clients was 39.7 (10.9) years old and the majority (619, 77.47%) were female.", [["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Most clients were healthy with 560 (70.09%) recording no comorbidities.", [["comorbidities", "PROBLEM", 57, 70]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint common comorbidities were asthma (69, 8.64%), diabetes mellitus (61, 7.63%) and obesity (50, 6.26%).", [["CC", "CHEMICAL", 0, 2], ["asthma", "DISEASE", 363, 369], ["diabetes mellitus", "DISEASE", 383, 400], ["obesity", "DISEASE", 417, 424], ["CC", "TEST", 0, 2], ["common comorbidities", "PROBLEM", 337, 357], ["asthma", "PROBLEM", 363, 369], ["diabetes mellitus", "PROBLEM", 383, 400], ["obesity", "PROBLEM", 417, 424], ["med", "ANATOMY", 99, 102], ["obesity", "OBSERVATION", 417, 424]]], ["Hypertension was excluded from reporting due to a recording error.", [["Hypertension", "DISEASE", 0, 12], ["Hypertension", "PROBLEM", 0, 12], ["a recording error", "PROBLEM", 48, 65]]], ["Table 1 depicts the baseline characteristics.(which was not certified by peer review)The median (interquartile range (IQR)) number of symptoms reported was 2 (1 to 4).", [["symptoms", "PROBLEM", 134, 142]]], ["The median (IQR) duration of symptoms prior to pre-registration was 4 (2 to 7) days.", [["symptoms", "PROBLEM", 29, 37]]], ["The most common symptom was headache, reported by 435 (54.44%) clients, followed by sore throat (361, 45.18%), cough (326, 40.80%) and myalgia (196, 24 .53%).", [["headache", "DISEASE", 28, 36], ["sore throat", "DISEASE", 84, 95], ["cough", "DISEASE", 111, 116], ["myalgia", "DISEASE", 135, 142], ["headache", "PROBLEM", 28, 36], ["sore throat", "PROBLEM", 84, 95], ["cough", "PROBLEM", 111, 116], ["myalgia", "PROBLEM", 135, 142]]], ["The frequency of other symptoms are shown in Table 2 .", [["other symptoms", "PROBLEM", 17, 31]]], ["Of these, 472 (80.82%) were also symptomatic.(which was not certified by peer review)Thirty three (4.13%) clients reported no symptoms or contact and had no indication to test according to pre-registration data, but 14 were still tested.(which was not certified by peer review)We found 105 positive results, representing 13.14% (95% CI: 10.97 ; 15.66) of clients using the pre-registration service and 17.77% (95% CI: 14.9 ; 21.06) of those with a valid positive or negative test result.", [["symptomatic", "PROBLEM", 33, 44], ["symptoms", "PROBLEM", 126, 134], ["pre-registration data", "TEST", 189, 210], ["CI", "TEST", 333, 335], ["CI", "TEST", 414, 416], ["symptomatic", "OBSERVATION_MODIFIER", 33, 44]]], ["There were 486 (60.83%) negative tests, 8 (1.00%) indeterminate, 9 (1.13%) not run at the laboratory and 191 (23.90%) clients who pre-registered but weren't tested.(which was not certified by peer review)Fever, altered smell, altered taste sensation and chills were the symptoms with the highest predictive value for SARS-CoV-2 infection as shown in Table 2 .", [["Fever", "DISEASE", 204, 209], ["taste sensation", "DISEASE", 234, 249], ["chills", "DISEASE", 254, 260], ["SARS-CoV-2 infection", "DISEASE", 317, 337], ["taste", "ORGANISM_SUBDIVISION", 234, 239], ["CoV-2", "ORGANISM", 322, 327], ["SARS-CoV-2", "SPECIES", 317, 327], ["tests", "TEST", 33, 38], ["Fever", "PROBLEM", 204, 209], ["altered smell", "PROBLEM", 211, 224], ["altered taste sensation", "PROBLEM", 226, 249], ["chills", "PROBLEM", 254, 260], ["the symptoms", "PROBLEM", 266, 278], ["SARS", "PROBLEM", 317, 321], ["CoV-2 infection", "PROBLEM", 322, 337], ["indeterminate", "OBSERVATION_MODIFIER", 50, 63], ["altered", "OBSERVATION_MODIFIER", 211, 218], ["smell", "OBSERVATION", 219, 224], ["infection", "OBSERVATION", 328, 337]]], ["Diarrhoea and irritability had the lowest predictive value with < 10% of these clients testing positive.", [["Diarrhoea", "DISEASE", 0, 9], ["irritability", "DISEASE", 14, 26], ["Diarrhoea", "PROBLEM", 0, 9], ["irritability", "PROBLEM", 14, 26], ["these clients testing", "TEST", 73, 94]]], ["Twelve (8.28%) asymptomatic clients tested positive.", [["asymptomatic clients tested positive", "PROBLEM", 15, 51]]], ["This included 3 of 33 clients with no reported symptom or contact.(which was not certified by peer review)There was a strong association between a greater number of symptoms and a positive test (p = 0.0002).", [["reported symptom", "PROBLEM", 38, 54], ["symptoms", "PROBLEM", 165, 173], ["a positive test", "TEST", 178, 193], ["strong", "OBSERVATION_MODIFIER", 118, 124], ["greater", "OBSERVATION_MODIFIER", 147, 154]]], ["Clients with a positive test had a mean (SD) of 3.3 (0.4) symptoms compared to 2.5 (0.2) symptoms amongst clients with a negative test.", [["a positive test", "TEST", 13, 28], ["symptoms", "PROBLEM", 58, 66], ["symptoms", "PROBLEM", 89, 97]]], ["We particularly noted an increased likelihood of a positive test in patients with 3 or 4+ symptoms (18.55% and 20.70% respectively) compared to 1 or 2 symptoms (8.57% and 6.75% respectively).(which was not certified by peer review).", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["a positive test", "PROBLEM", 49, 64], ["4+ symptoms", "PROBLEM", 87, 98], ["2 symptoms", "PROBLEM", 149, 159], ["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint(which was not certified by peer review)We also noted an increased likelihood of coronavirus infection in patients who had a 2 -4 or 5 -10 day duration of symptoms (17.70% and 16.95% respectively) compared to 0 -1, 11 -15 and 16+ days (9.45%, 11.11% and 7.41% respectively).DiscussionStreamlined staff testing is a critical component of a broader strategy to maximise the available frontline workforce in the face of the COVID-19 pandemic by decreasing absence.", [["CC", "CHEMICAL", 0, 2], ["coronavirus infection", "DISEASE", 417, 438], ["coronavirus", "ORGANISM", 417, 428], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 442, 450], ["CC", "TEST", 0, 2], ["coronavirus infection", "PROBLEM", 417, 438], ["symptoms", "PROBLEM", 491, 499], ["med", "ANATOMY", 99, 102], ["increased", "OBSERVATION_MODIFIER", 393, 402], ["coronavirus", "OBSERVATION_MODIFIER", 417, 428], ["infection", "OBSERVATION", 429, 438]]], ["[5] At our institution, 6 in 7 staff members tested negative for SARS-CoV-2 and were able to return to work earlier than they might otherwise have been able.", [["SARS", "DISEASE", 65, 69], ["SARS-CoV", "SPECIES", 65, 73], ["SARS", "PROBLEM", 65, 69]]], ["The remainder were detected and isolated, preventing further spread.DiscussionRapid and sustained uptake of the online pre-registration system shows that this format is acceptable to staff.", [["the online pre-registration system", "TEST", 108, 142]]], ["It allows for ease of access, decreases waiting times and expedites test results through prioritisation of staff samples.", [["expedites test", "TEST", 58, 72], ["staff samples", "TEST", 107, 120]]], ["During the period under review, unpublished departmental data showed that over 5 800 tests were performed at our TATC.", [["unpublished departmental data", "TEST", 32, 61]]], ["Its use for clusters from other medical institutions and non-medical facilities demonstrates the potential for further expansion of the system.DiscussionClients presenting via the pre-registration system were young with few comorbidities.", [["further expansion of the system", "PROBLEM", 111, 142], ["system", "ANATOMY", 136, 142]]], ["It is unclear if this is reflective of the broader staff population at this academic institution.DiscussionAlternatively it could indicate that risk assessment activities performed by the OHD had successfully shielded older, more at risk individuals from exposure; or that older staff members preferred not to use this hi-tech option.", [["risk assessment activities", "TEST", 144, 170], ["this hi-tech option", "TREATMENT", 314, 333]]], ["We were able to explain the large proportion of female clients in the study due to a large contingent of nursing staff testing.DiscussionFour staff groups were predominantly represented in the data: nurses, administrative staff, doctors and general assistants.", [["the study", "TEST", 66, 75], ["nursing staff testing", "TEST", 105, 126], ["large", "OBSERVATION_MODIFIER", 28, 33]]], ["This reflects staff with the most direct contact with patients, but other groups may be being missed.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["This is a period of time staff remain at work and are potentially highly infectious.", [["potentially highly", "UNCERTAINTY", 54, 72], ["infectious", "OBSERVATION", 73, 83]]], ["[6] There is a need to identify barriers to testing and develop strategies to encourage earlier presentation.Discussion.", [["testing", "TEST", 44, 51], ["strategies", "TREATMENT", 64, 74]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint A large proportion of staff pre-registered but never tested while a minority had laboratory issues but were not re-tested.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["laboratory issues", "PROBLEM", 418, 435], ["med", "ANATOMY", 99, 102], ["large", "OBSERVATION_MODIFIER", 339, 344]]], ["This indicates a significant loss to follow up, but is in keeping with the broader experience at our facility precipitated by the massive testing loads as the pandemic progressed and is not specific to the pre-registration system.", [["a significant loss", "PROBLEM", 15, 33], ["the massive testing loads", "PROBLEM", 126, 151], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["loss", "OBSERVATION", 29, 33], ["massive", "OBSERVATION_MODIFIER", 130, 137]]], ["It is unclear if these potentially infected individuals continued to work without ever testing or continued to isolate for the full 14 days.", [["individuals", "ORGANISM", 44, 55], ["infected individuals", "PROBLEM", 35, 55], ["ever testing", "TEST", 82, 94], ["unclear if", "UNCERTAINTY", 6, 16], ["infected", "OBSERVATION", 35, 43]]], ["Integration with a scaled up OHD will combat this in future and enhance surveillance and protection of staff and patients.", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["a scaled up OHD", "TREATMENT", 17, 32]]], ["[7] We noted altered smell and altered taste sensation together with flu-like symptoms to be most predictive symptoms of SARS-CoV-2 infection.", [["taste sensation", "DISEASE", 39, 54], ["flu-like symptoms", "DISEASE", 69, 86], ["SARS-CoV-2 infection", "DISEASE", 121, 141], ["taste", "ORGANISM_SUBDIVISION", 39, 44], ["SARS-CoV-2", "ORGANISM", 121, 131], ["SARS-CoV-2", "SPECIES", 121, 131], ["altered smell", "PROBLEM", 13, 26], ["altered taste sensation", "PROBLEM", 31, 54], ["flu-like symptoms", "PROBLEM", 69, 86], ["SARS", "PROBLEM", 121, 125], ["CoV-2 infection", "PROBLEM", 126, 141], ["altered", "OBSERVATION_MODIFIER", 13, 20], ["smell", "OBSERVATION", 21, 26], ["SARS", "OBSERVATION", 121, 125], ["infection", "OBSERVATION", 132, 141]]], ["This reflects that findings noted globally in mildly symptomatic outpatients apply to our local population and shows that they can be incorporated into local guidelines.", [["mildly symptomatic outpatients", "PROBLEM", 46, 76], ["mildly", "OBSERVATION_MODIFIER", 46, 52], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["[8] Over 8% of asymptomatic individuals, including several without a specific contact, tested positive for SARS-CoV-2.", [["individuals", "ORGANISM", 28, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["SARS-CoV", "SPECIES", 107, 115], ["asymptomatic individuals", "PROBLEM", 15, 39], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115]]], ["[9, 10] Many such asymptomatic and pre-symptomatic individuals may remain undetected as a vector for nosocomial spread to other staff and vulnerable patients.(which was not certified by peer review)[11] In a system reliant on self-presentation, asymptomatic and oligo-symptomatic individuals will inevitably be missed.", [["individuals", "ORGANISM", 51, 62], ["patients", "ORGANISM", 149, 157], ["individuals", "ORGANISM", 280, 291], ["patients", "SPECIES", 149, 157], ["Many such asymptomatic and pre-symptomatic individuals", "PROBLEM", 8, 62], ["asymptomatic", "PROBLEM", 245, 257], ["oligo-symptomatic individuals", "PROBLEM", 262, 291]]], ["Changes to the provincial community screening and testing strategy advising most symptomatic individuals to self-isolate without testing have significantly reduced the number of tests being performed at the TATC and an alternative surveillance system testing all staff at intervals may now be feasible.", [["the provincial community screening", "TEST", 11, 45], ["testing strategy", "TEST", 50, 66], ["tests", "TEST", 178, 183], ["the TATC", "TEST", 203, 211], ["an alternative surveillance system testing", "TEST", 216, 258]]], ["[12] It remains an unanswered question whether future staff testing and isolation strategies can exclude sufficiently low-risk symptomatic presentations allowing staff to remain at work with suitable precautions in place while awaiting a result.", [["staff testing", "TEST", 54, 67], ["isolation strategies", "TREATMENT", 72, 92], ["suitable precautions", "TREATMENT", 191, 211]]], ["Such a strategy could reduce unnecessary isolation and workforce depletion.", [["a strategy", "TREATMENT", 5, 15], ["unnecessary isolation", "TREATMENT", 29, 50], ["workforce depletion", "TREATMENT", 55, 74]]], ["In this study, no symptom could completely eliminate the risk, while asymptomatic infection is also shown.", [["infection", "DISEASE", 82, 91], ["this study", "TEST", 3, 13], ["symptom", "PROBLEM", 18, 25], ["asymptomatic infection", "PROBLEM", 69, 91], ["asymptomatic", "OBSERVATION_MODIFIER", 69, 81], ["infection", "OBSERVATION", 82, 91]]], ["We found it preferable to focus on rapid turnaround of results.(which was not certified by peer review)Limitations in this study are its retrospective nature and the reliance on client self-reported clinical information.Conclusion.", [["this study", "TEST", 118, 128]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. .0Staff coronavirus testing using an online pre-registration form is a viable and acceptable strategy.0While it does require a degree of technical know-how to set up, it can be inexpensively implemented using free or low cost third-party services.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["Staff coronavirus testing", "TEST", 271, 296], ["med", "ANATOMY", 99, 102]]], ["Benefits include streamlined testing, reduced clerical workload and errors, ease of data capturing and decreased risk of crossinfection.", [["crossinfection", "DISEASE", 121, 135], ["streamlined testing", "TEST", 17, 36], ["crossinfection", "PROBLEM", 121, 135], ["crossinfection", "OBSERVATION", 121, 135]]], ["Institutions also need to ensure that staff test timeously.0Hospital staff remain at high risk for SARS-CoV-2 infection and, once infected can become vectors for institutional outbreaks.", [["SARS-CoV-2 infection", "DISEASE", 99, 119], ["staff test timeously", "TEST", 38, 58], ["SARS", "PROBLEM", 99, 103], ["CoV", "PROBLEM", 104, 107], ["2 infection", "PROBLEM", 108, 119], ["infection", "OBSERVATION", 110, 119]]], ["Current guidelines provide advice on when to test and isolate staff who are symptomatic or have high-or low-risk contacts.", [["symptomatic", "PROBLEM", 76, 87], ["high-or low-risk contacts", "PROBLEM", 96, 121]]], ["These should be continuously updated as we learn more about the virus taking a balanced view to protect staff and maintain the available workforce.", [["the virus", "TREATMENT", 60, 69]]], ["Staff testing must also be seen as one component of a larger strategy aimed at protecting staff, such as wearing masks and face shields, regular hand washing, buddy screening, physical distancing, availability of PPE and special dispensation for COVID-19related leave.0.", [["hand", "ANATOMY", 145, 149], ["hand", "ORGANISM_SUBDIVISION", 145, 149], ["Staff testing", "TEST", 0, 13], ["masks and face shields", "TREATMENT", 113, 135], ["regular hand washing", "TREATMENT", 137, 157], ["buddy screening", "TEST", 159, 174], ["PPE", "PROBLEM", 213, 216], ["COVID", "TREATMENT", 246, 251], ["larger", "OBSERVATION_MODIFIER", 54, 60]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. .AcknowledgementsThe staff of the TBH COVID-19 Unit for their selflessness and dedication in caring for our patients, and in particular the clerical staff who open a prodigious number of folders every day.Competing interestsThe authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.Funding informationThe authors received no financial support for the research, authorship, and/or publication of this article.Data availability statementRaw data were generated at Tygerberg Hospital.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 377, 385], ["CC", "TEST", 0, 2], ["financial support", "TREATMENT", 680, 697], ["med", "ANATOMY", 99, 102]]], ["Derived data supporting the findings of this study are available from the corresponding author MSM on request.DisclaimerThe views expressed in this article are those of the author and not an official position of the institution or journal.Disclaimer.", [["this study", "TEST", 40, 50]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv preprint", "TREATMENT", 320, 336], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Tables and FiguresThe copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv preprint", "TREATMENT", 339, 355], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Tables and FiguresThe copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.13.20152876 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 339, 346], ["med", "ANATOMY", 99, 102]]]], "PMC7086765": [["Recently, bats have been recognized as a major reservoir of emerging viral infections that cause serious diseases in humans and other mammals [1].", [["viral infections", "DISEASE", 69, 85], ["bats", "ORGANISM", 10, 14], ["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123], ["emerging viral infections", "PROBLEM", 60, 85], ["serious diseases in humans", "PROBLEM", 97, 123]]], ["Several viruses that cause severe diseases in humans have been detected in bats, such as lyssaviruses related to rabies virus, Hendra virus, Nipah virus, Ebola virus, Marburg virus and severe acute respiratory syndrome (SARS) coronavirus [1].", [["rabies virus", "DISEASE", 113, 125], ["Hendra virus", "DISEASE", 127, 139], ["Nipah virus", "DISEASE", 141, 152], ["Ebola virus", "DISEASE", 154, 165], ["Marburg virus", "DISEASE", 167, 180], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 192, 237], ["humans", "ORGANISM", 46, 52], ["rabies virus", "ORGANISM", 113, 125], ["Hendra virus", "ORGANISM", 127, 139], ["Nipah virus", "ORGANISM", 141, 152], ["Ebola virus", "ORGANISM", 154, 165], ["Marburg virus", "ORGANISM", 167, 180], ["humans", "SPECIES", 46, 52], ["rabies virus", "SPECIES", 113, 125], ["Hendra virus", "SPECIES", 127, 139], ["Nipah virus", "SPECIES", 141, 152], ["Ebola virus", "SPECIES", 154, 165], ["Marburg virus", "SPECIES", 167, 180], ["humans", "SPECIES", 46, 52], ["rabies virus", "SPECIES", 113, 125], ["Hendra virus", "SPECIES", 127, 139], ["Nipah virus", "SPECIES", 141, 152], ["Ebola virus", "SPECIES", 154, 165], ["Marburg virus", "SPECIES", 167, 180], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 185, 237], ["Several viruses", "PROBLEM", 0, 15], ["severe diseases in humans", "PROBLEM", 27, 52], ["lyssaviruses", "PROBLEM", 89, 101], ["rabies virus", "PROBLEM", 113, 125], ["Hendra virus", "PROBLEM", 127, 139], ["Nipah virus", "PROBLEM", 141, 152], ["Ebola virus", "PROBLEM", 154, 165], ["Marburg virus", "PROBLEM", 167, 180], ["severe acute respiratory syndrome", "PROBLEM", 185, 218], ["SARS) coronavirus", "PROBLEM", 220, 237], ["viruses", "OBSERVATION", 8, 15], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["diseases", "OBSERVATION", 34, 42], ["severe", "OBSERVATION_MODIFIER", 185, 191], ["acute", "OBSERVATION_MODIFIER", 192, 197], ["respiratory syndrome", "OBSERVATION", 198, 218]]], ["Hence, there is a growing focus on bats as zoonotic hosts.", [["bats", "ORGANISM", 35, 39], ["growing", "OBSERVATION_MODIFIER", 18, 25], ["focus", "OBSERVATION", 26, 31]]]], "0537823ee7ac420f3f6e1a1261afa425dd4cd1a6": [["IntroductionCoronaviruses (CoVs) belong to the family Coronaviridae; they can infect a variety of hosts and cause various illnesses, including respiratory infections and enteric diseases [1] [2] [3] [4] [5] .", [["respiratory", "ANATOMY", 143, 154], ["respiratory infections", "DISEASE", 143, 165], ["enteric diseases", "DISEASE", 170, 186], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 54, 67], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 187, 206], ["CoVs", "PROTEIN", 27, 31], ["various illnesses", "PROBLEM", 114, 131], ["respiratory infections", "PROBLEM", 143, 165], ["enteric diseases", "PROBLEM", 170, 186]]], ["Based on phylogenetic analysis, we can classify CoVs into four major genera: alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV [5, 6] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 48, 52], ["alpha-CoV", "GENE_OR_GENE_PRODUCT", 77, 86], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["gamma-CoV", "GENE_OR_GENE_PRODUCT", 98, 107], ["delta-CoV", "GENE_OR_GENE_PRODUCT", 113, 122], ["CoVs", "PROTEIN", 48, 52], ["alpha-CoV, beta-CoV, gamma-CoV", "DNA", 77, 107], ["delta", "DNA", 113, 118], ["CoV", "DNA", 119, 122], ["phylogenetic analysis", "TEST", 9, 30], ["alpha", "TEST", 77, 82], ["CoV", "TEST", 83, 86], ["beta", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["gamma", "TEST", 98, 103], ["CoV", "TEST", 104, 107]]], ["Porcine deltacoronavirus, which belongs to delta-CoV, was first reported in an epidemiology investigation in Hong Kong [5] .", [["Porcine deltacoronavirus", "ORGANISM", 0, 24], ["delta-CoV", "GENE_OR_GENE_PRODUCT", 43, 52], ["Porcine", "SPECIES", 0, 7], ["Porcine deltacoronavirus", "SPECIES", 0, 24], ["Porcine deltacoronavirus", "PROBLEM", 0, 24]]], ["Thereafter, PDCoV was detected and isolated across the world [7] [8] [9] [10] [11] [12] [13] .", [["PDCoV", "CHEMICAL", 12, 17], ["PDCoV", "CHEMICAL", 12, 17], ["[7] [8] [9] [10] [11]", "CHEMICAL", 61, 82], ["PDCoV", "SIMPLE_CHEMICAL", 12, 17], ["[7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 61, 92], ["PDCoV", "PROTEIN", 12, 17], ["PDCoV", "TREATMENT", 12, 17]]], ["The PDCoV genome is approximately 25-kb long, containing a 5 \u8020 untranslated coding region (UTR), replication-associated genes (1a, 1b), a spike (s) gene, an envelope (e) gene, a matrix (m) gene, a nucleocapsid (n) gene, two nonstructural genes (ns6, ns7), and a 3 \u8020 UTR gene.IntroductionPrevious studies have reported that gene is highly conserved among all the genes of PDCoV; therefore, the gene has been commonly used as the target for diagnosis [6, 12] .", [["PDCoV", "GENE_OR_GENE_PRODUCT", 4, 9], ["1a, 1b", "GENE_OR_GENE_PRODUCT", 127, 133], ["envelope (e)", "GENE_OR_GENE_PRODUCT", 157, 169], ["matrix (m)", "GENE_OR_GENE_PRODUCT", 178, 188], ["nucleocapsid (n)", "GENE_OR_GENE_PRODUCT", 197, 213], ["ns6", "GENE_OR_GENE_PRODUCT", 245, 248], ["ns7", "GENE_OR_GENE_PRODUCT", 250, 253], ["PDCoV", "GENE_OR_GENE_PRODUCT", 371, 376], ["PDCoV genome", "DNA", 4, 16], ["5 \u8020 untranslated coding region", "DNA", 59, 89], ["UTR", "DNA", 91, 94], ["replication-associated genes", "DNA", 97, 125], ["1a", "DNA", 127, 129], ["spike (s) gene", "DNA", 138, 152], ["envelope (e) gene", "DNA", 157, 174], ["matrix (m) gene", "DNA", 178, 193], ["nucleocapsid (n) gene", "DNA", 197, 218], ["nonstructural genes", "DNA", 224, 243], ["ns6", "DNA", 245, 248], ["ns7", "DNA", 250, 253], ["3 \u8020 UTR gene", "DNA", 262, 274], ["PDCoV", "DNA", 371, 376], ["a 5 \u8020 untranslated coding region", "PROBLEM", 57, 89], ["a spike (s) gene", "PROBLEM", 136, 152], ["a nucleocapsid (n) gene", "PROBLEM", 195, 218], ["two nonstructural genes (ns6, ns7)", "PROBLEM", 220, 254], ["Previous studies", "TEST", 287, 303], ["PDCoV genome", "OBSERVATION", 4, 16], ["approximately", "OBSERVATION_MODIFIER", 20, 33], ["25-kb", "OBSERVATION_MODIFIER", 34, 39], ["nonstructural genes", "OBSERVATION", 224, 243]]], ["In pigs infected with PDCoV, watery diarrhea was the most common clinical symptom.", [["PDCoV", "CHEMICAL", 22, 27], ["watery diarrhea", "DISEASE", 29, 44], ["pigs", "ORGANISM", 3, 7], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["PDCoV", "SPECIES", 22, 27], ["PDCoV", "TREATMENT", 22, 27], ["watery diarrhea", "PROBLEM", 29, 44]]], ["Some of the newborn piglets infected with PDCoV would succumb to the virus and die eventually [8, 14, 15] .", [["PDCoV", "CHEMICAL", 42, 47], ["piglets", "ORGANISM", 20, 27], ["piglets", "SPECIES", 20, 27], ["PDCoV", "SPECIES", 42, 47], ["PDCoV", "TREATMENT", 42, 47], ["newborn", "OBSERVATION_MODIFIER", 12, 19], ["piglets", "OBSERVATION_MODIFIER", 20, 27], ["infected", "OBSERVATION", 28, 36]]], ["In pigs infected with PDCoV, the symptoms of diarrhea are very similar to that of porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis virus (TGEV); therefore, it is difficult to clinically distinguish these viral pathogens.IntroductionVarious diagnostic methods have been developed to rapidly diagnose PDCoV infection in pigs.", [["PDCoV", "CHEMICAL", 22, 27], ["diarrhea", "DISEASE", 45, 53], ["porcine epidemic diarrhea virus", "DISEASE", 82, 113], ["transmissible gastroenteritis virus", "DISEASE", 125, 160], ["TGEV", "DISEASE", 162, 166], ["infection", "DISEASE", 329, 338], ["pigs", "ORGANISM", 3, 7], ["porcine epidemic diarrhea virus", "ORGANISM", 82, 113], ["transmissible gastroenteritis virus", "ORGANISM", 125, 160], ["TGEV", "ORGANISM", 162, 166], ["PDCoV", "CANCER", 323, 328], ["pigs", "ORGANISM", 342, 346], ["pigs", "SPECIES", 3, 7], ["porcine epidemic diarrhea virus", "SPECIES", 82, 113], ["transmissible gastroenteritis virus", "SPECIES", 125, 160], ["pigs", "SPECIES", 342, 346], ["pigs", "SPECIES", 3, 7], ["PDCoV", "SPECIES", 22, 27], ["porcine epidemic diarrhea virus", "SPECIES", 82, 113], ["PEDV", "SPECIES", 115, 119], ["transmissible gastroenteritis virus", "SPECIES", 125, 160], ["TGEV", "SPECIES", 162, 166], ["PDCoV", "SPECIES", 323, 328], ["pigs", "SPECIES", 342, 346], ["PDCoV", "TREATMENT", 22, 27], ["the symptoms", "PROBLEM", 29, 41], ["diarrhea", "PROBLEM", 45, 53], ["porcine epidemic diarrhea virus", "PROBLEM", 82, 113], ["PEDV", "PROBLEM", 115, 119], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 125, 166], ["these viral pathogens", "PROBLEM", 222, 243], ["PDCoV infection", "PROBLEM", 323, 338], ["diarrhea", "OBSERVATION", 45, 53], ["gastroenteritis virus", "OBSERVATION", 139, 160], ["viral pathogens", "OBSERVATION", 228, 243], ["infection", "OBSERVATION", 329, 338]]], ["For the detection of specific antibody, the most commonly used serological assays included virus neutralization (VN) test, indirect fluorescent antibody (IFA) assay, and enzyme linked immunosorbent assay (ELISA) [16] [17] [18] .", [["specific antibody", "PROTEIN", 21, 38], ["indirect fluorescent antibody", "PROTEIN", 123, 152], ["IFA", "PROTEIN", 154, 157], ["the detection", "TEST", 4, 17], ["specific antibody", "PROBLEM", 21, 38], ["serological assays", "TEST", 63, 81], ["virus neutralization (VN) test", "TEST", 91, 121], ["indirect fluorescent antibody", "TEST", 123, 152], ["assay", "TEST", 159, 164], ["enzyme linked immunosorbent assay", "TEST", 170, 203]]], ["Polymerase chain reaction (PCR) and quantitative PCR (qPCR) are the most commonly used virological methods for the detection of nucleic acid.", [["nucleic acid", "CHEMICAL", 128, 140], ["nucleic acid", "SIMPLE_CHEMICAL", 128, 140], ["Polymerase chain reaction", "PROBLEM", 0, 25], ["PCR", "TEST", 27, 30], ["quantitative PCR (qPCR", "TEST", 36, 58], ["virological methods", "TREATMENT", 87, 106], ["nucleic acid", "PROBLEM", 128, 140]]], ["Various PDCoV-specific RT-PCRs and RT-qPCRs have been developed to detect PDCoV [2, 11, 12] .", [["PDCoV", "SIMPLE_CHEMICAL", 8, 13], ["PDCoV", "DNA", 8, 13], ["RT-qPCRs", "DNA", 35, 43], ["Various PDCoV", "TEST", 0, 13], ["specific RT-PCRs", "TEST", 14, 30], ["RT-qPCRs", "TEST", 35, 43]]], ["However, the detection limit of the gel-based RT-PCR for PDCoV detection has not been established [11, 12] .", [["the gel", "TEST", 32, 39], ["PDCoV detection", "TEST", 57, 72]]], ["Real-time RT-qPCR was more sensitive than conventional PCR [2, 19] .", [["time RT-qPCR", "TEST", 5, 17], ["conventional PCR", "TEST", 42, 58]]], ["Although the detection limit of nested PCR was similar to that of real-time RT-PCR, the additional amplification procedure made this test more complicated and easier for contamination.IntroductionAlthough many other methods, such as qPCR and loop-mediated isothermal amplification (LAMP), have been reported [19, 20] , conventional RT-PCR is still one of the most commonly used methods for virus detection due to its accessibility and convenience.", [["nested PCR", "TEST", 32, 42], ["the additional amplification procedure", "TREATMENT", 84, 122], ["this test", "TEST", 128, 137], ["contamination", "PROBLEM", 170, 183], ["qPCR", "TEST", 233, 237], ["loop-mediated isothermal amplification", "TREATMENT", 242, 280], ["conventional RT-PCR", "TEST", 319, 338], ["virus detection", "TEST", 390, 405]]], ["Thus the aim of the present study was to improve the sensitivity of conventional RT-PCR used for PDCoV detection via screening primers and optimizing PCR reaction conditions.", [["PDCoV", "SPECIES", 97, 102], ["the present study", "TEST", 16, 33], ["conventional RT-PCR", "TEST", 68, 87], ["PDCoV detection", "TEST", 97, 112], ["screening primers", "TEST", 117, 134], ["optimizing PCR reaction conditions", "PROBLEM", 139, 173]]], ["Meanwhile, there is no report about the SYBR green-based RT-qPCR assay for the detection of PDCoV.", [["SYBR green", "CHEMICAL", 40, 50], ["PDCoV", "SIMPLE_CHEMICAL", 92, 97], ["PDCoV", "SPECIES", 92, 97], ["the SYBR", "TEST", 36, 44], ["PDCoV", "TREATMENT", 92, 97]]], ["Thus, a SYBR green-based RT-qPCR assay was developed to compare the detection limit against conventional RT-PCR.", [["SYBR green", "CHEMICAL", 8, 18], ["SYBR", "GENE_OR_GENE_PRODUCT", 8, 12], ["a SYBR green-based RT-qPCR assay", "TEST", 6, 38], ["the detection", "TEST", 64, 77], ["conventional RT-PCR", "TEST", 92, 111]]], ["Furthermore, conventional RT-PCR and RT-qPCR were used to evaluate clinical samples.Viruses.Porcine deltacoronavirus (PDCoV) strain CHN-GD16-03 and swine acute diarrhea syndrome coronavirus (SADS-CoV) were provided by Professor Jing-Yun Ma, who works at the College of Animal Science, South China Agricultural University, Guangzhou, China.", [["samples", "ANATOMY", 76, 83], ["CHN-GD16-03", "CHEMICAL", 132, 143], ["acute diarrhea syndrome coronavirus", "DISEASE", 154, 189], ["Porcine deltacoronavirus", "ORGANISM", 92, 116], ["PDCoV", "ORGANISM", 118, 123], ["CHN-GD16-03", "ORGANISM", 132, 143], ["swine acute diarrhea syndrome coronavirus", "ORGANISM", 148, 189], ["SADS-CoV", "ORGANISM", 191, 199], ["Porcine", "SPECIES", 92, 99], ["swine", "SPECIES", 148, 153], ["Porcine deltacoronavirus (PDCoV) strain CHN-GD16-03", "SPECIES", 92, 143], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 148, 189], ["SADS-CoV", "SPECIES", 191, 199], ["conventional RT-PCR", "TEST", 13, 32], ["RT-qPCR", "TEST", 37, 44], ["clinical samples", "TEST", 67, 83], ["Viruses", "PROBLEM", 84, 91], ["Porcine deltacoronavirus (PDCoV)", "TREATMENT", 92, 124], ["swine acute diarrhea syndrome coronavirus", "PROBLEM", 148, 189], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["diarrhea", "OBSERVATION", 160, 168]]], ["Porcine reproductive respiratory syndrome virus (PRRSV) strain JXA1 was purchased from China Animal Disease Control Center, Beijing, China.", [["Porcine reproductive respiratory syndrome", "DISEASE", 0, 41], ["Porcine reproductive respiratory syndrome virus", "ORGANISM", 0, 47], ["PRRSV", "ORGANISM", 49, 54], ["Porcine", "SPECIES", 0, 7], ["PRRSV", "SPECIES", 49, 54], ["Porcine reproductive respiratory syndrome virus", "SPECIES", 0, 47], ["PRRSV", "SPECIES", 49, 54], ["JXA1", "SPECIES", 63, 67], ["Porcine reproductive respiratory syndrome virus (PRRSV) strain JXA1", "PROBLEM", 0, 67], ["reproductive", "OBSERVATION_MODIFIER", 8, 20], ["respiratory syndrome", "OBSERVATION", 21, 41]]], ["Pseudorabies virus (PRV) strain HB-98, classical swine fever virus (CSFV) strain C attenuate vaccine, porcine circovirus type 2 (PCV2) killed vaccine, transmissible gastroenteritis virus of swine (TGEV) attenuate vaccine, porcine epidemic diarrhea virus (PEDV) CV777 attenuate vaccine, porcine rotavirus (RV) NX attenuate vaccine, porcine parvovirus (PPV) CP-99 killed vaccine, and pig foot-and-mouth disease virus (FMDV) killed vaccine were purchased from commercial vaccine companies.", [["HB-98", "CHEMICAL", 32, 37], ["swine fever", "DISEASE", 49, 60], ["transmissible gastroenteritis", "DISEASE", 151, 180], ["porcine epidemic diarrhea", "DISEASE", 222, 247], ["CV777", "CHEMICAL", 261, 266], ["porcine parvovirus", "DISEASE", 331, 349], ["CP-99", "CHEMICAL", 356, 361], ["foot-and-mouth disease", "DISEASE", 386, 408], ["Pseudorabies virus", "ORGANISM", 0, 18], ["PRV) strain HB-98", "ORGANISM", 20, 37], ["classical swine fever virus", "ORGANISM", 39, 66], ["CSFV) strain C", "ORGANISM", 68, 82], ["porcine circovirus type 2", "ORGANISM", 102, 127], ["PCV2", "ORGANISM", 129, 133], ["transmissible gastroenteritis virus", "ORGANISM", 151, 186], ["swine", "ORGANISM", 190, 195], ["TGEV", "ORGANISM", 197, 201], ["porcine epidemic diarrhea virus", "ORGANISM", 222, 253], ["PEDV", "ORGANISM", 255, 259], ["porcine rotavirus", "ORGANISM", 286, 303], ["porcine parvovirus", "ORGANISM", 331, 349], ["CP-99", "ORGANISM", 356, 361], ["pig", "ORGANISM", 382, 385], ["foot-and-mouth disease virus", "ORGANISM", 386, 414], ["FMDV", "ORGANISM", 416, 420], ["Pseudorabies virus", "SPECIES", 0, 18], ["swine fever virus", "SPECIES", 49, 66], ["CSFV", "SPECIES", 68, 72], ["porcine circovirus type", "SPECIES", 102, 125], ["transmissible gastroenteritis virus", "SPECIES", 151, 186], ["swine", "SPECIES", 190, 195], ["TGEV", "SPECIES", 197, 201], ["porcine epidemic diarrhea virus", "SPECIES", 222, 253], ["porcine rotavirus", "SPECIES", 286, 303], ["porcine parvovirus", "SPECIES", 331, 349], ["pig foot-and-mouth disease virus", "SPECIES", 382, 414], ["FMDV", "SPECIES", 416, 420], ["Pseudorabies virus", "SPECIES", 0, 18], ["PRV", "SPECIES", 20, 23], ["HB-98", "SPECIES", 32, 37], ["swine fever virus", "SPECIES", 49, 66], ["CSFV", "SPECIES", 68, 72], ["porcine circovirus type 2", "SPECIES", 102, 127], ["PCV2", "SPECIES", 129, 133], ["transmissible gastroenteritis virus", "SPECIES", 151, 186], ["swine", "SPECIES", 190, 195], ["TGEV", "SPECIES", 197, 201], ["porcine epidemic diarrhea virus", "SPECIES", 222, 253], ["PEDV", "SPECIES", 255, 259], ["CV777", "SPECIES", 261, 266], ["rotavirus", "SPECIES", 294, 303], ["RV", "SPECIES", 305, 307], ["porcine parvovirus (PPV) CP-99", "SPECIES", 331, 361], ["pig foot-and-mouth disease virus", "SPECIES", 382, 414], ["FMDV", "SPECIES", 416, 420], ["Pseudorabies virus", "PROBLEM", 0, 18], ["strain HB", "TEST", 25, 34], ["classical swine fever virus", "PROBLEM", 39, 66], ["CSFV) strain C attenuate vaccine", "TREATMENT", 68, 100], ["porcine circovirus type 2 (PCV2) killed vaccine", "TREATMENT", 102, 149], ["transmissible gastroenteritis virus", "PROBLEM", 151, 186], ["swine (TGEV) attenuate vaccine", "TREATMENT", 190, 220], ["porcine epidemic diarrhea virus", "PROBLEM", 222, 253], ["PEDV)", "TREATMENT", 255, 260], ["attenuate vaccine", "TREATMENT", 267, 284], ["porcine rotavirus (RV)", "TREATMENT", 286, 308], ["NX attenuate vaccine", "TREATMENT", 309, 329], ["porcine parvovirus (PPV", "TREATMENT", 331, 354], ["CP", "TEST", 356, 358], ["killed vaccine", "TREATMENT", 362, 376], ["pig foot", "TREATMENT", 382, 390], ["mouth disease virus", "PROBLEM", 395, 414], ["pig foot", "ANATOMY", 382, 390], ["mouth", "ANATOMY", 395, 400]]], ["Swine influenza virus (SIV) was isolated and preserved in our laboratory.Generation of RNA Molecular Standard.Out of all the genes in PDCoV, we selected the highly conserved gene for the RNA standard preparation.", [["Swine influenza virus", "DISEASE", 0, 21], ["Swine influenza virus", "ORGANISM", 0, 21], ["SIV", "ORGANISM", 23, 26], ["PDCoV", "GENE_OR_GENE_PRODUCT", 134, 139], ["PDCoV", "DNA", 134, 139], ["highly conserved gene", "DNA", 157, 178], ["Swine influenza virus", "SPECIES", 0, 21], ["Swine influenza virus", "SPECIES", 0, 21], ["SIV", "SPECIES", 23, 26], ["Swine influenza virus", "PROBLEM", 0, 21], ["the RNA standard preparation", "TREATMENT", 183, 211], ["influenza virus", "OBSERVATION", 6, 21], ["RNA Molecular Standard", "OBSERVATION", 87, 109]]], ["By using TGuide virus DNA/RNA kit (Tiangen Biotech, Beijing, China), total nucleic acid was extracted from PDCoV Strain CHN-GD16-03.", [["nucleic acid", "CHEMICAL", 75, 87], ["CHN-GD16-03", "CHEMICAL", 120, 131], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["GD16-03", "CELL", 124, 131], ["TGuide virus DNA", "DNA", 9, 25], ["TGuide virus", "SPECIES", 9, 21], ["PDCoV Strain CHN-GD16-03", "SPECIES", 107, 131], ["TGuide virus DNA", "TREATMENT", 9, 25], ["total nucleic acid", "TREATMENT", 69, 87]]], ["We designed PCR primers (N-F and N-R) that were used for the amplification of the whole gene ( Table 1 ).", [["PCR primers", "DNA", 12, 23], ["whole gene", "DNA", 82, 92], ["PCR primers", "TEST", 12, 23], ["N-R)", "TREATMENT", 33, 37]]], ["The RT-PCR reaction protocol was as follows: reverse transcription step 42 \u2218 C/30 min, DNA denaturation at 95 \u2218 C/15 min, 30 cycles of 94 \u2218 C/30 s, 55 \u2218 C/30 s, and 72 \u2218 C/60 s, and additional extension at 72 \u2218 C for 10 min.", [["DNA", "CELLULAR_COMPONENT", 87, 90], ["The RT-PCR reaction protocol", "TEST", 0, 28], ["DNA denaturation", "TEST", 87, 103], ["C", "TEST", 140, 141], ["C", "TEST", 153, 154], ["C", "TEST", 170, 171]]], ["The PCR product was purified and ligated into pGEM-T Easy Vector (Promega, Madison, US).", [["pGEM", "PROTEIN", 46, 50], ["The PCR product", "TEST", 0, 15]]], ["One microgram of the plasmid, which was verified by sequencing, was linearized and transcribed in vitro by following the manufacturer's instructions provided in RiboMAX6 Large Scale RNA Production Systems (Promega, Madison, US).", [["plasmid", "ANATOMY", 21, 28], ["plasmid", "DNA", 21, 28], ["the plasmid", "TREATMENT", 17, 28], ["the manufacturer's instructions", "TREATMENT", 117, 148]]], ["The transcribed RNA was pretreated with DNase (Promega, Madison, US).", [["DNase", "GENE_OR_GENE_PRODUCT", 40, 45], ["transcribed RNA", "RNA", 4, 19], ["DNase", "PROTEIN", 40, 45], ["DNase", "TREATMENT", 40, 45], ["RNA", "OBSERVATION_MODIFIER", 16, 19]]], ["Then, it was purified with TRIzol Reagent (Invitrogen, Carlsbad, US).", [["TRIzol Reagent", "TREATMENT", 27, 41]]], ["The copy number of the RNA standard was calculated by using routine method.PrimerDesign.", [["routine method", "TREATMENT", 60, 74]]], ["Oligo 6.0 software (Molecular Biology Insights Inc., CO, US) was used to design primers, which were used in conventional RT-PCR and RT-qPCR assays for the detection of PDCoV.", [["PDCoV", "CANCER", 168, 173], ["PDCoV", "SPECIES", 168, 173], ["Oligo", "TEST", 0, 5], ["PCR", "TEST", 124, 127], ["RT-qPCR assays", "TEST", 132, 146], ["the detection", "TEST", 151, 164], ["PDCoV", "TREATMENT", 168, 173]]], ["The primers used in this study were included in Table 1 .RT-PCR.After isolating total RNA from samples, it was reverse transcribed into cDNA by following the manufacturer's instructions in PrimeScript6 1st Strand cDNA Synthesis Kit (Takara Biotechnology, Dalian, China).", [["samples", "ANATOMY", 95, 102], ["cDNA", "DNA", 136, 140], ["The primers", "TREATMENT", 0, 11], ["this study", "TEST", 20, 30], ["isolating total RNA", "TREATMENT", 70, 89], ["total RNA", "OBSERVATION_MODIFIER", 80, 89]]], ["Using Premix Taq6 kit, the PCR assay was performed under the following conditions: 1 L each primer (10 m), 25 L premix, 1 L cDNA, and 22 L distilled water.", [["Taq6", "GENE_OR_GENE_PRODUCT", 13, 17], ["Premix Taq6 kit", "PROTEIN", 6, 21], ["the PCR assay", "TEST", 23, 36], ["25 L premix", "TREATMENT", 107, 118], ["1 L cDNA", "TREATMENT", 120, 128], ["22 L distilled water", "TREATMENT", 134, 154]]], ["The reaction conditions were as follows: DNA denaturation at 95 \u2218 C for 15 min, 30 cycles of 94 \u2218 C/30 s, 55 \u2218 C/30 s, and 72 \u2218 C/60 s; 72 \u2218 C for 10 min.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["DNA denaturation", "PROBLEM", 41, 57]]], ["Using 2% agarose gel, electrophoresis was applied to the resultant PCR product.RT-qPCR.The synthesized cDNA was used in RT-qPCR assay.", [["agarose", "SIMPLE_CHEMICAL", 9, 16], ["synthesized cDNA", "DNA", 91, 107], ["2% agarose gel", "TREATMENT", 6, 20], ["electrophoresis", "TREATMENT", 22, 37], ["The synthesized cDNA", "TREATMENT", 87, 107], ["qPCR", "OBSERVATION", 82, 86]]], ["Moreover, SYBR Green6 Premix Ex Taq6 II Kit (Takara Biotechnology, Dalian, China) was used for performing RT-qPCR reaction.", [["SYBR", "TEST", 10, 14], ["Dalian, China)", "TREATMENT", 67, 81]]], ["The final volume of the reaction mixture was 50 L, and it consisted of the following ingredients: 1 L each primer (10 m), 25 L SYBR Green Premix, 1 L ROX Reference Dye II, 1 L cDNA, and 21 L distilled water.", [["the reaction mixture", "TEST", 20, 40], ["1 L cDNA", "TREATMENT", 172, 180], ["21 L distilled water", "TREATMENT", 186, 206], ["final", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16]]], ["The amplification was performed with an Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific, MA, US) under the following conditions: 95 \u2218 C for 30 s of initial denaturation, which was followed by 40 cycles of 95 \u2218 C for 5 s and 60 \u2218 C for 34 s.", [["an Applied Biosystems", "TREATMENT", 37, 58], ["initial denaturation", "PROBLEM", 171, 191]]], ["The conditions of the dissociation step were as follows: 95 \u2218 C for 5 s, 60 \u2218 C for 60 s, and 95 \u2218 C for 15 s.Sensitivity Test.For sensitivity analysis, the RNA molecular standard was tenfold diluted.", [["Sensitivity Test", "TEST", 110, 126], ["sensitivity analysis", "TEST", 131, 151]]], ["The diluted RNA standards were tested by conventional RT-PCR and RT-qPCR techniques.", [["The diluted RNA standards", "TREATMENT", 0, 25], ["PCR", "TEST", 57, 60], ["RT-qPCR techniques", "TREATMENT", 65, 83]]], ["Distilled water was served as the control.Specificity Test.In this experiment, we evaluated the specificity of the following two assays: RT-PCR and RT-qPCR.", [["Distilled water", "TREATMENT", 0, 15], ["Specificity Test", "TEST", 42, 58], ["RT-PCR", "TEST", 137, 143], ["RT-qPCR", "TEST", 148, 155]]], ["For this purpose, PDCoV and other swine pathogens, including SADS-CoV, PRRSV, PRV, CSFV, PCV2, TGEV, PEDV, RV, PPV, FMDV, and SIV, were tested individually by RT-PCR and RT-qPCR techniques.", [["PDCoV", "CHEMICAL", 18, 23], ["PDCoV", "ORGANISM", 18, 23], ["swine", "ORGANISM", 34, 39], ["SADS-CoV", "ORGANISM", 61, 69], ["PRRSV", "ORGANISM", 71, 76], ["PRV", "ORGANISM", 78, 81], ["CSFV", "ORGANISM", 83, 87], ["PCV2", "ORGANISM", 89, 93], ["TGEV", "ORGANISM", 95, 99], ["PEDV", "GENE_OR_GENE_PRODUCT", 101, 105], ["RV", "GENE_OR_GENE_PRODUCT", 107, 109], ["PPV", "GENE_OR_GENE_PRODUCT", 111, 114], ["FMDV", "ORGANISM", 116, 120], ["SIV", "ORGANISM", 126, 129], ["swine", "SPECIES", 34, 39], ["PRRSV", "SPECIES", 71, 76], ["CSFV", "SPECIES", 83, 87], ["TGEV", "SPECIES", 95, 99], ["FMDV", "SPECIES", 116, 120], ["PDCoV", "SPECIES", 18, 23], ["swine", "SPECIES", 34, 39], ["SADS-CoV", "SPECIES", 61, 69], ["PRRSV", "SPECIES", 71, 76], ["PRV", "SPECIES", 78, 81], ["CSFV", "SPECIES", 83, 87], ["PCV2", "SPECIES", 89, 93], ["TGEV", "SPECIES", 95, 99], ["PEDV", "SPECIES", 101, 105], ["RV", "SPECIES", 107, 109], ["FMDV", "SPECIES", 116, 120], ["SIV", "SPECIES", 126, 129], ["PDCoV", "TREATMENT", 18, 23], ["other swine pathogens", "PROBLEM", 28, 49], ["SADS", "TEST", 61, 65], ["PRRSV", "TREATMENT", 71, 76], ["PRV", "TREATMENT", 78, 81], ["CSFV", "TREATMENT", 83, 87], ["PCV2", "TREATMENT", 89, 93], ["TGEV", "TREATMENT", 95, 99], ["PEDV", "TREATMENT", 101, 105], ["RV", "TEST", 107, 109], ["PPV", "TREATMENT", 111, 114], ["FMDV", "TREATMENT", 116, 120], ["SIV", "TREATMENT", 126, 129], ["PCR", "TEST", 162, 165], ["RV", "ANATOMY", 107, 109]]], ["The genome of these viruses was extracted by the aforementioned procedure.Reproducibility.Using the diluted RNA molecular standards, three independent tests were performed on three different days.", [["the aforementioned procedure", "TREATMENT", 45, 73], ["Reproducibility", "TEST", 74, 89], ["three independent tests", "TEST", 133, 156], ["viruses", "OBSERVATION", 20, 27]]], ["Thus, the reproducibility of RT-PCR was determined.Reproducibility.The primer N-F/R was used for the amplification of whole n gene.", [["primer N-F/R", "DNA", 71, 83], ["whole n gene", "DNA", 118, 130], ["RT-PCR", "TEST", 29, 35], ["Reproducibility", "TEST", 51, 66], ["The primer N-F/R", "TREATMENT", 67, 83], ["the amplification of whole n gene", "TREATMENT", 97, 130]]], ["The primer PCR-F/R was used for performing conventional RT-PCR.", [["The primer PCR", "TEST", 0, 14], ["conventional RT-PCR", "TREATMENT", 43, 62]]], ["The primer qPCR-F/R was used for performing RT-qPCR.", [["The primer qPCR", "TEST", 0, 15], ["RT-qPCR", "TREATMENT", 44, 51]]], ["Intraassay and interassay coefficients of variation (CV) were calculated by using threshold cycle (C t ) values of serially diluted RNA molecular standards, which were detected by RT-qPCR in several replicates.", [["Intraassay", "TEST", 0, 10], ["threshold cycle", "TEST", 82, 97]]], ["Interassay coefficient of variation (CV) was determined by testing RNA standards in duplicate on three different days.Detection of Clinical Samples.We tested 84 clinical samples, including 24 fecal swab specimens, 30 fecal specimens, and 30 intestine specimens; these specimens were collected from a commercial swine farm in Guangdong province, China.", [["samples", "ANATOMY", 170, 177], ["fecal swab specimens", "ANATOMY", 192, 212], ["fecal specimens", "ANATOMY", 217, 232], ["intestine specimens", "ANATOMY", 241, 260], ["specimens", "ANATOMY", 268, 277], ["samples", "CANCER", 170, 177], ["fecal swab specimens", "ORGANISM_SUBSTANCE", 192, 212], ["intestine specimens", "CANCER", 241, 260], ["swine", "SPECIES", 311, 316], ["swine", "SPECIES", 311, 316], ["Clinical Samples", "TEST", 131, 147], ["clinical samples", "TEST", 161, 177], ["24 fecal swab specimens", "TEST", 189, 212], ["fecal specimens", "TEST", 217, 232], ["intestine specimens", "TEST", 241, 260], ["these specimens", "TEST", 262, 277], ["intestine", "ANATOMY", 241, 250]]], ["All these specimens were tested by both RT-PCR and RT-qPCR techniques in order to evaluate the detection capacity of developed assays.", [["specimens", "ANATOMY", 10, 19], ["specimens", "CANCER", 10, 19], ["All these specimens", "TEST", 0, 19], ["PCR", "TEST", 43, 46], ["RT-qPCR techniques", "TEST", 51, 69], ["the detection capacity", "TEST", 91, 113], ["assays", "TEST", 127, 133]]], ["A previously described RT-PCR method was also used to detect the samples [11] .", [["A previously described RT-PCR method", "TREATMENT", 0, 36], ["the samples", "TEST", 61, 72]]], ["This method was designated as one-step RT-PCR in order to distinguish it from conventional RT-PCR developed in present study.Sensitivity of RT-PCR and RT-qPCR.To determine the sensitivity of RT-PCR and RT-qPCR assay for PDCoV detection, we used tenfold dilutions that ranged from 2 \u00d710 6 to 2 \u00d710 0 copies/ L of RNA molecular standard.", [["PDCoV", "SPECIES", 220, 225], ["conventional RT-PCR", "TEST", 78, 97], ["present study", "TEST", 111, 124], ["Sensitivity", "TEST", 125, 136], ["RT", "TEST", 140, 142], ["PCR", "TEST", 143, 146], ["RT-qPCR", "TEST", 151, 158], ["RT-PCR", "TEST", 191, 197], ["RT-qPCR assay", "TEST", 202, 215], ["PDCoV detection", "TEST", 220, 235], ["tenfold dilutions", "TREATMENT", 245, 262]]], ["As shown in Figure 1(a) , the limit of detection of RT-PCR was 2 \u00d7 10 1 copies; no amplification product was produced by testing 2 \u00d7 10 0 copies of RNA and distilled water.", [["RT-PCR", "TEST", 52, 58]]], ["The results of other primers were not presented, which showed low sensitivity.Sensitivity of RT-PCR and RT-qPCR.Using RT-qPCR technique, we could detect as few as 2 \u00d7 10 1 copies of molecular RNA (Figure 1(b) ).", [["molecular RNA", "RNA", 182, 195], ["other primers", "TEST", 15, 28], ["low sensitivity", "PROBLEM", 62, 77], ["Sensitivity", "TEST", 78, 89], ["RT", "TEST", 93, 95], ["PCR", "TEST", 96, 99], ["RT-qPCR", "TEST", 104, 111], ["RT-qPCR technique", "TREATMENT", 118, 135]]], ["Melting dissociation analysis on the qPCR products showed the same melting temperature (T m ) which was 86.0 \u2218 C (Figure 1(c) ).", [["Melting dissociation analysis", "TEST", 0, 29], ["the qPCR products", "TEST", 33, 50]]], ["With an R 2 value of 0.996, we obtained a standard curve by plotting threshold cycle (C t ) versus RNA copy numbers.", [["an R 2 value", "TEST", 5, 17], ["a standard curve", "TEST", 40, 56]]], ["This indicates that the amplification efficiency of RT-qPCR technique was indeed remarkable (Figure 1(d) ).Specificity of RT-PCR and RT-qPCR.We had to determine whether RT-PCR and RT-qPCR assays had the specificity for PDCoV detection; therefore, several viral pathogens of swine (RV, PRV, FMDV, PEDV, PRRSV, CSFV, PCV2, TGEV, SIV, PPRV, and SADS-CoV) were tested by RT-PCR and RT-qPCR assays.", [["swine", "ORGANISM", 274, 279], ["FMDV", "ORGANISM", 290, 294], ["PEDV", "GENE_OR_GENE_PRODUCT", 296, 300], ["PRRSV", "ORGANISM", 302, 307], ["CSFV", "ORGANISM", 309, 313], ["PCV2", "ORGANISM", 315, 319], ["TGEV", "ORGANISM", 321, 325], ["SIV", "ORGANISM", 327, 330], ["PPRV", "GENE_OR_GENE_PRODUCT", 332, 336], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 342, 350], ["swine", "SPECIES", 274, 279], ["FMDV", "SPECIES", 290, 294], ["PRRSV", "SPECIES", 302, 307], ["TGEV", "SPECIES", 321, 325], ["PDCoV", "SPECIES", 219, 224], ["swine", "SPECIES", 274, 279], ["RV", "SPECIES", 281, 283], ["PRV", "SPECIES", 285, 288], ["FMDV", "SPECIES", 290, 294], ["PEDV", "SPECIES", 296, 300], ["PRRSV", "SPECIES", 302, 307], ["CSFV", "SPECIES", 309, 313], ["PCV2", "SPECIES", 315, 319], ["TGEV", "SPECIES", 321, 325], ["SIV", "SPECIES", 327, 330], ["PPRV", "SPECIES", 332, 336], ["SADS-CoV", "SPECIES", 342, 350], ["RT-qPCR technique", "TEST", 52, 69], ["Specificity", "TEST", 107, 118], ["RT-PCR", "TEST", 122, 128], ["RT-qPCR", "TEST", 133, 140], ["RT-PCR", "TEST", 169, 175], ["RT-qPCR assays", "TEST", 180, 194], ["PDCoV detection", "TEST", 219, 234], ["several viral pathogens", "PROBLEM", 247, 270], ["RV", "TEST", 281, 283], ["PRV", "TEST", 285, 288], ["FMDV", "PROBLEM", 290, 294], ["PEDV", "PROBLEM", 296, 300], ["PRRSV", "PROBLEM", 302, 307], ["CSFV", "PROBLEM", 309, 313], ["PCV2", "PROBLEM", 315, 319], ["TGEV", "PROBLEM", 321, 325], ["SIV", "PROBLEM", 327, 330], ["PPRV", "PROBLEM", 332, 336], ["SADS", "TEST", 342, 346], ["RT", "TEST", 367, 369], ["PCR", "TEST", 370, 373], ["RT-qPCR assays", "TEST", 378, 392]]], ["Only PDCoV target gene was amplified by RT-PCR and visualized by agarose electrophoresis (Figure 2(a) ).", [["PDCoV", "GENE_OR_GENE_PRODUCT", 5, 10], ["PDCoV target gene", "DNA", 5, 22], ["PDCoV target gene", "TREATMENT", 5, 22], ["PCR", "TEST", 43, 46], ["agarose electrophoresis", "TEST", 65, 88]]], ["PDCoV was found to have a strong fluorescence signal under RT-qPCR; the C t values of negative samples were greater than 35 (Figure 2(b) ).", [["samples", "ANATOMY", 95, 102], ["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["PDCoV", "SPECIES", 0, 5], ["the C t values", "TEST", 68, 82], ["strong", "OBSERVATION_MODIFIER", 26, 32], ["fluorescence", "OBSERVATION", 33, 45]]], ["Specific melting peaks are shown for only PDCoV detected by real-time RT-PCR (Figure 2(c) ).", [["PDCoV", "DNA", 42, 47], ["Specific melting peaks", "TEST", 0, 22], ["PDCoV", "TEST", 42, 47]]], ["These results indicate that both of these two assays showed good specificity.Reproducibility.Total three independent tests were performed on three different days to evaluate the reproducibility of RT-PCR; the sensitivity of the three trials was the same (Figure 1(a) ).Reproducibility.Intra-and interassay coefficients of variation (CV) of RT-qPCR were calculated by determining the C t values of multiple replicates.", [["these two assays", "TEST", 36, 52], ["Reproducibility", "TEST", 77, 92], ["Total three independent tests", "TEST", 93, 122], ["RT-PCR", "TEST", 197, 203], ["Reproducibility", "TEST", 269, 284], ["RT-qPCR", "TEST", 340, 347]]], ["Table 2 shows that both intra-and interassay variability were below 5%.", [["both intra-and interassay variability", "TEST", 19, 56]]], ["This indicates that realtime RT-PCR had good reproducibility.Detection of PDCoV in Clinical Samples.In this experiment, a total of 84 clinical samples were simultaneously detected by conventional RT-PCR and real-time RT-PCR.", [["samples", "ANATOMY", 143, 150], ["samples", "CANCER", 143, 150], ["realtime RT-PCR", "TEST", 20, 35], ["PDCoV", "PROBLEM", 74, 79], ["Clinical Samples", "TEST", 83, 99], ["conventional RT-PCR", "TEST", 183, 202]]], ["A one-step RT-PCR targeting the gene of PDCoV described in a previous study was also used to detect the samples.", [["samples", "ANATOMY", 104, 111], ["PDCoV", "GENE_OR_GENE_PRODUCT", 40, 45], ["PDCoV", "DNA", 40, 45], ["A one-step RT-PCR", "TREATMENT", 0, 17], ["a previous study", "TEST", 59, 75], ["the samples", "TEST", 100, 111]]], ["Table 3 presents the positive rates of PDCoV, which were detected by three methods in these samples.", [["samples", "ANATOMY", 92, 99], ["PDCoV", "GENE_OR_GENE_PRODUCT", 39, 44], ["the positive rates of PDCoV", "PROBLEM", 17, 44]]], ["Both conventional RT-PCR and real-time RT-PCR techniques showed an equally positive percentage for PDCoV, which was consistent with the sensitivity of the two assays.", [["Both conventional RT-PCR", "TEST", 0, 24], ["real-time RT-PCR techniques", "TEST", 29, 56], ["PDCoV", "PROBLEM", 99, 104], ["the two assays", "TEST", 151, 165], ["equally", "OBSERVATION_MODIFIER", 67, 74], ["positive", "OBSERVATION", 75, 83], ["consistent with", "UNCERTAINTY", 116, 131]]], ["The PDCoV-status of these samples determined by conventional RT-PCR was 100% in agreement with that of RT-qPCR.", [["samples", "ANATOMY", 26, 33], ["PDCoV", "GENE_OR_GENE_PRODUCT", 4, 9], ["samples", "CANCER", 26, 33], ["PDCoV", "PROTEIN", 4, 9], ["these samples", "TEST", 20, 33], ["conventional RT-PCR", "TEST", 48, 67]]], ["However, when these samples were tested by one-step RT-PCR, the overall positive rate was only 26.2% for PDCoV.", [["samples", "ANATOMY", 20, 27], ["samples", "CANCER", 20, 27], ["PDCoV", "SPECIES", 105, 110], ["these samples", "TEST", 14, 27], ["the overall positive rate", "TEST", 60, 85], ["PDCoV", "TREATMENT", 105, 110]]], ["This indicates that one-step RT-PCR was significantly less sensitive than the other two assays.DiscussionIt is important to note that PDCoV is a newly discovered coronavirus, which is circulating across the world [2, 9, 13, 14, 21] .", [["PDCoV", "CHEMICAL", 134, 139], ["PDCoV", "GENE_OR_GENE_PRODUCT", 134, 139], ["coronavirus", "ORGANISM", 162, 173], ["one-step RT-PCR", "TEST", 20, 35], ["a newly discovered coronavirus", "PROBLEM", 143, 173], ["coronavirus", "OBSERVATION", 162, 173]]], ["Low feed remuneration is observed in pigs infected with PDCoV pathogens; the impact of PDCoV was more severe in infected newborn piglets, which ultimately succumbed to the virus and died.", [["PDCoV", "CHEMICAL", 87, 92], ["pigs", "ORGANISM", 37, 41], ["PDCoV", "GENE_OR_GENE_PRODUCT", 87, 92], ["piglets", "ORGANISM", 129, 136], ["pigs", "SPECIES", 37, 41], ["piglets", "SPECIES", 129, 136], ["pigs", "SPECIES", 37, 41], ["PDCoV", "SPECIES", 56, 61], ["PDCoV", "SPECIES", 87, 92], ["Low feed remuneration", "TREATMENT", 0, 21], ["PDCoV pathogens", "PROBLEM", 56, 71], ["PDCoV", "TREATMENT", 87, 92], ["infected newborn piglets", "PROBLEM", 112, 136], ["feed remuneration", "OBSERVATION", 4, 21], ["more severe", "OBSERVATION_MODIFIER", 97, 108], ["infected", "OBSERVATION_MODIFIER", 112, 120], ["newborn piglets", "OBSERVATION", 121, 136]]], ["Currently, there are no effective treatments and vaccines against PDCoV infection.DiscussionTo monitor the health of pig herds, scientists need to develop a rapid diagnosis method that is suitable for most laboratories in China.", [["PDCoV infection", "DISEASE", 66, 81], ["PDCoV", "CANCER", 66, 71], ["pig", "ORGANISM", 117, 120], ["pig", "SPECIES", 117, 120], ["PDCoV", "SPECIES", 66, 71], ["pig", "SPECIES", 117, 120], ["effective treatments", "TREATMENT", 24, 44], ["vaccines", "TREATMENT", 49, 57], ["PDCoV infection", "PROBLEM", 66, 81], ["a rapid diagnosis method", "PROBLEM", 155, 179], ["no", "UNCERTAINTY", 21, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33]]], ["A rapid and accurate diagnosis would be helpful to identify and segregate infected animals in a timely manner.", [["infected", "OBSERVATION", 74, 82]]], ["Therefore, the main objective of present study is to establish the conventional RT-PCR and SYBR green-based RT-qPCR methods with high sensitivity for PDCoV detection.", [["SYBR green", "CHEMICAL", 91, 101], ["PDCoV", "SPECIES", 150, 155], ["present study", "TEST", 33, 46], ["the conventional RT-PCR", "TEST", 63, 86], ["SYBR green", "TEST", 91, 101], ["PDCoV detection", "TEST", 150, 165]]], ["The sensitivity of developed conventional RT-PCR is same as that of RT-qPCR.", [["conventional RT-PCR", "TEST", 29, 48], ["RT-qPCR", "TEST", 68, 75]]], ["After comparing the results of clinical samples analyzed by both assays, we concluded that these methods were sensitive, rapid, reliable, and cost-effective in nature.", [["samples", "ANATOMY", 40, 47], ["clinical samples", "TEST", 31, 47], ["these methods", "TEST", 91, 104]]], ["Several kinds of novel amplification methods, such as loop-mediated isothermal amplification (LAMP), insulated isothermal PCR (iiPCR), and probe-based real-time PCR, have been developed to detect PDCoV with better sensitivity [19, 20] .", [["novel amplification methods", "TREATMENT", 17, 44], ["loop-mediated isothermal amplification", "TREATMENT", 54, 92], ["insulated isothermal PCR", "TEST", 101, 125], ["probe-based real-time PCR", "TEST", 139, 164]]], ["Nevertheless, conventional RT-PCR is still widely used for detecting PDCoV [11, 12] .", [["PDCoV", "SPECIES", 69, 74], ["conventional RT-PCR", "TEST", 14, 33]]], ["Although previous studies have used conventional RT-PCR to detect PDCoV, the detection limits of these assays have not been defined till date [11, 12] .", [["PDCoV", "GENE_OR_GENE_PRODUCT", 66, 71], ["PDCoV", "PROTEIN", 66, 71], ["previous studies", "TEST", 9, 25], ["conventional RT-PCR", "TEST", 36, 55], ["PDCoV", "TEST", 66, 71], ["the detection", "TEST", 73, 86], ["these assays", "TEST", 97, 109]]], ["A previous report has described that the detection limit of LAMP method was 10 copies, which was 100 times more sensitive than conventional RT-PCR [20] .", [["LAMP method", "TEST", 60, 71], ["conventional RT-PCR", "TREATMENT", 127, 146]]], ["This indicates that RT-PCR can detect PDCoV with a detection limit of 1000 copies.", [["PDCoV", "CANCER", 38, 43], ["RT-PCR", "TEST", 20, 26]]], ["Recently, nano-particle-assisted PCR assays were used to increase the sensitivity of conventional PCR [22] [23] [24] .", [["nano-particle-assisted PCR assays", "TREATMENT", 10, 43], ["conventional PCR", "TEST", 85, 101]]], ["In the detection of duck Tembusu virus, the detection limit of nano-particle-assisted PCR was 1.8 \u00d7 10 2 copies [23] .", [["duck Tembusu virus", "ORGANISM", 20, 38], ["nano-particle", "SIMPLE_CHEMICAL", 63, 76], ["duck Tembusu virus", "SPECIES", 20, 38], ["duck Tembusu virus", "SPECIES", 20, 38], ["duck Tembusu virus", "PROBLEM", 20, 38], ["nano-particle-assisted PCR", "TEST", 63, 89]]], ["This indicates that the sensitivity of nano-particleassisted PCR was 10-fold more than that of conventional PCR assay [23] .", [["the sensitivity of nano-particleassisted PCR", "TEST", 20, 64], ["conventional PCR assay", "TEST", 95, 117]]], ["In theory, PCR assay can detect as few as 1 DNA/RNA molecule.", [["DNA", "CELLULAR_COMPONENT", 44, 47], ["PCR assay", "TEST", 11, 20], ["1 DNA/RNA molecule", "PROBLEM", 42, 60]]], ["However, the limit of detection for conventional PCR commonly could not achieve theoretical value because of various factors, such as primer design and reaction inhibitor in genome extract.DiscussionIn present study, our main objective was to ensure that conventional RT-PCR could detect PDCoV with better sensitivity.", [["extract", "ANATOMY", 181, 188], ["PDCoV", "CANCER", 288, 293], ["PDCoV", "SPECIES", 288, 293], ["conventional PCR", "TEST", 36, 52], ["various factors", "PROBLEM", 109, 124], ["primer design and reaction inhibitor", "TREATMENT", 134, 170], ["present study", "TEST", 202, 215], ["conventional RT-PCR", "TEST", 255, 274], ["PDCoV", "PROBLEM", 288, 293]]], ["The conservation of the target gene is important to the broad reactivity of the RT-PCR assay for detection of heterologous strains.", [["target gene", "DNA", 24, 35], ["the RT-PCR assay", "TEST", 76, 92], ["heterologous strains", "PROBLEM", 110, 130]]], ["The PDCoV gene was demonstrated to be highly conserved and chosen to be the target gene of RT-PCR and RT-qPCR in many studies [6, 12] .", [["PDCoV", "GENE_OR_GENE_PRODUCT", 4, 9], ["PDCoV gene", "DNA", 4, 14], ["The PDCoV gene", "TREATMENT", 0, 14], ["RT-PCR", "TEST", 91, 97], ["RT-qPCR", "TEST", 102, 109]]], ["Thus, the gene was selected as the target gene in our study.", [["target gene", "DNA", 35, 46], ["our study", "TEST", 50, 59]]], ["To improve the sensitivity of the conventional RT-PCR, we adjusted several primer pairs and optimized reaction conditions.", [["primer pairs", "DNA", 75, 87], ["the conventional RT-PCR", "TEST", 30, 53], ["optimized reaction conditions", "PROBLEM", 92, 121]]], ["It was found in our study that the sensitivity of the conventional RT-PCR assay could be significantly improved with selected primers.", [["our study", "TEST", 16, 25], ["the conventional RT-PCR assay", "TEST", 50, 79], ["selected primers", "TREATMENT", 117, 133]]], ["However, modulation of reaction conditions, such as annealing temperature and primer concentrations, had no effect on the performance of the assay.", [["reaction conditions", "PROBLEM", 23, 42], ["annealing temperature and primer concentrations", "PROBLEM", 52, 99], ["the assay", "TEST", 137, 146], ["reaction conditions", "OBSERVATION", 23, 42]]], ["The optimal sensitivity of RT-PCR was 2 \u00d7 10 1 copies by using the primers PCR-F/R for PDCoV detection, which was equal to that of SYBR greenbased RT-qPCR.", [["SYBR", "GENE_OR_GENE_PRODUCT", 131, 135], ["RT-PCR", "TEST", 27, 33], ["the primers PCR", "TEST", 63, 78], ["PDCoV detection", "TEST", 87, 102], ["SYBR", "TEST", 131, 135]]], ["The result was confirmed by the tests carried out in three independent days.", [["the tests", "TEST", 28, 37]]], ["The conventional RT-PCR had several advantages against the RT-qPCR as follows: RT-PCR does not require an expensive device for operation; moreover, RT-PCR is a cost-effective technique.", [["The conventional RT-PCR", "TEST", 0, 23], ["the RT-qPCR", "TEST", 55, 66], ["RT-PCR", "TEST", 79, 85], ["an expensive device", "TREATMENT", 103, 122], ["operation", "TREATMENT", 127, 136], ["RT-PCR", "TEST", 148, 154], ["a cost-effective technique", "TREATMENT", 158, 184]]], ["In present study, it was proved that the sensitivity of RT-PCR was significantly improved in resource-limiting settings.", [["RT-PCR", "TEST", 56, 62]]], ["The sequences of PDCoV gene have been used to generate the phylogenetic tree to analyze the epidemiology of PDCoV [13] .", [["PDCoV", "GENE_OR_GENE_PRODUCT", 17, 22], ["PDCoV gene", "DNA", 17, 27], ["PDCoV gene", "TREATMENT", 17, 27]]], ["In our study, the gene products were approximately 950 nt in length; these gene products could be sequenced directly, providing a robust tool for molecular epidemiology study.DiscussionFurthermore, 24 fecal swab specimens, 30 feces specimens, and 30 intestine specimens were simultaneously tested by conventional RT-PCR and SYBR green-based RT-PCR.", [["fecal swab specimens", "ANATOMY", 201, 221], ["feces specimens", "ANATOMY", 226, 241], ["intestine specimens", "ANATOMY", 250, 269], ["SYBR green", "CHEMICAL", 324, 334], ["fecal swab specimens", "ORGANISM_SUBSTANCE", 201, 221], ["intestine specimens", "CANCER", 250, 269], ["our study", "TEST", 3, 12], ["the gene products", "TREATMENT", 14, 31], ["these gene products", "TREATMENT", 69, 88], ["molecular epidemiology study", "TEST", 146, 174], ["24 fecal swab specimens", "TEST", 198, 221], ["feces specimens", "TEST", 226, 241], ["intestine specimens", "TEST", 250, 269], ["conventional RT-PCR", "TEST", 300, 319], ["SYBR green", "TEST", 324, 334], ["intestine", "ANATOMY", 250, 259]]], ["The detection result of the conventional RT-PCR assay was 100% in agreement with that of the RT-qPCR assay, indicating the high sensitivity of the conventional RT-PCR assay.", [["the conventional RT-PCR assay", "TEST", 24, 53], ["the RT-qPCR assay", "TEST", 89, 106], ["the conventional RT-PCR assay", "TEST", 143, 172]]], ["The positive rates detected by conventional RT-PCR and RT-qPCR were both 41.7%.", [["The positive rates", "TEST", 0, 18], ["conventional RT-PCR", "TEST", 31, 50], ["RT-qPCR", "TEST", 55, 62], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["rates", "OBSERVATION_MODIFIER", 13, 18]]], ["However, when the samples were tested by one-step RT-PCR [11] , an assay reported in a previous study, the positive rate was only 26.2%.", [["samples", "ANATOMY", 18, 25], ["the samples", "TEST", 14, 25], ["an assay", "TEST", 64, 72], ["a previous study", "TEST", 85, 101], ["the positive rate", "TEST", 103, 120]]], ["These results demonstrated that the previously reported conventional RT-PCR with low sensitivity would underestimate the prevalence of PDCoV infection in pig herd.", [["PDCoV", "CHEMICAL", 135, 140], ["infection", "DISEASE", 141, 150], ["PDCoV", "CANCER", 135, 140], ["pig", "ORGANISM", 154, 157], ["herd", "ORGANISM_SUBDIVISION", 158, 162], ["pig", "SPECIES", 154, 157], ["PDCoV", "SPECIES", 135, 140], ["pig", "SPECIES", 154, 157], ["conventional RT-PCR", "TEST", 56, 75], ["low sensitivity", "PROBLEM", 81, 96], ["PDCoV infection", "PROBLEM", 135, 150], ["PDCoV", "OBSERVATION_MODIFIER", 135, 140], ["infection", "OBSERVATION", 141, 150]]], ["Considering that most testing laboratories are equipped with thermocyclers rather than sophisticated quantitative PCR instruments, the highly sensitive conventional RT-PCR is more suitable for extensive applications in laboratories, which are specifically designed for PDCoV detection and surveillance.ConclusionIn this study, a highly specific and sensitive conventional RT-PCR assay was successfully established for the detection of PDCoV, with the same detection limit of 2 \u00d7 10 1 copies molecule as a SYBR green-based real-time RT-PCR assay.", [["PDCoV", "SIMPLE_CHEMICAL", 435, 440], ["PDCoV", "SPECIES", 269, 274], ["PDCoV", "SPECIES", 435, 440], ["most testing laboratories", "TEST", 17, 42], ["thermocyclers", "TREATMENT", 61, 74], ["conventional RT-PCR", "TEST", 152, 171], ["PDCoV detection", "TEST", 269, 284], ["surveillance", "TEST", 289, 301], ["this study", "TEST", 315, 325], ["conventional RT-PCR assay", "TEST", 359, 384], ["PDCoV", "PROBLEM", 435, 440], ["a SYBR green", "TEST", 503, 515]]], ["The performance of the conventional RT-PCR assay was validated using 84 clinical samples.", [["samples", "ANATOMY", 81, 88], ["the conventional RT-PCR assay", "TEST", 19, 48]]], ["The improved RT-PCR provided a cost-effective and highly sensitive method for the diagnosis of PDCoV infection, which is epidemic in pig herds across the world.Data AvailabilityThe data used to support the findings of this study are available from the corresponding author upon request.", [["PDCoV infection", "DISEASE", 95, 110], ["PDCoV", "CANCER", 95, 100], ["pig", "ORGANISM", 133, 136], ["pig", "SPECIES", 133, 136], ["PDCoV", "SPECIES", 95, 100], ["pig", "SPECIES", 133, 136], ["The improved RT-PCR", "PROBLEM", 0, 19], ["PDCoV infection", "PROBLEM", 95, 110], ["this study", "TEST", 218, 228], ["PDCoV", "OBSERVATION_MODIFIER", 95, 100], ["infection", "OBSERVATION", 101, 110], ["epidemic", "OBSERVATION_MODIFIER", 121, 129]]]], "05d2bc10b680dfc032d6c66ef5bc77d0db478cbe": [["TreatmentWhen the diagnosis of CAP has been made, physicians must choose between inpatient or outpatient treatment for the athlete.", [["CAP", "DISEASE", 31, 34], ["CAP", "PROBLEM", 31, 34], ["outpatient treatment", "TREATMENT", 94, 114]]], ["A clinical predication tool, the pneumonia severity index, has been developed based on the likelihood of mortality of a CAP patient [13, 16, 17] .", [["pneumonia", "DISEASE", 33, 42], ["CAP", "DISEASE", 120, 123], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["A clinical predication tool", "TEST", 0, 27], ["the pneumonia severity index", "PROBLEM", 29, 57], ["pneumonia", "OBSERVATION", 33, 42]]], ["This index is useful for identifying patients who are at low risk of mortality from CAP and who can be safely treated as outpatients [12] .", [["CAP", "DISEASE", 84, 87], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["This index", "TEST", 0, 10], ["CAP", "PROBLEM", 84, 87]]], ["In the training room setting, the most useful indicators are vital signs and physical examination findings.", [["vital signs", "TEST", 61, 72], ["physical examination findings", "TEST", 77, 106]]], ["The physician's clinical judgment should always override the index score.TreatmentThe most common contraindications to outpatient treatment are inability to maintain oral intake, unstable vital signs, history of substance abuse, mental/ cognitive impairment, or presence of comorbid conditions [12, 16, 18] .TreatmentBecause microbiologic data are not available at the time of clinical suspicion of CAP, most initial treatment regimens are empiric.", [["oral", "ANATOMY", 166, 170], ["substance abuse", "DISEASE", 212, 227], ["mental/ cognitive impairment", "DISEASE", 229, 257], ["CAP", "DISEASE", 399, 402], ["oral", "ORGANISM_SUBDIVISION", 166, 170], ["Treatment", "TREATMENT", 73, 82], ["outpatient treatment", "TREATMENT", 119, 139], ["unstable vital signs", "PROBLEM", 179, 199], ["mental/ cognitive impairment", "PROBLEM", 229, 257], ["comorbid conditions", "PROBLEM", 274, 293], ["Treatment", "TREATMENT", 308, 317], ["microbiologic data", "TEST", 325, 343], ["CAP", "PROBLEM", 399, 402], ["initial treatment regimens", "TREATMENT", 409, 435], ["empiric", "TREATMENT", 440, 447]]], ["Antibiotics that provide coverage against the most common organisms known to cause CAP (Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella) should be selected.", [["CAP", "DISEASE", 83, 86], ["Streptococcus pneumoniae", "DISEASE", 88, 112], ["Mycoplasma pneumoniae", "DISEASE", 114, 135], ["Chlamydia pneumoniae", "DISEASE", 137, 157], ["Streptococcus pneumoniae", "ORGANISM", 88, 112], ["Mycoplasma pneumoniae", "ORGANISM", 114, 135], ["Chlamydia pneumoniae", "ORGANISM", 137, 157], ["Streptococcus pneumoniae", "SPECIES", 88, 112], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["Chlamydia pneumoniae", "SPECIES", 137, 157], ["Streptococcus pneumoniae", "SPECIES", 88, 112], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["Chlamydia pneumoniae", "SPECIES", 137, 157], ["Antibiotics", "TREATMENT", 0, 11], ["coverage", "TREATMENT", 25, 33], ["CAP", "PROBLEM", 83, 86], ["Streptococcus pneumoniae", "PROBLEM", 88, 112], ["Mycoplasma pneumoniae", "PROBLEM", 114, 135], ["Chlamydia pneumoniae", "PROBLEM", 137, 157], ["Legionella", "PROBLEM", 159, 169]]], ["Macrolides are recommended if there are no significant risk factors for macrolide-resistant Streptococcus pneumoniae [18] .TreatmentThe American Thoracic Society (ATS) recommends not changing initial antibiotic treatment in the first 72 hours unless there is a worsening clinical situation [19] .", [["Macrolides", "CHEMICAL", 0, 10], ["macrolide", "CHEMICAL", 72, 81], ["Streptococcus pneumoniae", "DISEASE", 92, 116], ["Macrolides", "CHEMICAL", 0, 10], ["macrolide", "CHEMICAL", 72, 81], ["Macrolides", "SIMPLE_CHEMICAL", 0, 10], ["macrolide", "SIMPLE_CHEMICAL", 72, 81], ["Streptococcus pneumoniae", "ORGANISM", 92, 116], ["Streptococcus pneumoniae", "SPECIES", 92, 116], ["Streptococcus pneumoniae", "SPECIES", 92, 116], ["Macrolides", "TREATMENT", 0, 10], ["significant risk factors", "PROBLEM", 43, 67], ["macrolide-resistant Streptococcus pneumoniae", "PROBLEM", 72, 116], ["initial antibiotic treatment", "TREATMENT", 192, 220], ["a worsening clinical situation", "PROBLEM", 259, 289], ["Thoracic", "ANATOMY", 145, 153]]], ["Generally, most cases of CAP should be treated for 7 to 10 days.", [["CAP", "DISEASE", 25, 28], ["CAP", "PROBLEM", 25, 28]]], ["If atypical causes are suspected, therapy should last 10 to 14 days.", [["atypical causes", "PROBLEM", 3, 18], ["therapy", "TREATMENT", 34, 41]]], ["The severity of the clinical presentation and the presence of coexisting illnesses should be considered in the determination of antibiotic duration [19, 20] .ComplicationsMost patients recover from CAP without complications.", [["CAP", "DISEASE", 198, 201], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["coexisting illnesses", "PROBLEM", 62, 82], ["antibiotic duration", "TREATMENT", 128, 147], ["CAP", "PROBLEM", 198, 201], ["complications", "PROBLEM", 210, 223], ["illnesses", "OBSERVATION", 73, 82], ["CAP", "OBSERVATION_MODIFIER", 198, 201]]], ["One of the most common complications for the athlete is reactive airway disease.", [["airway", "ANATOMY", 65, 71], ["airway disease", "DISEASE", 65, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 65, 71], ["reactive airway disease", "PROBLEM", 56, 79], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["complications", "OBSERVATION", 23, 36], ["reactive airway disease", "OBSERVATION", 56, 79]]], ["Pulmonary function tests may show decreased forced expiratory volume in 1 second (FEV 1 ).", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary function tests", "TEST", 0, 24], ["decreased forced expiratory volume", "PROBLEM", 34, 68], ["decreased", "OBSERVATION_MODIFIER", 34, 43], ["forced", "OBSERVATION_MODIFIER", 44, 50], ["expiratory volume", "OBSERVATION", 51, 68]]], ["Transient airflow obstruction and hyper-responsiveness may be seen in these patients [21] .", [["airflow obstruction", "DISEASE", 10, 29], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Transient airflow obstruction", "PROBLEM", 0, 29], ["hyper-responsiveness", "PROBLEM", 34, 54], ["airflow", "OBSERVATION_MODIFIER", 10, 17], ["obstruction", "OBSERVATION", 18, 29], ["hyper", "OBSERVATION", 34, 39], ["may be seen", "UNCERTAINTY", 55, 66]]], ["Up to 40% of patients may demonstrate decreased FEV 1 [22, 23] .", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["decreased FEV", "PROBLEM", 38, 51], ["decreased", "OBSERVATION_MODIFIER", 38, 47]]], ["This abnormality typically resolves after 3 weeks but may last up to 2 months [22] [23] [24] .", [["This abnormality", "PROBLEM", 0, 16]]], ["This potential complication could inhibit an athlete's full return to play.", [["complication", "PROBLEM", 15, 27]]], ["If clinically indicated, the athlete may respond to short-term inhaled bronchodilator therapy [25, 26] .ComplicationsWhen the athlete has continued fever, other complications should be considered, such as pleural effusions, empyema, lung abscess, and secondary lung infection [1] .", [["pleural effusions", "ANATOMY", 205, 222], ["lung abscess", "ANATOMY", 233, 245], ["lung", "ANATOMY", 261, 265], ["fever", "DISEASE", 148, 153], ["pleural effusions", "DISEASE", 205, 222], ["empyema", "DISEASE", 224, 231], ["lung abscess", "DISEASE", 233, 245], ["lung infection", "DISEASE", 261, 275], ["pleural effusions", "PATHOLOGICAL_FORMATION", 205, 222], ["lung", "ORGAN", 233, 237], ["lung", "ORGAN", 261, 265], ["short-term inhaled bronchodilator therapy", "TREATMENT", 52, 93], ["fever", "PROBLEM", 148, 153], ["other complications", "PROBLEM", 155, 174], ["pleural effusions", "PROBLEM", 205, 222], ["empyema", "PROBLEM", 224, 231], ["lung abscess", "PROBLEM", 233, 245], ["secondary lung infection", "PROBLEM", 251, 275], ["pleural", "ANATOMY", 205, 212], ["effusions", "OBSERVATION", 213, 222], ["empyema", "OBSERVATION", 224, 231], ["lung", "ANATOMY", 233, 237], ["abscess", "OBSERVATION", 238, 245], ["secondary", "OBSERVATION_MODIFIER", 251, 260], ["lung", "ANATOMY", 261, 265], ["infection", "OBSERVATION", 266, 275]]], ["CAP patients are also susceptible to sepsis and meningitis [1] .Return to PlayFew studies are available on the amount of proper recovery time needed for athletes diagnosed with CAP.", [["CAP", "DISEASE", 0, 3], ["sepsis", "DISEASE", 37, 43], ["meningitis", "DISEASE", 48, 58], ["CAP", "DISEASE", 177, 180], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["sepsis", "PROBLEM", 37, 43], ["meningitis", "PROBLEM", 48, 58], ["PlayFew studies", "TEST", 74, 89], ["CAP", "PROBLEM", 177, 180], ["susceptible to", "UNCERTAINTY", 22, 36], ["sepsis", "OBSERVATION", 37, 43], ["meningitis", "OBSERVATION", 48, 58]]], ["Athletes treated with an effective drug regimen usually show improvement of symptoms within 72 hours.", [["an effective drug regimen", "TREATMENT", 22, 47], ["symptoms", "PROBLEM", 76, 84]]], ["A study by Metlay and colleagues [27] looked at time resolution of symptoms in patients who had CAP.", [["CAP", "DISEASE", 96, 99], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["A study", "TEST", 0, 7], ["symptoms", "PROBLEM", 67, 75], ["CAP", "PROBLEM", 96, 99]]], ["Median time to resolution was 3 days for fever, 6 days for dyspnea, 14 days for cough, and 14 days for fatigue [27] .", [["fever", "DISEASE", 41, 46], ["dyspnea", "DISEASE", 59, 66], ["cough", "DISEASE", 80, 85], ["fatigue", "DISEASE", 103, 110], ["fever", "PROBLEM", 41, 46], ["dyspnea", "PROBLEM", 59, 66], ["cough", "PROBLEM", 80, 85], ["fatigue", "PROBLEM", 103, 110]]], ["The athlete should be afebrile before return to training and competition.", [["afebrile", "PROBLEM", 22, 30]]], ["The athlete also should be re-evaluated by the team physician before clearance to assure normalcy of vital signs and respiratory status.", [["respiratory", "ANATOMY", 117, 128], ["vital signs", "TEST", 101, 112]]], ["It is recommended that exercise and training be resumed slowly when the athlete is able.", [["exercise and training", "TREATMENT", 23, 44]]], ["Athletes can usually return to play sooner if they exercise early in the recovery and benefit psychologically if they see progress is being made.ACUTE BRONCHITISBronchitis is defined as inflammation of the bronchial mucous membranes.", [["bronchial mucous membranes", "ANATOMY", 206, 232], ["bronchial mucous membranes", "MULTI-TISSUE_STRUCTURE", 206, 232], ["ACUTE BRONCHITISBronchitis", "PROBLEM", 145, 171], ["inflammation of the bronchial mucous membranes", "PROBLEM", 186, 232], ["BRONCHITISBronchitis", "OBSERVATION", 151, 171], ["inflammation", "OBSERVATION", 186, 198], ["bronchial", "ANATOMY", 206, 215], ["mucous membranes", "OBSERVATION", 216, 232]]], ["Acute bronchitis is a clinical syndrome characterized by cough (with or without sputum production) lasting up to 3 weeks, with evidence of concurrent upper airway infection [28, 29] .", [["sputum", "ANATOMY", 80, 86], ["upper airway", "ANATOMY", 150, 162], ["bronchitis", "DISEASE", 6, 16], ["cough", "DISEASE", 57, 62], ["airway infection", "DISEASE", 156, 172], ["upper airway", "MULTI-TISSUE_STRUCTURE", 150, 162], ["Acute bronchitis", "PROBLEM", 0, 16], ["a clinical syndrome", "PROBLEM", 20, 39], ["cough", "PROBLEM", 57, 62], ["sputum production", "PROBLEM", 80, 97], ["concurrent upper airway infection", "PROBLEM", 139, 172], ["bronchitis", "OBSERVATION", 6, 16], ["cough", "OBSERVATION", 57, 62], ["upper", "ANATOMY_MODIFIER", 150, 155], ["airway", "ANATOMY", 156, 162], ["infection", "OBSERVATION", 163, 172]]], ["Acute bronchitis is one of the most common conditions encountered in the primary care setting and a common ailment in the training room [29] .", [["bronchitis", "DISEASE", 6, 16], ["Acute bronchitis", "PROBLEM", 0, 16], ["bronchitis", "OBSERVATION", 6, 16]]], ["Acute bronchitis accounts for more than 10 million office visits yearly [30] [31] [32] .CausesRespiratory viral infections are the most common causes of acute bronchitis.", [["bronchitis", "DISEASE", 6, 16], ["CausesRespiratory viral infections", "DISEASE", 88, 122], ["bronchitis", "DISEASE", 159, 169], ["Acute bronchitis", "PROBLEM", 0, 16], ["CausesRespiratory viral infections", "PROBLEM", 88, 122], ["acute bronchitis", "PROBLEM", 153, 169], ["bronchitis", "OBSERVATION", 6, 16], ["viral infections", "OBSERVATION", 106, 122], ["most common", "OBSERVATION_MODIFIER", 131, 142], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["bronchitis", "OBSERVATION", 159, 169]]], ["Less than 10% of patients have a bacterial etiology.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["a bacterial etiology", "PROBLEM", 31, 51], ["bacterial", "OBSERVATION_MODIFIER", 33, 42]]], ["The most common viruses associated with acute bronchitis include influenza A and B viruses, adenovirus, rhinovirus, parainfluenza virus, coronavirus, and respiratory synctial virus.", [["bronchitis", "DISEASE", 46, 56], ["influenza A and B viruses", "DISEASE", 65, 90], ["rhinovirus, parainfluenza virus, coronavirus", "DISEASE", 104, 148], ["respiratory synctial virus", "DISEASE", 154, 180], ["influenza A", "ORGANISM", 65, 76], ["B viruses", "ORGANISM", 81, 90], ["adenovirus", "ORGANISM", 92, 102], ["rhinovirus", "ORGANISM", 104, 114], ["parainfluenza virus", "ORGANISM", 116, 135], ["coronavirus", "ORGANISM", 137, 148], ["respiratory synctial virus", "ORGANISM", 154, 180], ["rhinovirus", "SPECIES", 104, 114], ["parainfluenza virus, coronavirus", "SPECIES", 116, 148], ["B viruses", "SPECIES", 81, 90], ["parainfluenza virus", "SPECIES", 116, 135], ["respiratory synctial virus", "SPECIES", 154, 180], ["The most common viruses", "PROBLEM", 0, 23], ["acute bronchitis", "PROBLEM", 40, 56], ["influenza A and B viruses", "PROBLEM", 65, 90], ["adenovirus", "PROBLEM", 92, 102], ["rhinovirus", "PROBLEM", 104, 114], ["parainfluenza virus", "PROBLEM", 116, 135], ["coronavirus", "PROBLEM", 137, 148], ["respiratory synctial virus", "PROBLEM", 154, 180], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["viruses", "OBSERVATION", 16, 23], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["bronchitis", "OBSERVATION", 46, 56], ["influenza", "OBSERVATION", 65, 74], ["parainfluenza virus", "OBSERVATION", 116, 135], ["respiratory synctial virus", "OBSERVATION", 154, 180]]], ["The known bacteria that are significant agents in acute bronchitis are Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydia pneumoniae strain TWAR [33, 34] .", [["bronchitis", "DISEASE", 56, 66], ["Bordetella pertussis", "DISEASE", 71, 91], ["Mycoplasma pneumoniae", "DISEASE", 93, 114], ["Chlamydia pneumoniae", "DISEASE", 120, 140], ["Bordetella pertussis", "ORGANISM", 71, 91], ["Mycoplasma pneumoniae", "ORGANISM", 93, 114], ["Chlamydia pneumoniae", "ORGANISM", 120, 140], ["Bordetella pertussis", "SPECIES", 71, 91], ["Mycoplasma pneumoniae", "SPECIES", 93, 114], ["Chlamydia pneumoniae", "SPECIES", 120, 140], ["Bordetella pertussis", "SPECIES", 71, 91], ["Mycoplasma pneumoniae", "SPECIES", 93, 114], ["Chlamydia pneumoniae", "SPECIES", 120, 140], ["The known bacteria", "PROBLEM", 0, 18], ["acute bronchitis", "PROBLEM", 50, 66], ["Bordetella pertussis", "PROBLEM", 71, 91], ["Mycoplasma pneumoniae", "PROBLEM", 93, 114], ["Chlamydia pneumoniae strain", "PROBLEM", 120, 147], ["bacteria", "OBSERVATION", 10, 18], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["bronchitis", "OBSERVATION", 56, 66], ["Mycoplasma pneumoniae", "OBSERVATION", 93, 114]]], ["As in CAP, the organism responsible for acute bronchitis is unlikely to be identified in the ambulatory setting.", [["bronchitis", "DISEASE", 46, 56], ["the organism", "PROBLEM", 11, 23], ["acute bronchitis", "PROBLEM", 40, 56], ["responsible for", "UNCERTAINTY", 24, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["bronchitis", "OBSERVATION", 46, 56], ["unlikely to be", "UNCERTAINTY", 60, 74]]], ["When contemplating treatment options, it is important for the physician to understand the limited role of bacterial agents in acute bronchitis.", [["bronchitis", "DISEASE", 132, 142], ["treatment options", "TREATMENT", 19, 36], ["bacterial agents", "TREATMENT", 106, 122], ["acute bronchitis", "PROBLEM", 126, 142], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["bronchitis", "OBSERVATION", 132, 142]]], ["Acute bronchitis is one of the most common examples of misuse of antibiotics by the primary care physician [35] .Clinical EvaluationCough is the most common symptom in acute bronchitis.", [["bronchitis", "DISEASE", 6, 16], ["bronchitis", "DISEASE", 174, 184], ["Acute bronchitis", "PROBLEM", 0, 16], ["antibiotics", "TREATMENT", 65, 76], ["Clinical EvaluationCough", "TEST", 113, 137], ["acute bronchitis", "PROBLEM", 168, 184], ["bronchitis", "OBSERVATION", 6, 16], ["one of the most common", "OBSERVATION_MODIFIER", 20, 42], ["most common", "OBSERVATION_MODIFIER", 145, 156], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["bronchitis", "OBSERVATION", 174, 184]]], ["The patient may or may not have sputum production.", [["sputum", "ANATOMY", 32, 38], ["patient", "ORGANISM", 4, 11], ["sputum", "ORGANISM_SUBSTANCE", 32, 38], ["patient", "SPECIES", 4, 11], ["sputum production", "PROBLEM", 32, 49], ["sputum", "OBSERVATION", 32, 38]]], ["Fever is unusual in acute bronchitis.", [["Fever", "DISEASE", 0, 5], ["bronchitis", "DISEASE", 26, 36], ["Fever", "PROBLEM", 0, 5], ["acute bronchitis", "PROBLEM", 20, 36], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["bronchitis", "OBSERVATION", 26, 36]]], ["If fever is present, the clinician should consider influenza or pneumonia [36, 37] .", [["fever", "DISEASE", 3, 8], ["influenza", "DISEASE", 51, 60], ["pneumonia", "DISEASE", 64, 73], ["fever", "PROBLEM", 3, 8], ["influenza", "PROBLEM", 51, 60], ["pneumonia", "PROBLEM", 64, 73], ["pneumonia", "OBSERVATION", 64, 73]]], ["The patient may also complain of concurrent or prodromal symptoms of an upper respiratory infection (URI), including pharyngitis, coryza, and fatigue [38] .", [["respiratory", "ANATOMY", 78, 89], ["upper respiratory infection", "DISEASE", 72, 99], ["URI", "DISEASE", 101, 104], ["pharyngitis", "DISEASE", 117, 128], ["coryza", "DISEASE", 130, 136], ["fatigue", "DISEASE", 142, 149], ["patient", "ORGANISM", 4, 11], ["upper respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["patient", "SPECIES", 4, 11], ["prodromal symptoms", "PROBLEM", 47, 65], ["an upper respiratory infection", "PROBLEM", 69, 99], ["URI", "PROBLEM", 101, 104], ["pharyngitis", "PROBLEM", 117, 128], ["coryza", "PROBLEM", 130, 136], ["fatigue", "PROBLEM", 142, 149], ["upper", "ANATOMY_MODIFIER", 72, 77], ["respiratory", "ANATOMY", 78, 89], ["infection", "OBSERVATION", 90, 99], ["pharyngitis", "OBSERVATION", 117, 128]]], ["Most URI symptoms improve within 5 to 7 days [39] .", [["Most URI symptoms", "PROBLEM", 0, 17]]], ["In acute bronchitis, the cough can last up to 3 weeks [21] .Clinical EvaluationIt is imperative to document vital signs (temperature, pulse, respiratory rate, blood pressure, and oxygen saturation) of any athlete who presents with a respiratory complaint.", [["blood", "ANATOMY", 159, 164], ["respiratory", "ANATOMY", 233, 244], ["bronchitis", "DISEASE", 9, 19], ["cough", "DISEASE", 25, 30], ["oxygen", "CHEMICAL", 179, 185], ["respiratory complaint", "DISEASE", 233, 254], ["oxygen", "CHEMICAL", 179, 185], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["oxygen", "SIMPLE_CHEMICAL", 179, 185], ["acute bronchitis", "PROBLEM", 3, 19], ["the cough", "PROBLEM", 21, 30], ["vital signs", "TEST", 108, 119], ["temperature", "TEST", 121, 132], ["pulse", "TEST", 134, 139], ["respiratory rate", "TEST", 141, 157], ["blood pressure", "TEST", 159, 173], ["oxygen saturation", "TEST", 179, 196], ["a respiratory complaint", "PROBLEM", 231, 254], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["bronchitis", "OBSERVATION", 9, 19]]], ["Examination often reveals findings similar to URI symtoms: pharyngeal erythema, anterior cervical lymphadenopathy, and rhinorrhea [14] .DiagnosisThe diagnosis of acute bronchitis is considered a clinical diagnosis and should be suspected in cases of acute respiratory disease with prolonged cough that continues after other signs and symptoms of acute infection have resolved [38] .", [["pharyngeal", "ANATOMY", 59, 69], ["anterior cervical lymphadenopathy", "ANATOMY", 80, 113], ["respiratory", "ANATOMY", 256, 267], ["pharyngeal erythema", "DISEASE", 59, 78], ["anterior cervical lymphadenopathy", "DISEASE", 80, 113], ["rhinorrhea", "DISEASE", 119, 129], ["bronchitis", "DISEASE", 168, 178], ["respiratory disease", "DISEASE", 256, 275], ["cough", "DISEASE", 291, 296], ["infection", "DISEASE", 352, 361], ["pharyngeal", "ORGANISM_SUBDIVISION", 59, 69], ["Examination", "TEST", 0, 11], ["URI symtoms", "PROBLEM", 46, 57], ["pharyngeal erythema", "PROBLEM", 59, 78], ["anterior cervical lymphadenopathy", "PROBLEM", 80, 113], ["rhinorrhea", "PROBLEM", 119, 129], ["acute bronchitis", "PROBLEM", 162, 178], ["acute respiratory disease", "PROBLEM", 250, 275], ["prolonged cough", "PROBLEM", 281, 296], ["other signs and symptoms", "PROBLEM", 318, 342], ["acute infection", "PROBLEM", 346, 361], ["pharyngeal", "ANATOMY", 59, 69], ["erythema", "OBSERVATION", 70, 78], ["anterior", "ANATOMY_MODIFIER", 80, 88], ["cervical", "ANATOMY", 89, 97], ["lymphadenopathy", "OBSERVATION", 98, 113], ["rhinorrhea", "OBSERVATION", 119, 129], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["bronchitis", "OBSERVATION", 168, 178], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["respiratory", "ANATOMY", 256, 267], ["disease", "OBSERVATION", 268, 275], ["prolonged", "OBSERVATION_MODIFIER", 281, 290], ["cough", "OBSERVATION", 291, 296], ["acute", "OBSERVATION_MODIFIER", 346, 351], ["infection", "OBSERVATION", 352, 361]]], ["It may not be necessary to obtain any further studies in the appropriate clinical situation.", [["any further studies", "TEST", 34, 53]]], ["Abnormal vital signs (pulse >100, respiratory rate >24, or temperature >38 C) are an indication to consider further testing such as a chest radiograph.", [["chest", "ANATOMY", 134, 139], ["Abnormal vital signs", "PROBLEM", 0, 20], ["pulse", "TEST", 22, 27], ["respiratory rate", "TEST", 34, 50], ["temperature", "TEST", 59, 70], ["further testing", "TEST", 108, 123], ["a chest radiograph", "TEST", 132, 150], ["chest", "ANATOMY", 134, 139]]], ["Physical examination findings on chest examination of rales on auscultation or dullness to percussion are not consistent with acute bronchitis and require further investigation [14] .", [["chest", "ANATOMY", 33, 38], ["bronchitis", "DISEASE", 132, 142], ["chest", "ORGANISM_SUBDIVISION", 33, 38], ["Physical examination", "TEST", 0, 20], ["chest examination", "TEST", 33, 50], ["rales", "PROBLEM", 54, 59], ["auscultation", "TEST", 63, 75], ["dullness", "PROBLEM", 79, 87], ["percussion", "TEST", 91, 101], ["acute bronchitis", "PROBLEM", 126, 142], ["further investigation", "TEST", 155, 176], ["chest", "ANATOMY", 33, 38], ["rales", "OBSERVATION", 54, 59], ["dullness", "OBSERVATION", 79, 87], ["not consistent with", "UNCERTAINTY", 106, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["bronchitis", "OBSERVATION", 132, 142]]], ["Other diagnoses to consider in an athlete complaining of cough are postnasal drip, sinusitis, asthma, and gastroesophageal reflux.TreatmentWhen the clinical diagnosis of acute bronchitis has been established, the recommended therapy is symptomatic.", [["gastroesophageal", "ANATOMY", 106, 122], ["cough", "DISEASE", 57, 62], ["sinusitis", "DISEASE", 83, 92], ["asthma", "DISEASE", 94, 100], ["gastroesophageal reflux", "DISEASE", 106, 129], ["bronchitis", "DISEASE", 176, 186], ["cough", "PROBLEM", 57, 62], ["postnasal drip", "TREATMENT", 67, 81], ["sinusitis", "PROBLEM", 83, 92], ["asthma", "PROBLEM", 94, 100], ["gastroesophageal reflux", "PROBLEM", 106, 129], ["acute bronchitis", "PROBLEM", 170, 186], ["therapy", "TREATMENT", 225, 232], ["symptomatic", "PROBLEM", 236, 247], ["cough", "OBSERVATION", 57, 62], ["sinusitis", "OBSERVATION", 83, 92], ["asthma", "OBSERVATION", 94, 100], ["gastroesophageal", "ANATOMY", 106, 122], ["reflux", "OBSERVATION", 123, 129], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["bronchitis", "OBSERVATION", 176, 186]]], ["The physician may choose to use acetaminophen, ibuprofen, and nasal decongestants if appropriate.", [["nasal", "ANATOMY", 62, 67], ["acetaminophen", "CHEMICAL", 32, 45], ["ibuprofen", "CHEMICAL", 47, 56], ["acetaminophen", "CHEMICAL", 32, 45], ["ibuprofen", "CHEMICAL", 47, 56], ["acetaminophen", "SIMPLE_CHEMICAL", 32, 45], ["ibuprofen", "SIMPLE_CHEMICAL", 47, 56], ["nasal", "ORGANISM_SUBDIVISION", 62, 67], ["acetaminophen", "TREATMENT", 32, 45], ["ibuprofen", "TREATMENT", 47, 56], ["nasal decongestants", "TREATMENT", 62, 81], ["nasal", "ANATOMY", 62, 67]]], ["Routine antibiotic treatment of uncomplicated acute bronchitis is not recommended because the primary causes are most often viral infections [40, 41] .", [["bronchitis", "DISEASE", 52, 62], ["viral infections", "DISEASE", 124, 140], ["Routine antibiotic treatment", "TREATMENT", 0, 28], ["uncomplicated acute bronchitis", "PROBLEM", 32, 62], ["viral infections", "PROBLEM", 124, 140], ["uncomplicated", "OBSERVATION_MODIFIER", 32, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["bronchitis", "OBSERVATION", 52, 62]]], ["The exception to this is in the setting of Bordetella pertussis infection, which is discussed in detail later.ComplicationsPulmonary function test abnormalities may also be seen in athletes who have acute bronchitis.", [["Pulmonary", "ANATOMY", 123, 132], ["Bordetella pertussis infection", "DISEASE", 43, 73], ["bronchitis", "DISEASE", 205, 215], ["Bordetella pertussis", "ORGANISM", 43, 63], ["Pulmonary", "ORGAN", 123, 132], ["Bordetella pertussis", "SPECIES", 43, 63], ["Bordetella pertussis", "SPECIES", 43, 63], ["Bordetella pertussis infection", "PROBLEM", 43, 73], ["ComplicationsPulmonary function test abnormalities", "PROBLEM", 110, 160], ["acute bronchitis", "PROBLEM", 199, 215], ["infection", "OBSERVATION", 64, 73], ["may also be seen", "UNCERTAINTY", 161, 177], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["bronchitis", "OBSERVATION", 205, 215]]], ["Transient airflow obstruction and hyper-responsiveness may be seen in these patients [21] .", [["airflow obstruction", "DISEASE", 10, 29], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Transient airflow obstruction", "PROBLEM", 0, 29], ["hyper-responsiveness", "PROBLEM", 34, 54], ["airflow", "OBSERVATION_MODIFIER", 10, 17], ["obstruction", "OBSERVATION", 18, 29], ["hyper", "OBSERVATION", 34, 39], ["may be seen", "UNCERTAINTY", 55, 66]]], ["Up to 40% of patients may demonstrate decreased FEV 1 [22, 23] .", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["decreased FEV", "PROBLEM", 38, 51], ["decreased", "OBSERVATION_MODIFIER", 38, 47]]], ["This abnormality typically resolves after 3 weeks but may last up to 2 months [22] [23] [24] .", [["This abnormality", "PROBLEM", 0, 16]]], ["This potential complication could inhibit an athlete's full return to play.", [["complication", "PROBLEM", 15, 27]]], ["If clinically indicated, the athlete may respond to short-term inhaled bronchodilator therapy [25, 26] .", [["short-term inhaled bronchodilator therapy", "TREATMENT", 52, 93]]], ["It has been the authors' experience that athletes return to sport sooner when the reactive airway disease is treated.", [["airway", "ANATOMY", 91, 97], ["airway disease", "DISEASE", 91, 105], ["airway", "MULTI-TISSUE_STRUCTURE", 91, 97], ["the reactive airway disease", "PROBLEM", 78, 105], ["reactive airway disease", "OBSERVATION", 82, 105]]], ["Athletes who have asthma or other lung conditions may have worsening symptoms.Return to PlayThere are little data regarding appropriate return-to-play guidelines for athletes who have acute bronchitis.", [["lung", "ANATOMY", 34, 38], ["asthma", "DISEASE", 18, 24], ["bronchitis", "DISEASE", 190, 200], ["lung", "ORGAN", 34, 38], ["asthma", "PROBLEM", 18, 24], ["other lung conditions", "PROBLEM", 28, 49], ["worsening symptoms", "PROBLEM", 59, 77], ["acute bronchitis", "PROBLEM", 184, 200], ["asthma", "OBSERVATION", 18, 24], ["lung", "ANATOMY", 34, 38], ["conditions", "OBSERVATION", 39, 49], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["bronchitis", "OBSERVATION", 190, 200]]], ["It is important that there is proper follow-up with the team physician to ensure resolution of symptoms and to guarantee a clinical situation that does not worsen.", [["symptoms", "PROBLEM", 95, 103]]], ["All respiratory symptoms should be closely monitored by the athletic training staff.", [["respiratory", "ANATOMY", 4, 15], ["All respiratory symptoms", "PROBLEM", 0, 24], ["respiratory", "ANATOMY", 4, 15], ["symptoms", "OBSERVATION", 16, 24]]], ["If the athlete's symptoms do not resolve with symptomatic treatment, then the physician should consider other diagnoses, and further workup is necessary [42] .PERTUSSISBordetella pertussis, a gram-negative coccobacillus, is a commonly undiagnosed cause of acute bronchitis [43] .", [["PERTUSSISBordetella pertussis", "CHEMICAL", 159, 188], ["bronchitis", "DISEASE", 262, 272], ["PERTUSSISBordetella pertussis", "ORGANISM", 159, 188], ["PERTUSSISBordetella pertussis", "SPECIES", 159, 188], ["the athlete's symptoms", "PROBLEM", 3, 25], ["symptomatic treatment", "TREATMENT", 46, 67], ["further workup", "TEST", 125, 139], ["PERTUSSISBordetella pertussis", "PROBLEM", 159, 188], ["a gram-negative coccobacillus", "PROBLEM", 190, 219], ["acute bronchitis", "PROBLEM", 256, 272], ["negative coccobacillus", "OBSERVATION", 197, 219], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["bronchitis", "OBSERVATION", 262, 272]]], ["Pertussis, also known as whooping cough, is an acute, highly contagious infection of the respiratory airways.", [["respiratory airways", "ANATOMY", 89, 108], ["Pertussis", "DISEASE", 0, 9], ["whooping cough", "DISEASE", 25, 39], ["infection of the respiratory airways", "DISEASE", 72, 108], ["respiratory airways", "MULTI-TISSUE_STRUCTURE", 89, 108], ["Pertussis", "PROBLEM", 0, 9], ["whooping cough", "PROBLEM", 25, 39], ["an acute, highly contagious infection of the respiratory airways", "PROBLEM", 44, 108], ["whooping", "OBSERVATION_MODIFIER", 25, 33], ["cough", "OBSERVATION", 34, 39], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["highly", "OBSERVATION_MODIFIER", 54, 60], ["contagious", "OBSERVATION_MODIFIER", 61, 71], ["infection", "OBSERVATION", 72, 81], ["respiratory airways", "ANATOMY", 89, 108]]], ["Pertussis is transmitted person to person by contact with aerosolized droplets [44] .", [["Pertussis", "DISEASE", 0, 9], ["person", "SPECIES", 25, 31], ["person", "SPECIES", 35, 41], ["Pertussis", "PROBLEM", 0, 9]]], ["Because vaccine and natural immunity wane with age, pertussis has become a disease of adolescents and adults [46] .", [["pertussis", "CHEMICAL", 52, 61], ["adolescents", "SPECIES", 86, 97], ["pertussis", "SPECIES", 52, 61], ["vaccine", "TREATMENT", 8, 15], ["pertussis", "PROBLEM", 52, 61]]], ["Due to the amount of time that athletes spend training together and the high infectivity of pertussis, this diagnosis must not be missed in the training room.Clinical PresentationThe classic clinical course of pertussis is divided into three stages: catarrhal, paroxysmal, and convalescent (Box 1) [44, 47, 48] .", [["pertussis", "DISEASE", 92, 101], ["pertussis", "DISEASE", 210, 219], ["catarrhal", "DISEASE", 250, 259], ["pertussis", "PROBLEM", 92, 101], ["pertussis", "PROBLEM", 210, 219], ["catarrhal", "PROBLEM", 250, 259], ["paroxysmal", "PROBLEM", 261, 271], ["catarrhal", "OBSERVATION", 250, 259]]], ["Adolescents and adults may not display the typical phases of childhood infections.", [["infections", "DISEASE", 71, 81], ["adults", "ORGANISM", 16, 22], ["Adolescents", "SPECIES", 0, 11], ["childhood infections", "PROBLEM", 61, 81], ["infections", "OBSERVATION", 71, 81]]], ["In adults, the disease may be characterized by a persistent cough with URI symptoms [49] .", [["cough", "DISEASE", 60, 65], ["the disease", "PROBLEM", 11, 22], ["a persistent cough", "PROBLEM", 47, 65], ["URI symptoms", "PROBLEM", 71, 83], ["disease", "OBSERVATION", 15, 22], ["persistent", "OBSERVATION_MODIFIER", 49, 59], ["cough", "OBSERVATION", 60, 65]]], ["This presentation is likely to be the one encountered in the training room.", [["likely to be", "UNCERTAINTY", 21, 33]]], ["Athletes may report a cough with a paroxysmal quality lasting more than 2 weeks, post-tussive emesis, or inspiratory whooping [50] .DiagnosisThe most reliable diagnostic test for pertussis is by detection of the organism from nasopharynx secretions.", [["nasopharynx secretions", "ANATOMY", 226, 248], ["cough", "DISEASE", 22, 27], ["emesis", "DISEASE", 94, 100], ["whooping", "DISEASE", 117, 125], ["pertussis", "DISEASE", 179, 188], ["pertussis", "ORGANISM", 179, 188], ["nasopharynx secretions", "ORGANISM_SUBSTANCE", 226, 248], ["pertussis", "SPECIES", 179, 188], ["a cough", "PROBLEM", 20, 27], ["a paroxysmal quality", "PROBLEM", 33, 53], ["post-tussive emesis", "PROBLEM", 81, 100], ["inspiratory whooping", "PROBLEM", 105, 125], ["diagnostic test", "TEST", 159, 174], ["pertussis", "PROBLEM", 179, 188], ["the organism from nasopharynx secretions", "PROBLEM", 208, 248], ["inspiratory", "ANATOMY", 105, 116], ["nasopharynx", "ANATOMY", 226, 237], ["secretions", "OBSERVATION", 238, 248]]], ["The sensitivity of this test, however, is estimated to be 25% to 50% [51] .", [["this test", "TEST", 19, 28]]], ["The most sensitive test (80%-100%) is polymerase chain reaction (PCR).", [["The most sensitive test", "TEST", 0, 23], ["polymerase chain reaction", "PROBLEM", 38, 63], ["PCR", "TEST", 65, 68]]], ["Although PCR is a rapid and highly specific test, there is not yet a universally accepted technique.", [["PCR", "TEST", 9, 12]]], ["Nasopharyngeal culture is therefore recommended to make the definitive diagnosis [52] .", [["Nasopharyngeal culture", "ANATOMY", 0, 22], ["Nasopharyngeal culture", "TEST", 0, 22]]], ["For best yield, the nasopharyngeal swab should be inserted into the base of the nostril and remain in the posterior pharynx for 10 seconds before being withdrawn [48] .", [["nasopharyngeal swab", "ANATOMY", 20, 39], ["nostril", "ANATOMY", 80, 87], ["posterior pharynx", "ANATOMY", 106, 123], ["nasopharyngeal swab", "ORGAN", 20, 39], ["nostril", "ORGAN", 80, 87], ["posterior pharynx", "ORGAN", 106, 123], ["the nasopharyngeal swab", "TREATMENT", 16, 39], ["nasopharyngeal", "ANATOMY", 20, 34], ["swab", "OBSERVATION", 35, 39], ["base", "ANATOMY_MODIFIER", 68, 72], ["nostril", "ANATOMY", 80, 87], ["posterior", "ANATOMY_MODIFIER", 106, 115], ["pharynx", "ANATOMY", 116, 123]]], ["The Centers for Disease Control and Prevention (CDC) recommends that physicians report and treat pertussis when there is clinical suspicion and not wait for laboratory confirmation [54] .TreatmentIn the case of proven or presumed infection, therapy should be started as soon as pertussis is suspected [28] .", [["pertussis", "DISEASE", 97, 106], ["infection", "DISEASE", 230, 239], ["pertussis", "DISEASE", 278, 287], ["pertussis", "SPECIES", 97, 106], ["Disease Control", "TREATMENT", 16, 31], ["pertussis", "PROBLEM", 97, 106], ["laboratory confirmation", "TEST", 157, 180], ["TreatmentIn", "TREATMENT", 187, 198], ["infection", "PROBLEM", 230, 239], ["therapy", "TREATMENT", 241, 248], ["pertussis", "PROBLEM", 278, 287], ["presumed", "UNCERTAINTY", 221, 229], ["infection", "OBSERVATION", 230, 239]]], ["The recommended treatment is 2 g/d of erythromycin in four divided doses for 14 days [55, 56] .", [["erythromycin", "CHEMICAL", 38, 50], ["erythromycin", "CHEMICAL", 38, 50], ["erythromycin", "SIMPLE_CHEMICAL", 38, 50], ["treatment", "TREATMENT", 16, 25], ["erythromycin", "TREATMENT", 38, 50]]], ["If the athlete is unable to tolerate erythromycin, then two alternative regimens have shown equal efficacy: azithromycin and clarithromycin [57, 58] .", [["erythromycin", "CHEMICAL", 37, 49], ["azithromycin", "CHEMICAL", 108, 120], ["clarithromycin", "CHEMICAL", 125, 139], ["erythromycin", "CHEMICAL", 37, 49], ["azithromycin", "CHEMICAL", 108, 120], ["clarithromycin", "CHEMICAL", 125, 139], ["erythromycin", "SIMPLE_CHEMICAL", 37, 49], ["azithromycin", "SIMPLE_CHEMICAL", 108, 120], ["clarithromycin", "SIMPLE_CHEMICAL", 125, 139], ["erythromycin", "TREATMENT", 37, 49], ["two alternative regimens", "TREATMENT", 56, 80], ["azithromycin", "TREATMENT", 108, 120], ["clarithromycin", "TREATMENT", 125, 139]]], ["Azithromycin dose for adults is 500 mg in a single dose on day 1 then 250 mg per day on days 2 through 5 [59] .", [["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["Azithromycin dose", "TREATMENT", 0, 17]]], ["Clarithromycin dose for adults is 1 g per day in two divided doses for 7 days [59] .", [["Clarithromycin", "CHEMICAL", 0, 14], ["Clarithromycin", "CHEMICAL", 0, 14], ["Clarithromycin", "SIMPLE_CHEMICAL", 0, 14], ["Clarithromycin dose", "TREATMENT", 0, 19]]], ["Trimethoprim-sulfamethoxazole is an additional option for those who cannot tolerate macrolides.", [["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["macrolides", "CHEMICAL", 84, 94], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["macrolides", "CHEMICAL", 84, 94], ["Trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 0, 29], ["macrolides", "SIMPLE_CHEMICAL", 84, 94], ["Trimethoprim", "TREATMENT", 0, 12], ["sulfamethoxazole", "TREATMENT", 13, 29], ["macrolides", "TREATMENT", 84, 94]]], ["Athletes who have confirmed or probable pertussis should be isolated for 5 days from the start of treatment [28] .PreventionBecause the vaccine and natural immunity wane with age, it is recommended to extend immunization with the tetanus toxoid-reduced diphtheria toxoidacellular pertussis (Tdap) vaccine to the adolescent population.", [["pertussis", "DISEASE", 40, 49], ["tetanus toxoid", "CHEMICAL", 230, 244], ["diphtheria toxoidacellular pertussis", "CHEMICAL", 253, 289], ["Tdap", "CHEMICAL", 291, 295], ["Athletes", "ORGANISM", 0, 8], ["tetanus toxoid", "ORGANISM", 230, 244], ["diphtheria toxoidacellular pertussis", "ORGANISM", 253, 289], ["Tdap", "ORGANISM", 291, 295], ["diphtheria toxoidacellular pertussis", "SPECIES", 253, 289], ["diphtheria toxoidacellular pertussis", "SPECIES", 253, 289], ["pertussis", "PROBLEM", 40, 49], ["treatment", "TREATMENT", 98, 107], ["the vaccine", "TREATMENT", 132, 143], ["immunization", "TREATMENT", 208, 220], ["the tetanus toxoid", "TREATMENT", 226, 244], ["reduced diphtheria toxoidacellular pertussis (Tdap) vaccine", "TREATMENT", 245, 304], ["probable", "UNCERTAINTY", 31, 39], ["pertussis", "OBSERVATION", 40, 49]]], ["The CDC recommends a single dose of the Tdap vaccine (0.5 mL intramuscularly) for 11-to 18-year-olds who require a booster dose, provided they have completed the recommended primary diphtheria-tetanus-pertussis vaccine series [60, 61] .", [["Tdap", "CHEMICAL", 40, 44], ["diphtheria-tetanus-pertussis", "CHEMICAL", 182, 210], ["diphtheria-tetanus-pertussis", "ORGANISM", 182, 210], ["diphtheria-tetanus-pertussis", "SPECIES", 182, 210], ["the Tdap vaccine", "TREATMENT", 36, 52], ["a booster dose", "TREATMENT", 113, 127], ["primary diphtheria-tetanus-pertussis vaccine", "TREATMENT", 174, 218]]], ["The Advisory Committee of Immunization Practice also recommends a single dose of the Tdap vaccine for adults 19 to 64 years of age [59, 61] .ProphylaxisAthletes known to be in close contact with a known or suspected case of pertussis should be given prophylactic antibiotic treatment.", [["pertussis", "DISEASE", 224, 233], ["pertussis", "SPECIES", 224, 233], ["Immunization Practice", "TREATMENT", 26, 47], ["the Tdap vaccine", "TREATMENT", 81, 97], ["ProphylaxisAthletes", "TREATMENT", 141, 160], ["pertussis", "PROBLEM", 224, 233], ["prophylactic antibiotic treatment", "TREATMENT", 250, 283]]], ["The recommended regimen is full dosing of erythromycin for 14 days [61] [62] [63] .", [["erythromycin", "CHEMICAL", 42, 54], ["erythromycin", "CHEMICAL", 42, 54], ["erythromycin", "SIMPLE_CHEMICAL", 42, 54], ["The recommended regimen", "TREATMENT", 0, 23], ["erythromycin", "TREATMENT", 42, 54]]], ["If erythromycin cannot be tolerated, then a 5-day course of azithromycin is acceptable [61] .ComplicationsPertussis infections in the training room can lead to rapidly spreading illness among other athletes and staff.", [["erythromycin", "CHEMICAL", 3, 15], ["azithromycin", "CHEMICAL", 60, 72], ["Pertussis infections", "DISEASE", 106, 126], ["illness", "DISEASE", 178, 185], ["erythromycin", "CHEMICAL", 3, 15], ["azithromycin", "CHEMICAL", 60, 72], ["erythromycin", "SIMPLE_CHEMICAL", 3, 15], ["azithromycin", "SIMPLE_CHEMICAL", 60, 72], ["erythromycin", "TREATMENT", 3, 15], ["azithromycin", "TREATMENT", 60, 72], ["ComplicationsPertussis infections", "PROBLEM", 93, 126], ["infections", "OBSERVATION", 116, 126]]], ["Pertussis can also cause reactive airway disease and bronchitis.", [["airway", "ANATOMY", 34, 40], ["Pertussis", "DISEASE", 0, 9], ["reactive airway disease", "DISEASE", 25, 48], ["bronchitis", "DISEASE", 53, 63], ["airway", "ORGAN", 34, 40], ["Pertussis", "PROBLEM", 0, 9], ["reactive airway disease", "PROBLEM", 25, 48], ["bronchitis", "PROBLEM", 53, 63], ["can also cause", "UNCERTAINTY", 10, 24], ["reactive airway disease", "OBSERVATION", 25, 48], ["bronchitis", "OBSERVATION", 53, 63]]], ["Pertussis can be complicated by pneumonia, dehydration, weight loss, and sleep disturbance-all which can affect an athlete's return-toplay status and overall performance [33] .Return to PlayAthletes who have confirmed or probable pertussis should be isolated for 5 days from the start of treatment to prevent spreading the disease [28] .", [["Pertussis", "DISEASE", 0, 9], ["pneumonia", "DISEASE", 32, 41], ["dehydration", "DISEASE", 43, 54], ["weight loss", "DISEASE", 56, 67], ["sleep disturbance", "DISEASE", 73, 90], ["pertussis", "DISEASE", 230, 239], ["Pertussis", "PROBLEM", 0, 9], ["pneumonia", "PROBLEM", 32, 41], ["dehydration", "PROBLEM", 43, 54], ["weight loss", "PROBLEM", 56, 67], ["sleep disturbance", "PROBLEM", 73, 90], ["pertussis", "PROBLEM", 230, 239], ["treatment", "TREATMENT", 288, 297], ["spreading the disease", "PROBLEM", 309, 330], ["pneumonia", "OBSERVATION", 32, 41], ["dehydration", "OBSERVATION", 43, 54], ["weight loss", "OBSERVATION", 56, 67]]], ["When reactive airway disease is involved, those symptoms should also addressed, as noted in the bronchitis section.INFLUENZAInfluenza is an acute respiratory illness cause by influenza A or B viruses.", [["airway", "ANATOMY", 14, 20], ["respiratory", "ANATOMY", 146, 157], ["airway disease", "DISEASE", 14, 28], ["bronchitis", "DISEASE", 96, 106], ["INFLUENZAInfluenza", "CHEMICAL", 115, 133], ["respiratory illness", "DISEASE", 146, 165], ["influenza A or B viruses", "DISEASE", 175, 199], ["airway", "MULTI-TISSUE_STRUCTURE", 14, 20], ["influenza A", "ORGANISM", 175, 186], ["B viruses", "ORGANISM", 190, 199], ["B viruses", "SPECIES", 190, 199], ["reactive airway disease", "PROBLEM", 5, 28], ["those symptoms", "PROBLEM", 42, 56], ["the bronchitis section", "TREATMENT", 92, 114], ["an acute respiratory illness", "PROBLEM", 137, 165], ["influenza A", "PROBLEM", 175, 186], ["B viruses", "PROBLEM", 190, 199], ["reactive", "OBSERVATION_MODIFIER", 5, 13], ["airway", "ANATOMY", 14, 20], ["disease", "OBSERVATION", 21, 28], ["bronchitis", "OBSERVATION", 96, 106], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory illness", "OBSERVATION", 146, 165], ["influenza", "OBSERVATION", 175, 184]]], ["Influenza is a common seasonal cause of acute bronchitis [41] .Clinical PresentationThe diagnosis of influenza should be considered if the athlete presents during the winter months with the abrupt onset of fever, headache, myalgias, malaise, nausea, and vomiting.", [["Influenza", "DISEASE", 0, 9], ["bronchitis", "DISEASE", 46, 56], ["influenza", "DISEASE", 101, 110], ["fever", "DISEASE", 206, 211], ["headache", "DISEASE", 213, 221], ["myalgias", "DISEASE", 223, 231], ["nausea", "DISEASE", 242, 248], ["vomiting", "DISEASE", 254, 262], ["influenza", "ORGANISM", 101, 110], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["acute bronchitis", "PROBLEM", 40, 56], ["influenza", "PROBLEM", 101, 110], ["fever", "PROBLEM", 206, 211], ["headache", "PROBLEM", 213, 221], ["myalgias", "PROBLEM", 223, 231], ["malaise", "PROBLEM", 233, 240], ["nausea", "PROBLEM", 242, 248], ["vomiting", "PROBLEM", 254, 262], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["bronchitis", "OBSERVATION", 46, 56], ["influenza", "OBSERVATION", 101, 110], ["fever", "OBSERVATION", 206, 211]]], ["These symptoms are generally accompanied by cough and sore throat [64] [65] [66] [67] .Clinical PresentationIn uncomplicated influenza, there are few physical examination findings.", [["cough", "DISEASE", 44, 49], ["sore", "DISEASE", 54, 58], ["influenza", "DISEASE", 125, 134], ["These symptoms", "PROBLEM", 0, 14], ["cough", "PROBLEM", 44, 49], ["sore throat", "PROBLEM", 54, 65], ["Clinical PresentationIn uncomplicated influenza", "PROBLEM", 87, 134], ["few physical examination findings", "TEST", 146, 179], ["uncomplicated", "OBSERVATION_MODIFIER", 111, 124], ["influenza", "OBSERVATION", 125, 134], ["few", "OBSERVATION_MODIFIER", 146, 149]]], ["The health care provider in the training room should document vital signs.", [["vital signs", "TEST", 62, 73]]], ["The patient may appear flushed.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["flushed", "OBSERVATION", 23, 30]]], ["The findings may also include mild cervical lymphadenopathy and hyperemic oropharynx.", [["cervical", "ANATOMY", 35, 43], ["oropharynx", "ANATOMY", 74, 84], ["lymphadenopathy", "DISEASE", 44, 59], ["cervical lymphadenopathy", "PATHOLOGICAL_FORMATION", 35, 59], ["oropharynx", "ORGAN", 74, 84], ["mild cervical lymphadenopathy", "PROBLEM", 30, 59], ["hyperemic oropharynx", "PROBLEM", 64, 84], ["may also include", "UNCERTAINTY", 13, 29], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["cervical", "ANATOMY", 35, 43], ["lymphadenopathy", "OBSERVATION", 44, 59], ["hyperemic", "OBSERVATION_MODIFIER", 64, 73], ["oropharynx", "ANATOMY", 74, 84]]], ["The eyes may be watery or reddened [68] .", [["eyes", "ANATOMY", 4, 8], ["watery", "DISEASE", 16, 22], ["eyes", "ORGAN", 4, 8], ["watery", "PROBLEM", 16, 22], ["reddened", "PROBLEM", 26, 34], ["eyes", "ANATOMY", 4, 8], ["may be", "UNCERTAINTY", 9, 15], ["watery", "OBSERVATION", 16, 22], ["reddened", "OBSERVATION", 26, 34]]], ["Otherwise, the examination may be unremarkable.", [["the examination", "TEST", 11, 26], ["may be", "UNCERTAINTY", 27, 33], ["unremarkable", "OBSERVATION", 34, 46]]], ["It is important to assess the athlete's hydration status and neurologic status on examination.DiagnosisOutpatient laboratory diagnosis of influenza can be accomplished by the detection of the virus or viral antigen in nasal washes or throat swabs [69] .", [["neurologic", "ANATOMY", 61, 71], ["nasal", "ANATOMY", 218, 223], ["influenza", "DISEASE", 138, 147], ["nasal", "ORGANISM_SUBDIVISION", 218, 223], ["viral antigen", "PROTEIN", 201, 214], ["examination", "TEST", 82, 93], ["influenza", "PROBLEM", 138, 147], ["the virus", "PROBLEM", 188, 197], ["viral antigen", "PROBLEM", 201, 214], ["nasal washes", "TREATMENT", 218, 230], ["throat swabs", "PROBLEM", 234, 246]]], ["The virus may also be detected from sputum samples [68] .", [["sputum samples", "ANATOMY", 36, 50], ["sputum samples", "ORGANISM_SUBSTANCE", 36, 50], ["The virus", "PROBLEM", 0, 9], ["sputum samples", "TEST", 36, 50], ["virus", "OBSERVATION", 4, 9], ["may also be", "UNCERTAINTY", 10, 21]]], ["Rapid viral diagnostic tests are available for the ambulatory setting.TreatmentTwo classes of antiviral drugs are available for the treatment of influenza [70, 71] .", [["influenza", "DISEASE", 145, 154], ["Rapid viral diagnostic tests", "TEST", 0, 28], ["Treatment", "TREATMENT", 70, 79], ["antiviral drugs", "TREATMENT", 94, 109], ["influenza", "PROBLEM", 145, 154]]], ["The neuraminidase inhibitors zanamivir and oseltamivir are active against influenza A and influenza B. The M2 inhibitors amantadine and rimantidine are active against influenza A only [71] .", [["zanamivir", "CHEMICAL", 29, 38], ["oseltamivir", "CHEMICAL", 43, 54], ["influenza A", "DISEASE", 74, 85], ["amantadine", "CHEMICAL", 121, 131], ["rimantidine", "CHEMICAL", 136, 147], ["influenza A", "DISEASE", 167, 178], ["zanamivir", "CHEMICAL", 29, 38], ["oseltamivir", "CHEMICAL", 43, 54], ["amantadine", "CHEMICAL", 121, 131], ["rimantidine", "CHEMICAL", 136, 147], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 4, 17], ["zanamivir", "SIMPLE_CHEMICAL", 29, 38], ["oseltamivir", "SIMPLE_CHEMICAL", 43, 54], ["influenza A", "ORGANISM", 74, 85], ["influenza B.", "ORGANISM", 90, 102], ["M2", "GENE_OR_GENE_PRODUCT", 107, 109], ["amantadine", "SIMPLE_CHEMICAL", 121, 131], ["rimantidine", "SIMPLE_CHEMICAL", 136, 147], ["influenza A", "ORGANISM", 167, 178], ["influenza A", "SPECIES", 74, 85], ["The neuraminidase inhibitors zanamivir", "TREATMENT", 0, 38], ["oseltamivir", "TREATMENT", 43, 54], ["influenza", "PROBLEM", 74, 83], ["influenza B.", "TREATMENT", 90, 102], ["The M2 inhibitors amantadine", "TREATMENT", 103, 131], ["rimantidine", "TREATMENT", 136, 147], ["influenza", "PROBLEM", 167, 176]]], ["The maximum benefit of treatment is available if given within the first 24 to 30 hours of symptoms and in patients who have fever at the time of presentation [72] [73] [74] .", [["fever", "DISEASE", 124, 129], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["treatment", "TREATMENT", 23, 32], ["symptoms", "PROBLEM", 90, 98], ["fever", "PROBLEM", 124, 129]]], ["With appropriate treatment, the patient may have 2 to 3 days' shortening of the duration of symptoms [71] .TreatmentSymptomatic treatment is also important in influenza.", [["influenza", "DISEASE", 159, 168], ["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["appropriate treatment", "TREATMENT", 5, 26], ["symptoms", "PROBLEM", 92, 100], ["TreatmentSymptomatic treatment", "TREATMENT", 107, 137], ["influenza", "PROBLEM", 159, 168]]], ["Acetaminophen or ibuprofen may be beneficial for fever, headache, or myalgias.", [["Acetaminophen", "CHEMICAL", 0, 13], ["ibuprofen", "CHEMICAL", 17, 26], ["fever", "DISEASE", 49, 54], ["headache", "DISEASE", 56, 64], ["myalgias", "DISEASE", 69, 77], ["Acetaminophen", "CHEMICAL", 0, 13], ["ibuprofen", "CHEMICAL", 17, 26], ["Acetaminophen", "SIMPLE_CHEMICAL", 0, 13], ["ibuprofen", "SIMPLE_CHEMICAL", 17, 26], ["Acetaminophen", "TREATMENT", 0, 13], ["ibuprofen", "TREATMENT", 17, 26], ["fever", "PROBLEM", 49, 54], ["headache", "PROBLEM", 56, 64], ["myalgias", "PROBLEM", 69, 77]]], ["The use of aspirin in pediatric patients who have influenza should be avoided due to the risk of Reye's syndrome in this population [75] .", [["aspirin", "CHEMICAL", 11, 18], ["influenza", "DISEASE", 50, 59], ["Reye's syndrome", "DISEASE", 97, 112], ["aspirin", "CHEMICAL", 11, 18], ["aspirin", "SIMPLE_CHEMICAL", 11, 18], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["aspirin", "TREATMENT", 11, 18], ["influenza", "PROBLEM", 50, 59], ["Reye's syndrome", "PROBLEM", 97, 112]]], ["Cough suppressants may be helpful in the appropriate clinical scenario.", [["Cough suppressants", "TREATMENT", 0, 18]]], ["The athlete may also benefit from inhaled bronchodilator therapy if bronchial hyper-responsiveness and decreased FEV 1 are present [33] .", [["bronchial", "ANATOMY", 68, 77], ["FEV 1", "GENE_OR_GENE_PRODUCT", 113, 118], ["inhaled bronchodilator therapy", "TREATMENT", 34, 64], ["bronchial hyper-responsiveness", "PROBLEM", 68, 98], ["decreased FEV", "PROBLEM", 103, 116]]], ["Athletes should be instructed to maintain proper hydration and rest during the acute illness.ComplicationsClose follow-up of athletes who have severe influenza illnesses is imperative to ensure that no complications are arising.", [["influenza illnesses", "DISEASE", 150, 169], ["Athletes", "TREATMENT", 0, 8], ["proper hydration", "TREATMENT", 42, 58], ["the acute illness", "PROBLEM", 75, 92], ["severe influenza illnesses", "PROBLEM", 143, 169], ["complications", "PROBLEM", 202, 215], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["illness", "OBSERVATION", 85, 92], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["influenza", "OBSERVATION", 150, 159]]], ["Dehydration and acute bronchitis are common complications of influenza [68] .", [["Dehydration", "DISEASE", 0, 11], ["bronchitis", "DISEASE", 22, 32], ["influenza", "DISEASE", 61, 70], ["Dehydration", "PROBLEM", 0, 11], ["acute bronchitis", "PROBLEM", 16, 32], ["influenza", "PROBLEM", 61, 70], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["bronchitis", "OBSERVATION", 22, 32]]], ["Although rare, complications of influenza include pneumonia, myositis, rhabdomyolysis, myocarditis, encephalitis, meningitis, and Guillain-Barr\u00e9 syndrome [76] .PreventionThere are measures available to help prevent the illness caused by influenza.", [["influenza", "DISEASE", 32, 41], ["pneumonia", "DISEASE", 50, 59], ["myositis", "DISEASE", 61, 69], ["rhabdomyolysis", "DISEASE", 71, 85], ["myocarditis", "DISEASE", 87, 98], ["encephalitis", "DISEASE", 100, 112], ["meningitis", "DISEASE", 114, 124], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 130, 153], ["illness", "DISEASE", 219, 226], ["influenza", "DISEASE", 237, 246], ["Guillain-Barr\u00e9", "ORGANISM", 130, 144], ["influenza", "PROBLEM", 32, 41], ["pneumonia", "PROBLEM", 50, 59], ["myositis", "PROBLEM", 61, 69], ["rhabdomyolysis", "PROBLEM", 71, 85], ["myocarditis", "PROBLEM", 87, 98], ["encephalitis", "PROBLEM", 100, 112], ["meningitis", "PROBLEM", 114, 124], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 130, 153], ["the illness", "PROBLEM", 215, 226], ["influenza", "PROBLEM", 237, 246], ["influenza", "OBSERVATION", 32, 41], ["pneumonia", "OBSERVATION", 50, 59], ["myositis", "OBSERVATION", 61, 69], ["rhabdomyolysis", "OBSERVATION", 71, 85], ["myocarditis", "OBSERVATION", 87, 98], ["encephalitis", "OBSERVATION", 100, 112], ["meningitis", "OBSERVATION", 114, 124], ["Barr\u00e9 syndrome", "OBSERVATION", 139, 153], ["influenza", "OBSERVATION", 237, 246]]], ["Annual vaccination is available.", [["Annual vaccination", "TREATMENT", 0, 18]]], ["The currently available injectable vaccines are inactivated preparations of whole virus or split product.", [["The currently available injectable vaccines", "TREATMENT", 0, 43], ["whole virus", "PROBLEM", 76, 87]]], ["The whole virus vaccine is not available in the United States [72] .", [["The whole virus vaccine", "TREATMENT", 0, 23]]], ["The United States has also made an intranasal live-attenuated vaccine available for healthy patients aged 5 to 49 years [77] .", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["Although athletes are not on the CDC target-group list for vaccination, vaccination can be important tool to reduce the number of cases in training rooms.Return to PlayTo prevent the spread of influenza, the athlete should be kept from the training room, practices, and competitions until 5 days after the onset of symptoms.", [["influenza", "DISEASE", 193, 202], ["vaccination", "TREATMENT", 59, 70], ["vaccination", "TREATMENT", 72, 83], ["PlayTo", "TREATMENT", 164, 170], ["influenza", "PROBLEM", 193, 202], ["symptoms", "PROBLEM", 315, 323], ["influenza", "OBSERVATION", 193, 202]]], ["Return to full activity should be delayed until the illness has fully resolved.", [["the illness", "PROBLEM", 48, 59]]], ["Athletes should be evaluated for any signs of fever, dehydration, or impaired respiratory status before full clearance.MYOCARDITISMyocarditis is an inflammatory disease of the cardiac muscle that can have a wide spectrum of clinical presentations and outcomes.", [["respiratory", "ANATOMY", 78, 89], ["cardiac muscle", "ANATOMY", 176, 190], ["fever", "DISEASE", 46, 51], ["dehydration", "DISEASE", 53, 64], ["MYOCARDITISMyocarditis", "CHEMICAL", 119, 141], ["cardiac muscle", "DISEASE", 176, 190], ["cardiac muscle", "TISSUE", 176, 190], ["fever", "PROBLEM", 46, 51], ["dehydration", "PROBLEM", 53, 64], ["impaired respiratory status", "PROBLEM", 69, 96], ["MYOCARDITISMyocarditis", "PROBLEM", 119, 141], ["an inflammatory disease of the cardiac muscle", "PROBLEM", 145, 190], ["fever", "OBSERVATION", 46, 51], ["inflammatory", "OBSERVATION", 148, 160], ["cardiac muscle", "ANATOMY", 176, 190]]], ["Myocarditis is one of the most challenging diagnoses in cardiology.", [["Myocarditis", "DISEASE", 0, 11], ["Myocarditis", "PROBLEM", 0, 11]]], ["Acute myocarditis can progress to dilated cardiomyopathy, heart failure, arrhythmias, and death [78] .", [["heart", "ANATOMY", 58, 63], ["myocarditis", "DISEASE", 6, 17], ["dilated cardiomyopathy", "DISEASE", 34, 56], ["heart failure", "DISEASE", 58, 71], ["arrhythmias", "DISEASE", 73, 84], ["death", "DISEASE", 90, 95], ["heart", "ORGAN", 58, 63], ["Acute myocarditis", "PROBLEM", 0, 17], ["dilated cardiomyopathy", "PROBLEM", 34, 56], ["heart failure", "PROBLEM", 58, 71], ["arrhythmias", "PROBLEM", 73, 84], ["death", "PROBLEM", 90, 95], ["myocarditis", "OBSERVATION", 6, 17], ["dilated", "OBSERVATION_MODIFIER", 34, 41], ["cardiomyopathy", "OBSERVATION", 42, 56], ["heart", "ANATOMY", 58, 63], ["failure", "OBSERVATION", 64, 71], ["arrhythmias", "OBSERVATION", 73, 84]]], ["If unrecognized in the training room, myocarditis can produce lethal results.CausesMyocarditis has a wide variety of infectious and noninfectious causes.", [["myocarditis", "DISEASE", 38, 49], ["Myocarditis", "DISEASE", 83, 94], ["myocarditis", "PROBLEM", 38, 49], ["Myocarditis", "PROBLEM", 83, 94], ["infectious and noninfectious causes", "PROBLEM", 117, 152], ["myocarditis", "OBSERVATION", 38, 49], ["Myocarditis", "OBSERVATION", 83, 94], ["wide", "OBSERVATION_MODIFIER", 101, 105], ["variety", "OBSERVATION_MODIFIER", 106, 113], ["infectious", "OBSERVATION", 117, 127], ["noninfectious", "OBSERVATION_MODIFIER", 132, 145]]], ["The most common infectious causes are viruses.", [["viruses", "PROBLEM", 38, 45], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infectious", "OBSERVATION", 16, 26], ["viruses", "OBSERVATION", 38, 45]]], ["The most frequently associated viruses are coxsackievirus B, adenovirus, hepatitis C virus, cytomegalovirus, echovirus, influenza virus, and EBV.", [["coxsackievirus B", "DISEASE", 43, 59], ["hepatitis C virus", "DISEASE", 73, 90], ["cytomegalovirus, echovirus, influenza virus", "DISEASE", 92, 135], ["coxsackievirus B", "ORGANISM", 43, 59], ["adenovirus,", "ORGANISM", 61, 72], ["hepatitis C virus", "ORGANISM", 73, 90], ["cytomegalovirus", "ORGANISM", 92, 107], ["echovirus", "ORGANISM", 109, 118], ["influenza virus", "ORGANISM", 120, 135], ["EBV", "ORGANISM", 141, 144], ["coxsackievirus B", "SPECIES", 43, 59], ["hepatitis C virus", "SPECIES", 73, 90], ["influenza virus", "SPECIES", 120, 135], ["coxsackievirus B", "SPECIES", 43, 59], ["hepatitis C virus", "SPECIES", 73, 90], ["EBV", "SPECIES", 141, 144], ["The most frequently associated viruses", "PROBLEM", 0, 38], ["coxsackievirus B", "PROBLEM", 43, 59], ["adenovirus", "PROBLEM", 61, 71], ["hepatitis C virus", "PROBLEM", 73, 90], ["cytomegalovirus", "PROBLEM", 92, 107], ["echovirus", "PROBLEM", 109, 118], ["influenza virus", "PROBLEM", 120, 135], ["EBV", "PROBLEM", 141, 144], ["viruses", "OBSERVATION", 31, 38], ["coxsackievirus", "OBSERVATION", 43, 57], ["hepatitis", "ANATOMY", 73, 82], ["cytomegalovirus", "OBSERVATION", 92, 107]]], ["The most common causes of myocarditis found in the training room are likely viral illnesses, especially coxsackievirus B, adenovirus, and echovirus [79] .", [["myocarditis", "DISEASE", 26, 37], ["viral illnesses", "DISEASE", 76, 91], ["coxsackievirus B", "DISEASE", 104, 120], ["echovirus", "DISEASE", 138, 147], ["coxsackievirus B", "ORGANISM", 104, 120], ["adenovirus", "ORGANISM", 122, 132], ["coxsackievirus B", "SPECIES", 104, 120], ["adenovirus", "SPECIES", 122, 132], ["myocarditis", "PROBLEM", 26, 37], ["viral illnesses", "PROBLEM", 76, 91], ["coxsackievirus B", "PROBLEM", 104, 120], ["adenovirus", "PROBLEM", 122, 132], ["echovirus", "PROBLEM", 138, 147], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["myocarditis", "OBSERVATION", 26, 37], ["likely", "UNCERTAINTY", 69, 75], ["viral illnesses", "OBSERVATION", 76, 91]]], ["Myocarditis can also result from drug hypersensitivity, radiation, and chemical or physical agents [80, 81] .Clinical PresentationThe diagnosis of myocarditis requires a high index of suspicion in the appropriate clinical setting [79] .", [["Myocarditis", "DISEASE", 0, 11], ["drug hypersensitivity", "DISEASE", 33, 54], ["myocarditis", "DISEASE", 147, 158], ["Myocarditis", "PROBLEM", 0, 11], ["drug hypersensitivity", "PROBLEM", 33, 54], ["radiation", "TREATMENT", 56, 65], ["myocarditis", "PROBLEM", 147, 158], ["myocarditis", "OBSERVATION", 147, 158], ["high index", "OBSERVATION_MODIFIER", 170, 180]]], ["A wide range of symptoms can be present in an athlete suffering from myocarditis.", [["myocarditis", "DISEASE", 69, 80], ["A wide range of symptoms", "PROBLEM", 0, 24], ["myocarditis", "PROBLEM", 69, 80], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["myocarditis", "OBSERVATION", 69, 80]]], ["The patient may be asymptomatic or may simply give a history of a preceding URI or flu-like syndrome.", [["flu-like syndrome", "DISEASE", 83, 100], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["asymptomatic", "PROBLEM", 19, 31], ["a preceding URI", "PROBLEM", 64, 79], ["flu-like syndrome", "PROBLEM", 83, 100], ["URI", "OBSERVATION", 76, 79], ["flu", "OBSERVATION", 83, 86]]], ["The patient may also present with chest pain or symptoms of heart failure [78, 79] .", [["chest", "ANATOMY", 34, 39], ["heart", "ANATOMY", 60, 65], ["chest pain", "DISEASE", 34, 44], ["heart failure", "DISEASE", 60, 73], ["patient", "ORGANISM", 4, 11], ["chest", "ORGANISM_SUBDIVISION", 34, 39], ["heart", "ORGAN", 60, 65], ["patient", "SPECIES", 4, 11], ["chest pain", "PROBLEM", 34, 44], ["symptoms", "PROBLEM", 48, 56], ["heart failure", "PROBLEM", 60, 73], ["chest", "ANATOMY", 34, 39], ["heart", "ANATOMY", 60, 65], ["failure", "OBSERVATION", 66, 73]]], ["The athlete may present with fever, malaise, and arthralgias [82] .", [["fever", "DISEASE", 29, 34], ["arthralgias", "DISEASE", 49, 60], ["fever", "PROBLEM", 29, 34], ["malaise", "PROBLEM", 36, 43], ["arthralgias", "PROBLEM", 49, 60]]], ["The diagnosis of infective myocarditis should be considered when an athlete presents with cardiac complaints or arrhythmia issues in the course of a recognized systemic infection.Clinical PresentationIt is imperative to document vital signs in the training room.", [["cardiac", "ANATOMY", 90, 97], ["infective myocarditis", "DISEASE", 17, 38], ["cardiac complaints", "DISEASE", 90, 108], ["arrhythmia", "DISEASE", 112, 122], ["systemic infection", "DISEASE", 160, 178], ["cardiac", "ORGAN", 90, 97], ["infective myocarditis", "PROBLEM", 17, 38], ["cardiac complaints", "PROBLEM", 90, 108], ["arrhythmia issues", "PROBLEM", 112, 129], ["a recognized systemic infection", "PROBLEM", 147, 178], ["vital signs", "TEST", 229, 240], ["infective", "OBSERVATION_MODIFIER", 17, 26], ["myocarditis", "OBSERVATION", 27, 38], ["systemic", "OBSERVATION_MODIFIER", 160, 168], ["infection", "OBSERVATION", 169, 178]]], ["The physical examination may be normal.", [["The physical examination", "TEST", 0, 24], ["may be", "UNCERTAINTY", 25, 31], ["normal", "OBSERVATION", 32, 38]]], ["When the myocarditis is severe, the cardiac examination may reveal tachycardia, a muffled first heart sound along with a third heart sound, and a murmur of mitral regurgitation (MR).", [["cardiac", "ANATOMY", 36, 43], ["heart", "ANATOMY", 96, 101], ["heart", "ANATOMY", 127, 132], ["mitral", "ANATOMY", 156, 162], ["myocarditis", "DISEASE", 9, 20], ["tachycardia", "DISEASE", 67, 78], ["mitral regurgitation", "DISEASE", 156, 176], ["MR", "DISEASE", 178, 180], ["cardiac", "ORGAN", 36, 43], ["heart", "ORGAN", 96, 101], ["heart", "ORGAN", 127, 132], ["mitral regurgitation", "PATHOLOGICAL_FORMATION", 156, 176], ["the myocarditis", "PROBLEM", 5, 20], ["the cardiac examination", "TEST", 32, 55], ["tachycardia", "PROBLEM", 67, 78], ["a muffled first heart sound", "PROBLEM", 80, 107], ["a third heart sound", "PROBLEM", 119, 138], ["a murmur of mitral regurgitation", "PROBLEM", 144, 176], ["myocarditis", "OBSERVATION", 9, 20], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["tachycardia", "OBSERVATION", 67, 78], ["heart", "ANATOMY", 127, 132], ["sound", "OBSERVATION", 133, 138], ["murmur", "OBSERVATION", 146, 152], ["mitral", "ANATOMY", 156, 162], ["regurgitation", "OBSERVATION", 163, 176]]], ["The examination may also reveal findings of heart failure such as edema and pulmonary crackles from fluid overload, depending on the severity of the illness.", [["heart", "ANATOMY", 44, 49], ["edema", "ANATOMY", 66, 71], ["pulmonary", "ANATOMY", 76, 85], ["fluid", "ANATOMY", 100, 105], ["heart failure", "DISEASE", 44, 57], ["edema", "DISEASE", 66, 71], ["fluid overload", "DISEASE", 100, 114], ["heart", "ORGAN", 44, 49], ["edema", "PATHOLOGICAL_FORMATION", 66, 71], ["pulmonary", "ORGAN", 76, 85], ["fluid", "ORGANISM_SUBSTANCE", 100, 105], ["The examination", "TEST", 0, 15], ["heart failure", "PROBLEM", 44, 57], ["edema", "PROBLEM", 66, 71], ["pulmonary crackles", "PROBLEM", 76, 94], ["fluid overload", "PROBLEM", 100, 114], ["the illness", "PROBLEM", 145, 156], ["heart", "ANATOMY", 44, 49], ["failure", "OBSERVATION", 50, 57], ["edema", "OBSERVATION", 66, 71], ["pulmonary", "ANATOMY", 76, 85], ["crackles", "OBSERVATION", 86, 94], ["fluid overload", "OBSERVATION", 100, 114], ["illness", "OBSERVATION", 149, 156]]], ["When there is associated pericarditis, a pericardial friction rub may be heard [78, 79] .", [["pericardial", "ANATOMY", 41, 52], ["pericarditis", "DISEASE", 25, 37], ["associated pericarditis", "PROBLEM", 14, 37], ["a pericardial friction rub", "PROBLEM", 39, 65], ["pericarditis", "OBSERVATION", 25, 37], ["pericardial", "ANATOMY", 41, 52], ["friction rub", "OBSERVATION", 53, 65]]], ["The examination may also reveal findings consistent with a URI.DiagnosisRoutine blood and urine laboratory tests are generally normal in myocarditis.", [["blood", "ANATOMY", 80, 85], ["urine", "ANATOMY", 90, 95], ["URI", "DISEASE", 59, 62], ["myocarditis", "DISEASE", 137, 148], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["The examination", "TEST", 0, 15], ["a URI", "PROBLEM", 57, 62], ["DiagnosisRoutine blood", "TEST", 63, 85], ["urine laboratory tests", "TEST", 90, 112], ["myocarditis", "PROBLEM", 137, 148], ["consistent with", "UNCERTAINTY", 41, 56], ["URI", "OBSERVATION", 59, 62], ["normal", "OBSERVATION", 127, 133], ["myocarditis", "OBSERVATION", 137, 148]]], ["Cardiac enzymes may be elevated, specifically the Myoglobin binding (MB) fraction of creatine kinase (CK-MB) and troponin I [83, 84] .", [["Cardiac", "ANATOMY", 0, 7], ["creatine", "CHEMICAL", 85, 93], ["creatine", "CHEMICAL", 85, 93], ["Cardiac", "ORGAN", 0, 7], ["Myoglobin", "GENE_OR_GENE_PRODUCT", 50, 59], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 85, 100], ["CK-MB", "GENE_OR_GENE_PRODUCT", 102, 107], ["troponin I", "GENE_OR_GENE_PRODUCT", 113, 123], ["Myoglobin binding (MB) fraction", "PROTEIN", 50, 81], ["creatine kinase", "PROTEIN", 85, 100], ["CK", "PROTEIN", 102, 104], ["troponin I", "PROTEIN", 113, 123], ["Cardiac enzymes", "TEST", 0, 15], ["elevated", "PROBLEM", 23, 31], ["the Myoglobin binding", "TEST", 46, 67], ["creatine kinase", "TEST", 85, 100], ["CK-MB", "TEST", 102, 107], ["troponin I", "TEST", 113, 123]]], ["The EKG may be normal or abnormal.", [["The EKG", "TEST", 0, 7], ["normal", "OBSERVATION", 15, 21], ["abnormal", "OBSERVATION_MODIFIER", 25, 33]]], ["The most common EKG findings are transient, nonspecific ST-T wave abnormalities.", [["nonspecific ST-T wave abnormalities", "PROBLEM", 44, 79], ["transient", "OBSERVATION_MODIFIER", 33, 42], ["nonspecific", "OBSERVATION_MODIFIER", 44, 55]]], ["Chest radiograph findings range from normal to cardiomegaly.", [["cardiomegaly", "DISEASE", 47, 59], ["Chest radiograph", "TEST", 0, 16], ["cardiomegaly", "PROBLEM", 47, 59], ["normal", "OBSERVATION", 37, 43], ["cardiomegaly", "OBSERVATION", 47, 59]]], ["Pulmonary vascular congestion and edema may be exhibited in severe cases.", [["Pulmonary vascular", "ANATOMY", 0, 18], ["edema", "ANATOMY", 34, 39], ["Pulmonary vascular congestion", "DISEASE", 0, 29], ["edema", "DISEASE", 34, 39], ["Pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 0, 18], ["edema", "PATHOLOGICAL_FORMATION", 34, 39], ["Pulmonary vascular congestion", "PROBLEM", 0, 29], ["edema", "PROBLEM", 34, 39], ["vascular", "ANATOMY", 10, 18], ["congestion", "OBSERVATION", 19, 29], ["edema", "OBSERVATION", 34, 39], ["severe", "OBSERVATION_MODIFIER", 60, 66]]], ["One of the cardinal features of myocarditis can be found on echocardiography.", [["myocarditis", "DISEASE", 32, 43], ["myocarditis", "PROBLEM", 32, 43], ["echocardiography", "TEST", 60, 76], ["myocarditis", "OBSERVATION", 32, 43]]], ["Echocardiography may reveal decreased ventricular function.", [["ventricular", "ANATOMY", 38, 49], ["ventricular", "MULTI-TISSUE_STRUCTURE", 38, 49], ["Echocardiography", "TEST", 0, 16], ["decreased ventricular function", "PROBLEM", 28, 58], ["decreased", "OBSERVATION", 28, 37], ["ventricular function", "OBSERVATION", 38, 58]]], ["The ventricular dysfunction is generally global.", [["ventricular", "ANATOMY", 4, 15], ["ventricular dysfunction", "DISEASE", 4, 27], ["ventricular", "MULTI-TISSUE_STRUCTURE", 4, 15], ["The ventricular dysfunction", "PROBLEM", 0, 27], ["ventricular", "ANATOMY", 4, 15], ["dysfunction", "OBSERVATION", 16, 27], ["generally", "OBSERVATION_MODIFIER", 31, 40], ["global", "OBSERVATION_MODIFIER", 41, 47]]], ["Impairment of myocardial contractility may be evident on exercise-induced echocardiogram views.", [["myocardial", "ANATOMY", 14, 24], ["myocardial", "MULTI-TISSUE_STRUCTURE", 14, 24], ["Impairment of myocardial contractility", "PROBLEM", 0, 38], ["echocardiogram views", "TEST", 74, 94], ["myocardial", "ANATOMY", 14, 24], ["contractility", "OBSERVATION", 25, 38]]], ["Echocardiography may also reveal increased left ventricular (LV) diastolic dimensions with normal septal thickness [85] .DiagnosisCardiac MRI is becoming a more widely available tool to detect myocardial abnormalities.", [["left ventricular", "ANATOMY", 43, 59], ["LV", "ANATOMY", 61, 63], ["septal", "ANATOMY", 98, 104], ["myocardial", "ANATOMY", 193, 203], ["myocardial abnormalities", "DISEASE", 193, 217], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 43, 59], ["LV", "MULTI-TISSUE_STRUCTURE", 61, 63], ["septal", "MULTI-TISSUE_STRUCTURE", 98, 104], ["myocardial", "MULTI-TISSUE_STRUCTURE", 193, 203], ["Echocardiography", "TEST", 0, 16], ["DiagnosisCardiac MRI", "TEST", 121, 141], ["myocardial abnormalities", "PROBLEM", 193, 217], ["increased", "OBSERVATION", 33, 42], ["left ventricular", "ANATOMY", 43, 59], ["LV", "ANATOMY", 61, 63], ["diastolic", "OBSERVATION_MODIFIER", 65, 74], ["dimensions", "OBSERVATION_MODIFIER", 75, 85], ["normal", "OBSERVATION", 91, 97], ["septal thickness", "OBSERVATION", 98, 114], ["myocardial", "ANATOMY", 193, 203], ["abnormalities", "OBSERVATION", 204, 217]]], ["In myocarditis, the MRI may demonstrate myocardial edema and myocyte damage [86, 87] .", [["myocardial", "ANATOMY", 40, 50], ["myocyte", "ANATOMY", 61, 68], ["myocarditis", "DISEASE", 3, 14], ["myocardial edema", "DISEASE", 40, 56], ["myocardial edema", "PATHOLOGICAL_FORMATION", 40, 56], ["myocyte", "CELL", 61, 68], ["myocarditis", "PROBLEM", 3, 14], ["the MRI", "TEST", 16, 23], ["myocardial edema", "PROBLEM", 40, 56], ["myocyte damage", "PROBLEM", 61, 75], ["myocarditis", "OBSERVATION", 3, 14], ["myocardial", "ANATOMY", 40, 50], ["edema", "OBSERVATION", 51, 56], ["myocyte", "ANATOMY", 61, 68]]], ["The definitive diagnosis of myocarditis is made by endomyocardial biopsy with histologic evaluation [88] .", [["endomyocardial", "ANATOMY", 51, 65], ["myocarditis", "DISEASE", 28, 39], ["endomyocardial biopsy", "MULTI-TISSUE_STRUCTURE", 51, 72], ["myocarditis", "PROBLEM", 28, 39], ["endomyocardial biopsy", "TEST", 51, 72], ["histologic evaluation", "TEST", 78, 99], ["myocarditis", "OBSERVATION", 28, 39]]], ["Histologic evaluation of the biopsy shows mononuclear cellular infiltrates, myocyte necrosis, and disorganized myocardiac cytoskeleton [89, 90] .", [["biopsy", "ANATOMY", 29, 35], ["mononuclear cellular", "ANATOMY", 42, 62], ["myocyte", "ANATOMY", 76, 83], ["myocardiac cytoskeleton", "ANATOMY", 111, 134], ["necrosis", "DISEASE", 84, 92], ["mononuclear cellular", "CELL", 42, 62], ["myocyte", "CELL", 76, 83], ["myocardiac cytoskeleton", "CELLULAR_COMPONENT", 111, 134], ["Histologic evaluation", "TEST", 0, 21], ["the biopsy", "TEST", 25, 35], ["mononuclear cellular infiltrates", "PROBLEM", 42, 74], ["myocyte necrosis", "PROBLEM", 76, 92], ["disorganized myocardiac cytoskeleton", "PROBLEM", 98, 134], ["mononuclear cellular", "OBSERVATION", 42, 62], ["infiltrates", "OBSERVATION", 63, 74], ["myocyte", "ANATOMY", 76, 83], ["necrosis", "OBSERVATION", 84, 92], ["disorganized", "OBSERVATION_MODIFIER", 98, 110], ["myocardiac cytoskeleton", "OBSERVATION", 111, 134]]], ["Treatment Viral myocarditis is usually a self-limited disease, and treatment is generally supportive.", [["Viral myocarditis", "DISEASE", 10, 27], ["Treatment Viral myocarditis", "PROBLEM", 0, 27], ["a self-limited disease", "PROBLEM", 39, 61], ["myocarditis", "OBSERVATION", 16, 27]]], ["Myocarditis, however, may progress to dilated cardiomyopathy and heart failure.", [["heart", "ANATOMY", 65, 70], ["Myocarditis", "DISEASE", 0, 11], ["dilated cardiomyopathy", "DISEASE", 38, 60], ["heart failure", "DISEASE", 65, 78], ["heart", "ORGAN", 65, 70], ["Myocarditis", "PROBLEM", 0, 11], ["dilated cardiomyopathy", "PROBLEM", 38, 60], ["heart failure", "PROBLEM", 65, 78], ["dilated", "OBSERVATION_MODIFIER", 38, 45], ["cardiomyopathy", "OBSERVATION", 46, 60], ["heart", "ANATOMY", 65, 70], ["failure", "OBSERVATION", 71, 78]]], ["Most therapy regimens are directed toward treatment of the heart failure and potential arrhythmias in serious cases [78] .", [["heart", "ANATOMY", 59, 64], ["heart failure", "DISEASE", 59, 72], ["arrhythmias", "DISEASE", 87, 98], ["heart", "ORGAN", 59, 64], ["Most therapy regimens", "TREATMENT", 0, 21], ["the heart failure", "PROBLEM", 55, 72], ["potential arrhythmias", "PROBLEM", 77, 98], ["heart", "ANATOMY", 59, 64], ["failure", "OBSERVATION", 65, 72], ["arrhythmias", "OBSERVATION", 87, 98]]], ["Depending on the clinical situation, some patients may benefit from antiviral or immunosuppressive therapy [91] [92] [93] .ComplicationsMost patients who have viral myocarditis recover completely [94] ; however, athletes who have viral myocarditis are at risk for heart failure, cardiomyopathy, and associated pericarditis.", [["heart", "ANATOMY", 264, 269], ["myocarditis", "DISEASE", 165, 176], ["viral myocarditis", "DISEASE", 230, 247], ["heart failure", "DISEASE", 264, 277], ["cardiomyopathy", "DISEASE", 279, 293], ["pericarditis", "DISEASE", 310, 322], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 141, 149], ["heart", "ORGAN", 264, 269], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 141, 149], ["antiviral", "TREATMENT", 68, 77], ["immunosuppressive therapy", "TREATMENT", 81, 106], ["viral myocarditis", "PROBLEM", 159, 176], ["viral myocarditis", "PROBLEM", 230, 247], ["heart failure", "PROBLEM", 264, 277], ["cardiomyopathy", "PROBLEM", 279, 293], ["associated pericarditis", "PROBLEM", 299, 322], ["myocarditis", "OBSERVATION", 165, 176], ["myocarditis", "OBSERVATION", 236, 247], ["heart", "ANATOMY", 264, 269], ["failure", "OBSERVATION", 270, 277], ["cardiomyopathy", "OBSERVATION", 279, 293], ["pericarditis", "OBSERVATION", 310, 322]]], ["These athletes are also at risk for arrhythmias and sudden cardiac death [95] .Return to PlayExercise and training can be deleterious in athletes who have myocarditis.", [["cardiac", "ANATOMY", 59, 66], ["arrhythmias", "DISEASE", 36, 47], ["sudden cardiac death", "DISEASE", 52, 72], ["myocarditis", "DISEASE", 155, 166], ["cardiac", "ORGAN", 59, 66], ["arrhythmias", "PROBLEM", 36, 47], ["sudden cardiac death", "PROBLEM", 52, 72], ["myocarditis", "PROBLEM", 155, 166], ["cardiac", "ANATOMY", 59, 66], ["death", "OBSERVATION", 67, 72], ["myocarditis", "OBSERVATION", 155, 166]]], ["Based on the current Bethesda Conference recommendations, athletes who have ''probable or definitive evidence of myocarditis should be withdrawn from all competitive sports and undergo a prudent convalescent period of about six months following the onset of clinical manifestations'' [95] .", [["myocarditis", "DISEASE", 113, 124], ["myocarditis", "PROBLEM", 113, 124], ["clinical manifestations''", "PROBLEM", 258, 283], ["evidence of", "UNCERTAINTY", 101, 112], ["myocarditis", "OBSERVATION", 113, 124]]], ["After 6 months, athletes may return to training if the following conditions are met [95] :Return to PlayLV function, wall motion, and cardiac dimensions return to normal Clinically relevant arrhythmias are absent on ambulatory Holter monitoring and graded exercise testing Serum markers of inflammation and heart failure have normalized The EKG has normalized PERICARDITIS Pericarditis (inflammation of the pericardium) may be caused by a wide variety of infectious and noninfectious processes [96, 97] .", [["wall", "ANATOMY", 117, 121], ["cardiac", "ANATOMY", 134, 141], ["Serum", "ANATOMY", 273, 278], ["heart", "ANATOMY", 307, 312], ["pericardium", "ANATOMY", 407, 418], ["arrhythmias", "DISEASE", 190, 201], ["inflammation", "DISEASE", 290, 302], ["heart failure", "DISEASE", 307, 320], ["Pericarditis", "DISEASE", 373, 385], ["inflammation of the pericardium", "DISEASE", 387, 418], ["wall", "MULTI-TISSUE_STRUCTURE", 117, 121], ["cardiac", "ORGAN", 134, 141], ["Serum", "ORGANISM_SUBSTANCE", 273, 278], ["heart", "ORGAN", 307, 312], ["pericardium", "ORGAN", 407, 418], ["wall motion", "TEST", 117, 128], ["arrhythmias", "PROBLEM", 190, 201], ["ambulatory Holter monitoring", "TEST", 216, 244], ["graded exercise testing", "TEST", 249, 272], ["Serum markers", "TEST", 273, 286], ["inflammation", "PROBLEM", 290, 302], ["heart failure", "PROBLEM", 307, 320], ["The EKG", "TEST", 337, 344], ["normalized PERICARDITIS Pericarditis", "PROBLEM", 349, 385], ["inflammation of the pericardium", "PROBLEM", 387, 418], ["a wide variety of infectious and noninfectious processes", "PROBLEM", 437, 493], ["wall", "ANATOMY_MODIFIER", 117, 121], ["cardiac", "ANATOMY", 134, 141], ["inflammation", "OBSERVATION", 290, 302], ["heart", "ANATOMY", 307, 312], ["failure", "OBSERVATION", 313, 320], ["normalized", "OBSERVATION_MODIFIER", 349, 359], ["PERICARDITIS", "OBSERVATION_MODIFIER", 360, 372], ["Pericarditis", "OBSERVATION", 373, 385], ["inflammation", "OBSERVATION", 387, 399], ["pericardium", "ANATOMY", 407, 418], ["wide", "OBSERVATION_MODIFIER", 439, 443], ["variety", "OBSERVATION_MODIFIER", 444, 451], ["infectious", "OBSERVATION", 455, 465], ["noninfectious", "OBSERVATION_MODIFIER", 470, 483]]], ["Pericarditis can have a wide range of clinical presentations, from asymptomatic to severe hemodynamic compromise.", [["Pericarditis", "DISEASE", 0, 12], ["Pericarditis", "PROBLEM", 0, 12], ["severe hemodynamic compromise", "PROBLEM", 83, 112], ["wide", "OBSERVATION_MODIFIER", 24, 28], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["hemodynamic compromise", "OBSERVATION", 90, 112]]], ["Taking a careful history and knowledge of the clinical presentation of pericarditis are important in establishing the diagnosis.", [["pericarditis", "DISEASE", 71, 83], ["pericarditis", "PROBLEM", 71, 83], ["pericarditis", "OBSERVATION", 71, 83]]], ["When the diagnosis is missed, pericarditis can become life threatening for the athlete [98] .CausesPericardial disease has multiple causes including infectious, neoplastic, inflammatory, degenerative, vascular, and idiopathic causes.", [["neoplastic", "ANATOMY", 161, 171], ["vascular", "ANATOMY", 201, 209], ["pericarditis", "DISEASE", 30, 42], ["CausesPericardial disease", "DISEASE", 93, 118], ["vascular", "MULTI-TISSUE_STRUCTURE", 201, 209], ["pericarditis", "PROBLEM", 30, 42], ["CausesPericardial disease", "PROBLEM", 93, 118], ["infectious", "PROBLEM", 149, 159], ["neoplastic", "PROBLEM", 161, 171], ["inflammatory", "PROBLEM", 173, 185], ["degenerative, vascular, and idiopathic causes", "PROBLEM", 187, 232], ["pericarditis", "OBSERVATION", 30, 42], ["disease", "OBSERVATION", 111, 118], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["infectious", "OBSERVATION_MODIFIER", 149, 159], ["neoplastic", "OBSERVATION_MODIFIER", 161, 171], ["inflammatory", "OBSERVATION_MODIFIER", 173, 185], ["degenerative", "OBSERVATION", 187, 199], ["vascular", "ANATOMY", 201, 209], ["idiopathic", "OBSERVATION_MODIFIER", 215, 225]]], ["Infectious and idiopathic causes, likely the most common causes in the training room, are found in 90% of cases of acute pericarditis [99, 100] .", [["pericarditis", "DISEASE", 121, 133], ["idiopathic causes", "PROBLEM", 15, 32], ["acute pericarditis", "PROBLEM", 115, 133], ["idiopathic", "OBSERVATION_MODIFIER", 15, 25], ["most common", "OBSERVATION_MODIFIER", 45, 56], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["pericarditis", "OBSERVATION", 121, 133]]], ["The most common viral causes include coxsackievirus A and B, adenovirus, echovirus, and HIV.", [["coxsackievirus A and B, adenovirus, echovirus, and HIV", "DISEASE", 37, 91], ["coxsackievirus A", "ORGANISM", 37, 53], ["B", "GENE_OR_GENE_PRODUCT", 58, 59], ["adenovirus", "ORGANISM", 61, 71], ["HIV", "SPECIES", 88, 91], ["coxsackievirus A", "SPECIES", 37, 53], ["HIV", "SPECIES", 88, 91], ["coxsackievirus A and B", "PROBLEM", 37, 59], ["adenovirus", "PROBLEM", 61, 71], ["echovirus", "PROBLEM", 73, 82], ["HIV", "PROBLEM", 88, 91], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["coxsackievirus", "OBSERVATION", 37, 51]]], ["The most common bacterial causes in acute pericarditis are Staphylococcus, Pneumococcus, Streptococcus, Haemophilus, and Neisseria [101, 102] .Clinical PresentationThe presentation of acute pericarditis varies depending on the cause.", [["pericarditis", "DISEASE", 42, 54], ["pericarditis", "DISEASE", 190, 202], ["Streptococcus", "SPECIES", 89, 102], ["The most common bacterial causes", "PROBLEM", 0, 32], ["acute pericarditis", "PROBLEM", 36, 54], ["Staphylococcus", "PROBLEM", 59, 73], ["Pneumococcus", "PROBLEM", 75, 87], ["Streptococcus", "PROBLEM", 89, 102], ["Haemophilus", "PROBLEM", 104, 115], ["Neisseria", "PROBLEM", 121, 130], ["acute pericarditis", "PROBLEM", 184, 202], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["pericarditis", "OBSERVATION", 42, 54], ["Staphylococcus", "OBSERVATION", 59, 73], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["pericarditis", "OBSERVATION", 190, 202]]], ["In infectious or idiopathic acute pericarditis, the major clinical symptom is chest pain.", [["chest", "ANATOMY", 78, 83], ["idiopathic acute pericarditis", "DISEASE", 17, 46], ["chest pain", "DISEASE", 78, 88], ["chest", "ORGANISM_SUBDIVISION", 78, 83], ["idiopathic acute pericarditis", "PROBLEM", 17, 46], ["the major clinical symptom", "PROBLEM", 48, 74], ["chest pain", "PROBLEM", 78, 88], ["infectious", "OBSERVATION_MODIFIER", 3, 13], ["idiopathic", "OBSERVATION_MODIFIER", 17, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["pericarditis", "OBSERVATION", 34, 46], ["chest", "ANATOMY", 78, 83]]], ["The pain in pericarditis is thought to be due to inflammation of the adjacent pleura [103] .", [["pleura", "ANATOMY", 78, 84], ["pain", "DISEASE", 4, 8], ["pericarditis", "DISEASE", 12, 24], ["inflammation", "DISEASE", 49, 61], ["pleura", "ORGAN", 78, 84], ["The pain", "PROBLEM", 0, 8], ["pericarditis", "PROBLEM", 12, 24], ["inflammation of the adjacent pleura", "PROBLEM", 49, 84], ["pain", "OBSERVATION", 4, 8], ["pericarditis", "OBSERVATION", 12, 24], ["thought to be due to", "UNCERTAINTY", 28, 48], ["inflammation", "OBSERVATION", 49, 61], ["pleura", "ANATOMY", 78, 84]]], ["The patient may describe the pain as retrosternal, exacerbated by coughing or deep inspiratory effort.", [["pain", "DISEASE", 29, 33], ["retrosternal", "DISEASE", 37, 49], ["coughing", "DISEASE", 66, 74], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the pain", "PROBLEM", 25, 33], ["retrosternal", "PROBLEM", 37, 49], ["coughing", "PROBLEM", 66, 74], ["deep inspiratory effort", "PROBLEM", 78, 101], ["retrosternal", "ANATOMY", 37, 49], ["deep", "ANATOMY_MODIFIER", 78, 82], ["inspiratory effort", "OBSERVATION", 83, 101]]], ["The pain may also radiate to the back.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8], ["pain", "OBSERVATION", 4, 8], ["back", "ANATOMY", 33, 37]]], ["The chest pain in acute pericarditis is often positional-worsened in the supine position and relieved by sitting upright and leaning forward [97, 102, 104] .", [["chest", "ANATOMY", 4, 9], ["chest pain", "DISEASE", 4, 14], ["pericarditis", "DISEASE", 24, 36], ["chest", "ORGANISM_SUBDIVISION", 4, 9], ["The chest pain", "PROBLEM", 0, 14], ["acute pericarditis", "PROBLEM", 18, 36], ["chest", "ANATOMY", 4, 9], ["pain", "OBSERVATION", 10, 14], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["pericarditis", "OBSERVATION", 24, 36], ["positional", "OBSERVATION_MODIFIER", 46, 56], ["worsened", "OBSERVATION_MODIFIER", 57, 65]]], ["The athlete may also complain of fever.", [["fever", "DISEASE", 33, 38], ["fever", "PROBLEM", 33, 38], ["fever", "OBSERVATION", 33, 38]]], ["Patients may also present with an associated flu-like illness with cough, fatigue, myalgias, or arthralgias [105] .Clinical PresentationIt is imperative to document vital signs for athletes who have cardiac or respiratory complaints.", [["cardiac", "ANATOMY", 199, 206], ["respiratory", "ANATOMY", 210, 221], ["flu-like illness", "DISEASE", 45, 61], ["cough", "DISEASE", 67, 72], ["fatigue", "DISEASE", 74, 81], ["myalgias", "DISEASE", 83, 91], ["arthralgias", "DISEASE", 96, 107], ["cardiac or respiratory complaints", "DISEASE", 199, 232], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 199, 206], ["Patients", "SPECIES", 0, 8], ["an associated flu-like illness", "PROBLEM", 31, 61], ["cough", "PROBLEM", 67, 72], ["fatigue", "PROBLEM", 74, 81], ["myalgias", "PROBLEM", 83, 91], ["arthralgias", "PROBLEM", 96, 107], ["vital signs", "TEST", 165, 176], ["cardiac or respiratory complaints", "PROBLEM", 199, 232], ["flu", "OBSERVATION", 45, 48]]], ["The vitals signs may indicate severity of cardiac compromise.", [["cardiac", "ANATOMY", 42, 49], ["cardiac compromise", "DISEASE", 42, 60], ["cardiac", "ORGAN", 42, 49], ["The vitals signs", "TEST", 0, 16], ["cardiac compromise", "PROBLEM", 42, 60], ["cardiac", "ANATOMY", 42, 49], ["compromise", "OBSERVATION", 50, 60]]], ["The pericardial friction rub is the cardinal physical sign of acute pericarditis [99] .", [["pericardial", "ANATOMY", 4, 15], ["pericarditis", "DISEASE", 68, 80], ["The pericardial friction rub", "TEST", 0, 28], ["acute pericarditis", "PROBLEM", 62, 80], ["pericardial", "ANATOMY", 4, 15], ["friction rub", "OBSERVATION", 16, 28], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["pericarditis", "OBSERVATION", 68, 80]]], ["A pericardial rub may have three components per cardiac cycle: high pitched, scratching, and grating [106] .", [["pericardial", "ANATOMY", 2, 13], ["cardiac", "ANATOMY", 48, 55], ["A pericardial rub", "TREATMENT", 0, 17], ["cardiac cycle", "TEST", 48, 61], ["high pitched", "PROBLEM", 63, 75], ["scratching", "PROBLEM", 77, 87], ["pericardial", "ANATOMY", 2, 13], ["rub", "OBSERVATION", 14, 17], ["cardiac", "ANATOMY", 48, 55], ["high pitched", "OBSERVATION_MODIFIER", 63, 75]]], ["The rub can sometimes be elicited by use of firm pressure with the stethoscope's diaphragm at the left lower sternal border of the chest wall [96, 106] .", [["diaphragm", "ANATOMY", 81, 90], ["left lower sternal border", "ANATOMY", 98, 123], ["chest wall", "ANATOMY", 131, 141], ["diaphragm", "ORGAN", 81, 90], ["lower", "ORGANISM_SUBDIVISION", 103, 108], ["sternal border", "ORGANISM_SUBDIVISION", 109, 123], ["chest wall", "MULTI-TISSUE_STRUCTURE", 131, 141], ["firm pressure", "TREATMENT", 44, 57], ["firm", "OBSERVATION", 44, 48], ["diaphragm", "ANATOMY", 81, 90], ["left", "ANATOMY_MODIFIER", 98, 102], ["lower", "ANATOMY_MODIFIER", 103, 108], ["sternal", "ANATOMY", 109, 116], ["border", "ANATOMY_MODIFIER", 117, 123], ["chest", "ANATOMY", 131, 136], ["wall", "ANATOMY_MODIFIER", 137, 141]]], ["The rub can often be best appreciated with the patient upright and leaning forward and is often accentuated during inspiration [107] .", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["rub", "OBSERVATION", 4, 7]]], ["The physician should also look for signs of cardiac tamponade on examination: hypotension, tachycardia, jugular venous distention, and pulsus paradoxus (defined as an inspiratory systolic decrease in arterial pressure of 10 mm Hg during normal breathing) [98] .DiagnosisLaboratory tests to consider include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and cardiac enzymes.", [["cardiac", "ANATOMY", 44, 51], ["jugular venous", "ANATOMY", 104, 118], ["pulsus", "ANATOMY", 135, 141], ["arterial", "ANATOMY", 200, 208], ["blood", "ANATOMY", 316, 321], ["erythrocyte", "ANATOMY", 329, 340], ["cardiac", "ANATOMY", 397, 404], ["cardiac tamponade", "DISEASE", 44, 61], ["hypotension", "DISEASE", 78, 89], ["tachycardia", "DISEASE", 91, 102], ["jugular venous distention", "DISEASE", 104, 129], ["Hg", "CHEMICAL", 227, 229], ["cardiac", "ORGAN", 44, 51], ["jugular venous", "MULTI-TISSUE_STRUCTURE", 104, 118], ["arterial", "MULTI-TISSUE_STRUCTURE", 200, 208], ["blood", "ORGANISM_SUBSTANCE", 316, 321], ["erythrocyte", "CELL", 329, 340], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 367, 385], ["CRP", "GENE_OR_GENE_PRODUCT", 387, 390], ["C-reactive protein", "PROTEIN", 367, 385], ["CRP", "PROTEIN", 387, 390], ["cardiac enzymes", "PROTEIN", 397, 412], ["cardiac tamponade", "PROBLEM", 44, 61], ["examination", "TEST", 65, 76], ["hypotension", "PROBLEM", 78, 89], ["tachycardia", "PROBLEM", 91, 102], ["jugular venous distention", "PROBLEM", 104, 129], ["pulsus paradoxus", "PROBLEM", 135, 151], ["an inspiratory systolic decrease", "TEST", 164, 196], ["arterial pressure", "TEST", 200, 217], ["DiagnosisLaboratory tests", "TEST", 261, 286], ["complete blood count", "TEST", 307, 327], ["erythrocyte sedimentation rate", "TEST", 329, 359], ["ESR", "TEST", 361, 364], ["C-reactive protein", "TEST", 367, 385], ["CRP", "TEST", 387, 390], ["cardiac enzymes", "TEST", 397, 412], ["cardiac", "ANATOMY", 44, 51], ["tamponade", "OBSERVATION", 52, 61], ["hypotension", "OBSERVATION", 78, 89], ["jugular venous", "ANATOMY", 104, 118], ["distention", "OBSERVATION", 119, 129], ["pulsus paradoxus", "OBSERVATION", 135, 151], ["arterial pressure", "OBSERVATION", 200, 217], ["cardiac", "ANATOMY", 397, 404]]], ["A complete blood count may illustrate increased leukocyte count [97] .", [["blood", "ANATOMY", 11, 16], ["leukocyte", "ANATOMY", 48, 57], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["leukocyte", "CELL", 48, 57], ["A complete blood count", "TEST", 0, 22], ["increased leukocyte count", "PROBLEM", 38, 63]]], ["Laboratory signs of inflammation including elevated ESR and CRP are commonly found in patients who have acute pericarditis.", [["inflammation", "DISEASE", 20, 32], ["pericarditis", "DISEASE", 110, 122], ["CRP", "GENE_OR_GENE_PRODUCT", 60, 63], ["patients", "ORGANISM", 86, 94], ["ESR", "PROTEIN", 52, 55], ["CRP", "PROTEIN", 60, 63], ["patients", "SPECIES", 86, 94], ["Laboratory signs", "TEST", 0, 16], ["inflammation", "PROBLEM", 20, 32], ["elevated ESR", "PROBLEM", 43, 55], ["CRP", "TEST", 60, 63], ["acute pericarditis", "PROBLEM", 104, 122], ["inflammation", "OBSERVATION", 20, 32], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["pericarditis", "OBSERVATION", 110, 122]]], ["ESR and CRP are not highly specific findings because they can be elevated in multiple disease processes.", [["CRP", "GENE_OR_GENE_PRODUCT", 8, 11], ["ESR", "PROTEIN", 0, 3], ["CRP", "PROTEIN", 8, 11], ["ESR", "TEST", 0, 3], ["CRP", "TEST", 8, 11], ["multiple disease processes", "PROBLEM", 77, 103], ["elevated", "OBSERVATION_MODIFIER", 65, 73], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["disease", "OBSERVATION", 86, 93]]], ["Serum cardiac enzymes, CK-MB, and troponin I may also be elevated in acute pericarditis [104, 108] .", [["Serum", "ANATOMY", 0, 5], ["pericarditis", "DISEASE", 75, 87], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cardiac", "ORGAN", 6, 13], ["CK-MB", "GENE_OR_GENE_PRODUCT", 23, 28], ["troponin I", "GENE_OR_GENE_PRODUCT", 34, 44], ["Serum cardiac enzymes", "PROTEIN", 0, 21], ["CK", "PROTEIN", 23, 25], ["troponin I", "PROTEIN", 34, 44], ["Serum cardiac enzymes", "TEST", 0, 21], ["CK-MB", "TEST", 23, 28], ["troponin I", "TEST", 34, 44], ["acute pericarditis", "PROBLEM", 69, 87], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["pericarditis", "OBSERVATION", 75, 87]]], ["If the history and physical examination are appropriate, further laboratory testing should be ordered, including antinuclear antibody, tuberculin skin test, HIV serology, and blood cultures [109] .DiagnosisThe EKG is abnormal in 90% of patients who have acute pericarditis [101, [110] [111] [112] .", [["skin", "ANATOMY", 146, 150], ["blood cultures", "ANATOMY", 175, 189], ["pericarditis", "DISEASE", 260, 272], ["antinuclear antibody", "GENE_OR_GENE_PRODUCT", 113, 133], ["skin", "ORGAN", 146, 150], ["HIV", "ORGANISM", 157, 160], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["patients", "ORGANISM", 236, 244], ["antinuclear antibody", "PROTEIN", 113, 133], ["HIV", "SPECIES", 157, 160], ["patients", "SPECIES", 236, 244], ["HIV", "SPECIES", 157, 160], ["physical examination", "TEST", 19, 39], ["further laboratory testing", "TEST", 57, 83], ["antinuclear antibody", "TEST", 113, 133], ["tuberculin skin test", "TEST", 135, 155], ["HIV serology", "TEST", 157, 169], ["blood cultures", "TEST", 175, 189], ["The EKG", "TEST", 206, 213], ["abnormal", "PROBLEM", 217, 225], ["acute pericarditis", "PROBLEM", 254, 272], ["skin", "ANATOMY", 146, 150], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["pericarditis", "OBSERVATION", 260, 272]]], ["The characteristic EKG changes found often evolve through stages.", [["The characteristic EKG changes", "PROBLEM", 0, 30]]], ["Early in pericarditis (the first few hours to days), ST-segment elevation without change in QRS morphology occurs in multiple leads.", [["pericarditis", "DISEASE", 9, 21], ["Early in pericarditis", "PROBLEM", 0, 21], ["ST-segment elevation", "PROBLEM", 53, 73], ["pericarditis", "OBSERVATION", 9, 21], ["segment", "ANATOMY_MODIFIER", 56, 63], ["elevation", "OBSERVATION", 64, 73], ["without", "UNCERTAINTY", 74, 81], ["change", "OBSERVATION_MODIFIER", 82, 88], ["QRS morphology", "OBSERVATION", 92, 106], ["multiple", "OBSERVATION_MODIFIER", 117, 125], ["leads", "OBSERVATION_MODIFIER", 126, 131]]], ["PR-segment depression may also be present.", [["depression", "DISEASE", 11, 21], ["PR", "PROTEIN", 0, 2], ["PR-segment depression", "PROBLEM", 0, 21], ["segment", "ANATOMY_MODIFIER", 3, 10], ["depression", "OBSERVATION", 11, 21], ["may also be", "UNCERTAINTY", 22, 33]]], ["Several days later, the ST and PR segments return to baseline.", [["PR", "PROTEIN", 31, 33], ["the ST and PR segments return", "PROBLEM", 20, 49], ["segments", "ANATOMY_MODIFIER", 34, 42]]], ["This stage is followed by diffuse T-wave inversions.", [["diffuse T-wave inversions", "PROBLEM", 26, 51], ["diffuse", "OBSERVATION_MODIFIER", 26, 33], ["-wave inversions", "OBSERVATION", 35, 51]]], ["The EKG may normalize or the T-wave inversion may persist for weeks or months [102, 104] .DiagnosisIn acute pericarditis, the chest radiograph is generally normal; however, when at least 200 mL of pericardial effusion is present, the chest radiograph may reveal an enlarged cardiac silhouette [102] .", [["chest", "ANATOMY", 126, 131], ["pericardial effusion", "ANATOMY", 197, 217], ["chest", "ANATOMY", 234, 239], ["cardiac", "ANATOMY", 274, 281], ["pericarditis", "DISEASE", 108, 120], ["pericardial effusion", "DISEASE", 197, 217], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 197, 217], ["The EKG", "TEST", 0, 7], ["the T-wave inversion", "PROBLEM", 25, 45], ["acute pericarditis", "PROBLEM", 102, 120], ["the chest radiograph", "TEST", 122, 142], ["pericardial effusion", "PROBLEM", 197, 217], ["the chest radiograph", "TEST", 230, 250], ["an enlarged cardiac silhouette", "PROBLEM", 262, 292], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["pericarditis", "OBSERVATION", 108, 120], ["chest", "ANATOMY", 126, 131], ["generally", "OBSERVATION_MODIFIER", 146, 155], ["normal", "OBSERVATION", 156, 162], ["pericardial", "ANATOMY", 197, 208], ["effusion", "OBSERVATION", 209, 217], ["chest", "ANATOMY", 234, 239], ["enlarged", "OBSERVATION", 265, 273], ["cardiac", "ANATOMY", 274, 281], ["silhouette", "ANATOMY_MODIFIER", 282, 292]]], ["An echocardiogram should also be obtained in patients who have suspected acute pericarditis.", [["pericarditis", "DISEASE", 79, 91], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["An echocardiogram", "TEST", 0, 17], ["acute pericarditis", "PROBLEM", 73, 91], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["pericarditis", "OBSERVATION", 79, 91]]], ["The echocardiogram is often normal unless there is an associated pericardial effusion [113, 114] .TreatmentThe physician's initial treatment decision is whether the athlete will be treated as an inpatient or an outpatient.", [["pericardial", "ANATOMY", 65, 76], ["pericardial effusion", "DISEASE", 65, 85], ["The echocardiogram", "TEST", 0, 18], ["an associated pericardial effusion", "PROBLEM", 51, 85], ["normal", "OBSERVATION", 28, 34], ["pericardial", "ANATOMY", 65, 76], ["effusion", "OBSERVATION", 77, 85]]], ["If the athlete has simple, uncomplicated acute pericarditis and is clinically stable, then outpatient treatment with close follow-up may be appropriate [97, 115] .", [["pericarditis", "DISEASE", 47, 59], ["uncomplicated acute pericarditis", "PROBLEM", 27, 59], ["uncomplicated", "OBSERVATION_MODIFIER", 27, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["pericarditis", "OBSERVATION", 47, 59], ["stable", "OBSERVATION_MODIFIER", 78, 84]]], ["If high-risk features are present or if the patient is clinically unstable, then inpatient treatment is recommended.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["high-risk features", "PROBLEM", 3, 21], ["inpatient treatment", "TREATMENT", 81, 100]]], ["High-risk features are illustrated in Box 2 [97, 115] .TreatmentWhen the clinical situation identifies a cause other than viral or idiopathic disease, specific treatment is indicated for the underlying disorder.", [["viral or idiopathic disease", "DISEASE", 122, 149], ["High-risk features", "PROBLEM", 0, 18], ["viral or idiopathic disease", "PROBLEM", 122, 149], ["specific treatment", "TREATMENT", 151, 169], ["the underlying disorder", "PROBLEM", 187, 210], ["-risk", "OBSERVATION_MODIFIER", 4, 9], ["idiopathic", "OBSERVATION", 131, 141]]], ["Primary therapy goals for idiopathic or viral pericarditis are pain relief, resolution of inflammation, and resolution of effusion if present [97] .", [["idiopathic or viral pericarditis", "DISEASE", 26, 58], ["pain", "DISEASE", 63, 67], ["inflammation", "DISEASE", 90, 102], ["effusion", "DISEASE", 122, 130], ["Primary therapy", "TREATMENT", 0, 15], ["idiopathic or viral pericarditis", "PROBLEM", 26, 58], ["pain relief", "PROBLEM", 63, 74], ["inflammation", "PROBLEM", 90, 102], ["effusion", "PROBLEM", 122, 130], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["pericarditis", "OBSERVATION", 46, 58], ["inflammation", "OBSERVATION", 90, 102], ["resolution", "OBSERVATION_MODIFIER", 108, 118], ["effusion", "OBSERVATION", 122, 130]]], ["Current recommendations include the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).", [["nonsteroidal", "ANATOMY", 61, 73], ["aspirin", "CHEMICAL", 43, 50], ["aspirin", "CHEMICAL", 43, 50], ["aspirin", "SIMPLE_CHEMICAL", 43, 50], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 61, 97], ["NSAIDs", "SIMPLE_CHEMICAL", 99, 105], ["aspirin", "TREATMENT", 43, 50], ["other nonsteroidal anti-inflammatory drugs", "TREATMENT", 55, 97], ["NSAIDs", "TREATMENT", 99, 105]]], ["Colchicine may also be considered in the treatment of acute pericarditis [116] .", [["Colchicine", "CHEMICAL", 0, 10], ["pericarditis", "DISEASE", 60, 72], ["Colchicine", "CHEMICAL", 0, 10], ["Colchicine", "SIMPLE_CHEMICAL", 0, 10], ["Colchicine", "TREATMENT", 0, 10], ["acute pericarditis", "PROBLEM", 54, 72], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["pericarditis", "OBSERVATION", 60, 72]]], ["Corticosteroids should be considered if the patient is refractory to NSAIDs or colchicine.", [["colchicine", "CHEMICAL", 79, 89], ["colchicine", "CHEMICAL", 79, 89], ["patient", "ORGANISM", 44, 51], ["NSAIDs", "SIMPLE_CHEMICAL", 69, 75], ["colchicine", "SIMPLE_CHEMICAL", 79, 89], ["patient", "SPECIES", 44, 51], ["Corticosteroids", "TREATMENT", 0, 15], ["NSAIDs", "TREATMENT", 69, 75], ["colchicine", "TREATMENT", 79, 89]]], ["Close monitoring and follow-up are imperative for all athletes diagnosed with acute pericarditis.ComplicationsAlthough pericarditis usually resolves within a few days to weeks, life-threatening complications can occur [97] .", [["pericarditis", "DISEASE", 84, 96], ["pericarditis", "DISEASE", 119, 131], ["Close monitoring", "TEST", 0, 16], ["acute pericarditis", "PROBLEM", 78, 96], ["pericarditis", "PROBLEM", 119, 131], ["life-threatening complications", "PROBLEM", 177, 207], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["pericarditis", "OBSERVATION", 84, 96], ["pericarditis", "OBSERVATION", 119, 131]]], ["When an associated pericardial effusion is present, it may proceed to a cardiac tamponade, which is a cardiac emergency [98] .", [["pericardial effusion", "ANATOMY", 19, 39], ["cardiac", "ANATOMY", 72, 79], ["cardiac", "ANATOMY", 102, 109], ["pericardial effusion", "DISEASE", 19, 39], ["cardiac tamponade", "DISEASE", 72, 89], ["pericardial", "ORGAN", 19, 30], ["cardiac", "ORGAN", 72, 79], ["an associated pericardial effusion", "PROBLEM", 5, 39], ["a cardiac tamponade", "PROBLEM", 70, 89], ["pericardial", "ANATOMY", 19, 30], ["effusion", "OBSERVATION", 31, 39], ["cardiac", "ANATOMY", 72, 79], ["tamponade", "OBSERVATION", 80, 89]]], ["When the pericardial inflammation does not resolve, it may lead to chronic pericarditis.", [["pericardial", "ANATOMY", 9, 20], ["pericardial inflammation", "DISEASE", 9, 33], ["pericarditis", "DISEASE", 75, 87], ["pericardial", "MULTI-TISSUE_STRUCTURE", 9, 20], ["the pericardial inflammation", "PROBLEM", 5, 33], ["chronic pericarditis", "PROBLEM", 67, 87], ["pericardial", "ANATOMY", 9, 20], ["inflammation", "OBSERVATION", 21, 33], ["may lead to", "UNCERTAINTY", 55, 66], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["pericarditis", "OBSERVATION", 75, 87]]], ["Chronic pericarditis may subsequently lead to constrictive pericarditis.Return to PlayThe current Bethesda Conference Guidelines recommend exclusion of the athlete who has acute pericarditis from competitive sports [95] .", [["pericarditis", "DISEASE", 8, 20], ["constrictive pericarditis", "DISEASE", 46, 71], ["pericarditis", "DISEASE", 178, 190], ["Chronic pericarditis", "PROBLEM", 0, 20], ["constrictive pericarditis", "PROBLEM", 46, 71], ["acute pericarditis", "PROBLEM", 172, 190], ["pericarditis", "OBSERVATION", 8, 20], ["constrictive", "OBSERVATION_MODIFIER", 46, 58], ["pericarditis", "OBSERVATION", 59, 71], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["pericarditis", "OBSERVATION", 178, 190]]], ["These athletes can return to full activity only when there is no evidence of active disease, which includes no evidence of effusion on echocardiogram and normalized serum inflammatory markers.", [["serum", "ANATOMY", 165, 170], ["effusion", "DISEASE", 123, 131], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["serum inflammatory markers", "PROTEIN", 165, 191], ["active disease", "PROBLEM", 77, 91], ["effusion", "PROBLEM", 123, 131], ["echocardiogram", "TEST", 135, 149], ["normalized serum inflammatory markers", "PROBLEM", 154, 191], ["no evidence of", "UNCERTAINTY", 62, 76], ["active", "OBSERVATION_MODIFIER", 77, 83], ["disease", "OBSERVATION", 84, 91], ["no evidence of", "UNCERTAINTY", 108, 122], ["effusion", "OBSERVATION", 123, 131], ["inflammatory markers", "OBSERVATION", 171, 191]]], ["If concurrent myocarditis is associated with acute pericarditis, then myocarditis return-to-play criteria must also be met [95] .ACUTE RHEUMATIC FEVERAcute rheumatic fever (ARF) is an inflammatory disease that may develop after an infection with Streptococcus bacteria and can involve the heart, joints, skin, and brain [117] .", [["heart", "ANATOMY", 289, 294], ["joints", "ANATOMY", 296, 302], ["skin", "ANATOMY", 304, 308], ["brain", "ANATOMY", 314, 319], ["myocarditis", "DISEASE", 14, 25], ["pericarditis", "DISEASE", 51, 63], ["myocarditis", "DISEASE", 70, 81], ["FEVERAcute rheumatic fever", "DISEASE", 145, 171], ["ARF", "DISEASE", 173, 176], ["infection", "DISEASE", 231, 240], ["heart", "ORGAN", 289, 294], ["joints", "MULTI-TISSUE_STRUCTURE", 296, 302], ["skin", "ORGAN", 304, 308], ["brain", "ORGAN", 314, 319], ["concurrent myocarditis", "PROBLEM", 3, 25], ["acute pericarditis", "PROBLEM", 45, 63], ["myocarditis", "PROBLEM", 70, 81], ["ACUTE RHEUMATIC FEVERAcute rheumatic fever", "PROBLEM", 129, 171], ["ARF", "PROBLEM", 173, 176], ["an inflammatory disease", "PROBLEM", 181, 204], ["an infection", "PROBLEM", 228, 240], ["Streptococcus bacteria", "PROBLEM", 246, 268], ["myocarditis", "OBSERVATION", 14, 25], ["associated with", "UNCERTAINTY", 29, 44], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["pericarditis", "OBSERVATION", 51, 63], ["myocarditis", "OBSERVATION", 70, 81], ["RHEUMATIC", "OBSERVATION_MODIFIER", 135, 144], ["FEVERAcute", "OBSERVATION_MODIFIER", 145, 155], ["rheumatic", "OBSERVATION_MODIFIER", 156, 165], ["fever", "OBSERVATION", 166, 171], ["inflammatory", "OBSERVATION_MODIFIER", 184, 196], ["infection", "OBSERVATION", 231, 240], ["Streptococcus bacteria", "OBSERVATION", 246, 268], ["heart", "ANATOMY", 289, 294], ["joints", "ANATOMY", 296, 302], ["skin", "ANATOMY", 304, 308], ["brain", "ANATOMY", 314, 319]]], ["The cardiac manifestations associated with ARF-valvulitis and carditis-can be potentially serious illnesses found in the training room.", [["cardiac", "ANATOMY", 4, 11], ["cardiac manifestations", "DISEASE", 4, 26], ["ARF-valvulitis", "DISEASE", 43, 57], ["carditis", "DISEASE", 62, 70], ["cardiac", "ORGAN", 4, 11], ["ARF", "GENE_OR_GENE_PRODUCT", 43, 46], ["The cardiac manifestations", "PROBLEM", 0, 26], ["ARF", "PROBLEM", 43, 46], ["valvulitis", "PROBLEM", 47, 57], ["carditis", "PROBLEM", 62, 70], ["serious illnesses", "PROBLEM", 90, 107], ["cardiac", "ANATOMY", 4, 11], ["manifestations", "OBSERVATION", 12, 26], ["ARF", "OBSERVATION", 43, 46], ["valvulitis", "OBSERVATION", 47, 57], ["carditis", "OBSERVATION", 62, 70]]], ["The carditis of ARF is a pancarditis that involves the pericardium, myocardium, and endocardium to varying degrees [118] .", [["pericardium", "ANATOMY", 55, 66], ["myocardium", "ANATOMY", 68, 78], ["endocardium", "ANATOMY", 84, 95], ["carditis", "DISEASE", 4, 12], ["ARF", "DISEASE", 16, 19], ["pancarditis", "DISEASE", 25, 36], ["ARF", "GENE_OR_GENE_PRODUCT", 16, 19], ["pericardium", "TISSUE", 55, 66], ["myocardium", "MULTI-TISSUE_STRUCTURE", 68, 78], ["endocardium", "MULTI-TISSUE_STRUCTURE", 84, 95], ["The carditis of ARF", "PROBLEM", 0, 19], ["a pancarditis", "PROBLEM", 23, 36], ["carditis", "OBSERVATION", 4, 12], ["ARF", "OBSERVATION", 16, 19], ["pancarditis", "OBSERVATION", 25, 36], ["pericardium", "ANATOMY", 55, 66], ["myocardium", "ANATOMY", 68, 78], ["endocardium", "ANATOMY", 84, 95], ["varying", "OBSERVATION_MODIFIER", 99, 106], ["degrees", "OBSERVATION_MODIFIER", 107, 114]]], ["The valvulitis most frequently affects the mitral valve, aortic valve, or both [117] .", [["valvulitis", "ANATOMY", 4, 14], ["mitral valve", "ANATOMY", 43, 55], ["aortic valve", "ANATOMY", 57, 69], ["valvulitis", "DISEASE", 4, 14], ["valvulitis", "CANCER", 4, 14], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 43, 55], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 57, 69], ["The valvulitis", "PROBLEM", 0, 14], ["aortic valve", "TREATMENT", 57, 69], ["valvulitis", "OBSERVATION", 4, 14], ["mitral valve", "ANATOMY", 43, 55], ["aortic valve", "ANATOMY", 57, 69]]], ["Although the incidence of ARF has declined dramatically in the United States, scattered outbreaks in North America have confirmed the potentially serious consequences of this infection [119, 120] .", [["ARF", "DISEASE", 26, 29], ["infection", "DISEASE", 175, 184], ["ARF", "GENE_OR_GENE_PRODUCT", 26, 29], ["ARF", "PROBLEM", 26, 29], ["this infection", "PROBLEM", 170, 184], ["ARF", "OBSERVATION", 26, 29], ["declined", "OBSERVATION_MODIFIER", 34, 42], ["dramatically", "OBSERVATION_MODIFIER", 43, 55], ["scattered", "OBSERVATION_MODIFIER", 78, 87], ["outbreaks", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 175, 184]]], ["Cause ARF results from infection with a ''rheumatogenic'' strain of group A streptococcus.", [["ARF", "DISEASE", 6, 9], ["infection", "DISEASE", 23, 32], ["group A streptococcus", "DISEASE", 68, 89], ["ARF", "GENE_OR_GENE_PRODUCT", 6, 9], ["group A streptococcus", "ORGANISM", 68, 89], ["A streptococcus", "SPECIES", 74, 89], ["ARF", "PROBLEM", 6, 9], ["infection", "PROBLEM", 23, 32], ["a ''rheumatogenic'' strain", "PROBLEM", 38, 64], ["group A streptococcus", "PROBLEM", 68, 89], ["infection", "OBSERVATION", 23, 32]]], ["The known serotypes associated with ARF are serotypes 1, 3, 5, 6, 14, 18, 19, 24, 27, and 29 [121] .", [["ARF", "DISEASE", 36, 39], ["ARF", "GENE_OR_GENE_PRODUCT", 36, 39], ["3", "GENE_OR_GENE_PRODUCT", 57, 58], ["5", "GENE_OR_GENE_PRODUCT", 60, 61], ["serotypes 1, 3, 5, 6, 14, 18, 19, 24, 27", "DNA", 44, 84], ["The known serotypes", "PROBLEM", 0, 19], ["ARF", "PROBLEM", 36, 39], ["serotypes", "TEST", 44, 53], ["serotypes", "OBSERVATION", 10, 19], ["ARF", "OBSERVATION", 36, 39], ["serotypes", "OBSERVATION_MODIFIER", 44, 53]]], ["ARF primarily affects children between age 6 and 15 years and occurs approximately 20 days after initial infection [122] .", [["ARF", "DISEASE", 0, 3], ["infection", "DISEASE", 105, 114], ["ARF", "GENE_OR_GENE_PRODUCT", 0, 3], ["children", "ORGANISM", 22, 30], ["ARF", "PROTEIN", 0, 3], ["children", "SPECIES", 22, 30], ["ARF", "PROBLEM", 0, 3], ["initial infection", "PROBLEM", 97, 114], ["infection", "OBSERVATION", 105, 114]]], ["Studies have shown that an estimated 3% of individuals who have untreated group A streptococcal pharyngitis develop rheumatic fever [123] .Clinical PresentationThe clinical presentation is variable.", [["streptococcal pharyngitis", "DISEASE", 82, 107], ["rheumatic fever", "DISEASE", 116, 131], ["individuals", "ORGANISM", 43, 54], ["Studies", "TEST", 0, 7], ["A streptococcal pharyngitis", "PROBLEM", 80, 107], ["rheumatic fever", "PROBLEM", 116, 131], ["streptococcal", "OBSERVATION_MODIFIER", 82, 95], ["pharyngitis", "OBSERVATION", 96, 107], ["variable", "OBSERVATION_MODIFIER", 189, 197]]], ["The onset of rheumatic fever follows a latent period of 7 to 35 days after a preceding group A streptococcal infection [126] .", [["rheumatic fever", "DISEASE", 13, 28], ["streptococcal infection", "DISEASE", 95, 118], ["rheumatic fever", "PROBLEM", 13, 28], ["a preceding group A streptococcal infection", "PROBLEM", 75, 118], ["rheumatic", "OBSERVATION_MODIFIER", 13, 22], ["fever", "OBSERVATION", 23, 28], ["streptococcal", "OBSERVATION_MODIFIER", 95, 108], ["infection", "OBSERVATION", 109, 118]]], ["Although patients who have ARF may have any or all of the Jones criteria clinical features, the most common are polyarthritis (50%-75%) and carditis (40%-60%) [117] .Clinical PresentationOn examination, the carditis is usually associated with a murmur of valvulitis [118] .", [["ARF", "DISEASE", 27, 30], ["polyarthritis", "DISEASE", 112, 125], ["carditis", "DISEASE", 140, 148], ["carditis", "DISEASE", 207, 215], ["valvulitis", "DISEASE", 255, 265], ["patients", "ORGANISM", 9, 17], ["ARF", "GENE_OR_GENE_PRODUCT", 27, 30], ["patients", "SPECIES", 9, 17], ["ARF", "PROBLEM", 27, 30], ["polyarthritis", "PROBLEM", 112, 125], ["carditis", "TEST", 140, 148], ["Clinical PresentationOn examination", "TEST", 166, 201], ["the carditis", "PROBLEM", 203, 215], ["a murmur of valvulitis", "PROBLEM", 243, 265], ["polyarthritis", "OBSERVATION", 112, 125], ["carditis", "OBSERVATION", 140, 148], ["carditis", "OBSERVATION", 207, 215], ["murmur", "OBSERVATION", 245, 251]]], ["The examination may reveal sinus tachycardia, an S 3 gallop, a pericardial friction rub, and cardiomegaly.", [["sinus", "ANATOMY", 27, 32], ["pericardial", "ANATOMY", 63, 74], ["sinus tachycardia", "DISEASE", 27, 44], ["pericardial friction rub", "DISEASE", 63, 87], ["cardiomegaly", "DISEASE", 93, 105], ["The examination", "TEST", 0, 15], ["sinus tachycardia", "PROBLEM", 27, 44], ["a pericardial friction rub", "PROBLEM", 61, 87], ["cardiomegaly", "PROBLEM", 93, 105], ["sinus", "ANATOMY", 27, 32], ["tachycardia", "OBSERVATION", 33, 44], ["pericardial", "ANATOMY", 63, 74], ["friction rub", "OBSERVATION", 75, 87], ["cardiomegaly", "OBSERVATION", 93, 105]]], ["The valvulitis may be characterized by a pansystolic murmur of MR, best heard at the apex, with radiation to the left axilla.", [["valvulitis", "ANATOMY", 4, 14], ["left axilla", "ANATOMY", 113, 124], ["valvulitis", "DISEASE", 4, 14], ["MR", "DISEASE", 63, 65], ["valvulitis", "CANCER", 4, 14], ["axilla", "ORGAN", 118, 124], ["MR", "PROTEIN", 63, 65], ["a pansystolic murmur of MR", "PROBLEM", 39, 65], ["may be characterized", "UNCERTAINTY", 15, 35], ["pansystolic", "OBSERVATION_MODIFIER", 41, 52], ["murmur", "OBSERVATION", 53, 59], ["apex", "ANATOMY_MODIFIER", 85, 89], ["radiation", "OBSERVATION", 96, 105], ["left", "ANATOMY_MODIFIER", 113, 117], ["axilla", "ANATOMY", 118, 124]]], ["The MR murmur may also be heard with or without a low-pitched middiastolic (Carey Coombs) murmur [127] .DiagnosisThe diagnosis of ARF is clinical but requires supporting evidence from clinical presentation and microbiologic and immunologic laboratory results.", [["MR murmur", "DISEASE", 4, 13], ["ARF", "DISEASE", 130, 133], ["ARF", "GENE_OR_GENE_PRODUCT", 130, 133], ["MR", "PROTEIN", 4, 6], ["The MR murmur", "PROBLEM", 0, 13], ["a low-pitched middiastolic (Carey Coombs) murmur", "PROBLEM", 48, 96], ["ARF", "PROBLEM", 130, 133], ["microbiologic", "TEST", 210, 223], ["murmur", "OBSERVATION", 7, 13], ["may also be", "UNCERTAINTY", 14, 25], ["ARF", "OBSERVATION", 130, 133]]], ["To fulfill the Jones criteria, two major criteria (or one major and two minor criteria) plus evidence of an antecedent streptococcal infection are required [118, 124, 125] .", [["streptococcal infection", "DISEASE", 119, 142], ["an antecedent streptococcal infection", "PROBLEM", 105, 142], ["antecedent", "OBSERVATION_MODIFIER", 108, 118], ["streptococcal", "OBSERVATION_MODIFIER", 119, 132], ["infection", "OBSERVATION", 133, 142]]], ["Throat cultures should be obtained in suspected ARF [117] .", [["Throat cultures", "ANATOMY", 0, 15], ["ARF", "DISEASE", 48, 51], ["Throat cultures", "CELL", 0, 15], ["Throat cultures", "TEST", 0, 15], ["ARF", "PROBLEM", 48, 51]]], ["Specific antibody tests, such as antistreptolysin and anti-DNAse B should also be obtained to help confirm the diagnosis [117] .", [["antistreptolysin", "GENE_OR_GENE_PRODUCT", 33, 49], ["anti-DNAse B", "GENE_OR_GENE_PRODUCT", 54, 66], ["antistreptolysin", "PROTEIN", 33, 49], ["anti-DNAse B", "PROTEIN", 54, 66], ["Specific antibody tests", "TEST", 0, 23], ["antistreptolysin", "TREATMENT", 33, 49], ["anti-DNAse B", "TREATMENT", 54, 66]]], ["Acute phase reactants, CRP, Previous rheumatic fever or rheumatic heart disease and ESR are also usually elevated in ARF [117] .", [["heart", "ANATOMY", 66, 71], ["rheumatic fever", "DISEASE", 37, 52], ["rheumatic heart disease", "DISEASE", 56, 79], ["ARF", "DISEASE", 117, 120], ["CRP", "GENE_OR_GENE_PRODUCT", 23, 26], ["heart", "ORGAN", 66, 71], ["CRP", "PROTEIN", 23, 26], ["Acute phase reactants", "PROBLEM", 0, 21], ["CRP", "TEST", 23, 26], ["Previous rheumatic fever", "PROBLEM", 28, 52], ["rheumatic heart disease", "PROBLEM", 56, 79], ["ESR", "TEST", 84, 87], ["ARF", "PROBLEM", 117, 120], ["rheumatic", "OBSERVATION_MODIFIER", 37, 46], ["fever", "OBSERVATION", 47, 52], ["rheumatic", "OBSERVATION_MODIFIER", 56, 65], ["heart", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79], ["elevated", "OBSERVATION_MODIFIER", 105, 113]]], ["EKG and echocardiography are important diagnostic tools to assess for cardiac involvement [118, 124, 125] .", [["cardiac", "ANATOMY", 70, 77], ["cardiac", "ORGAN", 70, 77], ["EKG", "TEST", 0, 3], ["echocardiography", "TEST", 8, 24], ["diagnostic tools", "TEST", 39, 55], ["cardiac involvement", "TEST", 70, 89]]], ["The EKG may show prolonged PR intervals, which is a nonspecific finding [118] .", [["PR", "PROTEIN", 27, 29], ["The EKG", "TEST", 0, 7], ["prolonged PR intervals", "PROBLEM", 17, 39], ["nonspecific", "OBSERVATION_MODIFIER", 52, 63]]], ["The echocardiogram also reveals associated valvulitis or pericarditis, if present.TreatmentHospital admission is recommended for all cases to ensure complete and proper investigation.", [["valvulitis", "DISEASE", 43, 53], ["pericarditis", "DISEASE", 57, 69], ["The echocardiogram", "TEST", 0, 18], ["associated valvulitis", "PROBLEM", 32, 53], ["pericarditis", "PROBLEM", 57, 69], ["valvulitis", "OBSERVATION", 43, 53], ["pericarditis", "OBSERVATION", 57, 69]]], ["The main treatment goals are to confirm the diagnosis, treat cardiac failure, shorten the duration of symptoms, and ensure ongoing secondary prophylaxis and clinical follow-up [128] .", [["cardiac", "ANATOMY", 61, 68], ["cardiac failure", "DISEASE", 61, 76], ["cardiac", "ORGAN", 61, 68], ["cardiac failure", "PROBLEM", 61, 76], ["symptoms", "PROBLEM", 102, 110], ["ongoing secondary prophylaxis", "TREATMENT", 123, 152], ["main", "OBSERVATION_MODIFIER", 4, 8], ["cardiac", "ANATOMY", 61, 68], ["failure", "OBSERVATION", 69, 76]]], ["The mainstay of treatment for ARF is NSAIDs, most commonly aspirin.", [["ARF", "DISEASE", 30, 33], ["aspirin", "CHEMICAL", 59, 66], ["aspirin", "CHEMICAL", 59, 66], ["NSAIDs", "SIMPLE_CHEMICAL", 37, 43], ["aspirin", "SIMPLE_CHEMICAL", 59, 66], ["treatment", "TREATMENT", 16, 25], ["ARF", "PROBLEM", 30, 33], ["NSAIDs", "TREATMENT", 37, 43], ["aspirin", "TREATMENT", 59, 66]]], ["Duration of NSAID treatment should be maintained until all symptoms have resolved and laboratory values are normal [129] .", [["NSAID", "SIMPLE_CHEMICAL", 12, 17], ["NSAID treatment", "TREATMENT", 12, 27], ["all symptoms", "PROBLEM", 55, 67], ["laboratory values", "TEST", 86, 103]]], ["Depending on the severity of carditis, steroid treatment may be indicated.", [["carditis", "DISEASE", 29, 37], ["steroid", "CHEMICAL", 39, 46], ["steroid", "CHEMICAL", 39, 46], ["steroid", "SIMPLE_CHEMICAL", 39, 46], ["carditis", "PROBLEM", 29, 37], ["steroid treatment", "TREATMENT", 39, 56], ["carditis", "OBSERVATION", 29, 37]]], ["Antibiotic treatment with penicillin should also be given for 10 days [123] .", [["penicillin", "CHEMICAL", 26, 36], ["penicillin", "CHEMICAL", 26, 36], ["penicillin", "SIMPLE_CHEMICAL", 26, 36], ["Antibiotic treatment", "TREATMENT", 0, 20], ["penicillin", "TREATMENT", 26, 36]]], ["The athlete also needs long-term antibiotic prophylaxis after the acute episode has resolved.", [["long-term antibiotic prophylaxis", "TREATMENT", 23, 55], ["the acute episode", "PROBLEM", 62, 79], ["long-term", "OBSERVATION_MODIFIER", 23, 32], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["resolved", "OBSERVATION_MODIFIER", 84, 92]]], ["All family contacts should be cultured and treated for streptococcal infection if indicated [123] .TreatmentComplications ARF can cause permanent cardiac damage.", [["cardiac", "ANATOMY", 146, 153], ["streptococcal infection", "DISEASE", 55, 78], ["ARF", "DISEASE", 122, 125], ["cardiac damage", "DISEASE", 146, 160], ["ARF", "GENE_OR_GENE_PRODUCT", 122, 125], ["cardiac", "ORGAN", 146, 153], ["streptococcal infection", "PROBLEM", 55, 78], ["ARF", "PROBLEM", 122, 125], ["permanent cardiac damage", "PROBLEM", 136, 160], ["infection", "OBSERVATION", 69, 78], ["cardiac", "ANATOMY", 146, 153], ["damage", "OBSERVATION", 154, 160]]], ["The mitral valve is more commonly involved than the aortic valve.", [["mitral valve", "ANATOMY", 4, 16], ["aortic valve", "ANATOMY", 52, 64], ["mitral valve", "PATHOLOGICAL_FORMATION", 4, 16], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 52, 64], ["mitral valve", "ANATOMY", 4, 16], ["aortic valve", "ANATOMY", 52, 64]]], ["Mitral stenosis (MS) is the classic finding in rheumatic heart disease and may require surgical correction [95] .", [["Mitral", "ANATOMY", 0, 6], ["heart", "ANATOMY", 57, 62], ["Mitral stenosis", "DISEASE", 0, 15], ["MS", "DISEASE", 17, 19], ["rheumatic heart disease", "DISEASE", 47, 70], ["Mitral", "MULTI-TISSUE_STRUCTURE", 0, 6], ["heart", "ORGAN", 57, 62], ["Mitral stenosis (MS)", "PROBLEM", 0, 20], ["rheumatic heart disease", "PROBLEM", 47, 70], ["surgical correction", "TREATMENT", 87, 106], ["stenosis", "OBSERVATION", 7, 15], ["rheumatic", "OBSERVATION_MODIFIER", 47, 56], ["heart", "ANATOMY", 57, 62], ["disease", "OBSERVATION", 63, 70]]], ["Other potential complications of ARF include heart failure, myocarditis, pericarditis, arrhythmias, and endocarditis.", [["heart", "ANATOMY", 45, 50], ["ARF", "DISEASE", 33, 36], ["heart failure", "DISEASE", 45, 58], ["myocarditis", "DISEASE", 60, 71], ["pericarditis", "DISEASE", 73, 85], ["arrhythmias", "DISEASE", 87, 98], ["endocarditis", "DISEASE", 104, 116], ["ARF", "GENE_OR_GENE_PRODUCT", 33, 36], ["heart", "ORGAN", 45, 50], ["ARF", "PROBLEM", 33, 36], ["heart failure", "PROBLEM", 45, 58], ["myocarditis", "PROBLEM", 60, 71], ["pericarditis", "PROBLEM", 73, 85], ["arrhythmias", "PROBLEM", 87, 98], ["endocarditis", "PROBLEM", 104, 116], ["complications", "OBSERVATION", 16, 29], ["ARF", "OBSERVATION", 33, 36], ["heart", "ANATOMY", 45, 50], ["failure", "OBSERVATION", 51, 58], ["myocarditis", "OBSERVATION", 60, 71], ["pericarditis", "OBSERVATION", 73, 85], ["arrhythmias", "OBSERVATION", 87, 98], ["endocarditis", "OBSERVATION", 104, 116]]], ["The arrhythmia most commonly associated with MS is atrial fibrillation [117, 126] .", [["atrial", "ANATOMY", 51, 57], ["arrhythmia", "DISEASE", 4, 14], ["MS", "DISEASE", 45, 47], ["atrial fibrillation", "DISEASE", 51, 70], ["The arrhythmia", "PROBLEM", 0, 14], ["MS", "PROBLEM", 45, 47], ["atrial fibrillation", "PROBLEM", 51, 70], ["arrhythmia", "OBSERVATION", 4, 14], ["atrial", "ANATOMY", 51, 57], ["fibrillation", "OBSERVATION", 58, 70]]], ["The athlete must have close monitoring and follow-up before any return to exercise.Return to PlayIf the athlete has no cardiac involvement with ARF, then after antibiotic treatment is complete and the athlete is afebrile, gradual return to play may be initiated with close physician observation (normally about 3 to 4 weeks into treatment).", [["cardiac", "ANATOMY", 119, 126], ["ARF", "DISEASE", 144, 147], ["cardiac", "ORGAN", 119, 126], ["ARF", "GENE_OR_GENE_PRODUCT", 144, 147], ["close monitoring", "TEST", 22, 38], ["cardiac involvement", "PROBLEM", 119, 138], ["ARF", "PROBLEM", 144, 147], ["antibiotic treatment", "TREATMENT", 160, 180], ["afebrile", "PROBLEM", 212, 220], ["no", "UNCERTAINTY", 116, 118], ["cardiac", "ANATOMY", 119, 126], ["involvement", "OBSERVATION", 127, 138], ["ARF", "OBSERVATION", 144, 147]]], ["The athlete should also have resolution of polyarthralgias and chorea if present before return to play.", [["polyarthralgias", "DISEASE", 43, 58], ["chorea", "DISEASE", 63, 69], ["polyarthralgias", "PROBLEM", 43, 58], ["chorea", "PROBLEM", 63, 69]]], ["Prolonged bed rest is no longer recommended after ARF [95] .Return to PlayAll athletes who have cardiac involvement should be followed by their primary care physician, cardiologist, and dentist.", [["cardiac", "ANATOMY", 96, 103], ["ARF", "GENE_OR_GENE_PRODUCT", 50, 53], ["cardiac", "ORGAN", 96, 103], ["Prolonged bed rest", "TREATMENT", 0, 18], ["ARF", "PROBLEM", 50, 53]]], ["When there is associated myocarditis or pericarditis, physicians should refer to the previously described return-to-play guidelines.", [["myocarditis", "DISEASE", 25, 36], ["pericarditis", "DISEASE", 40, 52], ["myocarditis", "PROBLEM", 25, 36], ["pericarditis", "PROBLEM", 40, 52], ["myocarditis", "OBSERVATION", 25, 36], ["pericarditis", "OBSERVATION", 40, 52]]], ["Although MS rarely causes sudden cardiac death, careful consideration must be given if MS is present in an athlete [95] .", [["cardiac", "ANATOMY", 33, 40], ["MS", "DISEASE", 9, 11], ["sudden cardiac death", "DISEASE", 26, 46], ["cardiac", "ORGAN", 33, 40], ["sudden cardiac death", "PROBLEM", 26, 46], ["MS", "PROBLEM", 87, 89], ["cardiac", "ANATOMY", 33, 40], ["death", "OBSERVATION", 41, 46]]], ["Exercise in athletes who have MS can cause sudden increases in pulmonary capillary and pulmonary artery pressures, resulting in sudden acute pulmonary edema.", [["pulmonary capillary", "ANATOMY", 63, 82], ["pulmonary artery", "ANATOMY", 87, 103], ["pulmonary", "ANATOMY", 141, 150], ["MS", "DISEASE", 30, 32], ["sudden increases in pulmonary capillary and pulmonary artery pressures", "DISEASE", 43, 113], ["acute pulmonary edema", "DISEASE", 135, 156], ["pulmonary capillary", "TISSUE", 63, 82], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 87, 103], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 141, 156], ["MS", "PROBLEM", 30, 32], ["sudden increases in pulmonary capillary and pulmonary artery pressures", "PROBLEM", 43, 113], ["sudden acute pulmonary edema", "PROBLEM", 128, 156], ["pulmonary capillary", "ANATOMY", 63, 82], ["pulmonary artery", "ANATOMY", 87, 103], ["pressures", "OBSERVATION_MODIFIER", 104, 113], ["sudden", "OBSERVATION_MODIFIER", 128, 134], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["pulmonary", "ANATOMY", 141, 150], ["edema", "OBSERVATION", 151, 156]]], ["It is important to assess the severity of MS at rest and during sport-related exercise with echocardiography, including measurement of pulmonary artery systolic pressure [95] .", [["pulmonary artery", "ANATOMY", 135, 151], ["MS", "DISEASE", 42, 44], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 135, 151], ["MS", "PROBLEM", 42, 44], ["echocardiography", "TEST", 92, 108], ["pulmonary artery systolic pressure", "TEST", 135, 169], ["pulmonary artery", "ANATOMY", 135, 151]]], ["Depending on the severity of MS, the Bethesda Conference Guidelines should be followed [95] .ENDOCARDITISInfective endocarditis (IE) is a serious febrile infection that rapidly damages cardiac structures, spreads to extracardiac sites and, if untreated, can progress to death within weeks [130] .", [["cardiac structures", "ANATOMY", 185, 203], ["extracardiac sites", "ANATOMY", 216, 234], ["MS", "DISEASE", 29, 31], ["endocarditis", "DISEASE", 115, 127], ["IE", "DISEASE", 129, 131], ["febrile infection", "DISEASE", 146, 163], ["damages cardiac structures", "DISEASE", 177, 203], ["death", "DISEASE", 270, 275], ["cardiac structures", "TISSUE", 185, 203], ["extracardiac sites", "MULTI-TISSUE_STRUCTURE", 216, 234], ["MS", "PROBLEM", 29, 31], [".ENDOCARDITISInfective endocarditis", "PROBLEM", 92, 127], ["a serious febrile infection", "PROBLEM", 136, 163], ["rapidly damages cardiac structures", "PROBLEM", 169, 203], ["endocarditis", "OBSERVATION", 115, 127], ["serious", "OBSERVATION_MODIFIER", 138, 145], ["febrile", "OBSERVATION_MODIFIER", 146, 153], ["infection", "OBSERVATION", 154, 163]]], ["To avoid overlooking the diagnosis of IE, a high index of suspicion must be maintained.", [["IE", "DISEASE", 38, 40], ["a high index of suspicion", "PROBLEM", 42, 67]]], ["In the training room, the most likely case of endocarditis may be found in an athlete who has structural heart disease such as bicuspid aortic valves, mitral valve prolapse, or rheumatic heart disease.CausesA variety of microbial agents can cause IE.", [["heart", "ANATOMY", 105, 110], ["aortic", "ANATOMY", 136, 142], ["mitral valve", "ANATOMY", 151, 163], ["heart", "ANATOMY", 187, 192], ["endocarditis", "DISEASE", 46, 58], ["heart disease", "DISEASE", 105, 118], ["bicuspid aortic valves", "DISEASE", 127, 149], ["mitral valve prolapse", "DISEASE", 151, 172], ["rheumatic heart disease", "DISEASE", 177, 200], ["IE", "DISEASE", 247, 249], ["heart", "ORGAN", 105, 110], ["aortic valves", "MULTI-TISSUE_STRUCTURE", 136, 149], ["heart", "ORGAN", 187, 192], ["endocarditis", "PROBLEM", 46, 58], ["structural heart disease", "PROBLEM", 94, 118], ["bicuspid aortic valves", "PROBLEM", 127, 149], ["mitral valve prolapse", "PROBLEM", 151, 172], ["rheumatic heart disease", "PROBLEM", 177, 200], ["microbial agents", "TREATMENT", 220, 236], ["most likely", "UNCERTAINTY", 26, 37], ["endocarditis", "OBSERVATION", 46, 58], ["heart", "ANATOMY", 105, 110], ["disease", "OBSERVATION", 111, 118], ["bicuspid", "OBSERVATION", 127, 135], ["aortic valves", "ANATOMY", 136, 149], ["mitral valve", "ANATOMY", 151, 163], ["prolapse", "OBSERVATION", 164, 172], ["rheumatic", "OBSERVATION_MODIFIER", 177, 186], ["heart", "ANATOMY", 187, 192], ["disease", "OBSERVATION", 193, 200], ["microbial agents", "OBSERVATION", 220, 236]]], ["Staphylococci, streptococci, and enterococci represent most cases.", [["streptococci", "CELL", 15, 27], ["Staphylococci", "PROBLEM", 0, 13], ["streptococci", "PROBLEM", 15, 27], ["enterococci", "PROBLEM", 33, 44], ["streptococci", "OBSERVATION", 15, 27], ["enterococci", "OBSERVATION", 33, 44]]], ["The most common risk factor in athletes is structural heart disease.", [["heart", "ANATOMY", 54, 59], ["heart disease", "DISEASE", 54, 67], ["heart", "ORGAN", 54, 59], ["structural heart disease", "PROBLEM", 43, 67], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["heart", "ANATOMY", 54, 59], ["disease", "OBSERVATION", 60, 67]]], ["The skin, upper respiratory tract, and oral cavity are the primary portal of entry for streptococci and staphylococci organisms [131, 132] .", [["skin", "ANATOMY", 4, 8], ["upper respiratory tract", "ANATOMY", 10, 33], ["oral cavity", "ANATOMY", 39, 50], ["staphylococci", "DISEASE", 104, 117], ["skin", "ORGAN", 4, 8], ["upper respiratory", "ORGANISM_SUBDIVISION", 10, 27], ["tract", "ORGANISM_SUBDIVISION", 28, 33], ["oral cavity", "ORGAN", 39, 50], ["The skin, upper respiratory tract, and oral cavity", "PROBLEM", 0, 50], ["streptococci", "PROBLEM", 87, 99], ["staphylococci organisms", "PROBLEM", 104, 127], ["skin", "ANATOMY", 4, 8], ["upper", "ANATOMY_MODIFIER", 10, 15], ["respiratory tract", "ANATOMY", 16, 33], ["oral cavity", "ANATOMY", 39, 50], ["portal", "ANATOMY", 67, 73]]], ["Bacteremia can then ensue, leading to seeding of cardiac and extracardiac sites.Clinical PresentationIn IE, the interval between the presumed initiating bacteremia and the onset of symptoms is less than 14 days [133] .", [["cardiac", "ANATOMY", 49, 56], ["extracardiac sites", "ANATOMY", 61, 79], ["Bacteremia", "DISEASE", 0, 10], ["bacteremia", "DISEASE", 153, 163], ["cardiac", "ORGAN", 49, 56], ["extracardiac sites", "MULTI-TISSUE_STRUCTURE", 61, 79], ["Bacteremia", "PROBLEM", 0, 10], ["seeding of cardiac and extracardiac sites", "PROBLEM", 38, 79], ["bacteremia", "PROBLEM", 153, 163], ["symptoms", "PROBLEM", 181, 189], ["cardiac", "ANATOMY", 49, 56], ["extracardiac", "ANATOMY", 61, 73], ["bacteremia", "OBSERVATION", 153, 163]]], ["Endocarditis symptoms may develop slowly (subacute) or suddenly (acute) [134] .", [["Endocarditis", "DISEASE", 0, 12], ["Endocarditis symptoms", "PROBLEM", 0, 21], ["acute", "OBSERVATION_MODIFIER", 65, 70]]], ["Fever is the most common symptom.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["the most common symptom", "PROBLEM", 9, 32], ["most common", "OBSERVATION_MODIFIER", 13, 24]]], ["Other common symptoms include chills, night sweats, anorexia, dyspnea, cough, chest pain, and myalgias [134] .", [["chest", "ANATOMY", 78, 83], ["chills", "DISEASE", 30, 36], ["night sweats", "DISEASE", 38, 50], ["anorexia", "DISEASE", 52, 60], ["dyspnea", "DISEASE", 62, 69], ["cough", "DISEASE", 71, 76], ["chest pain", "DISEASE", 78, 88], ["myalgias", "DISEASE", 94, 102], ["Other common symptoms", "PROBLEM", 0, 21], ["chills", "PROBLEM", 30, 36], ["night sweats", "PROBLEM", 38, 50], ["anorexia", "PROBLEM", 52, 60], ["dyspnea", "PROBLEM", 62, 69], ["cough", "PROBLEM", 71, 76], ["chest pain", "PROBLEM", 78, 88], ["myalgias", "PROBLEM", 94, 102], ["chills", "OBSERVATION", 30, 36], ["chest", "ANATOMY", 78, 83]]], ["The most common findings on physical examination are fever and a heart murmur.", [["heart", "ANATOMY", 65, 70], ["fever", "DISEASE", 53, 58], ["heart murmur", "DISEASE", 65, 77], ["heart", "ORGAN", 65, 70], ["physical examination", "TEST", 28, 48], ["fever", "PROBLEM", 53, 58], ["a heart murmur", "PROBLEM", 63, 77], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["fever", "OBSERVATION", 53, 58], ["heart", "ANATOMY", 65, 70], ["murmur", "OBSERVATION", 71, 77]]], ["The murmur is usually a regurgitant heart murmur in the mitral or aortic valve position.", [["heart", "ANATOMY", 36, 41], ["mitral", "ANATOMY", 56, 62], ["aortic valve", "ANATOMY", 66, 78], ["heart murmur", "DISEASE", 36, 48], ["heart", "ORGAN", 36, 41], ["mitral", "MULTI-TISSUE_STRUCTURE", 56, 62], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 66, 78], ["The murmur", "PROBLEM", 0, 10], ["a regurgitant heart murmur", "PROBLEM", 22, 48], ["murmur", "OBSERVATION", 4, 10], ["regurgitant", "OBSERVATION", 24, 35], ["heart", "ANATOMY", 36, 41], ["murmur", "OBSERVATION", 42, 48], ["mitral", "OBSERVATION", 56, 62], ["aortic valve", "ANATOMY", 66, 78], ["position", "OBSERVATION_MODIFIER", 79, 87]]], ["In an athlete who has a pre-existing murmur, a new or changing murmur may be noted.", [["a pre-existing murmur", "PROBLEM", 22, 43], ["a new or changing murmur", "PROBLEM", 45, 69], ["murmur", "OBSERVATION", 37, 43], ["new", "OBSERVATION_MODIFIER", 47, 50], ["murmur", "OBSERVATION", 63, 69]]], ["Other findings on examination may include splenomegaly or cardinal peripheral manifestations such as petechiae, splinter hemorrhages, Osler's nodes, Janeway's lesions, or Roth's spots [130] .DiagnosisThe diagnosis of IE should be investigated when athletes who have fever also present with one or more of the cardinal manifestations of IE.", [["petechiae", "ANATOMY", 101, 110], ["lesions", "ANATOMY", 159, 166], ["splenomegaly", "DISEASE", 42, 54], ["petechiae", "DISEASE", 101, 110], ["hemorrhages", "DISEASE", 121, 132], ["IE", "DISEASE", 217, 219], ["fever", "DISEASE", 266, 271], ["IE", "DISEASE", 336, 338], ["petechiae", "PATHOLOGICAL_FORMATION", 101, 110], ["lesions", "PATHOLOGICAL_FORMATION", 159, 166], ["examination", "TEST", 18, 29], ["splenomegaly", "PROBLEM", 42, 54], ["cardinal peripheral manifestations", "PROBLEM", 58, 92], ["petechiae", "PROBLEM", 101, 110], ["splinter hemorrhages", "PROBLEM", 112, 132], ["Osler's nodes", "PROBLEM", 134, 147], ["Janeway's lesions", "PROBLEM", 149, 166], ["Roth's spots", "PROBLEM", 171, 183], ["fever", "PROBLEM", 266, 271], ["may include", "UNCERTAINTY", 30, 41], ["splenomegaly", "OBSERVATION", 42, 54], ["cardinal", "ANATOMY_MODIFIER", 58, 66], ["peripheral", "ANATOMY_MODIFIER", 67, 77], ["petechiae", "OBSERVATION", 101, 110], ["splinter", "OBSERVATION_MODIFIER", 112, 120], ["hemorrhages", "OBSERVATION", 121, 132], ["nodes", "ANATOMY", 142, 147], ["lesions", "OBSERVATION", 159, 166]]], ["The incorporation of clinical, laboratory, and echocardiographic data is central to the diagnosis [134, 135] .", [["echocardiographic data", "TEST", 47, 69]]], ["Nonspecific laboratory findings may include leukocytosis and elevated ESR and CRP [135] .", [["leukocytosis", "DISEASE", 44, 56], ["CRP [135]", "GENE_OR_GENE_PRODUCT", 78, 87], ["ESR", "PROTEIN", 70, 73], ["CRP", "PROTEIN", 78, 81], ["Nonspecific laboratory findings", "PROBLEM", 0, 31], ["leukocytosis", "PROBLEM", 44, 56], ["elevated ESR", "PROBLEM", 61, 73], ["CRP", "TEST", 78, 81], ["may include", "UNCERTAINTY", 32, 43], ["leukocytosis", "OBSERVATION", 44, 56]]], ["EKG may reveal new atrioventricular, fascicular, or bundle branch block depending on cardiac involvement [134] .", [["atrioventricular", "ANATOMY", 19, 35], ["fascicular", "ANATOMY", 37, 47], ["bundle branch", "ANATOMY", 52, 65], ["cardiac", "ANATOMY", 85, 92], ["atrioventricular", "MULTI-TISSUE_STRUCTURE", 19, 35], ["cardiac", "ORGAN", 85, 92], ["EKG", "TEST", 0, 3], ["new atrioventricular, fascicular", "PROBLEM", 15, 47], ["bundle branch block", "PROBLEM", 52, 71], ["new", "OBSERVATION_MODIFIER", 15, 18], ["atrioventricular", "OBSERVATION", 19, 35], ["fascicular", "ANATOMY_MODIFIER", 37, 47], ["bundle branch block", "OBSERVATION", 52, 71]]], ["The modified Duke criteria represent a diagnostic guideline for evaluating patients who have suspected IE that takes into account blood culture results, echocardiogram criteria, and history and physical examination characteristics [136] .TreatmentTreatment with parental antibiotics is usually started in the hospital but may be completed as an outpatient when the patient is afebrile and follow-up blood cultures are negative [135] .", [["blood", "ANATOMY", 130, 135], ["blood", "ANATOMY", 399, 404], ["patients", "ORGANISM", 75, 83], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["patient", "ORGANISM", 365, 372], ["blood", "ORGANISM_SUBSTANCE", 399, 404], ["patients", "SPECIES", 75, 83], ["patient", "SPECIES", 365, 372], ["blood culture", "TEST", 130, 143], ["echocardiogram criteria", "TEST", 153, 176], ["physical examination", "TEST", 194, 214], ["parental antibiotics", "TREATMENT", 262, 282], ["afebrile", "PROBLEM", 376, 384], ["follow-up blood cultures", "TEST", 389, 413]]], ["Antibiotic therapy should be selected as appropriate based on blood culture and sensitivities results.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["Antibiotic therapy", "TREATMENT", 0, 18], ["blood culture", "TEST", 62, 75]]], ["Initial therapy in native-valve IE with no history of intravenous drug abuse should be directed against streptococci organisms.", [["intravenous", "ANATOMY", 54, 65], ["drug abuse", "DISEASE", 66, 76], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 65], ["Initial therapy", "TREATMENT", 0, 15], ["native-valve", "TREATMENT", 19, 31], ["intravenous drug abuse", "TREATMENT", 54, 76], ["streptococci organisms", "PROBLEM", 104, 126], ["valve", "ANATOMY", 26, 31]]], ["Penicillin and gentamycin remain first-line therapy in this situation.", [["Penicillin", "CHEMICAL", 0, 10], ["gentamycin", "CHEMICAL", 15, 25], ["Penicillin", "CHEMICAL", 0, 10], ["gentamycin", "CHEMICAL", 15, 25], ["Penicillin", "SIMPLE_CHEMICAL", 0, 10], ["gentamycin", "SIMPLE_CHEMICAL", 15, 25], ["Penicillin", "TREATMENT", 0, 10], ["gentamycin", "TREATMENT", 15, 25], ["first-line therapy", "TREATMENT", 33, 51], ["line therapy", "OBSERVATION", 39, 51]]], ["Depending on the pathogen involved, antibiotic treatment should last between 2 and 6 weeks [135] .ComplicationsValvular damage may lead to aortic regurgitation (AR) or MR in patients who have IE.", [["Valvular", "ANATOMY", 111, 119], ["aortic", "ANATOMY", 139, 145], ["Valvular damage", "DISEASE", 111, 126], ["aortic regurgitation", "DISEASE", 139, 159], ["MR", "DISEASE", 168, 170], ["IE", "DISEASE", 192, 194], ["Valvular", "ORGAN", 111, 119], ["aortic", "MULTI-TISSUE_STRUCTURE", 139, 145], ["patients", "ORGANISM", 174, 182], ["MR", "PROTEIN", 168, 170], ["patients", "SPECIES", 174, 182], ["antibiotic treatment", "TREATMENT", 36, 56], ["ComplicationsValvular damage", "PROBLEM", 98, 126], ["aortic regurgitation (AR", "PROBLEM", 139, 163], ["MR", "PROBLEM", 168, 170], ["aortic", "ANATOMY", 139, 145], ["regurgitation", "OBSERVATION", 146, 159]]], ["If left untreated, IE can progress to severe heart failure and potentially fatal arrhythmias [135] .", [["heart", "ANATOMY", 45, 50], ["IE", "DISEASE", 19, 21], ["heart failure", "DISEASE", 45, 58], ["arrhythmias", "DISEASE", 81, 92], ["heart", "ORGAN", 45, 50], ["severe heart failure", "PROBLEM", 38, 58], ["fatal arrhythmias", "PROBLEM", 75, 92], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["heart", "ANATOMY", 45, 50], ["failure", "OBSERVATION", 51, 58]]], ["In addition, complications from septic emboli may result, such as stroke, kidney failure, or pulmonary embolism.Return to PlayFrom an infectious standpoint, before return to competition, the athlete should complete at least 2 to 6 weeks of appropriate antibiotic treatment and remain afebrile with negative follow-up blood cultures.", [["kidney", "ANATOMY", 74, 80], ["pulmonary", "ANATOMY", 93, 102], ["blood", "ANATOMY", 317, 322], ["septic emboli", "DISEASE", 32, 45], ["stroke", "DISEASE", 66, 72], ["kidney failure", "DISEASE", 74, 88], ["pulmonary embolism", "DISEASE", 93, 111], ["kidney", "ORGAN", 74, 80], ["pulmonary", "ORGAN", 93, 102], ["blood", "ORGANISM_SUBSTANCE", 317, 322], ["septic emboli", "PROBLEM", 32, 45], ["stroke", "PROBLEM", 66, 72], ["kidney failure", "PROBLEM", 74, 88], ["pulmonary embolism", "PROBLEM", 93, 111], ["appropriate antibiotic treatment", "TREATMENT", 240, 272], ["afebrile", "PROBLEM", 284, 292], ["blood cultures", "TEST", 317, 331], ["septic", "OBSERVATION_MODIFIER", 32, 38], ["emboli", "OBSERVATION", 39, 45], ["kidney", "ANATOMY", 74, 80], ["failure", "OBSERVATION", 81, 88], ["pulmonary", "ANATOMY", 93, 102], ["embolism", "OBSERVATION", 103, 111], ["infectious", "OBSERVATION", 134, 144]]], ["Athletes require close monitoring with frequent follow-up.", [["close monitoring", "TEST", 17, 33]]], ["When the antimicrobial treatment is complete, repeat echocardiography should be performed to establish a new baseline [135] .", [["the antimicrobial treatment", "TREATMENT", 5, 32], ["repeat echocardiography", "TEST", 46, 69]]], ["Repeat physical examinations are important to look for any signs of heart failure.", [["heart", "ANATOMY", 68, 73], ["heart failure", "DISEASE", 68, 81], ["heart", "ORGAN", 68, 73], ["Repeat physical examinations", "TEST", 0, 28], ["heart failure", "PROBLEM", 68, 81], ["heart", "ANATOMY", 68, 73], ["failure", "OBSERVATION", 74, 81]]], ["Before any initiation of antibiotic therapy for any febrile illnesses, the athlete should have three sets of blood cultures obtained from separate sites.", [["blood cultures", "ANATOMY", 109, 123], ["febrile illnesses", "DISEASE", 52, 69], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["antibiotic therapy", "TREATMENT", 25, 43], ["any febrile illnesses", "PROBLEM", 48, 69], ["blood cultures", "TEST", 109, 123]]], ["The athlete also requires thorough dental evaluations to ensure oral hygiene.Return to PlayFrom a cardiac standpoint, the athlete may have residual MR or AR.", [["oral", "ANATOMY", 64, 68], ["cardiac", "ANATOMY", 98, 105], ["oral", "ORGANISM_SUBDIVISION", 64, 68], ["MR", "PROTEIN", 148, 150], ["AR", "PROTEIN", 154, 156], ["thorough dental evaluations", "TEST", 26, 53], ["residual MR", "PROBLEM", 139, 150], ["AR", "PROBLEM", 154, 156], ["cardiac", "ANATOMY", 98, 105]]], ["Athletes who have MR from IE may be restricted from competition.", [["MR", "DISEASE", 18, 20], ["IE", "DISEASE", 26, 28], ["MR", "PROTEIN", 18, 20], ["MR", "TEST", 18, 20]]], ["Current recommendations are based on the severity of MR, echocardiogram findings of LV size and function, and pulmonary artery pressure readings [95] :Return to PlayAthletes who have mild to moderate MR in normal sinus rhythm, with normal LV size, LV function, and pulmonary artery pressures, can participate in all competitive sports.", [["LV", "ANATOMY", 84, 86], ["pulmonary artery", "ANATOMY", 110, 126], ["sinus", "ANATOMY", 213, 218], ["LV", "ANATOMY", 239, 241], ["LV", "ANATOMY", 248, 250], ["pulmonary artery", "ANATOMY", 265, 281], ["MR", "DISEASE", 53, 55], ["MR", "DISEASE", 200, 202], ["LV", "MULTI-TISSUE_STRUCTURE", 84, 86], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 110, 126], ["sinus", "ORGAN", 213, 218], ["LV", "MULTI-TISSUE_STRUCTURE", 239, 241], ["LV", "MULTI-TISSUE_STRUCTURE", 248, 250], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 265, 281], ["MR", "PROTEIN", 53, 55], ["MR", "PROTEIN", 200, 202], ["MR", "TEST", 53, 55], ["echocardiogram", "TEST", 57, 71], ["pulmonary artery pressure readings", "TEST", 110, 144], ["mild to moderate MR", "PROBLEM", 183, 202], ["LV function", "TEST", 248, 259], ["pulmonary artery pressures", "PROBLEM", 265, 291], ["LV", "ANATOMY", 84, 86], ["size", "OBSERVATION_MODIFIER", 87, 91], ["pulmonary artery", "ANATOMY", 110, 126], ["mild", "OBSERVATION_MODIFIER", 183, 187], ["moderate", "OBSERVATION_MODIFIER", 191, 199], ["normal sinus rhythm", "OBSERVATION", 206, 225], ["normal", "OBSERVATION", 232, 238], ["LV", "ANATOMY", 239, 241], ["size", "OBSERVATION_MODIFIER", 242, 246], ["LV function", "OBSERVATION", 248, 259], ["pulmonary artery", "ANATOMY", 265, 281], ["pressures", "OBSERVATION_MODIFIER", 282, 291]]], ["Athletes who have mild LV enlargement (<60 mm) may participate but are restricted to certain classes of sports.", [["LV", "ANATOMY", 23, 25], ["LV enlargement", "DISEASE", 23, 37], ["LV", "ORGAN", 23, 25], ["mild LV enlargement", "PROBLEM", 18, 37], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["LV", "ANATOMY", 23, 25], ["enlargement", "OBSERVATION", 26, 37]]], ["Athletes who have severe MR, LV enlargement (>60 mm), LV systolic dysfunction, or elevated pulmonary artery pressures should not participate in any competitive sports.Return to PlayIf AR is present in any athlete who has IE, the current recommendations are to assess the severity of AR with echocardiography and measurement of LV end diastolic size [95] :Return to PlayAthletes who have mild to moderate AR and normal LV end diastolic size may participate in all competitive sports.", [["LV", "ANATOMY", 29, 31], ["LV", "ANATOMY", 54, 56], ["pulmonary artery", "ANATOMY", 91, 107], ["LV", "ANATOMY", 327, 329], ["LV", "ANATOMY", 418, 420], ["MR", "DISEASE", 25, 27], ["LV enlargement", "DISEASE", 29, 43], ["LV systolic dysfunction", "DISEASE", 54, 77], ["LV", "MULTI-TISSUE_STRUCTURE", 29, 31], ["LV", "MULTI-TISSUE_STRUCTURE", 54, 56], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 91, 107], ["PlayIf AR", "GENE_OR_GENE_PRODUCT", 177, 186], ["LV", "MULTI-TISSUE_STRUCTURE", 418, 420], ["MR", "PROTEIN", 25, 27], ["PlayIf AR", "PROTEIN", 177, 186], ["AR", "PROTEIN", 404, 406], ["severe MR", "PROBLEM", 18, 27], ["LV enlargement", "PROBLEM", 29, 43], ["LV systolic dysfunction", "PROBLEM", 54, 77], ["elevated pulmonary artery pressures", "PROBLEM", 82, 117], ["AR", "PROBLEM", 283, 285], ["echocardiography", "TEST", 291, 307], ["LV end diastolic size", "TEST", 327, 348], ["mild to moderate AR", "PROBLEM", 387, 406], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["LV", "ANATOMY", 29, 31], ["enlargement", "OBSERVATION", 32, 43], ["LV systolic", "ANATOMY", 54, 65], ["dysfunction", "OBSERVATION", 66, 77], ["elevated", "OBSERVATION", 82, 90], ["pulmonary artery", "ANATOMY", 91, 107], ["pressures", "OBSERVATION_MODIFIER", 108, 117], ["LV", "ANATOMY", 327, 329], ["diastolic", "OBSERVATION_MODIFIER", 334, 343], ["size", "OBSERVATION_MODIFIER", 344, 348], ["mild", "OBSERVATION_MODIFIER", 387, 391], ["moderate", "OBSERVATION_MODIFIER", 395, 403], ["AR", "OBSERVATION", 404, 406], ["normal", "OBSERVATION", 411, 417], ["LV", "ANATOMY", 418, 420], ["end diastolic", "OBSERVATION", 421, 434], ["size", "OBSERVATION_MODIFIER", 435, 439]]], ["Athletes who have severe AR and increased LV diastolic diameter (>65 mm)Return to Playshould not participate in sports.", [["LV", "ANATOMY", 42, 44], ["LV diastolic", "MULTI-TISSUE_STRUCTURE", 42, 54], ["severe AR", "PROBLEM", 18, 27], ["increased LV diastolic diameter", "PROBLEM", 32, 63], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["AR", "OBSERVATION", 25, 27], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["LV diastolic", "ANATOMY", 42, 54], ["diameter", "OBSERVATION_MODIFIER", 55, 63]]], ["Symptomatic athletes who have mild to moderate AR should not participate in sports regardless of LV size.SUMMARYPulmonary and cardiac infections in the athlete can have a wide range of presentations and complications.", [["LV", "ANATOMY", 97, 99], ["cardiac", "ANATOMY", 126, 133], ["cardiac infections", "DISEASE", 126, 144], ["LV", "MULTI-TISSUE_STRUCTURE", 97, 99], ["cardiac", "ORGAN", 126, 133], ["Symptomatic athletes", "PROBLEM", 0, 20], ["mild to moderate AR", "PROBLEM", 30, 49], ["cardiac infections", "PROBLEM", 126, 144], ["complications", "PROBLEM", 203, 216], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["AR", "OBSERVATION", 47, 49], ["LV", "ANATOMY", 97, 99], ["size", "OBSERVATION_MODIFIER", 100, 104], ["cardiac", "ANATOMY", 126, 133], ["infections", "OBSERVATION", 134, 144], ["wide", "OBSERVATION_MODIFIER", 171, 175]]], ["These infections may present few problems for the training athlete or become life-threatening.", [["infections", "DISEASE", 6, 16], ["These infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16], ["few", "OBSERVATION_MODIFIER", 29, 32]]]], "748ef951c31564eb3eb37a7bc947ce5ff4cb5fdd": [["RNA pseudoknots are important motifs that are formed by base pairing between the nucleotides in a loop region and complementary bases outside the loop ( Figure 1A ).", [["nucleotides", "CHEMICAL", 81, 92], ["RNA pseudoknots", "RNA", 0, 15], ["loop region", "DNA", 98, 109], ["RNA pseudoknots", "PROBLEM", 0, 15], ["a loop region", "TREATMENT", 96, 109], ["pseudoknots", "OBSERVATION", 4, 15], ["base", "ANATOMY_MODIFIER", 56, 60], ["loop", "ANATOMY_MODIFIER", 98, 102], ["bases", "ANATOMY_MODIFIER", 128, 133], ["loop", "OBSERVATION_MODIFIER", 146, 150]]], ["They exist widely in viral RNA (1) (2) (3) , rRNA (4, 5) , mRNA (6-10), tmRNA (11, 12) , ribozymes (13, 14) , telomerase RNA (15) (16) (17) (18) , aptamers (19) , and others and are important for ribosomal frameshifting (20, 21) , riboswitches (22) , catalysis (13, 17) , etc. (23) .", [["ribosomal", "ANATOMY", 196, 205], ["viral RNA (1) (2) (3)", "GENE_OR_GENE_PRODUCT", 21, 42], ["rRNA", "GENE_OR_GENE_PRODUCT", 45, 49], ["tmRNA", "GENE_OR_GENE_PRODUCT", 72, 77], ["telomerase RNA (15) (16) (17)", "GENE_OR_GENE_PRODUCT", 110, 139], ["ribosomal", "CELLULAR_COMPONENT", 196, 205], ["rRNA", "DNA", 45, 49], ["mRNA", "RNA", 59, 63], ["tmRNA", "DNA", 72, 77], ["ribozymes", "DNA", 89, 98], ["rRNA", "TEST", 45, 49], ["mRNA", "TEST", 59, 63], ["tmRNA", "TEST", 72, 77], ["ribozymes", "TEST", 89, 98], ["telomerase RNA", "TEST", 110, 124], ["aptamers", "TEST", 147, 155], ["ribosomal frameshifting", "PROBLEM", 196, 219], ["catalysis", "TEST", 251, 260], ["widely", "OBSERVATION_MODIFIER", 11, 17], ["viral RNA", "OBSERVATION", 21, 30], ["ribosomal frameshifting", "OBSERVATION", 196, 219]]], ["A typical H-type RNA pseudoknot ( Figure 1B) is formed by two stems and two or three loops (2) .", [["H-type RNA pseudoknot", "RNA", 10, 31], ["A typical H-type RNA pseudoknot", "PROBLEM", 0, 31], ["H-type", "OBSERVATION_MODIFIER", 10, 16], ["RNA pseudoknot", "OBSERVATION", 17, 31], ["two stems", "OBSERVATION_MODIFIER", 58, 67], ["loops", "ANATOMY_MODIFIER", 85, 90]]], ["Loop 1 spans the deep major groove of stem 2, and loop 3 spans the shallow minor groove of stem 1.", [["stem 2", "ANATOMY", 38, 44], ["stem 1", "ANATOMY", 91, 97], ["Loop 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["stem 2", "CELL", 38, 44], ["stem 1", "CELL", 91, 97], ["Loop 1", "PROTEIN", 0, 6], ["loop", "TEST", 50, 54], ["deep", "ANATOMY_MODIFIER", 17, 21], ["major groove", "ANATOMY_MODIFIER", 22, 34], ["stem 2", "ANATOMY_MODIFIER", 38, 44], ["loop 3", "ANATOMY_MODIFIER", 50, 56], ["shallow", "OBSERVATION_MODIFIER", 67, 74], ["minor", "OBSERVATION_MODIFIER", 75, 80], ["groove", "ANATOMY_MODIFIER", 81, 87], ["stem 1", "ANATOMY_MODIFIER", 91, 97]]], ["Loop 2, which is usually zero or one nucleotide, separates stems 1 and 2.", [["nucleotide", "CHEMICAL", 37, 47], ["Loop 2", "GENE_OR_GENE_PRODUCT", 0, 6]]], ["For the formation of a pseudoknot, the lengths of the other loops have to meet some requirements (24) .", [["the other loops", "PROBLEM", 50, 65], ["pseudoknot", "OBSERVATION", 23, 33], ["loops", "OBSERVATION", 60, 65]]], ["Examination of the natural pseudoknots collected in Pseudo-Base (25) revealed different length distributions for each pseudoknot loop and stem (26) .", [["Examination", "TEST", 0, 11], ["the natural pseudoknots", "TEST", 15, 38], ["different length distributions", "PROBLEM", 78, 108], ["natural pseudoknots", "OBSERVATION", 19, 38], ["Base", "ANATOMY_MODIFIER", 59, 63], ["different", "OBSERVATION_MODIFIER", 78, 87], ["length", "OBSERVATION_MODIFIER", 88, 94], ["pseudoknot loop", "OBSERVATION", 118, 133], ["stem", "OBSERVATION_MODIFIER", 138, 142]]]], "PMC7424615": [["\u201cI never thought we\u2019d have so many videos of hand-washing,\u201d YouTube CEO Susan Wojcicki candidly remarked in an interview for CNN on 19 April.", [["hand", "ANATOMY", 45, 49], ["hand", "ORGANISM_SUBDIVISION", 45, 49]]], ["Just 2 weeks prior, YouTube had already said it would tighten its grip around channels spreading misinformation after a live-stream interview of renowned British conspiracy theorist David Icke\u2014in which he falsely linked the spread of the coronavirus to 5G technology\u2014gained substantial traction online (Kelion, 2020).", [["coronavirus", "DISEASE", 238, 249], ["coronavirus", "ORGANISM", 238, 249]]]], "a51659a324f74a7cf16acd3b1180d203cab2b8d4": [["characteristic, a rodent parvovirus has been used in a phase \u0399 /\u0399 \u0399 a clinical trial to prevent tumour recurrence in patients with glioblastoma multiforma 5 .", [["tumour", "ANATOMY", 96, 102], ["glioblastoma", "ANATOMY", 131, 143], ["parvovirus", "DISEASE", 25, 35], ["tumour", "DISEASE", 96, 102], ["glioblastoma", "DISEASE", 131, 143], ["parvovirus", "ORGANISM", 25, 35], ["tumour", "CANCER", 96, 102], ["patients", "ORGANISM", 117, 125], ["glioblastoma", "CANCER", 131, 143], ["rodent", "SPECIES", 18, 24], ["patients", "SPECIES", 117, 125], ["rodent parvovirus", "SPECIES", 18, 35], ["a rodent parvovirus", "PROBLEM", 16, 35], ["a clinical trial", "TREATMENT", 68, 84], ["tumour recurrence", "PROBLEM", 96, 113], ["glioblastoma multiforma", "PROBLEM", 131, 154], ["parvovirus", "OBSERVATION", 25, 35], ["tumour", "OBSERVATION_MODIFIER", 96, 102], ["recurrence", "OBSERVATION", 103, 113], ["glioblastoma", "OBSERVATION", 131, 143]]], ["Currently, the clinical application of several chemotherapeutic agents is limited because of their severe toxic effects to healthy cells.", [["cells", "ANATOMY", 131, 136], ["cells", "CELL", 131, 136], ["healthy cells", "CELL_TYPE", 123, 136], ["several chemotherapeutic agents", "TREATMENT", 39, 70], ["their severe toxic effects to healthy cells", "PROBLEM", 93, 136], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["toxic", "OBSERVATION", 106, 111]]], ["Anti-cancer therapy using a virus that can selectively target cancer cells has become a popular approach.", [["cancer cells", "ANATOMY", 62, 74], ["cancer", "DISEASE", 62, 68], ["cancer cells", "CELL", 62, 74], ["cancer cells", "CELL_TYPE", 62, 74], ["Anti-cancer therapy", "TREATMENT", 0, 19], ["a virus", "PROBLEM", 26, 33], ["a popular approach", "TREATMENT", 86, 104]]], ["CPV is a virus that can be potentially used to treat cancer 13 .", [["cancer", "ANATOMY", 53, 59], ["cancer", "DISEASE", 53, 59], ["CPV", "ORGANISM", 0, 3], ["cancer", "CANCER", 53, 59], ["CPV", "SPECIES", 0, 3], ["CPV", "PROBLEM", 0, 3], ["a virus", "PROBLEM", 7, 14], ["cancer", "PROBLEM", 53, 59], ["virus", "OBSERVATION", 9, 14], ["cancer", "OBSERVATION", 53, 59]]], ["A previous study has shown that CPV2 NS1 can lead to regression of skin tumours in Wistar rats without producing toxic side effects on healthy cells 14 .", [["skin tumours", "ANATOMY", 67, 79], ["cells", "ANATOMY", 143, 148], ["skin tumours", "DISEASE", 67, 79], ["CPV2 NS1", "ORGANISM", 32, 40], ["skin tumours", "CANCER", 67, 79], ["Wistar rats", "ORGANISM", 83, 94], ["cells", "CELL", 143, 148], ["CPV2 NS1", "PROTEIN", 32, 40], ["rats", "SPECIES", 90, 94], ["CPV2", "SPECIES", 32, 36], ["A previous study", "TEST", 0, 16], ["CPV2 NS1", "PROBLEM", 32, 40], ["skin tumours", "PROBLEM", 67, 79], ["toxic side effects on healthy cells", "PROBLEM", 113, 148], ["skin", "ANATOMY", 67, 71], ["tumours", "OBSERVATION", 72, 79]]], ["Moreover, the CPV NS1 protein shows anti-tumour activity in a mouse mammary tumour model, and it further stimulates the immune cells to attack the tumour 15 .", [["mammary tumour", "ANATOMY", 68, 82], ["immune cells", "ANATOMY", 120, 132], ["tumour", "ANATOMY", 147, 153], ["mammary tumour", "DISEASE", 68, 82], ["tumour", "DISEASE", 147, 153], ["CPV", "ORGANISM", 14, 17], ["NS1", "GENE_OR_GENE_PRODUCT", 18, 21], ["anti-tumour", "CANCER", 36, 47], ["mouse", "ORGANISM", 62, 67], ["mammary tumour", "CANCER", 68, 82], ["immune cells", "CELL", 120, 132], ["tumour", "CANCER", 147, 153], ["CPV NS1 protein", "PROTEIN", 14, 29], ["immune cells", "CELL_TYPE", 120, 132], ["mouse", "SPECIES", 62, 67], ["CPV", "SPECIES", 14, 17], ["mouse", "SPECIES", 62, 67], ["the CPV NS1 protein", "TEST", 10, 29], ["anti-tumour activity", "PROBLEM", 36, 56], ["a mouse mammary tumour model", "TREATMENT", 60, 88], ["anti-tumour activity", "OBSERVATION", 36, 56], ["mammary", "ANATOMY", 68, 75]]]], "PMC7367513": [["Patients & study design ::: Materials & methodsPatients with appointments between 17 January 2020 and 10 May 2020 were retrospectively reviewed on the appointment list of patients who were going to receive CT at our healthcare center.", [["Patients", "ORGANISM", 0, 8], ["Patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 171, 179], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 47, 55], ["patients", "SPECIES", 171, 179], ["CT", "TEST", 206, 208]]], ["Patients who did not come for CT on the date of their appointment were identified by reviewing the patient records.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 99, 106], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 99, 106], ["CT", "TEST", 30, 32]]], ["The CT postponement rates were calculated for the 60-day periods before and after 10 March 2020, when the first COVID-19 case was diagnosed in Turkey.", [["The CT postponement rates", "TEST", 0, 25]]], ["We planned to include all adult patients (>18 years of age) with postponed CT and histopathologically diagnosed cancer.", [["cancer", "ANATOMY", 112, 118], ["cancer", "DISEASE", 112, 118], ["patients", "ORGANISM", 32, 40], ["cancer", "CANCER", 112, 118], ["patients", "SPECIES", 32, 40], ["postponed CT", "TEST", 65, 77], ["histopathologically diagnosed cancer", "PROBLEM", 82, 118], ["cancer", "OBSERVATION", 112, 118]]], ["Illiterate patients, those with symptomatic brain metastases that could disrupt cognitive functions, those with psychiatric disorders and those with anxiety disorders were excluded from the study.", [["brain metastases", "ANATOMY", 44, 60], ["brain metastases", "DISEASE", 44, 60], ["cognitive functions", "DISEASE", 80, 99], ["psychiatric disorders", "DISEASE", 112, 133], ["anxiety disorders", "DISEASE", 149, 166], ["patients", "ORGANISM", 11, 19], ["brain", "ORGAN", 44, 49], ["patients", "SPECIES", 11, 19], ["symptomatic brain metastases", "PROBLEM", 32, 60], ["psychiatric disorders", "PROBLEM", 112, 133], ["anxiety disorders", "PROBLEM", 149, 166], ["the study", "TEST", 186, 195], ["symptomatic", "OBSERVATION_MODIFIER", 32, 43], ["brain", "ANATOMY", 44, 49], ["metastases", "OBSERVATION", 50, 60]]], ["To obtain the most accurate information about the psychiatric and anxiety disorders of the patients, we made a two-step evaluation.", [["psychiatric", "DISEASE", 50, 61], ["anxiety disorders", "DISEASE", 66, 83], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["the psychiatric and anxiety disorders", "PROBLEM", 46, 83], ["a two-step evaluation", "TEST", 109, 130]]], ["Firstly, we examined the follow-up notes and histories in our patient follow-up forms in detail and hospital patient electronic data file were retrospectively screened for any information about psychiatric problems.", [["psychiatric", "DISEASE", 194, 205], ["patient", "ORGANISM", 62, 69], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 109, 116], ["psychiatric problems", "PROBLEM", 194, 214]]], ["Secondly, we asked each patient whether they had a history of psychiatric or anxiety disorder.Patients & study design ::: Materials & methodsData on patients\u2019 age, sex, comorbidities, history of smoking, marital status, number of children, educational background, place of residence and household, cancer type, disease stage, CT regimen and date of CT postponement were obtained from the hospital records.", [["cancer", "ANATOMY", 298, 304], ["psychiatric", "DISEASE", 62, 73], ["anxiety disorder", "DISEASE", 77, 93], ["smoking", "CHEMICAL", 195, 202], ["cancer", "DISEASE", 298, 304], ["patient", "ORGANISM", 24, 31], ["Patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 149, 157], ["children", "ORGANISM", 230, 238], ["cancer", "CANCER", 298, 304], ["patient", "SPECIES", 24, 31], ["Patients", "SPECIES", 94, 102], ["patients", "SPECIES", 149, 157], ["children", "SPECIES", 230, 238], ["anxiety disorder", "PROBLEM", 77, 93], ["cancer type, disease stage", "PROBLEM", 298, 324], ["CT regimen", "TREATMENT", 326, 336], ["CT postponement", "TEST", 349, 364], ["cancer", "OBSERVATION", 298, 304]]], ["A patient questionnaire (prepared using the Google survey program) that involved the Beck anxiety inventory (BAI) and questions about COVID-19 fear was sent to patients on WhatsApp, along with the informed consent form.", [["anxiety", "DISEASE", 90, 97], ["patient", "ORGANISM", 2, 9], ["patients", "ORGANISM", 160, 168], ["patient", "SPECIES", 2, 9], ["patients", "SPECIES", 160, 168]]], ["A database was created using the data obtained from the hospital records and the patients\u2019 responses in the questionnaire.Identification of the causes of CT postponement & the formation of patient groups ::: Materials & methodsThe reasons given by the patients who postponed CT were first investigated using the hospital records.", [["patients", "ORGANISM", 81, 89], ["patient", "ORGANISM", 189, 196], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 81, 89], ["patient", "SPECIES", 189, 196], ["patients", "SPECIES", 252, 260], ["A database", "TEST", 0, 10], ["CT postponement", "TEST", 154, 169], ["CT", "TEST", 275, 277]]], ["Patients who reported that they did not come to their CT appointment due to COV-FA according to the hospital records were called by phone to confirm their reason for CT postponement and the COV-FA group was formed.", [["COV-FA", "CHEMICAL", 190, 196], ["Patients", "ORGANISM", 0, 8], ["COV-FA", "SIMPLE_CHEMICAL", 190, 196], ["Patients", "SPECIES", 0, 8], ["CT postponement", "TEST", 166, 181], ["the COV", "TEST", 186, 193]]], ["Patients who had postponed their CT but had no record of the reason for the postponement in the hospital records were called; those who stated they postponed their CT due to COV-FA were also included in the COV-FA group.", [["Patients", "ORGANISM", 0, 8], ["COV-FA", "SIMPLE_CHEMICAL", 174, 180], ["COV-FA", "SIMPLE_CHEMICAL", 207, 213], ["Patients", "SPECIES", 0, 8], ["their CT", "TEST", 27, 35], ["their CT", "TEST", 158, 166], ["COV-FA", "TEST", 174, 180]]], ["During the telephone conversations with patients in the COV-FA group, the patients were invited to participate in the survey study and all of these patients (30 patients) agreed.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 161, 169], ["the survey study", "TEST", 114, 130]]], ["Those with postponed CT due to neutropenia, thrombocytopenia, acute renal failure, drug-related side effects like skin toxicity and non-COV-FA reasons such as infection and thrombosis were also invited to participate in the survey study and formed the \u2018other\u2019 group (80 patients).", [["renal", "ANATOMY", 68, 73], ["skin", "ANATOMY", 114, 118], ["neutropenia", "DISEASE", 31, 42], ["thrombocytopenia", "DISEASE", 44, 60], ["acute renal failure", "DISEASE", 62, 81], ["skin toxicity", "DISEASE", 114, 127], ["infection", "DISEASE", 159, 168], ["thrombosis", "DISEASE", 173, 183], ["renal", "ORGAN", 68, 73], ["skin", "ORGAN", 114, 118], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["postponed CT", "TEST", 11, 23], ["neutropenia", "PROBLEM", 31, 42], ["thrombocytopenia", "PROBLEM", 44, 60], ["acute renal failure", "PROBLEM", 62, 81], ["side effects", "PROBLEM", 96, 108], ["skin toxicity", "PROBLEM", 114, 127], ["non-COV-FA reasons", "PROBLEM", 132, 150], ["infection", "PROBLEM", 159, 168], ["thrombosis", "PROBLEM", 173, 183], ["the survey study", "TEST", 220, 236], ["neutropenia", "OBSERVATION", 31, 42], ["thrombocytopenia", "OBSERVATION", 44, 60], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["renal", "ANATOMY", 68, 73], ["failure", "OBSERVATION", 74, 81], ["skin", "ANATOMY", 114, 118], ["toxicity", "OBSERVATION", 119, 127], ["infection", "OBSERVATION", 159, 168], ["thrombosis", "OBSERVATION", 173, 183]]], ["The demographic and clinical characteristics, questionnaire responses and BAI scores of both groups (30 patients in the \u2018COV-FA\u2019 and 80 patients in the \u2018other\u2019 group) were compared.", [["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 136, 144], ["questionnaire responses", "TEST", 46, 69], ["BAI scores", "TEST", 74, 84]]], ["Factors associated with CT postponement due to COV-FA were identified.Telemedicine application ::: Materials & methodsWe started the telemedicine practice 35 days after the first COVID-19 case in Turkey for patients who had been receiving treatment at the Medical Oncology Chemotherapy Day Unit.", [["COV-FA", "SIMPLE_CHEMICAL", 47, 53], ["patients", "ORGANISM", 207, 215], ["COV", "PROTEIN", 47, 50], ["patients", "SPECIES", 207, 215], ["CT postponement", "TEST", 24, 39], ["COV-FA", "PROBLEM", 47, 53], ["Telemedicine application", "TREATMENT", 70, 94], ["treatment", "TREATMENT", 239, 248]]], ["As part of this practice, patients with a booked CT appointment were called by a medical oncology specialist doctor a few days before their appointment.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["During these phone calls, patients were asked whether they had any symptoms of COVID-19 (fever, cough, sputum and shortness of breath), whether they had been in contact with someone infected with COVID-19 and whether they had traveled abroad in the last 14 days.", [["COVID", "DISEASE", 79, 84], ["fever", "DISEASE", 89, 94], ["cough", "DISEASE", 96, 101], ["shortness of breath", "DISEASE", 114, 133], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["any symptoms", "PROBLEM", 63, 75], ["COVID", "TEST", 79, 84], ["fever", "PROBLEM", 89, 94], ["cough", "PROBLEM", 96, 101], ["sputum", "PROBLEM", 103, 109], ["shortness of breath", "PROBLEM", 114, 133]]], ["The patients were also informed about whether there were COVID-19 cases in our healthcare center as of the day the phone call was made.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Any questions the patients asked about COVID-19 were answered.Follow-up of the COV-FA group & termination of the study ::: Materials & methodsThe hospital records of the patients who postponed their CT appointments due to COV-FA on the day of freezing the database for the present study were reviewed again and a record of whether they had returned to our clinic to receive CT again was added to the database.", [["COV-FA", "CHEMICAL", 222, 228], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 170, 178], ["the study", "TEST", 109, 118], ["COV", "TEST", 222, 225], ["the present study", "TEST", 269, 286], ["CT", "TEST", 374, 376]]], ["The dates when patients returned to receive CT again were recorded.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["CT", "TEST", 44, 46]]], ["Those who had not yet been readmitted for CT administration were interviewed by phone and the last contact date for these patients was recorded as May 28, 2020, the date of freezing the study database.Beck Anxiety Inventory ::: Materials & methodsThe BAI is a multiple-choice self-report inventory used for measuring the severity of anxiety in children and adults [11].", [["anxiety", "DISEASE", 333, 340], ["patients", "ORGANISM", 122, 130], ["children", "ORGANISM", 344, 352], ["patients", "SPECIES", 122, 130], ["children", "SPECIES", 344, 352], ["CT administration", "TEST", 42, 59], ["the study database", "TEST", 182, 200], ["Beck Anxiety", "PROBLEM", 201, 213], ["anxiety", "PROBLEM", 333, 340]]], ["It was developed by Beck et al. and a study of its reliability and validity in Turkey was carried out by Ulusoy et al. [12] The questions used in this measure ask about common symptoms of anxiety that the subject has had during the past week (including the day on which the test is taken), such as numbness and tingling, sweating not due to heat and fear of the worst happening [11].", [["anxiety", "DISEASE", 188, 195], ["numbness", "DISEASE", 298, 306], ["a study", "TEST", 36, 43], ["common symptoms", "PROBLEM", 169, 184], ["anxiety", "PROBLEM", 188, 195], ["numbness", "PROBLEM", 298, 306], ["tingling", "PROBLEM", 311, 319], ["sweating", "PROBLEM", 321, 329]]], ["The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely) [11].", [["BAI", "DNA", 4, 7], ["a scale value", "TEST", 59, 72]]], ["Higher total scores indicate more severe anxiety symptoms [11].Statistical analysis ::: Materials & methodsData analysis was performed using IBM SSPS Statistics for Windows v.20.0 software (IBM, NY, USA).", [["anxiety", "DISEASE", 41, 48], ["Higher total scores", "PROBLEM", 0, 19], ["more severe anxiety symptoms", "PROBLEM", 29, 57], ["methodsData analysis", "TEST", 100, 120]]], ["Qualitative variables were expressed as frequencies and percentage, whereas the quantitative variables were expressed as mean (\u00b1 standard deviation) or median.", [["Qualitative variables", "PROBLEM", 0, 21]]], ["The conformity of the numerical data to the normal distribution was assessed using the Kolmogorov\u2013Smirnov test.", [["the Kolmogorov\u2013Smirnov test", "TEST", 83, 110], ["normal", "OBSERVATION", 44, 50]]], ["The Student t test was used to compare the parametric data and the Mann\u2013Whitney U test was used to compare the nonparametric data.", [["Student t test", "DNA", 4, 18], ["The Student t test", "TEST", 0, 18], ["the parametric data", "TEST", 39, 58], ["the Mann\u2013Whitney U test", "TEST", 63, 86], ["the nonparametric data", "TEST", 107, 129]]], ["Pearson's chi-square or Fisher's exact test was performed to compare the categorical data.", [["Fisher's exact test", "TEST", 24, 43], ["the categorical data", "TEST", 69, 89]]], ["TCBT was defined as the elapsed time from CT postponement until either return for treatment or the last contact.", [["CT postponement", "TEST", 42, 57], ["treatment", "TREATMENT", 82, 91]]], ["TCBT was determined using the Kaplan\u2013Meier method and the log-rank test was used for univariate comparison.", [["TCBT", "SIMPLE_CHEMICAL", 0, 4], ["the log-rank test", "TEST", 54, 71], ["univariate comparison", "TEST", 85, 106]]], ["A multivariate Cox regression model was used to identify independent predictive factors on TCBT.", [["A multivariate Cox regression model", "TEST", 0, 35]]], ["All statistical analyses were two-way and the level of statistical significance was set at p < 0.05.ResultsOf 2112 patients with CT appointments in the 60-day period preceding the first COVID-19 case (10 March 2020), 245 (11.6%) had their CT appointment postponed; of a total of 1549 patients with a CT appointment in the 60-day period following the first COVID-19 case, 220 (14.2%) had their CT appointment postponed (\u03c72 = 5.729, p = 0.017).", [["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 284, 292], ["All statistical analyses", "TEST", 0, 24], ["a CT", "TEST", 298, 302], ["their CT", "TEST", 387, 395]]], ["The three most common reasons for postponing CT after COVID-19 were neutropenia (23.1%), thrombocytopenia (20.9%) and COV-FA (13.6%; Table 1); 27 patients (17.4%) postponed CT due to COV-FA before the introduction of the telemedicine practice, but only three patients (4.6%) postponed CT for this reason (p = 0.012; Figure 1) after the telemedicine practice was initiated.ResultsThe median age of the 110 patients who participated in the study was 63 years (range 54\u201370); 36.4% were male and 63.6% were female.", [["neutropenia", "DISEASE", 68, 79], ["thrombocytopenia", "DISEASE", 89, 105], ["COV-FA", "CHEMICAL", 183, 189], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 259, 267], ["patients", "ORGANISM", 405, 413], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 405, 413], ["postponing CT", "TEST", 34, 47], ["COVID", "TEST", 54, 59], ["neutropenia", "PROBLEM", 68, 79], ["thrombocytopenia", "PROBLEM", 89, 105], ["COV-FA", "TEST", 118, 124], ["CT", "TEST", 173, 175], ["COV-FA", "PROBLEM", 183, 189], ["CT", "TEST", 285, 287], ["the telemedicine practice", "TREATMENT", 332, 357], ["the study", "TEST", 434, 443], ["thrombocytopenia", "OBSERVATION", 89, 105]]], ["The demographic and clinical characteristics of all patients in the COV-FA group and the other group are shown in Table 2.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["The percentage of female patients in the COV-FA group was significantly higher than that in the other group (80.0 vs 57.5%, p = 0.049).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["the COV-FA group", "TEST", 37, 53], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["There was no significant difference between the two groups in terms of age, disease stage or CT administration modality.ResultsIn total, 110 patients who responded to the questionnaire, including those with COV-FA-related CT postponement or CT postponement due to other reasons, were compared in terms of their social characteristics, survey results and BAI.", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["disease stage", "PROBLEM", 76, 89], ["CT administration modality", "TEST", 93, 119], ["COV-FA", "TEST", 207, 213], ["CT postponement", "TEST", 222, 237], ["CT postponement", "TEST", 241, 256], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["The groups were similar in terms of marital status, place of residence, educational background, comorbidity, history of smoking and access to the hospital.", [["smoking", "CHEMICAL", 120, 127], ["comorbidity", "PROBLEM", 96, 107]]], ["The COV-FA group had a higher rate of \u2018Yes\u2019 responses to the questions \u2018Are you afraid of COVID-19?\u2019, \u2018Does it bother you to think about COVID-19?\u2019, \u2018Does the concern of getting COVID-19 disrupt your sleep?\u2019, \u2018Do you worry about COVID-19 news and stories you read on social media?\u2019, \u2018Does the thought of getting COVID-19 give you palpitations?\u2019 than the other group (Table 3).", [["palpitations", "DISEASE", 330, 342], ["COVID-19", "CHEMICAL", 178, 186], ["palpitations", "PROBLEM", 330, 342]]], ["The mean BAI of the COV-FA group was significantly higher than that of the other group (18.9 vs 3.3, p < 0.001).ResultsAs of the date when the study analyses were performed, 16 of the 30 patients in the COV-FA group returned to receive CT again, while 14 were not admitted by our clinic for CT again.", [["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the COV-FA group", "TEST", 16, 32], ["vs", "TEST", 93, 95], ["p", "TEST", 101, 102], ["the study analyses", "TEST", 139, 157], ["CT", "TEST", 236, 238], ["CT", "TEST", 291, 293], ["COV", "OBSERVATION_MODIFIER", 20, 23], ["higher", "OBSERVATION_MODIFIER", 51, 57]]], ["We contacted those 14 patients and they stated they did not want to return to their treatment for a while due to the pandemic process.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["the pandemic process", "PROBLEM", 113, 133], ["pandemic", "OBSERVATION", 117, 125]]], ["The median CT postponement time of the patients in the COV-FA group was 47 days (range 19\u201372; Figure 2).ResultsFollowing univariate analysis of the factors that may affect the TCBT of the patients, advanced age (\u226560 years) and advanced-stage disease were associated with longer TCBT.", [["COV-FA", "CHEMICAL", 55, 61], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 188, 196], ["univariate analysis", "TEST", 121, 140], ["advanced-stage disease", "PROBLEM", 227, 249], ["disease", "OBSERVATION", 242, 249]]], ["The median TCBT of patients with stage II, III and IV disease were 33, 53 and 70 days, respectively (p = 0.048; Table 4).", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["stage II, III and IV disease", "PROBLEM", 33, 61], ["stage II", "OBSERVATION_MODIFIER", 33, 41], ["disease", "OBSERVATION", 54, 61]]], ["The median TCBT of those receiving palliative treatment was 70 days and the mean for those who did not receive palliative treatment was 45 days (p = 0.072).ResultsAs a result of the univariate analysis, a Cox regression model was created based on the factors whose p-value was <0.20 (age, stage and treatment modality; Table 5).", [["palliative treatment", "TREATMENT", 35, 55], ["palliative treatment", "TREATMENT", 111, 131], ["the univariate analysis", "TEST", 178, 201], ["a Cox regression model", "TEST", 203, 225], ["p-value", "TEST", 265, 272], ["treatment modality", "TREATMENT", 299, 317]]], ["As a result of the multivariate analysis, advanced age (\u226560 years) was found to be an independent factor predicting TCBT (hazard ratio = 0.291, p = 0.043).DiscussionAs far as we know, ours is the first study to investigate COV-FA within the context of CT adherence in patients with cancer receiving active CT.", [["cancer", "ANATOMY", 282, 288], ["TCBT", "DISEASE", 116, 120], ["cancer", "DISEASE", 282, 288], ["COV-FA", "SIMPLE_CHEMICAL", 223, 229], ["patients", "ORGANISM", 268, 276], ["cancer", "CANCER", 282, 288], ["patients", "SPECIES", 268, 276], ["the multivariate analysis", "TEST", 15, 40], ["hazard ratio", "TEST", 122, 134], ["the first study", "TEST", 192, 207], ["COV", "TEST", 223, 226], ["CT adherence", "TREATMENT", 252, 264], ["cancer", "PROBLEM", 282, 288], ["active CT", "TEST", 299, 308], ["cancer", "OBSERVATION", 282, 288]]], ["In the present study, it was seen that the CT postponement rate increased significantly following the first COVID-19 case in Turkey and COV-FA was identified as the third most frequent reason for CT postponement.", [["COV-FA", "SIMPLE_CHEMICAL", 136, 142], ["the CT postponement rate", "TEST", 39, 63], ["COV-FA", "TEST", 136, 142], ["CT postponement", "TEST", 196, 211]]], ["COV-FA-related CT postponement was more frequent in women than in men.", [["women", "ORGANISM", 52, 57], ["men", "ORGANISM", 66, 69], ["women", "SPECIES", 52, 57], ["men", "SPECIES", 66, 69], ["CT postponement", "TEST", 15, 30]]], ["Patient age was also found to be an independent factor that predicted TCBT.", [["Patient", "ORGANISM", 0, 7], ["Patient", "SPECIES", 0, 7]]], ["Patients aged \u226560 years had longer TCBT than those aged <60 years.DiscussionStudies have shown that anxiety disorders have negative effects on adherence to CT in patients with cancer [4,5].", [["cancer", "ANATOMY", 176, 182], ["anxiety disorders", "DISEASE", 100, 117], ["cancer", "DISEASE", 176, 182], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 162, 170], ["cancer", "CANCER", 176, 182], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 162, 170], ["anxiety disorders", "PROBLEM", 100, 117], ["CT", "TEST", 156, 158], ["cancer", "PROBLEM", 176, 182]]], ["In their study involving 135 patients with colon cancer, Zhu et al. investigated the causes that led to postponement of adjuvant CT initiation; they concluded that anxiety is an independent predictive factor for postponing CT [5].", [["colon cancer", "ANATOMY", 43, 55], ["colon cancer", "DISEASE", 43, 55], ["anxiety", "DISEASE", 164, 171], ["patients", "ORGANISM", 29, 37], ["colon cancer", "CANCER", 43, 55], ["patients", "SPECIES", 29, 37], ["their study", "TEST", 3, 14], ["colon cancer", "PROBLEM", 43, 55], ["adjuvant CT initiation", "TREATMENT", 120, 142], ["anxiety", "PROBLEM", 164, 171], ["postponing CT", "TEST", 212, 225], ["colon", "ANATOMY", 43, 48], ["cancer", "OBSERVATION", 49, 55]]], ["In a prospective study that included 50 patients with advanced lung cancer, Greer et al. showed that anxiety is one of the factors that negatively affects adherence to chemotherapy [4].", [["lung cancer", "ANATOMY", 63, 74], ["lung cancer", "DISEASE", 63, 74], ["anxiety", "DISEASE", 101, 108], ["patients", "ORGANISM", 40, 48], ["lung cancer", "CANCER", 63, 74], ["patients", "SPECIES", 40, 48], ["a prospective study", "TEST", 3, 22], ["advanced lung cancer", "PROBLEM", 54, 74], ["anxiety", "PROBLEM", 101, 108], ["chemotherapy", "TREATMENT", 168, 180], ["lung", "ANATOMY", 63, 67], ["cancer", "OBSERVATION", 68, 74]]], ["The present study also investigates how elevated anxiety and fear in society during the pandemic can affect the chemotherapy process.", [["anxiety", "DISEASE", 49, 56], ["The present study", "TEST", 0, 17], ["elevated anxiety", "PROBLEM", 40, 56], ["the chemotherapy process", "TREATMENT", 108, 132]]], ["The significant difference found in the CT postponement rates in our oncology center before and after the first COVID-19 case (11.6 vs 14.2%) suggested that it could be due to COV-FA.", [["COV-FA", "SIMPLE_CHEMICAL", 176, 182], ["COV", "PROTEIN", 176, 179], ["the first COVID", "TEST", 102, 117], ["COV-FA", "PROBLEM", 176, 182], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["difference", "OBSERVATION_MODIFIER", 16, 26]]], ["COV-FA was the third most common cause among the reasons for postponing CT after the first COVID-19 case.", [["COV", "GENE_OR_GENE_PRODUCT", 0, 3], ["postponing CT", "TEST", 61, 74]]], ["Patients who have had COVID-19 infection may be more likely to develop fear and anxiety; however, because there were no COVID-19 infected patients in our study, we could not comment on CT postponement rates in these patients.DiscussionThe present study revealed that female sex can be a risk factor for COV-FA, which is consistent with the literature.", [["infection", "DISEASE", 31, 40], ["anxiety", "DISEASE", 80, 87], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 216, 224], ["COV-FA", "SIMPLE_CHEMICAL", 303, 309], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 216, 224], ["COVID-19 infection", "PROBLEM", 22, 40], ["anxiety", "PROBLEM", 80, 87], ["COVID", "TEST", 120, 125], ["our study", "TEST", 150, 159], ["CT postponement rates", "TEST", 185, 206], ["The present study", "TEST", 235, 252], ["COV-FA", "PROBLEM", 303, 309], ["infection", "OBSERVATION", 31, 40], ["consistent with", "UNCERTAINTY", 320, 335]]], ["Many studies have proven that anxiety disorders occur more often in women [13].", [["anxiety disorders", "DISEASE", 30, 47], ["women", "ORGANISM", 68, 73], ["women", "SPECIES", 68, 73], ["Many studies", "TEST", 0, 12], ["anxiety disorders", "PROBLEM", 30, 47]]], ["In the study conducted by Braamse et al. to investigate factors associated with the causes of anxiety and depression in patients with colorectal cancer, women were twice as likely as men to have anxiety [14].", [["colorectal cancer", "ANATOMY", 134, 151], ["anxiety", "DISEASE", 94, 101], ["depression", "DISEASE", 106, 116], ["colorectal cancer", "DISEASE", 134, 151], ["anxiety", "DISEASE", 195, 202], ["patients", "ORGANISM", 120, 128], ["colorectal cancer", "CANCER", 134, 151], ["women", "ORGANISM", 153, 158], ["men", "ORGANISM", 183, 186], ["patients", "SPECIES", 120, 128], ["women", "SPECIES", 153, 158], ["men", "SPECIES", 183, 186], ["the study", "TEST", 3, 12], ["anxiety", "PROBLEM", 94, 101], ["depression", "PROBLEM", 106, 116], ["colorectal cancer", "PROBLEM", 134, 151], ["anxiety", "PROBLEM", 195, 202], ["colorectal", "ANATOMY", 134, 144], ["cancer", "OBSERVATION", 145, 151]]], ["The relationship between anxiety and female sex has been found to be similar in studies of the COVID-19 pandemic, including one in Turkey [7,15].", [["anxiety", "DISEASE", 25, 32], ["anxiety", "PROBLEM", 25, 32], ["the COVID", "TEST", 91, 100]]], ["A meta-analysis showed that COVID-19 anxiety was particularly more common in female healthcare workers than in male healthcare workers [15].", [["anxiety", "DISEASE", 37, 44], ["A meta-analysis", "TEST", 0, 15], ["COVID", "TEST", 28, 33], ["anxiety", "PROBLEM", 37, 44]]], ["One study showed that chronic diseases and living in the city center also increase the risk of anxiety [13].", [["chronic diseases", "DISEASE", 22, 38], ["anxiety", "DISEASE", 95, 102], ["One study", "TEST", 0, 9], ["chronic diseases", "PROBLEM", 22, 38], ["anxiety", "PROBLEM", 95, 102], ["chronic", "OBSERVATION_MODIFIER", 22, 29], ["diseases", "OBSERVATION", 30, 38]]], ["In the present study, there was no significant difference between the patients with CT postponement due to COV-FA and those with CT postponement due to other reasons in terms of chronic diseases and place of residence.DiscussionTelemedicine provides an important advantage in protecting patients with cancer from COVID-19 infection because these patients already have immunosuppression [16]; 35 days after the first COVID-19 case in Turkey, we started interviewing follow-up patients at our oncology center using telemedicine.", [["cancer", "ANATOMY", 301, 307], ["cancer", "DISEASE", 301, 307], ["infection", "DISEASE", 322, 331], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 287, 295], ["cancer", "CANCER", 301, 307], ["COVID-19", "ORGANISM", 313, 321], ["patients", "ORGANISM", 346, 354], ["patients", "ORGANISM", 475, 483], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 287, 295], ["patients", "SPECIES", 346, 354], ["patients", "SPECIES", 475, 483], ["the present study", "TEST", 3, 20], ["CT postponement", "TEST", 84, 99], ["COV-FA", "TEST", 107, 113], ["CT postponement", "TEST", 129, 144], ["chronic diseases", "PROBLEM", 178, 194], ["cancer", "PROBLEM", 301, 307], ["COVID-19 infection", "PROBLEM", 313, 331], ["immunosuppression", "TREATMENT", 368, 385], ["no", "UNCERTAINTY", 32, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["difference", "OBSERVATION", 47, 57], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["diseases", "OBSERVATION", 186, 194]]], ["Patients\u2019 follow-up, examination results and treatment responses were all evaluated during video calls.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["examination", "TEST", 21, 32]]], ["Moreover, the patients were questioned about whether they had symptoms of COVID-19, thereby ensuring the early diagnosis of a possible COVID-19 infection and reducing the risk of these patients infecting other patients in the CT day unit.", [["infection", "DISEASE", 144, 153], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 210, 218], ["symptoms", "PROBLEM", 62, 70], ["COVID", "TEST", 74, 79], ["COVID-19 infection", "PROBLEM", 135, 153], ["infection", "OBSERVATION", 144, 153]]], ["During the interviews, we shared up-to-date information about whether COVID-19 cases were seen in our healthcare center and encouraged patients to continue their treatment by informing them about the undesired consequences of treatment discontinuation.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["their treatment", "TREATMENT", 156, 171], ["treatment discontinuation", "TREATMENT", 226, 251]]], ["These interviews using telemedicine might have yielded positive results, especially in terms of CT postponement rates.", [["CT postponement rates", "TEST", 96, 117]]], ["CT postponement rates related to COV-FA decreased after the telemedicine application had started; however, it would not be correct to associate this decrease in COV-FA-related CT postponement rate to telemedicine alone.DiscussionWe have not encountered any study in the literature that examines the TCBT in patients with postponed CT.", [["COV-FA", "CHEMICAL", 33, 39], ["COV-FA", "SIMPLE_CHEMICAL", 33, 39], ["FA", "SIMPLE_CHEMICAL", 165, 167], ["TCBT", "CANCER", 299, 303], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 307, 315], ["CT postponement rates", "TEST", 0, 21], ["COV", "TEST", 33, 36], ["the telemedicine application", "TREATMENT", 56, 84], ["this decrease in COV-FA", "PROBLEM", 144, 167], ["any study", "TEST", 253, 262], ["postponed CT", "TEST", 321, 333]]], ["In the present study, the median TCBT of the patients who postponed CT due to COV-FA was 47 days (range 19\u201372).", [["COV", "DISEASE", 78, 81], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["the present study", "TEST", 3, 20], ["CT", "TEST", 68, 70], ["COV-FA", "TEST", 78, 84]]], ["The multivariate analysis showed that only advanced age is an independent factor that predicts TCBT.", [["The multivariate analysis", "TEST", 0, 25]]], ["We believe that the long TCBT of the elderly patients herein may be related to the coverage of this information in the news.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["As a matter of fact, one of the questions the patients were asked as part of the present study was whether they were following news or social media concerning COVID-19; the majority (76.7%) of the patients who postponed their CT due to COV-FA responded \u2018Yes\u2019 to this question.DiscussionRepeated media exposure to community crisis can lead to increased anxiety and studies have shown that media and social media exposure might increase COVID-19 anxiety [19,20].", [["anxiety", "DISEASE", 352, 359], ["anxiety", "DISEASE", 444, 451], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 197, 205], ["COV-FA", "SIMPLE_CHEMICAL", 236, 242], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 197, 205], ["COVID", "TEST", 159, 164], ["their CT", "TEST", 220, 228], ["community crisis", "PROBLEM", 313, 329], ["increased anxiety", "PROBLEM", 342, 359], ["studies", "TEST", 364, 371], ["social media exposure", "TREATMENT", 398, 419], ["anxiety", "PROBLEM", 444, 451]]], ["People have been exposed to news of COVID-19 in different ways and have different ideas of the severity of the pandemic.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["COVID", "TEST", 36, 41], ["the pandemic", "PROBLEM", 107, 119], ["pandemic", "OBSERVATION", 111, 119]]], ["Our study did not measure media exposure or social media exposure by an objective method; however, rates of following the news or social media concerning COVID-19 were similar between the \u2018COV-FA\u2019 and \u2018other\u2019 groups in our study.", [["Our study", "TEST", 0, 9], ["an objective method", "TEST", 69, 88], ["COVID", "TEST", 154, 159], ["our study", "TEST", 219, 228]]], ["Considering that the difference between rural and urban residents might affect COVID-19 anxiety, we compared the \u2018COV-FA\u2019 and \u2018other\u2019 groups in terms of the regions where the patients live but did not find any difference between the groups.DiscussionThe present study has some limitations.", [["anxiety", "DISEASE", 88, 95], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["anxiety", "PROBLEM", 88, 95], ["The present study", "TEST", 250, 267]]], ["Patients included in the present study were very heterogeneous in terms of their cancer diagnoses and only a small number of patients were included.", [["cancer", "ANATOMY", 81, 87], ["cancer", "DISEASE", 81, 87], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 81, 87], ["patients", "ORGANISM", 125, 133], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 125, 133], ["the present study", "TEST", 21, 38], ["very", "OBSERVATION_MODIFIER", 44, 48], ["heterogeneous", "OBSERVATION", 49, 62], ["cancer", "OBSERVATION", 81, 87], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["Another limitation arising from the retrospective design of the study is that the elapsed time from the date of survey delivery to the patients and the date of CT postponement was not the same for all patients.", [["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 201, 209], ["the study", "TEST", 60, 69], ["CT postponement", "TEST", 160, 175]]], ["Patients with psychiatric disorders were excluded from the study; however, cancer-related anxiety that we have not yet noticed (especially in patients at the beginning of the diagnosis and treatment process) might be confounding some of the results.", [["cancer", "ANATOMY", 75, 81], ["psychiatric disorders", "DISEASE", 14, 35], ["cancer", "DISEASE", 75, 81], ["anxiety", "DISEASE", 90, 97], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 75, 81], ["patients", "ORGANISM", 142, 150], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 142, 150], ["psychiatric disorders", "PROBLEM", 14, 35], ["the study", "TEST", 55, 64], ["cancer", "PROBLEM", 75, 81], ["anxiety", "PROBLEM", 90, 97], ["treatment process", "TREATMENT", 189, 206], ["cancer", "OBSERVATION", 75, 81]]], ["Our study was conducted within a short period of time after the first COVID-19 case.", [["Our study", "TEST", 0, 9]]], ["It would be useful to support our findings using longitudinal studies to generalize our results, because different results can be obtained with long-term studies.ConclusionsThe present study concludes that COV-FA increases CT postponement rates, telemedicine can contribute to reducing COV-FA-related CT postponement rates, female sex can be a risk factor for COV-FA-related CT postponement and advanced age is a factor that could predict increased TCBT.", [["COV-FA", "CHEMICAL", 206, 212], ["COV-FA", "SIMPLE_CHEMICAL", 206, 212], ["longitudinal studies", "TEST", 49, 69], ["long-term studies", "TEST", 144, 161], ["The present study", "TEST", 173, 190], ["COV", "TEST", 206, 209], ["reducing COV-FA", "PROBLEM", 277, 292], ["CT postponement rates", "PROBLEM", 301, 322], ["COV-FA", "PROBLEM", 360, 366], ["CT postponement", "PROBLEM", 375, 390], ["increased TCBT", "PROBLEM", 439, 453]]]], "364cead576f72be17ef8bf8da931dfdca2aed5c6": [["IntroductionH irschsprung's disease (HSCR), also called Hirschsprung disease, congenital aganglionic megacolon or congenital megacolon, is a type of megacolon induced by deficiency or dysfunction of ganglion cells in the distal intestine.", [["ganglion cells", "ANATOMY", 199, 213], ["distal intestine", "ANATOMY", 221, 237], ["irschsprung's disease", "DISEASE", 14, 35], ["HSCR", "DISEASE", 37, 41], ["Hirschsprung disease", "DISEASE", 56, 76], ["congenital aganglionic megacolon", "DISEASE", 78, 110], ["congenital megacolon", "DISEASE", 114, 134], ["megacolon", "DISEASE", 149, 158], ["megacolon", "PATHOLOGICAL_FORMATION", 149, 158], ["ganglion cells", "CELL", 199, 213], ["distal intestine", "ORGAN", 221, 237], ["ganglion cells", "CELL_TYPE", 199, 213], ["IntroductionH irschsprung's disease (HSCR)", "PROBLEM", 0, 42], ["Hirschsprung disease", "PROBLEM", 56, 76], ["congenital aganglionic megacolon", "PROBLEM", 78, 110], ["congenital megacolon", "PROBLEM", 114, 134], ["megacolon", "PROBLEM", 149, 158], ["deficiency", "PROBLEM", 170, 180], ["dysfunction of ganglion cells in the distal intestine", "PROBLEM", 184, 237], ["disease", "OBSERVATION", 28, 35], ["Hirschsprung disease", "OBSERVATION", 56, 76], ["congenital", "OBSERVATION_MODIFIER", 78, 88], ["aganglionic megacolon", "OBSERVATION", 89, 110], ["congenital", "OBSERVATION_MODIFIER", 114, 124], ["megacolon", "OBSERVATION", 125, 134], ["megacolon", "OBSERVATION", 149, 158], ["deficiency", "OBSERVATION", 170, 180], ["ganglion cells", "OBSERVATION", 199, 213], ["distal", "ANATOMY_MODIFIER", 221, 227], ["intestine", "ANATOMY", 228, 237]]], ["[1] In HSCR, the affected colon segment cannot relax the bowels; therefore, HSCR is characterized by fecal retention, intestinal obstruction, constipation and abdominal distention.", [["colon", "ANATOMY", 26, 31], ["bowels", "ANATOMY", 57, 63], ["fecal", "ANATOMY", 101, 106], ["intestinal", "ANATOMY", 118, 128], ["abdominal", "ANATOMY", 159, 168], ["HSCR", "DISEASE", 7, 11], ["HSCR", "DISEASE", 76, 80], ["fecal retention", "DISEASE", 101, 116], ["intestinal obstruction", "DISEASE", 118, 140], ["constipation", "DISEASE", 142, 154], ["abdominal distention", "DISEASE", 159, 179], ["colon", "ORGAN", 26, 31], ["bowels", "ORGAN", 57, 63], ["fecal", "ORGANISM_SUBDIVISION", 101, 106], ["intestinal", "ORGAN", 118, 128], ["abdominal", "ORGANISM_SUBDIVISION", 159, 168], ["HSCR", "PROBLEM", 7, 11], ["HSCR", "PROBLEM", 76, 80], ["fecal retention", "PROBLEM", 101, 116], ["intestinal obstruction", "PROBLEM", 118, 140], ["constipation", "PROBLEM", 142, 154], ["abdominal distention", "PROBLEM", 159, 179], ["HSCR", "OBSERVATION", 7, 11], ["colon", "ANATOMY", 26, 31], ["segment", "ANATOMY_MODIFIER", 32, 39], ["bowels", "ANATOMY", 57, 63], ["HSCR", "OBSERVATION", 76, 80], ["fecal retention", "OBSERVATION", 101, 116], ["intestinal", "ANATOMY", 118, 128], ["obstruction", "OBSERVATION", 129, 140], ["constipation", "OBSERVATION", 142, 154], ["abdominal", "ANATOMY", 159, 168], ["distention", "OBSERVATION", 169, 179]]], ["[2] HSCR usually occurs in children, especially boys, and seriously impacts quality of life and, possibly, mortality.", [["HSCR", "DISEASE", 4, 8], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["HSCR", "PROBLEM", 4, 8]]], ["[3] In Japan, the incidence rate of HSCR is approximately one in 5000 births.", [["HSCR", "DISEASE", 36, 40], ["HSCR", "OBSERVATION", 36, 40]]], ["[4] Treatment strategies of HSCR include resection of the abnormal colon segment and reanastomosis.", [["colon", "ANATOMY", 67, 72], ["HSCR", "DISEASE", 28, 32], ["reanastomosis", "DISEASE", 85, 98], ["colon segment", "MULTI-TISSUE_STRUCTURE", 67, 80], ["Treatment strategies", "TREATMENT", 4, 24], ["HSCR", "PROBLEM", 28, 32], ["resection", "TREATMENT", 41, 50], ["the abnormal colon segment", "PROBLEM", 54, 80], ["reanastomosis", "TREATMENT", 85, 98], ["resection", "OBSERVATION", 41, 50], ["abnormal", "OBSERVATION_MODIFIER", 58, 66], ["colon", "ANATOMY", 67, 72], ["segment", "ANATOMY_MODIFIER", 73, 80], ["reanastomosis", "OBSERVATION", 85, 98]]], ["However, some children still have bowel dysfunction after treatment and need a lifetime of intestinal fistulas.", [["bowel", "ANATOMY", 34, 39], ["intestinal", "ANATOMY", 91, 101], ["bowel dysfunction", "DISEASE", 34, 51], ["intestinal fistulas", "DISEASE", 91, 110], ["children", "ORGANISM", 14, 22], ["bowel", "ORGAN", 34, 39], ["intestinal fistulas", "PATHOLOGICAL_FORMATION", 91, 110], ["children", "SPECIES", 14, 22], ["bowel dysfunction", "PROBLEM", 34, 51], ["treatment", "TREATMENT", 58, 67], ["intestinal fistulas", "TREATMENT", 91, 110], ["bowel", "ANATOMY", 34, 39], ["dysfunction", "OBSERVATION", 40, 51], ["intestinal", "ANATOMY", 91, 101], ["fistulas", "OBSERVATION", 102, 110]]], ["[5] Thus, it is necessary to investigate the mechanisms of HSCR and to develop novel targeted treatment strategies for this disease.IntroductionTo date, several studies have explored the key genes involved in HSCR.", [["HSCR", "DISEASE", 59, 63], ["HSCR", "DISEASE", 209, 213], ["HSCR", "DNA", 209, 213], ["HSCR", "PROBLEM", 59, 63], ["novel targeted treatment strategies", "TREATMENT", 79, 114], ["this disease", "PROBLEM", 119, 131], ["several studies", "TEST", 153, 168], ["HSCR", "OBSERVATION", 209, 213]]], ["For instance, the RET gene, which encodes a tyrosine-kinase receptor, plays an important role in the development of HSCR by affecting the enteric ganglia.", [["enteric ganglia", "ANATOMY", 138, 153], ["tyrosine", "CHEMICAL", 44, 52], ["HSCR", "DISEASE", 116, 120], ["tyrosine", "CHEMICAL", 44, 52], ["RET", "GENE_OR_GENE_PRODUCT", 18, 21], ["enteric ganglia", "ORGAN", 138, 153], ["RET gene", "DNA", 18, 26], ["tyrosine-kinase receptor", "PROTEIN", 44, 68], ["a tyrosine-kinase receptor", "TREATMENT", 42, 68], ["HSCR", "PROBLEM", 116, 120], ["HSCR", "OBSERVATION", 116, 120], ["enteric ganglia", "ANATOMY", 138, 153]]], ["[6] Previous studies have demonstrated that neuregulin 1 (NRG1) can serve as an HSCR susceptibility locus via mediating the development of the enteric ganglia precursors.", [["enteric ganglia", "ANATOMY", 143, 158], ["neuregulin 1", "GENE_OR_GENE_PRODUCT", 44, 56], ["NRG1", "GENE_OR_GENE_PRODUCT", 58, 62], ["enteric ganglia", "ANATOMICAL_SYSTEM", 143, 158], ["neuregulin 1", "PROTEIN", 44, 56], ["NRG1", "PROTEIN", 58, 62], ["HSCR susceptibility locus", "DNA", 80, 105], ["enteric ganglia precursors", "CELL_TYPE", 143, 169], ["Previous studies", "TEST", 4, 20], ["an HSCR susceptibility locus", "PROBLEM", 77, 105], ["HSCR", "OBSERVATION", 80, 84], ["enteric ganglia", "ANATOMY", 143, 158]]], ["[7, 8] The ablation of glial cell line-derived neurotrophic factor (GDNF) family receptor \u03b1 1 (GFR\u03b1 1 ), which is a high affi nity receptor for GDNF, can cause rapid and extensive death of enteric neurons and result in colon aganglionosis reminiscent of HSCR in mice during late gestation.", [["enteric neurons", "ANATOMY", 189, 204], ["colon", "ANATOMY", 219, 224], ["death", "DISEASE", 180, 185], ["colon aganglionosis", "DISEASE", 219, 238], ["HSCR", "DISEASE", 254, 258], ["glial cell line-derived neurotrophic factor (GDNF) family receptor \u03b1 1", "GENE_OR_GENE_PRODUCT", 23, 93], ["GFR\u03b1 1", "GENE_OR_GENE_PRODUCT", 95, 101], ["GDNF", "GENE_OR_GENE_PRODUCT", 144, 148], ["enteric neurons", "CELL", 189, 204], ["colon", "ORGAN", 219, 224], ["mice", "ORGANISM", 262, 266], ["glial cell line-derived neurotrophic factor (GDNF) family receptor \u03b1 1", "PROTEIN", 23, 93], ["GFR\u03b1 1", "PROTEIN", 95, 101], ["affi nity receptor", "PROTEIN", 121, 139], ["GDNF", "PROTEIN", 144, 148], ["enteric neurons", "CELL_TYPE", 189, 204], ["mice", "SPECIES", 262, 266], ["mice", "SPECIES", 262, 266], ["The ablation", "TREATMENT", 7, 19], ["glial cell line", "TREATMENT", 23, 38], ["GFR", "TEST", 95, 98], ["GDNF", "PROBLEM", 144, 148], ["rapid and extensive death of enteric neurons", "PROBLEM", 160, 204], ["colon aganglionosis", "PROBLEM", 219, 238], ["HSCR", "PROBLEM", 254, 258], ["glial cell line", "OBSERVATION", 23, 38], ["enteric neurons", "ANATOMY", 189, 204], ["colon", "ANATOMY", 219, 224], ["aganglionosis", "OBSERVATION", 225, 238], ["HSCR", "OBSERVATION", 254, 258]]], ["[9] Neurotrophin 3 (NTF3) and neurotrophic tyrosine kinase receptor 3 (NTRK3) may function in the pathogenesis of HSCR by affecting the development of the enteric nervous system (ENS) through the NTF3/NTRK3 signaling pathway.", [["enteric nervous system", "ANATOMY", 155, 177], ["ENS", "ANATOMY", 179, 182], ["tyrosine", "CHEMICAL", 43, 51], ["HSCR", "DISEASE", 114, 118], ["tyrosine", "CHEMICAL", 43, 51], ["[9] Neurotrophin 3", "GENE_OR_GENE_PRODUCT", 0, 18], ["NTF3", "GENE_OR_GENE_PRODUCT", 20, 24], ["neurotrophic tyrosine kinase receptor 3", "GENE_OR_GENE_PRODUCT", 30, 69], ["NTRK3", "GENE_OR_GENE_PRODUCT", 71, 76], ["enteric nervous system", "ANATOMICAL_SYSTEM", 155, 177], ["ENS", "ANATOMICAL_SYSTEM", 179, 182], ["NTF3", "GENE_OR_GENE_PRODUCT", 196, 200], ["NTRK3", "GENE_OR_GENE_PRODUCT", 201, 206], ["[9] Neurotrophin 3", "PROTEIN", 0, 18], ["NTF3", "PROTEIN", 20, 24], ["neurotrophic tyrosine kinase receptor 3", "PROTEIN", 30, 69], ["NTRK3", "PROTEIN", 71, 76], ["NTF3", "PROTEIN", 196, 200], ["NTRK3", "PROTEIN", 201, 206], ["Neurotrophin 3 (NTF3)", "TREATMENT", 4, 25], ["neurotrophic tyrosine kinase receptor", "TREATMENT", 30, 67], ["HSCR", "PROBLEM", 114, 118], ["the NTF3/NTRK3 signaling pathway", "TREATMENT", 192, 224], ["HSCR", "OBSERVATION", 114, 118], ["enteric nervous", "ANATOMY", 155, 170]]], ["[10, 11] Duan et al [12] found mutations of the endothelin 3 (EDN-3) and endothelin receptor type B (EDNRB) genes in short-segment HSCR in the Chinese population and determined that these genes may be correlated with the pathogenesis of HSCR.", [["HSCR", "DISEASE", 131, 135], ["HSCR", "DISEASE", 237, 241], ["endothelin 3", "GENE_OR_GENE_PRODUCT", 48, 60], ["EDN-3", "GENE_OR_GENE_PRODUCT", 62, 67], ["endothelin receptor type B", "GENE_OR_GENE_PRODUCT", 73, 99], ["EDNRB", "GENE_OR_GENE_PRODUCT", 101, 106], ["endothelin 3 (EDN-3) and endothelin receptor type B (EDNRB) genes", "DNA", 48, 113], ["short-segment HSCR", "DNA", 117, 135], ["the endothelin", "TEST", 44, 58], ["EDN", "TEST", 62, 65], ["endothelin receptor type B (EDNRB) genes in short-segment HSCR", "PROBLEM", 73, 135], ["HSCR", "PROBLEM", 237, 241], ["HSCR", "OBSERVATION", 237, 241]]], ["Cantrell et al [13] reported that interaction between sex determining region Y (SRY)-box 10 (Sox10) and endothelin receptor type B (EdnrB) affects the development of the ENS in mouse models and can affect the epistatic network, producing phenotypic variation among patients with aganglionosis.IntroductionRNA-sequencing (or massively parallel cDNA sequencing), which can detect gene changes, gene fusion, and somatic mutation, is an accurate method for quantifying and characterizing transcriptomes.", [["ENS", "ANATOMY", 170, 173], ["aganglionosis", "DISEASE", 279, 292], ["sex determining region Y (SRY)-box 10", "GENE_OR_GENE_PRODUCT", 54, 91], ["Sox10", "GENE_OR_GENE_PRODUCT", 93, 98], ["endothelin receptor type B", "GENE_OR_GENE_PRODUCT", 104, 130], ["EdnrB", "GENE_OR_GENE_PRODUCT", 132, 137], ["ENS", "ANATOMICAL_SYSTEM", 170, 173], ["mouse", "ORGANISM", 177, 182], ["patients", "ORGANISM", 265, 273], ["sex determining region Y (SRY)-box 10", "DNA", 54, 91], ["Sox10", "DNA", 93, 98], ["endothelin receptor type B", "PROTEIN", 104, 130], ["EdnrB", "PROTEIN", 132, 137], ["mouse", "SPECIES", 177, 182], ["patients", "SPECIES", 265, 273], ["mouse", "SPECIES", 177, 182], ["endothelin receptor type B (EdnrB)", "TREATMENT", 104, 138], ["the epistatic network", "PROBLEM", 205, 226], ["aganglionosis", "PROBLEM", 279, 292], ["IntroductionRNA", "TEST", 293, 308], ["massively parallel cDNA sequencing", "TEST", 324, 358], ["gene changes", "PROBLEM", 378, 390], ["gene fusion", "PROBLEM", 392, 403], ["somatic mutation", "PROBLEM", 409, 425], ["aganglionosis", "OBSERVATION", 279, 292]]], ["[14] Using RNA-sequencing data, Saeed et al [15] analyzed differentially expressed genes (DEGs) between abnormal and normal bowel segments in patients with HSCR relative to controls and found that reelin (RELN), galanin/GMAP prepropeptide (GAL), growth associated protein 43 (GAP43), Neurensin-1 (NRSN1), and gamma 2 subunit of the gamma-aminobutyric acid receptor type A (GABRG2) correlate with the pathogenesis of HSCR.", [["bowel", "ANATOMY", 124, 129], ["HSCR", "DISEASE", 156, 160], ["gamma-aminobutyric acid", "CHEMICAL", 332, 355], ["HSCR", "DISEASE", 416, 420], ["gamma-aminobutyric acid", "CHEMICAL", 332, 355], ["bowel segments", "MULTI-TISSUE_STRUCTURE", 124, 138], ["patients", "ORGANISM", 142, 150], ["reelin", "GENE_OR_GENE_PRODUCT", 197, 203], ["RELN", "GENE_OR_GENE_PRODUCT", 205, 209], ["galanin", "GENE_OR_GENE_PRODUCT", 212, 219], ["GMAP prepropeptide", "GENE_OR_GENE_PRODUCT", 220, 238], ["GAL", "GENE_OR_GENE_PRODUCT", 240, 243], ["growth associated protein 43", "GENE_OR_GENE_PRODUCT", 246, 274], ["GAP43", "GENE_OR_GENE_PRODUCT", 276, 281], ["Neurensin-1", "GENE_OR_GENE_PRODUCT", 284, 295], ["NRSN1", "GENE_OR_GENE_PRODUCT", 297, 302], ["gamma 2", "GENE_OR_GENE_PRODUCT", 309, 316], ["gamma-aminobutyric acid receptor type A", "GENE_OR_GENE_PRODUCT", 332, 371], ["GABRG2", "GENE_OR_GENE_PRODUCT", 373, 379], ["differentially expressed genes", "DNA", 58, 88], ["DEGs", "DNA", 90, 94], ["reelin", "PROTEIN", 197, 203], ["RELN", "PROTEIN", 205, 209], ["galanin", "PROTEIN", 212, 219], ["GMAP prepropeptide", "PROTEIN", 220, 238], ["GAL", "PROTEIN", 240, 243], ["growth associated protein 43", "PROTEIN", 246, 274], ["GAP43", "PROTEIN", 276, 281], ["Neurensin-1", "PROTEIN", 284, 295], ["NRSN1", "PROTEIN", 297, 302], ["gamma 2 subunit", "PROTEIN", 309, 324], ["gamma-aminobutyric acid receptor type A", "PROTEIN", 332, 371], ["GABRG2", "PROTEIN", 373, 379], ["patients", "SPECIES", 142, 150], ["RNA-sequencing data", "TEST", 11, 30], ["expressed genes (DEGs)", "PROBLEM", 73, 95], ["abnormal and normal bowel segments", "PROBLEM", 104, 138], ["HSCR", "PROBLEM", 156, 160], ["reelin (RELN)", "TREATMENT", 197, 210], ["galanin", "TEST", 212, 219], ["protein", "TEST", 264, 271], ["GAP43", "TEST", 276, 281], ["Neurensin", "TEST", 284, 293], ["HSCR", "PROBLEM", 416, 420], ["normal", "OBSERVATION", 117, 123], ["bowel segments", "ANATOMY", 124, 138], ["HSCR", "OBSERVATION", 416, 420]]], ["It is proposed that different analysis processes and thresholds can generate different results.", [["different analysis processes", "PROBLEM", 20, 48]]], ["[16] To gain a more comprehensive understanding of the pathogenesis of HSCR, RNA-sequencing data were used to analyze DEGs between expansion and narrow segment samples.", [["samples", "ANATOMY", 160, 167], ["HSCR", "DISEASE", 71, 75], ["HSCR", "DNA", 71, 75], ["DEGs", "DNA", 118, 122], ["RNA-sequencing data", "TEST", 77, 96], ["expansion and narrow segment samples", "PROBLEM", 131, 167], ["narrow segment", "OBSERVATION_MODIFIER", 145, 159]]], ["In addition, enrichment analysis, protein-protein interaction (PPI) network construction and module analysis were carried out separately to screen critical genes in HSCR.Sample collectionThis study was approved by the Institutional Review Board of the Second Affiliated Hospital of Xi'an Jiaotong University.", [["HSCR", "DISEASE", 165, 169], ["HSCR", "DNA", 165, 169], ["enrichment analysis", "TEST", 13, 32], ["protein", "TEST", 34, 41], ["PPI) network construction", "TREATMENT", 63, 88], ["module analysis", "TEST", 93, 108], ["Sample collection", "TEST", 170, 187], ["This study", "TEST", 187, 197], ["HSCR", "OBSERVATION", 165, 169], ["collection", "OBSERVATION", 177, 187]]], ["In addition, all participants provided their informed consent.", [["participants", "SPECIES", 17, 29]]], ["Using electronic colonoscopy, expansion segments and narrow segments of colon tissues were excised from children with HSCR who were treated in the Second Affiliated Hospital of Xi'an Jiaotong University from September 2014 to July 2015.", [["colon tissues", "ANATOMY", 72, 85], ["HSCR", "DISEASE", 118, 122], ["colon tissues", "TISSUE", 72, 85], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112], ["electronic colonoscopy", "TEST", 6, 28], ["expansion segments and narrow segments of colon tissues", "PROBLEM", 30, 85], ["expansion", "OBSERVATION_MODIFIER", 30, 39], ["segments", "OBSERVATION_MODIFIER", 40, 48], ["narrow", "OBSERVATION_MODIFIER", 53, 59], ["segments", "OBSERVATION_MODIFIER", 60, 68], ["colon tissues", "ANATOMY", 72, 85]]], ["The expansion segments and the narrow segments were randomly mixed in their respective groups to form 2 sequencing samples.", [["samples", "ANATOMY", 115, 122], ["The expansion segments and the narrow segments", "PROBLEM", 0, 46], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["segments", "OBSERVATION_MODIFIER", 14, 22], ["narrow", "OBSERVATION_MODIFIER", 31, 37], ["segments", "OBSERVATION_MODIFIER", 38, 46], ["randomly", "OBSERVATION_MODIFIER", 52, 60], ["mixed", "OBSERVATION_MODIFIER", 61, 66]]], ["All the patients were diagnosed with HSCR by barium enema and anorectal manometry evaluation before surgical treatment.", [["anorectal", "ANATOMY", 62, 71], ["HSCR", "DISEASE", 37, 41], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["HSCR", "PROBLEM", 37, 41], ["barium enema", "TEST", 45, 57], ["anorectal manometry evaluation", "TEST", 62, 92], ["surgical treatment", "TREATMENT", 100, 118], ["anorectal", "ANATOMY", 62, 71]]], ["Before surgery, a suction rectal biopsy was obtained to verify aganglionosis.", [["rectal", "ANATOMY", 26, 32], ["aganglionosis", "DISEASE", 63, 76], ["rectal biopsy", "MULTI-TISSUE_STRUCTURE", 26, 39], ["surgery", "TREATMENT", 7, 14], ["a suction rectal biopsy", "TEST", 16, 39], ["aganglionosis", "PROBLEM", 63, 76], ["aganglionosis", "OBSERVATION", 63, 76]]], ["After surgery, pathological staining was performed to establish a definitive diagnosis.", [["surgery", "TREATMENT", 6, 13], ["pathological staining", "TEST", 15, 36]]], ["The isolated tissues were cut into small pieces (<0.5 cm) and soaked in 5 times the volume of RNAlater (Ambion, Foster City, CA, USA) at 4\u00b0C overnight then stored at -80\u00b0C.RNA extraction and RNA-sequencing library constructionTotal RNA was extracted from the expansion and the narrow segments of colon tissues using TRIzol reagent (Invitrogen, Shanghai, China) according to the manufacturer's instructions.", [["tissues", "ANATOMY", 13, 20], ["pieces", "ANATOMY", 41, 47], ["colon tissues", "ANATOMY", 296, 309], ["tissues", "TISSUE", 13, 20], ["colon tissues", "TISSUE", 296, 309], ["RNA extraction", "TREATMENT", 172, 186], ["RNA", "TEST", 191, 194], ["sequencing library constructionTotal RNA", "PROBLEM", 195, 235], ["the expansion", "PROBLEM", 255, 268], ["TRIzol reagent", "TREATMENT", 316, 330], ["Invitrogen", "TREATMENT", 332, 342], ["isolated tissues", "OBSERVATION", 4, 20], ["small", "OBSERVATION_MODIFIER", 35, 40], ["pieces", "OBSERVATION_MODIFIER", 41, 47], ["<0.5 cm", "OBSERVATION_MODIFIER", 49, 56], ["expansion", "OBSERVATION_MODIFIER", 259, 268], ["narrow", "OBSERVATION_MODIFIER", 277, 283], ["segments", "OBSERVATION_MODIFIER", 284, 292], ["colon tissues", "ANATOMY", 296, 309]]], ["The integrity and purity of total RNA were detected using 2% agarose gel electrophoresis and spectrophotometry (Merinton, Beijing, China), respectively.", [["agarose", "SIMPLE_CHEMICAL", 61, 68], ["total RNA", "RNA", 28, 37], ["total RNA", "TREATMENT", 28, 37], ["2% agarose gel electrophoresis", "TREATMENT", 58, 88], ["integrity", "OBSERVATION_MODIFIER", 4, 13], ["purity", "OBSERVATION_MODIFIER", 18, 24]]], ["Finally, RNA-seq library construction and high-throughput sequencing were separately carried out using a NEBNext \u00ae Ultra\u2122 RNA Library Prep Kit for Illumina \u00ae (New England Biolabs, Ipswich, MA, USA) and an Illumina Hiseq 2500 v4 100PE System (Illumina, San Diego, CA, USA).Data preprocessing and DEG screeningThe NGSQC Toolkit [17] was used to preprocess the pairedend sequencing data and filter out low quality sequences.", [["low quality sequences", "DNA", 399, 420], ["RNA", "TEST", 9, 12], ["a NEBNext \u00ae Ultra\u2122 RNA", "TREATMENT", 103, 125], ["Illumina", "TEST", 147, 155], ["an Illumina Hiseq", "TEST", 202, 219], ["Data preprocessing", "TEST", 272, 290], ["DEG screening", "TEST", 295, 308]]], ["Using TopHat2 software, [18] sequence alignment of the preprocessed data was performed with the hg19 human genome sequences from the UCSC website (http:// genome.ucsc.edu) as references.", [["human", "ORGANISM", 101, 106], ["TopHat2 software", "DNA", 6, 22], ["hg19 human genome sequences", "DNA", 96, 123], ["UCSC website", "DNA", 133, 145], ["human", "SPECIES", 101, 106], ["hg19", "SPECIES", 96, 100], ["human", "SPECIES", 101, 106], ["the preprocessed data", "TEST", 51, 72]]], ["[19] Subsequently, the expression levels of genes were calculated using Cuffdiffs software [20] to obtain a gene expression matrix of samples.", [["samples", "ANATOMY", 134, 141]]], ["The \"edgeR\" package [21] in R was used to screen for DEGs between the expansion and the narrow segment samples.", [["samples", "ANATOMY", 103, 110], ["The \"edgeR\" package", "TREATMENT", 0, 19], ["the expansion", "TEST", 66, 79], ["expansion", "OBSERVATION_MODIFIER", 70, 79], ["narrow", "OBSERVATION_MODIFIER", 88, 94]]], ["The thresholds were P value <0.05 and |log 2 fold change (FC)| >1.Functional and pathway enrichment analysesGene Ontology (GO, http://www.geneontology.org/) seeks to develop and use a series of controlled, structured vocabularies for annotating sequences, genes and their products.", [["The thresholds", "TEST", 0, 14], ["P value", "TEST", 20, 27], ["annotating sequences", "TEST", 234, 254]]], ["[22] The Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www. genome.jp/kegg/) aims to integrate biological systems information of genomic, chemical and systemic functional aspects.", [["kegg", "PROTEIN", 78, 82]]], ["[23] Using DAVID software, GO functional and KEGG pathway enrichment analyses of DEGs were performed.", [["DEGs", "DNA", 81, 85], ["DAVID software", "TEST", 11, 25]]], ["Terms involving more than 2 genes and with a P value <0.05 were selected.PPI network construction and module analysisThe Search Tool for the Retrieval of Interacting Genes (STRING, http://string-db.org/) database gives a critical evaluation and integration of PPIs consisting of functional and physical associations.", [["Interacting Genes", "DNA", 154, 171], ["a P value", "TEST", 43, 52], ["PPI network construction", "TREATMENT", 73, 97], ["module analysis", "TEST", 102, 117], ["a critical evaluation", "TEST", 219, 240], ["PPIs", "TREATMENT", 260, 264]]], ["[24] Using the STRING database, [24] the PPI relationships among the DEGs were analyzed, with the required confidence (combined score) >0.4 as the threshold.", [["the STRING database", "TEST", 11, 30], ["the PPI relationships", "TREATMENT", 37, 58]]], ["After the PPIs were searched, the PPI networkOriginal articleWorld J Pediatr, Vol 13 No 3 .", [["the PPIs", "TREATMENT", 6, 14], ["the PPI", "TREATMENT", 30, 37]]], ["June 15, 2017 . www.wjpch.com was constructed using Cytoscape software (http://www. cytoscape.org/).", [["Cytoscape software", "TEST", 52, 70]]], ["[25] In the PPI network, nodes represented proteins, and their degrees were equal to the number of edges linked to them.", [["PPI network", "MULTI-TISSUE_STRUCTURE", 12, 23], ["nodes", "OBSERVATION", 25, 30]]], ["Moreover, module analysis was performed for the PPI network using the MCODE plugin [26] in Cytoscape with the default parameters.Analysis of DEGsDEGs with a P value <0.05 and |log 2 FC| >1 between the expansion and the narrow segment samples were analyzed.", [["samples", "ANATOMY", 234, 241], ["DEGsDEGs", "DNA", 141, 149], ["module analysis", "TEST", 10, 25], ["the PPI network", "TREATMENT", 44, 59], ["the MCODE plugin", "TREATMENT", 66, 82], ["the default parameters", "TEST", 106, 128], ["DEGsDEGs", "TEST", 141, 149], ["a P value", "TEST", 155, 164], ["the expansion", "TEST", 197, 210], ["the narrow segment samples", "TEST", 215, 241], ["narrow", "OBSERVATION_MODIFIER", 219, 225]]], ["Compared with narrow segment samples, 117 DEGs were identified in the expansion segment samples, including 47 up-regulated and 70 downregulated genes.Functional and pathway enrichment analysesUsing the DAVID software, enrichment analyses were carried out on the up-regulated genes and the downregulated genes separately.", [["samples", "ANATOMY", 29, 36], ["samples", "ANATOMY", 88, 95], ["70 downregulated genes", "DNA", 127, 149], ["-regulated genes", "DNA", 264, 280], ["downregulated genes", "DNA", 289, 308], ["narrow segment samples", "TEST", 14, 36], ["117 DEGs", "TEST", 38, 46], ["the expansion segment samples", "TEST", 66, 95], ["enrichment analyses", "TEST", 173, 192], ["enrichment analyses", "TEST", 218, 237], ["narrow", "OBSERVATION_MODIFIER", 14, 20], ["expansion", "OBSERVATION_MODIFIER", 70, 79], ["segment", "OBSERVATION_MODIFIER", 80, 87], ["downregulated genes", "OBSERVATION", 130, 149]]], ["The up-regulated genes were significantly enriched in 43 GO terms, and the top 10 GO terms are listed in Table 1 Table 2) .PPI network construction and module analysisThe PPI network of the DEGs had 59 nodes and 113 interactions (Fig. 1 ).", [["up-regulated genes", "DNA", 4, 22], ["DEGs", "DNA", 190, 194], ["PPI network construction", "TREATMENT", 123, 147], ["module analysis", "TEST", 152, 167], ["The PPI network", "TREATMENT", 167, 182], ["the DEGs", "TEST", 186, 194], ["PPI network", "OBSERVATION", 171, 182], ["nodes", "OBSERVATION", 202, 207]]], ["In particular, FOS (degree=20), early growth response 1 (EGR1, degree=16), activating transcription factor 3 (ATF3, degree=9), nitric oxide synthase 1 (NOS1, degree=8), CCL5 (degree=8), DUSP1 (degree=7), CXC chemokine ligand 3 (CXCL3, degree=6), vasoactive intestinal peptide (VIP, degree=6), FBJ murine osteosarcoma viral oncogene homolog B (FOSB, degree=5), and nitric oxide synthase 2 (NOS2, degree=4) had higher degrees and could interact with others genes in the PPI network.", [["nitric oxide", "CHEMICAL", 127, 139], ["nitric oxide", "CHEMICAL", 364, 376], ["nitric oxide", "CHEMICAL", 127, 139], ["nitric oxide", "CHEMICAL", 364, 376], ["FOS", "GENE_OR_GENE_PRODUCT", 15, 18], ["early growth response 1", "GENE_OR_GENE_PRODUCT", 32, 55], ["EGR1", "GENE_OR_GENE_PRODUCT", 57, 61], ["activating transcription factor 3", "GENE_OR_GENE_PRODUCT", 75, 108], ["ATF3", "GENE_OR_GENE_PRODUCT", 110, 114], ["nitric oxide synthase 1", "GENE_OR_GENE_PRODUCT", 127, 150], ["NOS1", "GENE_OR_GENE_PRODUCT", 152, 156], ["CCL5", "GENE_OR_GENE_PRODUCT", 169, 173], ["DUSP1", "GENE_OR_GENE_PRODUCT", 186, 191], ["CXC chemokine ligand 3", "GENE_OR_GENE_PRODUCT", 204, 226], ["CXCL3", "GENE_OR_GENE_PRODUCT", 228, 233], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 246, 275], ["VIP", "GENE_OR_GENE_PRODUCT", 277, 280], ["FBJ murine osteosarcoma viral oncogene homolog B", "GENE_OR_GENE_PRODUCT", 293, 341], ["nitric oxide synthase 2", "GENE_OR_GENE_PRODUCT", 364, 387], ["NOS2", "GENE_OR_GENE_PRODUCT", 389, 393], ["PPI network", "MULTI-TISSUE_STRUCTURE", 468, 479], ["FOS", "PROTEIN", 15, 18], ["early growth response 1", "PROTEIN", 32, 55], ["EGR1", "PROTEIN", 57, 61], ["activating transcription factor 3", "PROTEIN", 75, 108], ["ATF3", "PROTEIN", 110, 114], ["nitric oxide synthase 1", "PROTEIN", 127, 150], ["NOS1", "PROTEIN", 152, 156], ["CCL5", "PROTEIN", 169, 173], ["DUSP1", "PROTEIN", 186, 191], ["CXC chemokine ligand 3", "PROTEIN", 204, 226], ["CXCL3", "PROTEIN", 228, 233], ["FBJ murine osteosarcoma viral oncogene homolog B", "PROTEIN", 293, 341], ["FOSB", "PROTEIN", 343, 347], ["nitric oxide synthase 2", "PROTEIN", 364, 387], ["NOS2", "PROTEIN", 389, 393], ["murine", "SPECIES", 297, 303], ["FOS", "TEST", 15, 18], ["early growth response", "PROBLEM", 32, 53], ["EGR1", "TEST", 57, 61], ["activating transcription factor", "TEST", 75, 106], ["ATF3", "TEST", 110, 114], ["nitric oxide synthase", "TREATMENT", 127, 148], ["CCL5 (degree", "TEST", 169, 181], ["DUSP1 (degree", "TEST", 186, 199], ["CXC chemokine ligand", "TEST", 204, 224], ["CXCL3", "TEST", 228, 233], ["degree", "TEST", 235, 241], ["vasoactive intestinal peptide", "TREATMENT", 246, 275], ["FBJ murine osteosarcoma", "TREATMENT", 293, 316], ["nitric oxide synthase", "TREATMENT", 364, 385], ["vasoactive intestinal", "ANATOMY", 246, 267]]], ["Afterwards, module analysis was performed for the PPI network, and two significant modules (module 1 and module 2) were identified (Fig. 2) .", [["module analysis", "TEST", 12, 27], ["the PPI network", "TREATMENT", 46, 61], ["significant", "OBSERVATION_MODIFIER", 71, 82]]], ["The top 10 enriched functions among the genes in module 1 are shown in Table 3 and include G-protein coupled receptor protein signaling pathway (P<0.001), cell surface receptor linked signal transduction (P<0.001) and taxis (P<0.005), which involved CXCL3 and CCL5.", [["cell surface", "ANATOMY", 155, 167], ["G-protein coupled receptor protein", "GENE_OR_GENE_PRODUCT", 91, 125], ["cell", "CELL", 155, 159], ["CXCL3", "GENE_OR_GENE_PRODUCT", 250, 255], ["CCL5", "GENE_OR_GENE_PRODUCT", 260, 264], ["module 1", "DNA", 49, 57], ["cell surface receptor", "PROTEIN", 155, 176], ["CXCL3", "PROTEIN", 250, 255], ["CCL5", "PROTEIN", 260, 264], ["G", "TEST", 91, 92], ["P", "TEST", 145, 146], ["cell surface receptor", "TEST", 155, 176], ["signal transduction", "TEST", 184, 203], ["P", "TEST", 205, 206], ["taxis", "TEST", 218, 223], ["CXCL3", "TEST", 250, 255], ["CCL5", "PROBLEM", 260, 264], ["top", "OBSERVATION_MODIFIER", 4, 7], ["CCL5", "ANATOMY", 260, 264]]], ["The genes in module 2 were enriched in functions such as regulation of transcription from RNA polymerase II promoter (P<0.001), DNA-dependent regulation of transcription (P<0.001) and regulation of RNA metabolic process (P<0.001) ( Table 3 ).DiscussionAs the main component of the peripheral nervous system, the ENS is a complex network of glia and neurons within the intestinal wall, [27, 28] and a developmental disorder of the ENS has been correlated with HSCR.", [["peripheral nervous system", "ANATOMY", 281, 306], ["ENS", "ANATOMY", 312, 315], ["glia", "ANATOMY", 340, 344], ["neurons", "ANATOMY", 349, 356], ["intestinal wall", "ANATOMY", 368, 383], ["ENS", "ANATOMY", 430, 433], ["disorder of the ENS", "DISEASE", 414, 433], ["HSCR", "DISEASE", 459, 463], ["module 2", "GENE_OR_GENE_PRODUCT", 13, 21], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 90, 107], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 281, 306], ["ENS", "ANATOMICAL_SYSTEM", 312, 315], ["glia", "CELL", 340, 344], ["neurons", "CELL", 349, 356], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 368, 383], ["ENS", "ANATOMICAL_SYSTEM", 430, 433], ["module 2", "DNA", 13, 21], ["RNA polymerase II promoter", "DNA", 90, 116], ["glia", "CELL_TYPE", 340, 344], ["HSCR", "DNA", 459, 463], ["The genes in module 2", "PROBLEM", 0, 21], ["RNA polymerase II promoter", "TREATMENT", 90, 116], ["DNA-dependent regulation of transcription", "TREATMENT", 128, 169], ["RNA metabolic process", "PROBLEM", 198, 219], ["a developmental disorder of the ENS", "PROBLEM", 398, 433], ["HSCR", "PROBLEM", 459, 463], ["main", "OBSERVATION_MODIFIER", 259, 263], ["peripheral", "ANATOMY_MODIFIER", 281, 291], ["nervous system", "ANATOMY", 292, 306], ["glia", "ANATOMY", 340, 344], ["intestinal wall", "ANATOMY", 368, 383]]], ["[29] In this study, 117 DEGs were identified in the expansion segment samples, including 47 up-regulated and 70 downregulated genes.", [["samples", "ANATOMY", 70, 77], ["70 downregulated genes", "DNA", 109, 131], ["this study", "TEST", 8, 18], ["DEGs", "TEST", 24, 28], ["the expansion segment samples", "TEST", 48, 77], ["expansion", "OBSERVATION_MODIFIER", 52, 61], ["segment", "ANATOMY_MODIFIER", 62, 69]]], ["In the PPI network, FOS (degree=20), EGR1 (degree=16), ATF3 (degree=9), NOS1 (degree=8), CCL5 (degree=8), DUSP1 (degree=7), CXCL3 (degree=6), VIP (degree=6), FOSB (degree=5), and NOS2 (degree=4) had higher degrees, which had interactions with other genes.", [["FOS", "GENE_OR_GENE_PRODUCT", 20, 23], ["EGR1", "GENE_OR_GENE_PRODUCT", 37, 41], ["ATF3", "GENE_OR_GENE_PRODUCT", 55, 59], ["NOS1", "GENE_OR_GENE_PRODUCT", 72, 76], ["CCL5", "GENE_OR_GENE_PRODUCT", 89, 93], ["NOS2", "GENE_OR_GENE_PRODUCT", 179, 183], ["FOS", "PROTEIN", 20, 23], ["EGR1", "PROTEIN", 37, 41], ["ATF3", "PROTEIN", 55, 59], ["NOS1", "PROTEIN", 72, 76], ["CCL5", "PROTEIN", 89, 93], ["DUSP1", "PROTEIN", 106, 111], ["CXCL3", "PROTEIN", 124, 129], ["VIP", "PROTEIN", 142, 145], ["FOSB", "PROTEIN", 158, 162], ["NOS2", "PROTEIN", 179, 183], ["the PPI network", "TEST", 3, 18], ["FOS (degree", "TEST", 20, 31], ["EGR1 (degree", "TEST", 37, 49], ["ATF3", "TEST", 55, 59], ["degree", "TEST", 61, 67], ["NOS1 (degree", "TEST", 72, 84], ["CCL5 (degree", "TEST", 89, 101], ["DUSP1", "TEST", 106, 111], ["degree", "TEST", 113, 119], ["CXCL3", "TEST", 124, 129], ["VIP (degree", "TEST", 142, 153], ["FOSB (degree", "TEST", 158, 170], ["NOS2", "TEST", 179, 183], ["higher degrees", "OBSERVATION_MODIFIER", 199, 213]]], ["Moreover, two significant modules (module 1 and module 2) were identified in the PPI network.DiscussionFunctional enrichment analysis showed that FOS and DUSP1 were implicated in response to endogenous stimulus.", [["FOS", "GENE_OR_GENE_PRODUCT", 146, 149], ["DUSP1", "GENE_OR_GENE_PRODUCT", 154, 159], ["FOS", "DNA", 146, 149], ["DUSP1", "PROTEIN", 154, 159], ["two significant modules (module 1 and module 2)", "PROBLEM", 10, 57], ["the PPI network", "TREATMENT", 77, 92], ["DiscussionFunctional enrichment analysis", "TEST", 93, 133], ["FOS and DUSP1", "PROBLEM", 146, 159], ["endogenous stimulus", "TEST", 191, 210], ["two", "OBSERVATION_MODIFIER", 10, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["modules", "OBSERVATION", 26, 33], ["PPI network", "OBSERVATION", 81, 92]]], ["The c-fos gene is related to apoptosis and regeneration of damaged retinal ganglion cells (RGCs), indicating that the c-fos-mediated cascade precisely correlates with apoptosis and that regeneration of RGC plays a critical role in neuronal survival and regeneration.", [["retinal ganglion cells", "ANATOMY", 67, 89], ["RGCs", "ANATOMY", 91, 95], ["RGC", "ANATOMY", 202, 205], ["neuronal", "ANATOMY", 231, 239], ["c-fos", "GENE_OR_GENE_PRODUCT", 4, 9], ["retinal ganglion cells", "CELL", 67, 89], ["RGCs", "CELL", 91, 95], ["c-fos-", "GENE_OR_GENE_PRODUCT", 118, 124], ["RGC", "CELLULAR_COMPONENT", 202, 205], ["neuronal", "CELL", 231, 239], ["c-fos gene", "DNA", 4, 14], ["damaged retinal ganglion cells", "CELL_TYPE", 59, 89], ["RGCs", "CELL_TYPE", 91, 95], ["RGC", "CELL_TYPE", 202, 205], ["apoptosis", "PROBLEM", 29, 38], ["damaged retinal ganglion cells", "PROBLEM", 59, 89], ["the c-fos-mediated cascade", "PROBLEM", 114, 140], ["apoptosis", "PROBLEM", 167, 176], ["regeneration of RGC", "PROBLEM", 186, 205], ["related to", "UNCERTAINTY", 18, 28], ["apoptosis", "OBSERVATION", 29, 38], ["damaged retinal ganglion cells", "OBSERVATION", 59, 89], ["neuronal survival", "OBSERVATION", 231, 248]]], ["[30] As a member of the Fos family, FosB is up-regulated after an acute increase in central venous pressure in unanesthetized rats.", [["central venous", "ANATOMY", 84, 98], ["Fos", "GENE_OR_GENE_PRODUCT", 24, 27], ["FosB", "GENE_OR_GENE_PRODUCT", 36, 40], ["central venous", "MULTI-TISSUE_STRUCTURE", 84, 98], ["rats", "ORGANISM", 126, 130], ["Fos family", "PROTEIN", 24, 34], ["FosB", "PROTEIN", 36, 40], ["rats", "SPECIES", 126, 130], ["an acute increase", "PROBLEM", 63, 80], ["central venous pressure in unanesthetized rats", "TREATMENT", 84, 130], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["increase", "OBSERVATION", 72, 80], ["central", "ANATOMY_MODIFIER", 84, 91], ["venous", "ANATOMY", 92, 98], ["pressure", "OBSERVATION_MODIFIER", 99, 107]]], ["[31] DUSP1 can specially regulate sensory input neurons of the telencephalon and thalamus, which may reduce stimulus-induced expression of immediate early genes such as EGR1.", [["sensory input neurons", "ANATOMY", 34, 55], ["telencephalon", "ANATOMY", 63, 76], ["thalamus", "ANATOMY", 81, 89], ["[31] DUSP1", "SIMPLE_CHEMICAL", 0, 10], ["neurons", "CELL", 48, 55], ["telencephalon", "MULTI-TISSUE_STRUCTURE", 63, 76], ["thalamus", "MULTI-TISSUE_STRUCTURE", 81, 89], ["EGR1", "GENE_OR_GENE_PRODUCT", 169, 173], ["[31] DUSP1", "PROTEIN", 0, 10], ["immediate early genes", "DNA", 139, 160], ["EGR1", "PROTEIN", 169, 173], ["DUSP1", "TREATMENT", 5, 10], ["sensory input", "OBSERVATION", 34, 47], ["telencephalon", "ANATOMY", 63, 76], ["thalamus", "ANATOMY", 81, 89]]], ["[32] These fi ndings suggest that FOS, FOSB, DUSP1 and EGR1 might be correlated with the development of HSCR.DiscussionEnrichment analyses indicated that CCL5 was involved in the pathway of prion diseases, while CXCL3 and CCL5 were functionally enriched in taxis.", [["HSCR", "DISEASE", 104, 108], ["prion diseases", "DISEASE", 190, 204], ["FOS", "GENE_OR_GENE_PRODUCT", 34, 37], ["FOSB", "GENE_OR_GENE_PRODUCT", 39, 43], ["DUSP1", "GENE_OR_GENE_PRODUCT", 45, 50], ["EGR1", "GENE_OR_GENE_PRODUCT", 55, 59], ["CCL5", "GENE_OR_GENE_PRODUCT", 154, 158], ["CXCL3", "GENE_OR_GENE_PRODUCT", 212, 217], ["CCL5", "GENE_OR_GENE_PRODUCT", 222, 226], ["FOS", "PROTEIN", 34, 37], ["FOSB", "PROTEIN", 39, 43], ["DUSP1", "PROTEIN", 45, 50], ["EGR1", "PROTEIN", 55, 59], ["CCL5", "PROTEIN", 154, 158], ["CXCL3", "PROTEIN", 212, 217], ["CCL5", "PROTEIN", 222, 226], ["These fi ndings", "TEST", 5, 20], ["HSCR", "PROBLEM", 104, 108], ["Enrichment analyses", "TEST", 119, 138], ["prion diseases", "PROBLEM", 190, 204], ["CXCL3", "TEST", 212, 217], ["CCL5", "TEST", 222, 226], ["HSCR", "OBSERVATION", 104, 108], ["CCL5", "ANATOMY", 222, 226]]], ["Inhibition of CCL5 by neutralizing mAb decreased the severity of central nervous system (CNS) disease in a viral model of demyelination.", [["central nervous system", "ANATOMY", 65, 87], ["CNS", "ANATOMY", 89, 92], ["central nervous system (CNS) disease", "DISEASE", 65, 101], ["demyelination", "DISEASE", 122, 135], ["CCL5", "GENE_OR_GENE_PRODUCT", 14, 18], ["central nervous system", "ANATOMICAL_SYSTEM", 65, 87], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["CCL5", "PROTEIN", 14, 18], ["neutralizing mAb", "PROTEIN", 22, 38], ["Inhibition of CCL5", "TREATMENT", 0, 18], ["neutralizing mAb", "TREATMENT", 22, 38], ["central nervous system (CNS) disease", "PROBLEM", 65, 101], ["demyelination", "PROBLEM", 122, 135], ["central", "ANATOMY_MODIFIER", 65, 72], ["nervous system", "ANATOMY", 73, 87], ["CNS", "ANATOMY", 89, 92], ["disease", "OBSERVATION", 94, 101], ["viral model", "OBSERVATION", 107, 118], ["demyelination", "OBSERVATION", 122, 135]]], ["[33] CC receptor 5 (CCR5) and its primary ligand CCL5 play critical roles in promoting the transport of leukocytes into the CNS of mice infected by mouse hepatitis virus (MHV).", [["leukocytes", "ANATOMY", 104, 114], ["CNS", "ANATOMY", 124, 127], ["CC", "CHEMICAL", 5, 7], ["mouse hepatitis virus", "DISEASE", 148, 169], ["[33] CC receptor 5", "GENE_OR_GENE_PRODUCT", 0, 18], ["CCR5", "GENE_OR_GENE_PRODUCT", 20, 24], ["CCL5", "GENE_OR_GENE_PRODUCT", 49, 53], ["leukocytes", "CELL", 104, 114], ["CNS", "ANATOMICAL_SYSTEM", 124, 127], ["mice", "ORGANISM", 131, 135], ["mouse hepatitis virus", "ORGANISM", 148, 169], ["MHV", "ORGANISM", 171, 174], ["[33] CC receptor 5", "PROTEIN", 0, 18], ["CCR5", "PROTEIN", 20, 24], ["CCL5", "PROTEIN", 49, 53], ["leukocytes", "CELL_TYPE", 104, 114], ["mice", "SPECIES", 131, 135], ["mouse", "SPECIES", 148, 153], ["hepatitis virus", "SPECIES", 154, 169], ["mice", "SPECIES", 131, 135], ["mouse hepatitis virus", "SPECIES", 148, 169], ["MHV", "SPECIES", 171, 174], ["mouse hepatitis virus", "PROBLEM", 148, 169], ["CNS", "ANATOMY", 124, 127]]], ["[34] [35] [36] CXCL3 has a low expression level in 12-O-tetradecanoyl phorbol-13-acetate inducible sequence 21 (Tis21)-null cerebellar granule neuron precursor cells (GCPs) of lesions and the external granular layer, and CXCL3 activation induced by Tis21 contributes to migration of GCPs.", [["cerebellar granule neuron precursor cells", "ANATOMY", 124, 165], ["GCPs", "ANATOMY", 167, 171], ["lesions", "ANATOMY", 176, 183], ["external granular layer", "ANATOMY", 192, 215], ["GCPs", "ANATOMY", 283, 287], ["12-O-tetradecanoyl phorbol-13-acetate", "CHEMICAL", 51, 88], ["Tis21", "CHEMICAL", 249, 254], ["[34] [35] [36] CXCL3", "CHEMICAL", 0, 20], ["12-O-tetradecanoyl phorbol-13-acetate", "CHEMICAL", 51, 88], ["[34] [35] [36] CXCL3", "SIMPLE_CHEMICAL", 0, 20], ["12-O-tetradecanoyl phorbol-13-acetate", "SIMPLE_CHEMICAL", 51, 88], ["Tis21", "GENE_OR_GENE_PRODUCT", 112, 117], ["cerebellar granule neuron precursor cells", "CELL", 124, 165], ["GCPs", "CANCER", 167, 171], ["lesions", "CANCER", 176, 183], ["granular layer", "TISSUE", 201, 215], ["CXCL3", "GENE_OR_GENE_PRODUCT", 221, 226], ["Tis21", "GENE_OR_GENE_PRODUCT", 249, 254], ["GCPs", "PATHOLOGICAL_FORMATION", 283, 287], ["Tis21", "PROTEIN", 112, 117], ["cerebellar granule neuron precursor cells", "CELL_TYPE", 124, 165], ["GCPs", "CELL_TYPE", 167, 171], ["CXCL3", "PROTEIN", 221, 226], ["Tis21", "PROTEIN", 249, 254], ["CXCL3", "TEST", 15, 20], ["a low expression level", "PROBLEM", 25, 47], ["tetradecanoyl phorbol", "TEST", 56, 77], ["acetate inducible sequence", "TEST", 81, 107], ["Tis21", "TEST", 112, 117], ["null cerebellar granule neuron precursor cells", "PROBLEM", 119, 165], ["lesions", "PROBLEM", 176, 183], ["the external granular layer", "PROBLEM", 188, 215], ["CXCL3 activation", "PROBLEM", 221, 237], ["migration of GCPs", "PROBLEM", 270, 287], ["low expression", "OBSERVATION_MODIFIER", 27, 41], ["cerebellar", "ANATOMY", 124, 134], ["granule neuron", "OBSERVATION", 135, 149], ["precursor cells", "OBSERVATION", 150, 165], ["lesions", "OBSERVATION", 176, 183], ["external", "OBSERVATION_MODIFIER", 192, 200], ["granular", "OBSERVATION_MODIFIER", 201, 209], ["layer", "OBSERVATION_MODIFIER", 210, 215], ["migration", "OBSERVATION_MODIFIER", 270, 279]]], ["[37] Therefore, CCL5 and CXCL3 might be implicated in the pathogenesis of HSCR.DiscussionIn addition, as a member of the ATF/cyclic AMP responsive element binding family of transcription factors, ATF3 is activated in motoneurons and sensory neurons in the spinal cord after nerve injury and may be a promising marker of nerve injury in the nervous system.", [["motoneurons", "ANATOMY", 217, 228], ["sensory neurons", "ANATOMY", 233, 248], ["spinal cord", "ANATOMY", 256, 267], ["nerve", "ANATOMY", 274, 279], ["nerve", "ANATOMY", 320, 325], ["nervous system", "ANATOMY", 340, 354], ["HSCR", "DISEASE", 74, 78], ["AMP", "CHEMICAL", 132, 135], ["nerve injury", "DISEASE", 274, 286], ["nerve injury", "DISEASE", 320, 332], ["cyclic AMP", "CHEMICAL", 125, 135], ["CCL5", "GENE_OR_GENE_PRODUCT", 16, 20], ["CXCL3", "GENE_OR_GENE_PRODUCT", 25, 30], ["ATF", "GENE_OR_GENE_PRODUCT", 121, 124], ["cyclic AMP responsive element binding family", "GENE_OR_GENE_PRODUCT", 125, 169], ["ATF3", "GENE_OR_GENE_PRODUCT", 196, 200], ["motoneurons", "CELL", 217, 228], ["sensory neurons", "CELL", 233, 248], ["spinal cord", "ORGAN", 256, 267], ["nerve", "MULTI-TISSUE_STRUCTURE", 274, 279], ["nerve", "MULTI-TISSUE_STRUCTURE", 320, 325], ["nervous system", "ANATOMICAL_SYSTEM", 340, 354], ["CCL5", "PROTEIN", 16, 20], ["CXCL3", "PROTEIN", 25, 30], ["ATF/cyclic AMP responsive element binding family", "PROTEIN", 121, 169], ["transcription factors", "PROTEIN", 173, 194], ["ATF3", "PROTEIN", 196, 200], ["sensory neurons", "CELL_TYPE", 233, 248], ["CXCL3", "TREATMENT", 25, 30], ["HSCR", "PROBLEM", 74, 78], ["the ATF/cyclic AMP responsive element binding", "TREATMENT", 117, 162], ["transcription factors", "TREATMENT", 173, 194], ["nerve injury", "PROBLEM", 274, 286], ["nerve injury in the nervous system", "PROBLEM", 320, 354], ["HSCR", "OBSERVATION", 74, 78], ["sensory neurons", "ANATOMY", 233, 248], ["spinal cord", "ANATOMY", 256, 267], ["nerve", "ANATOMY", 274, 279], ["injury", "OBSERVATION", 280, 286], ["nerve", "ANATOMY", 320, 325], ["injury", "OBSERVATION", 326, 332], ["nervous system", "ANATOMY", 340, 354]]], ["[38] ATF3 can promote neurite elongation of dorsal root ganglion, indicating that ATF3 helps nerve regeneration by improving the intrinsic growth state of injured neurons.", [["neurite", "ANATOMY", 22, 29], ["dorsal root ganglion", "ANATOMY", 44, 64], ["nerve", "ANATOMY", 93, 98], ["neurons", "ANATOMY", 163, 170], ["ATF3", "GENE_OR_GENE_PRODUCT", 5, 9], ["neurite", "CELL", 22, 29], ["dorsal root ganglion", "MULTI-TISSUE_STRUCTURE", 44, 64], ["ATF3", "GENE_OR_GENE_PRODUCT", 82, 86], ["nerve", "TISSUE", 93, 98], ["neurons", "CELL", 163, 170], ["ATF3", "PROTEIN", 5, 9], ["ATF3", "PROTEIN", 82, 86], ["injured neurons", "CELL_TYPE", 155, 170], ["neurite elongation of dorsal root ganglion", "PROBLEM", 22, 64], ["ATF3 helps nerve regeneration", "PROBLEM", 82, 111], ["injured neurons", "PROBLEM", 155, 170], ["neurite elongation", "OBSERVATION", 22, 40], ["dorsal", "ANATOMY_MODIFIER", 44, 50], ["root ganglion", "ANATOMY", 51, 64], ["nerve", "ANATOMY", 93, 98], ["injured neurons", "OBSERVATION", 155, 170]]], ["[39] [40] [41] [42] VIP is a neurotransmitter in the mucosa, lamina propria, and myenteric plexus of the small and large intestine, which can respond to secretomotor refl exes and activate adenylate cyclase.", [["mucosa", "ANATOMY", 53, 59], ["lamina propria", "ANATOMY", 61, 75], ["myenteric plexus", "ANATOMY", 81, 97], ["intestine", "ANATOMY", 121, 130], ["[39] [40] [41] [42]", "CHEMICAL", 0, 19], ["[39] [40] [41] [42] VIP", "CHEMICAL", 0, 23], ["adenylate", "CHEMICAL", 189, 198], ["[39] [40] [41] [42] VIP", "SIMPLE_CHEMICAL", 0, 23], ["mucosa", "MULTI-TISSUE_STRUCTURE", 53, 59], ["lamina propria", "TISSUE", 61, 75], ["myenteric plexus", "MULTI-TISSUE_STRUCTURE", 81, 97], ["intestine", "ORGAN", 121, 130], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 189, 206], ["secretomotor refl exes", "PROTEIN", 153, 175], ["adenylate cyclase", "PROTEIN", 189, 206], ["myenteric plexus of the small and large intestine", "PROBLEM", 81, 130], ["activate adenylate cyclase", "PROBLEM", 180, 206], ["mucosa", "ANATOMY", 53, 59], ["lamina propria", "ANATOMY", 61, 75], ["myenteric plexus", "ANATOMY", 81, 97], ["small", "OBSERVATION_MODIFIER", 105, 110], ["large intestine", "ANATOMY", 115, 130]]], ["[43] A previous study has shown that VIP functions in reducing the net intestinal fluid absorption in patients with chemical colitis, which can be completely inhibited by its antagonist [4Cl-d-Phe6, Leu17]VIP.", [["intestinal fluid", "ANATOMY", 71, 87], ["colitis", "DISEASE", 125, 132], ["[4Cl-d-Phe6, Leu17]VIP", "CHEMICAL", 186, 208], ["VIP", "GENE_OR_GENE_PRODUCT", 37, 40], ["intestinal fluid", "ORGANISM_SUBSTANCE", 71, 87], ["patients", "ORGANISM", 102, 110], ["[4Cl-d-Phe6", "SIMPLE_CHEMICAL", 186, 197], ["Leu17]VIP", "SIMPLE_CHEMICAL", 199, 208], ["patients", "SPECIES", 102, 110], ["A previous study", "TEST", 5, 21], ["VIP functions", "PROBLEM", 37, 50], ["the net intestinal fluid absorption", "PROBLEM", 63, 98], ["chemical colitis", "PROBLEM", 116, 132], ["intestinal", "ANATOMY", 71, 81], ["fluid absorption", "OBSERVATION", 82, 98], ["colitis", "OBSERVATION", 125, 132]]], ["[44] Nitric oxide synthases (NOS) are the predominant enzymes producing nitric oxide (NO) from conversion of L-arginine and generally need NADPH and oxygen co-substrates.", [["Nitric oxide", "CHEMICAL", 5, 17], ["nitric oxide", "CHEMICAL", 72, 84], ["NO", "CHEMICAL", 86, 88], ["L-arginine", "CHEMICAL", 109, 119], ["NADPH", "CHEMICAL", 139, 144], ["oxygen", "CHEMICAL", 149, 155], ["[44] Nitric oxide", "CHEMICAL", 0, 17], ["nitric oxide", "CHEMICAL", 72, 84], ["NO", "CHEMICAL", 86, 88], ["L-arginine", "CHEMICAL", 109, 119], ["NADPH", "CHEMICAL", 139, 144], ["oxygen", "CHEMICAL", 149, 155], ["[44] Nitric oxide synthases", "SIMPLE_CHEMICAL", 0, 27], ["NOS", "GENE_OR_GENE_PRODUCT", 29, 32], ["nitric oxide", "SIMPLE_CHEMICAL", 72, 84], ["NO", "SIMPLE_CHEMICAL", 86, 88], ["L-arginine", "SIMPLE_CHEMICAL", 109, 119], ["NADPH", "SIMPLE_CHEMICAL", 139, 144], ["oxygen", "SIMPLE_CHEMICAL", 149, 155], ["[44] Nitric oxide synthases", "PROTEIN", 0, 27], ["NOS", "PROTEIN", 29, 32], ["Nitric oxide synthases", "TREATMENT", 5, 27], ["the predominant enzymes", "TEST", 38, 61], ["nitric oxide", "TREATMENT", 72, 84], ["L-arginine", "TREATMENT", 109, 119], ["NADPH", "TREATMENT", 139, 144], ["oxygen co-substrates", "TREATMENT", 149, 169]]], ["[45] Additionally, NO produced by the enteric nervous system is conducive for maintaining gut homeostasis through regulation of vascular tone, gut motility, mucosal barrier function, blood supply, immunity and secretions.", [["enteric nervous system", "ANATOMY", 38, 60], ["gut", "ANATOMY", 90, 93], ["vascular", "ANATOMY", 128, 136], ["gut", "ANATOMY", 143, 146], ["mucosal barrier", "ANATOMY", 157, 172], ["blood", "ANATOMY", 183, 188], ["NO", "CHEMICAL", 19, 21], ["NO", "CHEMICAL", 19, 21], ["NO", "GENE_OR_GENE_PRODUCT", 19, 21], ["enteric nervous system", "ANATOMICAL_SYSTEM", 38, 60], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["vascular", "MULTI-TISSUE_STRUCTURE", 128, 136], ["gut", "ORGANISM_SUBDIVISION", 143, 146], ["mucosal barrier", "TISSUE", 157, 172], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["mucosal barrier function", "TEST", 157, 181], ["enteric nervous", "ANATOMY", 38, 53], ["vascular", "ANATOMY", 128, 136]]], ["[46] These findings suggest that ATF3, VIP, NOS1 and NOS2 might also function in HSCR by affecting the nervous system.DiscussionIn conclusion, based on the bioinformatics analyses, 117 DEGs were identified in the expansion segment samples.", [["nervous system", "ANATOMY", 103, 117], ["samples", "ANATOMY", 231, 238], ["HSCR", "DISEASE", 81, 85], ["ATF3", "GENE_OR_GENE_PRODUCT", 33, 37], ["VIP", "GENE_OR_GENE_PRODUCT", 39, 42], ["NOS1", "GENE_OR_GENE_PRODUCT", 44, 48], ["NOS2", "GENE_OR_GENE_PRODUCT", 53, 57], ["nervous system", "ANATOMICAL_SYSTEM", 103, 117], ["ATF3", "PROTEIN", 33, 37], ["VIP", "PROTEIN", 39, 42], ["NOS1", "PROTEIN", 44, 48], ["NOS2", "PROTEIN", 53, 57], ["ATF3", "TEST", 33, 37], ["the bioinformatics analyses", "TEST", 152, 179], ["117 DEGs", "TEST", 181, 189], ["the expansion segment samples", "TEST", 209, 238], ["nervous system", "ANATOMY", 103, 117]]], ["Moreover, several genes (including FOS, EGR1, ATF3, NOS1, CCL5, DUSP1, CXCL3, VIP, FOSB, and NOS2) might be involved in the development of HSCR through their impact on the nervous system.", [["nervous system", "ANATOMY", 172, 186], ["HSCR", "DISEASE", 139, 143], ["FOS", "GENE_OR_GENE_PRODUCT", 35, 38], ["EGR1", "GENE_OR_GENE_PRODUCT", 40, 44], ["ATF3", "GENE_OR_GENE_PRODUCT", 46, 50], ["NOS1", "GENE_OR_GENE_PRODUCT", 52, 56], ["CCL5", "GENE_OR_GENE_PRODUCT", 58, 62], ["DUSP1", "GENE_OR_GENE_PRODUCT", 64, 69], ["CXCL3", "GENE_OR_GENE_PRODUCT", 71, 76], ["VIP", "GENE_OR_GENE_PRODUCT", 78, 81], ["FOSB", "GENE_OR_GENE_PRODUCT", 83, 87], ["NOS2", "GENE_OR_GENE_PRODUCT", 93, 97], ["nervous system", "ANATOMICAL_SYSTEM", 172, 186], ["FOS", "DNA", 35, 38], ["EGR1", "DNA", 40, 44], ["ATF3", "DNA", 46, 50], ["NOS1", "DNA", 52, 56], ["CCL5", "DNA", 58, 62], ["DUSP1", "DNA", 64, 69], ["CXCL3", "DNA", 71, 76], ["VIP", "DNA", 78, 81], ["FOSB", "DNA", 83, 87], ["NOS2", "DNA", 93, 97], ["EGR1", "TEST", 40, 44], ["ATF3", "TEST", 46, 50], ["NOS1", "TEST", 52, 56], ["CCL5", "TEST", 58, 62], ["DUSP1", "TEST", 64, 69], ["CXCL3", "TEST", 71, 76], ["HSCR", "PROBLEM", 139, 143], ["HSCR", "OBSERVATION", 139, 143], ["nervous system", "ANATOMY", 172, 186]]], ["However, these predicted results must be further confi rmed through experimental studies, such as quantitative real-time polymerase chain reaction (qRT-PCR) in the future.", [["experimental studies", "TEST", 68, 88]]]], "PMC3179960": [["BackgroundChikungunya Virus (ChikV) is an Alphavirus of the Togaviridae family transmitted to humans through arthropods bites (mosquitoes of the Aedes genus).", [["Chikungunya Virus", "DISEASE", 10, 27], ["arthropods bites", "DISEASE", 109, 125], ["Chikungunya Virus", "ORGANISM", 10, 27], ["ChikV", "GENE_OR_GENE_PRODUCT", 29, 34], ["Togaviridae", "GENE_OR_GENE_PRODUCT", 60, 71], ["humans", "ORGANISM", 94, 100], ["Aedes genus", "ORGANISM", 145, 156], ["Chikungunya Virus", "SPECIES", 10, 27], ["humans", "SPECIES", 94, 100], ["Chikungunya Virus", "SPECIES", 10, 27], ["ChikV", "SPECIES", 29, 34], ["humans", "SPECIES", 94, 100], ["BackgroundChikungunya Virus (ChikV", "PROBLEM", 0, 34], ["Chikungunya Virus", "OBSERVATION", 10, 27]]], ["First described during a Tanzanian outbreak in 1952 [1], ChikV was recently responsible for a massive re-emerging outbreak in a large tropical area (East Africa and Indian Ocean in 2006, India, Thailand and Indonesia in 2007) and a limited epidemic in Italy in 2007.", [["ChikV", "GENE_OR_GENE_PRODUCT", 57, 62], ["ChikV", "PROBLEM", 57, 62], ["large", "OBSERVATION_MODIFIER", 128, 133]]], ["In 2005-2006, the virus has reached Reunion Island, a south French territory, with an estimated 270 000 cases (1/3rd of the population) and severe forms of the disease, like encephalopathy, in a context of arthralgia, rash, headache and a strong lymphopenia were reported.", [["encephalopathy", "DISEASE", 174, 188], ["arthralgia", "DISEASE", 206, 216], ["rash", "DISEASE", 218, 222], ["headache", "DISEASE", 224, 232], ["lymphopenia", "DISEASE", 246, 257], ["the virus", "PROBLEM", 14, 23], ["the disease", "PROBLEM", 156, 167], ["encephalopathy", "PROBLEM", 174, 188], ["arthralgia", "PROBLEM", 206, 216], ["rash", "PROBLEM", 218, 222], ["headache", "PROBLEM", 224, 232], ["a strong lymphopenia", "PROBLEM", 237, 257], ["Reunion Island", "OBSERVATION", 36, 50], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["disease", "OBSERVATION", 160, 167], ["encephalopathy", "OBSERVATION", 174, 188], ["arthralgia", "OBSERVATION", 206, 216], ["strong", "OBSERVATION_MODIFIER", 239, 245], ["lymphopenia", "OBSERVATION", 246, 257]]], ["This 12 Kb positive-strand RNA virus contains two open reading frames (ORFs).", [["open reading frames", "DNA", 50, 69], ["ORFs", "DNA", 71, 75], ["This 12 Kb positive", "TEST", 0, 19], ["strand RNA virus", "PROBLEM", 20, 36], ["strand RNA virus", "OBSERVATION", 20, 36], ["two", "OBSERVATION_MODIFIER", 46, 49], ["open", "OBSERVATION_MODIFIER", 50, 54]]], ["The 5' ORF, for the viral replication complex, encodes the non-structural proteins, nsp1, 2, 3, and 4.", [["nsp1", "GENE_OR_GENE_PRODUCT", 84, 88], ["2", "GENE_OR_GENE_PRODUCT", 90, 91], ["3", "GENE_OR_GENE_PRODUCT", 93, 94], ["4", "GENE_OR_GENE_PRODUCT", 100, 101], ["5' ORF", "DNA", 4, 10], ["viral replication complex", "PROTEIN", 20, 45], ["non-structural proteins", "PROTEIN", 59, 82], ["nsp1, 2, 3, and 4", "PROTEIN", 84, 101], ["The 5' ORF", "PROBLEM", 0, 10], ["the viral replication complex", "PROBLEM", 16, 45], ["the non-structural proteins", "TEST", 55, 82], ["nsp1", "TEST", 84, 88], ["viral replication", "OBSERVATION", 20, 37], ["non-structural proteins", "OBSERVATION", 59, 82]]], ["The 3'ORF, for the structural proteins, encodes for the capsid, envelope glycoproteins (E1 and E2), E3 and 6k proteins.", [["E1", "GENE_OR_GENE_PRODUCT", 88, 90], ["E2", "GENE_OR_GENE_PRODUCT", 95, 97], ["E3", "GENE_OR_GENE_PRODUCT", 100, 102], ["6k proteins", "GENE_OR_GENE_PRODUCT", 107, 118], ["3'ORF", "DNA", 4, 9], ["structural proteins", "PROTEIN", 19, 38], ["capsid", "PROTEIN", 56, 62], ["envelope glycoproteins", "PROTEIN", 64, 86], ["E1", "PROTEIN", 88, 90], ["E2", "PROTEIN", 95, 97], ["E3 and 6k proteins", "PROTEIN", 100, 118], ["The 3'ORF", "PROBLEM", 0, 9], ["the structural proteins", "PROBLEM", 15, 38], ["the capsid, envelope glycoproteins (E1 and E2)", "TREATMENT", 52, 98], ["E3 and 6k proteins", "TREATMENT", 100, 118]]], ["Interestingly, infection with positive-strand RNA viruses may result in the rearrangement of intracellular membranes, constituting scaffolds for viral genome replication [2].BackgroundMacro-autophagy, referred herein to autophagy, is a fundamental homeostatic process that leads to the degradation and recycling of long-lived proteins and organelles [3,4].", [["intracellular membranes", "ANATOMY", 93, 116], ["organelles", "ANATOMY", 339, 349], ["infection", "DISEASE", 15, 24], ["intracellular membranes", "CELLULAR_COMPONENT", 93, 116], ["organelles", "CELLULAR_COMPONENT", 339, 349], ["long-lived proteins", "PROTEIN", 315, 334], ["infection", "PROBLEM", 15, 24], ["strand RNA viruses", "PROBLEM", 39, 57], ["intracellular membranes", "PROBLEM", 93, 116], ["viral genome replication", "TREATMENT", 145, 169], ["BackgroundMacro-autophagy", "PROBLEM", 174, 199], ["a fundamental homeostatic process", "PROBLEM", 234, 267], ["the degradation", "PROBLEM", 282, 297], ["infection", "OBSERVATION", 15, 24], ["intracellular membranes", "OBSERVATION", 93, 116]]], ["The molecular machinery of autophagy was identified in yeast by genetic screening with the discovery of 30 AuTophaGy-related genes (ATG) [5].", [["AuTophaGy", "GENE_OR_GENE_PRODUCT", 107, 116], ["AuTophaGy", "PROTEIN", 107, 116], ["ATG", "DNA", 132, 135], ["yeast", "SPECIES", 55, 60], ["yeast", "SPECIES", 55, 60], ["genetic screening", "TEST", 64, 81], ["autophagy", "OBSERVATION", 27, 36]]], ["Most of these genes have now been identified in other organisms as orthologs, suggesting that autophagy is a highly conserved mechanism in eukaryotes [6].", [["autophagy", "PROBLEM", 94, 103]]], ["The hallmark of autophagy is the formation of double or multiple membrane-bound vesicles called autophagosomes, which sequester a portion of the cytoplasm and fuse, after maturation, with lysosomes to digest their contents.", [["membrane", "ANATOMY", 65, 73], ["vesicles", "ANATOMY", 80, 88], ["autophagosomes", "ANATOMY", 96, 110], ["cytoplasm", "ANATOMY", 145, 154], ["lysosomes", "ANATOMY", 188, 197], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["vesicles", "CELLULAR_COMPONENT", 80, 88], ["autophagosomes", "CELLULAR_COMPONENT", 96, 110], ["cytoplasm", "ORGANISM_SUBSTANCE", 145, 154], ["lysosomes", "CELLULAR_COMPONENT", 188, 197], ["double or multiple membrane-bound vesicles", "PROBLEM", 46, 88], ["autophagosomes", "PROBLEM", 96, 110], ["lysosomes", "TREATMENT", 188, 197], ["hallmark", "OBSERVATION_MODIFIER", 4, 12], ["autophagy", "OBSERVATION", 16, 25], ["double", "OBSERVATION_MODIFIER", 46, 52], ["multiple", "OBSERVATION_MODIFIER", 56, 64], ["membrane", "OBSERVATION_MODIFIER", 65, 73], ["bound vesicles", "OBSERVATION", 74, 88], ["cytoplasm", "OBSERVATION", 145, 154]]], ["Formation of the autophagosome requires two ubiquitin-like systems: a conjugate of Atg5-Atg12 and a conjugate in which microtubule-associated protein light chain 3, LC3, is cleaved to produce LC3-I and LC3-II.", [["autophagosome", "ANATOMY", 17, 30], ["microtubule", "ANATOMY", 119, 130], ["autophagosome", "CELLULAR_COMPONENT", 17, 30], ["Atg5", "GENE_OR_GENE_PRODUCT", 83, 87], ["Atg12", "GENE_OR_GENE_PRODUCT", 88, 93], ["microtubule-associated protein light chain 3", "GENE_OR_GENE_PRODUCT", 119, 163], ["LC3", "GENE_OR_GENE_PRODUCT", 165, 168], ["LC3-I", "GENE_OR_GENE_PRODUCT", 192, 197], ["LC3-II.", "GENE_OR_GENE_PRODUCT", 202, 209], ["ubiquitin", "PROTEIN", 44, 53], ["Atg5", "PROTEIN", 83, 87], ["Atg12", "PROTEIN", 88, 93], ["microtubule-associated protein light chain 3", "PROTEIN", 119, 163], ["LC3", "PROTEIN", 165, 168], ["LC3", "PROTEIN", 192, 195], ["LC3", "PROTEIN", 202, 205], ["Atg5", "TEST", 83, 87], ["protein light chain", "TEST", 142, 161], ["LC3", "TEST", 192, 195], ["autophagosome", "OBSERVATION", 17, 30]]], ["Autophagy is first a fundamental cell surviving process during starvation conditions but also participates in various processes such as development and tumor suppression [7].", [["cell", "ANATOMY", 33, 37], ["tumor", "ANATOMY", 152, 157], ["tumor", "DISEASE", 152, 157], ["cell", "CELL", 33, 37], ["tumor", "CANCER", 152, 157], ["tumor suppression", "PROBLEM", 152, 169], ["fundamental cell", "OBSERVATION", 21, 37], ["tumor", "OBSERVATION", 152, 157]]], ["Futhermore, autophagy plays a role in both innate and adaptive immunity in response to pathogens [8].", [["pathogens", "PROBLEM", 87, 96]]], ["Indeed, the antiviral action of autophagy has been characterized in infection by sindbis virus, tobacco mosaic virus, vesicular stomatitis virus, herpes simplex virus type 1 and the DNA virus parvovirus B19 [9-11].", [["infection", "DISEASE", 68, 77], ["vesicular stomatitis", "DISEASE", 118, 138], ["herpes simplex virus", "DISEASE", 146, 166], ["parvovirus B19", "DISEASE", 192, 206], ["sindbis virus", "ORGANISM", 81, 94], ["tobacco mosaic virus", "ORGANISM", 96, 116], ["vesicular stomatitis virus", "ORGANISM", 118, 144], ["herpes simplex virus type 1", "ORGANISM", 146, 173], ["DNA virus parvovirus B19", "ORGANISM", 182, 206], ["tobacco mosaic virus", "SPECIES", 96, 116], ["vesicular stomatitis virus", "SPECIES", 118, 144], ["herpes simplex virus", "SPECIES", 146, 166], ["virus parvovirus B19", "SPECIES", 186, 206], ["sindbis virus", "SPECIES", 81, 94], ["tobacco mosaic virus", "SPECIES", 96, 116], ["vesicular stomatitis virus", "SPECIES", 118, 144], ["herpes simplex virus type 1", "SPECIES", 146, 173], ["DNA virus parvovirus B19", "SPECIES", 182, 206], ["autophagy", "PROBLEM", 32, 41], ["infection", "PROBLEM", 68, 77], ["sindbis virus", "PROBLEM", 81, 94], ["tobacco mosaic virus", "PROBLEM", 96, 116], ["vesicular stomatitis virus", "PROBLEM", 118, 144], ["herpes simplex virus type 1", "PROBLEM", 146, 173], ["the DNA virus parvovirus B19", "TEST", 178, 206], ["infection", "OBSERVATION", 68, 77], ["mosaic virus", "OBSERVATION", 104, 116], ["vesicular stomatitis virus", "OBSERVATION", 118, 144]]], ["In contrast, some viruses have evolved strategies to interfere, escape or even exploit the autophagic machinery.", [["some viruses", "PROBLEM", 13, 25], ["viruses", "OBSERVATION", 18, 25]]], ["This is the case for certain positive-stranded RNA viruses, such as coronaviruses, picornaviruses, murine hepatitis virus, equine arterivirus, coxsackievirus, hepatitis C virus and dengue virus, which use the autophagosomal machinery to facilitate the assembly of RNA replication complexes [12-15].", [["autophagosomal", "ANATOMY", 209, 223], ["murine hepatitis virus", "DISEASE", 99, 121], ["coxsackievirus, hepatitis C", "DISEASE", 143, 170], ["dengue", "DISEASE", 181, 187], ["coronaviruses", "ORGANISM", 68, 81], ["murine hepatitis virus", "ORGANISM", 99, 121], ["equine arterivirus", "ORGANISM", 123, 141], ["coxsackievirus,", "ORGANISM", 143, 158], ["hepatitis C virus", "ORGANISM", 159, 176], ["dengue virus", "ORGANISM", 181, 193], ["autophagosomal", "CELLULAR_COMPONENT", 209, 223], ["RNA replication complexes", "PROTEIN", 264, 289], ["murine", "SPECIES", 99, 105], ["hepatitis virus", "SPECIES", 106, 121], ["equine", "SPECIES", 123, 129], ["hepatitis C virus", "SPECIES", 159, 176], ["dengue virus", "SPECIES", 181, 193], ["murine hepatitis virus", "SPECIES", 99, 121], ["equine arterivirus", "SPECIES", 123, 141], ["hepatitis C virus", "SPECIES", 159, 176], ["dengue virus", "SPECIES", 181, 193], ["certain positive-stranded RNA viruses", "PROBLEM", 21, 58], ["coronaviruses", "PROBLEM", 68, 81], ["picornaviruses", "PROBLEM", 83, 97], ["murine hepatitis virus", "PROBLEM", 99, 121], ["equine arterivirus", "PROBLEM", 123, 141], ["coxsackievirus", "PROBLEM", 143, 157], ["hepatitis C virus", "PROBLEM", 159, 176], ["dengue virus", "PROBLEM", 181, 193], ["the autophagosomal machinery", "TREATMENT", 205, 233], ["stranded RNA viruses", "OBSERVATION", 38, 58], ["hepatitis virus", "OBSERVATION", 106, 121]]], ["More recently, Rodriguez-Rocha et al. found that autophagy-induced in adenovirus infection promotes viral infection and oncolysis [16].", [["infection", "DISEASE", 81, 90], ["viral infection", "DISEASE", 100, 115], ["adenovirus", "ORGANISM", 70, 80], ["adenovirus", "SPECIES", 70, 80], ["autophagy", "PROBLEM", 49, 58], ["adenovirus infection", "PROBLEM", 70, 90], ["viral infection", "PROBLEM", 100, 115], ["adenovirus infection", "OBSERVATION", 70, 90], ["viral infection", "OBSERVATION", 100, 115]]], ["Here, we explore the role of the autophagy machinery in ChikV-infected cells by monitoring the presence of double-membrane vesicles and the distribution of LC3.", [["cells", "ANATOMY", 71, 76], ["membrane vesicles", "ANATOMY", 114, 131], ["ChikV", "GENE_OR_GENE_PRODUCT", 56, 61], ["cells", "CELL", 71, 76], ["membrane vesicles", "CELLULAR_COMPONENT", 114, 131], ["LC3", "GENE_OR_GENE_PRODUCT", 156, 159], ["ChikV-infected cells", "CELL_LINE", 56, 76], ["LC3", "PROTEIN", 156, 159], ["the autophagy machinery", "TREATMENT", 29, 52], ["ChikV-infected cells", "TREATMENT", 56, 76], ["double-membrane vesicles", "TREATMENT", 107, 131], ["infected cells", "OBSERVATION", 62, 76], ["double", "OBSERVATION", 107, 113], ["membrane vesicles", "OBSERVATION", 114, 131], ["LC3", "OBSERVATION", 156, 159]]], ["As well, we demonstrate the effects of perturbing the autophagy pathway, using pharmacological inhibitors or RNA interference, on viral replication.", [["the autophagy pathway", "TREATMENT", 50, 71], ["pharmacological inhibitors", "TREATMENT", 79, 105], ["RNA interference", "PROBLEM", 109, 125], ["viral replication", "TREATMENT", 130, 147]]], ["The present study provides the first evidence that cellular autophagy is promoted in ChikV-infected cells and contributes to enhance ChikV replication.Cells and culture conditions ::: Materials and methodsThe HEK.293 cell lines were maintained at 37\u00b0C in an humidified atmosphere containing 5% CO2 in complete medium (Dulbecco's modified Eagle's medium) supplemented with 10% heat inactivated fetal calf serum together with penicillin (100 \u03bcg/ml), streptomycin (100 U/ml), sodium pyruvate (1 mM), L-glutamine (5 mM) and fungizone (0.5 \u03bcg/ml) available from Dutscher (Brumath, France).", [["cellular", "ANATOMY", 51, 59], ["cells", "ANATOMY", 100, 105], ["Cells", "ANATOMY", 151, 156], ["HEK", "ANATOMY", 209, 212], ["293 cell lines", "ANATOMY", 213, 227], ["fetal calf serum", "ANATOMY", 393, 409], ["CO2", "CHEMICAL", 294, 297], ["penicillin", "CHEMICAL", 424, 434], ["streptomycin", "CHEMICAL", 448, 460], ["sodium pyruvate", "CHEMICAL", 473, 488], ["L-glutamine", "CHEMICAL", 497, 508], ["fungizone", "CHEMICAL", 520, 529], ["CO2", "CHEMICAL", 294, 297], ["penicillin", "CHEMICAL", 424, 434], ["streptomycin", "CHEMICAL", 448, 460], ["sodium pyruvate", "CHEMICAL", 473, 488], ["L-glutamine", "CHEMICAL", 497, 508], ["fungizone", "CHEMICAL", 520, 529], ["cellular", "CELL", 51, 59], ["ChikV", "GENE_OR_GENE_PRODUCT", 85, 90], ["cells", "CELL", 100, 105], ["ChikV", "GENE_OR_GENE_PRODUCT", 133, 138], ["Cells", "CELL", 151, 156], ["HEK", "CELL", 209, 212], ["293 cell lines", "CELL", 213, 227], ["CO2", "SIMPLE_CHEMICAL", 294, 297], ["calf", "ORGANISM", 399, 403], ["serum", "ORGANISM_SUBSTANCE", 404, 409], ["penicillin", "SIMPLE_CHEMICAL", 424, 434], ["streptomycin", "SIMPLE_CHEMICAL", 448, 460], ["sodium pyruvate", "SIMPLE_CHEMICAL", 473, 488], ["L-glutamine", "SIMPLE_CHEMICAL", 497, 508], ["fungizone", "SIMPLE_CHEMICAL", 520, 529], ["ChikV-infected cells", "CELL_LINE", 85, 105], ["HEK", "CELL_LINE", 209, 212], ["293 cell lines", "CELL_LINE", 213, 227], ["calf", "SPECIES", 399, 403], ["The present study", "TEST", 0, 17], ["cellular autophagy", "PROBLEM", 51, 69], ["ChikV-infected cells", "PROBLEM", 85, 105], ["ChikV replication", "TREATMENT", 133, 150], ["culture conditions", "TEST", 161, 179], ["293 cell lines", "TREATMENT", 213, 227], ["an humidified atmosphere", "TREATMENT", 255, 279], ["5% CO2 in complete medium (Dulbecco's modified Eagle's medium", "TREATMENT", 291, 352], ["10% heat inactivated fetal calf serum", "TREATMENT", 372, 409], ["penicillin", "TREATMENT", 424, 434], ["streptomycin", "TREATMENT", 448, 460], ["sodium pyruvate", "TEST", 473, 488], ["L-glutamine", "TREATMENT", 497, 508], ["fungizone", "TREATMENT", 520, 529], ["cellular autophagy", "OBSERVATION", 51, 69], ["infected cells", "OBSERVATION", 91, 105], ["cell lines", "OBSERVATION", 217, 227]]], ["HEK.293 cells constitutively expressing a GFP-LC3 transgene were generated by transfection of the GFP-LC3 plasmid (kindly provided by M. Biard-Piechaczyk, Montpellier, France).", [["HEK.293 cells", "ANATOMY", 0, 13], ["HEK.293 cells", "CELL", 0, 13], ["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["LC3", "GENE_OR_GENE_PRODUCT", 46, 49], ["GFP", "GENE_OR_GENE_PRODUCT", 98, 101], ["LC3", "GENE_OR_GENE_PRODUCT", 102, 105], ["HEK.293 cells", "CELL_LINE", 0, 13], ["GFP-LC3 transgene", "DNA", 42, 59], ["GFP-LC3 plasmid", "DNA", 98, 113], ["a GFP", "TEST", 40, 45], ["the GFP", "TEST", 94, 101]]], ["Transfected cells were initially selected with 400 \u03bcg/ml of G418 and kept for maintenance with 40 \u03bcg/ml of G418.Viral stock and inhibition/activation assays ::: Materials and methodsWe used a viral isolate (ChikV clone #4) amplified from a patient's serum sample isolated during the 2006 epidemic [17].", [["cells", "ANATOMY", 12, 17], ["serum sample", "ANATOMY", 250, 262], ["G418", "CHEMICAL", 60, 64], ["G418", "CHEMICAL", 107, 111], ["G418", "CHEMICAL", 60, 64], ["G418", "CHEMICAL", 107, 111], ["cells", "CELL", 12, 17], ["ChikV clone #4", "CELL", 207, 221], ["patient", "ORGANISM", 240, 247], ["serum", "ORGANISM_SUBSTANCE", 250, 255], ["patient", "SPECIES", 240, 247], ["Transfected cells", "PROBLEM", 0, 17], ["G418", "TREATMENT", 60, 64], ["G418", "TREATMENT", 107, 111], ["a viral isolate (ChikV clone #", "TREATMENT", 190, 220], ["a patient's serum sample", "TEST", 238, 262]]], ["One step qRT-PCR was used to amplify the E1 gene.Viral stock and inhibition/activation assays ::: Materials and methodsIn infection experiments, biochemical reagents (inhibitor or activator) were added two hours before infection with ChikV (MOI = 1) and samples were analyzed at 24 h and 48 h post-infection.Primers used for RT-PCR ::: Materials and methodsThe following primers were used:Primers used for RT-PCR ::: Materials and methodsHu GAPDH_F, 5'-GAACGGGAAGCTTGTCATCA-3' (position 291-310), and Hu GAPDH_R, 5'-TGACCTTGCCCACAGCCTTG-3' (position 744 -763); sequence reference NM_002046; amplicon 473 bp.Primers used for RT-PCR ::: Materials and methodsCHIK E1_F, 5'-AAGCTYCGCGTCCTTTACCAAG-3' (position 10387-10400), and CHIK E1_R, 5' -CCAAATTGTCCYGGTCTTCCT-3' (position 10595-10575); sequence reference EU-037962.1; amplicon 209 bp.Reagents and antibodies ::: Materials and methodsRapamycin, an autophagy inducer, was purchased from Sigma, and used at a 1 \u03bcM final concentration.", [["samples", "ANATOMY", 254, 261], ["infection", "DISEASE", 122, 131], ["infection", "DISEASE", 219, 228], ["infection", "DISEASE", 298, 307], ["Rapamycin", "CHEMICAL", 885, 894], ["Rapamycin", "CHEMICAL", 885, 894], ["E1", "GENE_OR_GENE_PRODUCT", 41, 43], ["5'-GAACGGGAAGCTTGTCATCA-3", "GENE_OR_GENE_PRODUCT", 450, 475], ["5'-TGACCTTGCCCACAGCCTTG-3", "GENE_OR_GENE_PRODUCT", 513, 538], ["CHIK", "GENE_OR_GENE_PRODUCT", 656, 660], ["Rapamycin", "SIMPLE_CHEMICAL", 885, 894], ["qRT", "DNA", 9, 12], ["E1 gene", "DNA", 41, 48], ["Hu GAPDH_R", "DNA", 501, 511], ["position 744 -763", "DNA", 541, 558], ["amplicon 473 bp", "DNA", 591, 606], ["CHIK E1_R", "DNA", 724, 733], ["position 10595-10575", "DNA", 765, 785], ["EU-037962.1", "DNA", 807, 818], ["amplicon 209 bp", "DNA", 820, 835], ["antibodies", "PROTEIN", 849, 859], ["One step qRT-PCR", "TEST", 0, 16], ["infection experiments", "PROBLEM", 122, 143], ["biochemical reagents (inhibitor or activator)", "TREATMENT", 145, 190], ["infection", "PROBLEM", 219, 228], ["ChikV (MOI", "TREATMENT", 234, 244], ["infection", "PROBLEM", 298, 307], ["RT-PCR", "TEST", 325, 331], ["The following primers", "TREATMENT", 357, 378], ["RT-PCR", "TEST", 406, 412], ["methodsHu GAPDH_F", "TEST", 431, 448], ["GAACGGGAAGCTTGTCATCA", "TEST", 453, 473], ["Hu GAPDH_R", "TEST", 501, 511], ["TGACCTTGCCCACAGCCTTG", "TEST", 516, 536], ["amplicon", "TEST", 591, 599], ["bp", "TEST", 604, 606], ["RT-PCR", "TEST", 624, 630], ["AAGCTYCGCGTCCTTTACCAAG", "TEST", 670, 692], ["amplicon", "TEST", 820, 828], ["bp", "TEST", 833, 835], ["Materials", "TREATMENT", 864, 873], ["methodsRapamycin", "TREATMENT", 878, 894], ["an autophagy inducer", "TREATMENT", 896, 916], ["infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 298, 307]]], ["3-Methyl-Adenine, an autophagy inhibitor, was purchased from Sigma, and used at a 10 mM final concentration.", [["3-Methyl-Adenine", "CHEMICAL", 0, 16], ["3-Methyl-Adenine", "CHEMICAL", 0, 16], ["3-Methyl-Adenine", "SIMPLE_CHEMICAL", 0, 16], ["Methyl-Adenine", "TREATMENT", 2, 16], ["an autophagy inhibitor", "TREATMENT", 18, 40], ["a 10 mM final concentration", "TREATMENT", 80, 107]]], ["Beclin-1 small interfering RNA (siRNA) was purchased from Eurogentec.", [["Beclin-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["Beclin-1 small interfering RNA", "RNA", 0, 30], ["Beclin", "TEST", 0, 6], ["small interfering RNA (siRNA)", "PROBLEM", 9, 38], ["small", "OBSERVATION_MODIFIER", 9, 14], ["interfering", "OBSERVATION", 15, 26]]], ["FDO anti-serum was obtained from a patient with acute Chikungunya, described in (Krejbich-Trotot, et al. 2011 [18]).", [["Chikungunya", "DISEASE", 54, 65], ["FDO", "GENE_OR_GENE_PRODUCT", 0, 3], ["patient", "ORGANISM", 35, 42], ["FDO", "PROTEIN", 0, 3], ["patient", "SPECIES", 35, 42], ["FDO anti-serum", "TEST", 0, 14], ["acute Chikungunya", "PROBLEM", 48, 65], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["Chikungunya", "OBSERVATION", 54, 65]]], ["Monoclonal mouse anti-ChikV antibodies (clones 6C and 4F), a kind gift from Biomerieux, Marcy l'Etoile, France, and IMTSSA (Armed Forces Institute of Tropical Medicine, Pharo), Marseille, France, were used to detect ChikV.", [["mouse", "ORGANISM", 11, 16], ["Monoclonal mouse anti-ChikV antibodies", "PROTEIN", 0, 38], ["4F", "PROTEIN", 54, 56], ["ChikV", "PROTEIN", 216, 221], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["Monoclonal mouse anti-ChikV antibodies", "TREATMENT", 0, 38], ["Tropical Medicine", "TREATMENT", 150, 167], ["ChikV", "PROBLEM", 216, 221]]], ["The GFP-LC3 plasmid was kindly provided by Martine Biard-Piechaczyk.", [["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["LC3", "GENE_OR_GENE_PRODUCT", 8, 11], ["GFP-LC3 plasmid", "DNA", 4, 19], ["The GFP", "TEST", 0, 7], ["LC3 plasmid", "TREATMENT", 8, 19]]], ["Anti-Beclin and anti-Actin antibodies were purchased from Sigma.Cell immunofluorescence staining ::: Materials and methodsAdherent cells were grown and infected on glass coverslips, fixed and permeabilized at different times post infection by immersion in frozen ethanol for 5 min and conserved at - 20\u00b0C. Coverslips were incubated in primary antibodies (1/200) in PBS-BSA 1% and then with secondary antibody conjugated to Alexa594 (1/1000).", [["Cell", "ANATOMY", 64, 68], ["cells", "ANATOMY", 131, 136], ["infection", "DISEASE", 230, 239], ["ethanol", "CHEMICAL", 263, 270], ["Alexa594", "CHEMICAL", 423, 431], ["ethanol", "CHEMICAL", 263, 270], ["Alexa594", "CHEMICAL", 423, 431], ["Anti-Beclin", "GENE_OR_GENE_PRODUCT", 0, 11], ["anti-Actin antibodies", "GENE_OR_GENE_PRODUCT", 16, 37], ["Cell", "CELL", 64, 68], ["Adherent cells", "CELL", 122, 136], ["ethanol", "SIMPLE_CHEMICAL", 263, 270], ["Alexa594", "SIMPLE_CHEMICAL", 423, 431], ["Anti-Beclin", "PROTEIN", 0, 11], ["anti-Actin antibodies", "PROTEIN", 16, 37], ["primary antibodies", "PROTEIN", 335, 353], ["secondary antibody", "PROTEIN", 390, 408], ["Anti-Beclin", "TREATMENT", 0, 11], ["anti-Actin antibodies", "TREATMENT", 16, 37], ["Adherent cells", "PROBLEM", 122, 136], ["glass coverslips", "TREATMENT", 164, 180], ["infection", "PROBLEM", 230, 239], ["primary antibodies", "TEST", 335, 353], ["PBS", "TEST", 365, 368], ["BSA", "TEST", 369, 372], ["secondary antibody conjugated", "PROBLEM", 390, 419], ["Adherent cells", "OBSERVATION", 122, 136], ["infected", "OBSERVATION_MODIFIER", 152, 160], ["glass coverslips", "OBSERVATION_MODIFIER", 164, 180], ["infection", "OBSERVATION", 230, 239]]], ["Nucleus morphology was revealed by DAPI staining (final concentration: 100 ng/ml).", [["DAPI", "CHEMICAL", 35, 39], ["DAPI", "SIMPLE_CHEMICAL", 35, 39], ["Nucleus morphology", "TEST", 0, 18], ["DAPI staining", "TEST", 35, 48], ["DAPI staining", "OBSERVATION", 35, 48]]], ["Coverslips were mounted in Vectashield H-1000 (Vectorlabs, Clinisciences) and fluorescence was observed using a Nikon Eclipse E2000-U microscope.", [["Nikon Eclipse E2000-U microscope", "DNA", 112, 144], ["Coverslips", "TEST", 0, 10]]], ["Images were obtained using the Nikon Digital sight PS-U1 camera system and the imaging software NIS-Element AR.Electron micrographs of ChikV-infected HEK.293 cells ::: Materials and methodsCells infected with Chikungunya virus at MOI = 5 were processed for electron microscopy as described in [19].Western blotting ::: Materials and methodsCells were harvested with a scraper and resuspended in lysis buffer (PBS1X, TritonX100 1%, EDTA 1 mM containing a cocktail of protease inhibitors: PMSF, pepstatin A, leupeptin, aprotinin all at 1 \u03bcg/ml final concentration).", [["HEK.293 cells", "ANATOMY", 150, 163], ["Cells", "ANATOMY", 189, 194], ["Cells", "ANATOMY", 340, 345], ["Chikungunya virus", "DISEASE", 209, 226], ["PBS1X", "CHEMICAL", 409, 414], ["pepstatin A", "CHEMICAL", 493, 504], ["EDTA", "CHEMICAL", 431, 435], ["PMSF", "CHEMICAL", 487, 491], ["pepstatin A", "CHEMICAL", 493, 504], ["leupeptin", "CHEMICAL", 506, 515], ["aprotinin", "CHEMICAL", 517, 526], ["ChikV", "GENE_OR_GENE_PRODUCT", 135, 140], ["HEK.293 cells", "CELL", 150, 163], ["Cells", "CELL", 189, 194], ["Chikungunya virus", "ORGANISM", 209, 226], ["Cells", "CELL", 340, 345], ["PBS1X", "SIMPLE_CHEMICAL", 409, 414], ["PMSF", "SIMPLE_CHEMICAL", 487, 491], ["pepstatin A", "SIMPLE_CHEMICAL", 493, 504], ["leupeptin", "SIMPLE_CHEMICAL", 506, 515], ["aprotinin", "SIMPLE_CHEMICAL", 517, 526], ["Nikon Digital sight PS-U1 camera", "DNA", 31, 63], ["NIS-Element AR", "DNA", 96, 110], ["ChikV-infected HEK.293 cells", "CELL_LINE", 135, 163], ["Chikungunya virus", "SPECIES", 209, 226], ["Chikungunya virus", "SPECIES", 209, 226], ["Images", "TEST", 0, 6], ["the imaging", "TEST", 75, 86], ["Electron micrographs", "TEST", 111, 131], ["ChikV", "PROBLEM", 135, 140], ["Cells infected", "PROBLEM", 189, 203], ["Chikungunya virus", "PROBLEM", 209, 226], ["electron microscopy", "TEST", 257, 276], ["a scraper", "TREATMENT", 366, 375], ["lysis buffer", "TREATMENT", 395, 407], ["PBS1X", "TREATMENT", 409, 414], ["TritonX100", "TREATMENT", 416, 426], ["EDTA", "TREATMENT", 431, 435], ["protease inhibitors", "TREATMENT", 466, 485], ["PMSF", "TREATMENT", 487, 491], ["pepstatin A", "TREATMENT", 493, 504], ["leupeptin", "TREATMENT", 506, 515], ["aprotinin", "TREATMENT", 517, 526], ["ChikV", "OBSERVATION", 135, 140]]], ["Protein extracts were mixed with one volume of loading buffer (Tris 0,1 M, Glycerol 10%, SDS 2%) according to Laemmli's protocol.", [["extracts", "ANATOMY", 8, 16], ["Glycerol", "CHEMICAL", 75, 83], ["Glycerol", "CHEMICAL", 75, 83], ["extracts", "ORGANISM_SUBSTANCE", 8, 16], ["Tris 0,1 M", "SIMPLE_CHEMICAL", 63, 73], ["Glycerol", "SIMPLE_CHEMICAL", 75, 83], ["Protein extracts", "TEST", 0, 16], ["loading buffer (Tris", "TREATMENT", 47, 67], ["Glycerol", "TREATMENT", 75, 83], ["SDS", "TREATMENT", 89, 92], ["Laemmli's protocol", "TREATMENT", 110, 128]]], ["About 50 \u03bcg of each sample was loaded onto a 4-12% precasted NuPAGE gels (Invitrogen).", [["sample", "ANATOMY", 20, 26], ["NuPAGE", "CHEMICAL", 61, 67], ["a 4-12% precasted NuPAGE gels", "TREATMENT", 43, 72]]], ["After electrophoretic migration, proteins were electrotransferred onto a nitrocellulose membrane (Millipore).", [["membrane", "ANATOMY", 88, 96], ["nitrocellulose", "CHEMICAL", 73, 87], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["electrophoretic migration", "TREATMENT", 6, 31], ["a nitrocellulose membrane", "TREATMENT", 71, 96], ["migration", "OBSERVATION_MODIFIER", 22, 31]]], ["Membranes were incubated with primary antibodies and followed by horseradish peroxydase-conjugated secondary antibody.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["horseradish peroxydase", "SIMPLE_CHEMICAL", 65, 87], ["primary antibodies", "PROTEIN", 30, 48], ["horseradish peroxydase-conjugated secondary antibody", "PROTEIN", 65, 117], ["horseradish", "SPECIES", 65, 76], ["primary antibodies", "TREATMENT", 30, 48], ["horseradish peroxydase", "TEST", 65, 87]]], ["After further washes, the immune complexes were revealed by ECL (PerkinElmer).RNA Interference ::: Materials and methodsCells were grown to 50% to 80% confluence and transiently transfected with an annealed beclin-1 siRNA using FuGEN HD (Roche) according to the manufacter's intructions.", [["Cells", "ANATOMY", 120, 125], ["FuGEN", "CHEMICAL", 228, 233], ["Cells", "CELL", 120, 125], ["beclin-1", "GENE_OR_GENE_PRODUCT", 207, 215], ["immune complexes", "PROTEIN", 26, 42], ["annealed beclin-1 siRNA", "DNA", 198, 221], ["further washes", "TREATMENT", 6, 20], ["the immune complexes", "TEST", 22, 42], ["Cells", "TEST", 120, 125], ["an annealed beclin", "TREATMENT", 195, 213], ["FuGEN HD (Roche)", "TREATMENT", 228, 244], ["the manufacter's intructions", "TREATMENT", 258, 286]]], ["An aspecific (unrelated) siRNA was used as a negative control.", [["An aspecific (unrelated) siRNA", "TREATMENT", 0, 30]]], ["The silencing efficiency was assessed by Western Blot analyses of whole cell extract using an anti-Beclin-1 antibody.", [["cell extract", "ANATOMY", 72, 84], ["cell", "CELL", 72, 76], ["anti-Beclin-1 antibody", "GENE_OR_GENE_PRODUCT", 94, 116], ["anti-Beclin-1 antibody", "PROTEIN", 94, 116], ["The silencing efficiency", "PROBLEM", 0, 24], ["whole cell extract", "TREATMENT", 66, 84], ["an anti-Beclin", "TEST", 91, 105], ["silencing efficiency", "OBSERVATION", 4, 24]]], ["The sense oligonucleotide specific for Beclin-1 was: 5'-CAGUUUGGCACAAUCAAUA-3'.Statistics ::: Materials and methodsAll values are expressed as means +/- sd and as percentages of 3 independent experiments, each using triplicate culture plates.", [["Beclin-1", "GENE_OR_GENE_PRODUCT", 39, 47], ["Beclin", "PROTEIN", 39, 45], ["Beclin", "TEST", 39, 45], ["All values", "TEST", 115, 125], ["triplicate culture plates", "TEST", 216, 241]]], ["Comparisons between different treatment regimes have been analyzed by the Mann-Whitney exact test (Graph-Pad, San Diego, CA, USA).", [["different treatment regimes", "TREATMENT", 20, 47]]], ["Degrees of significance are indicated in the figure captions as follow: * p < 0.05; ** p < 0.01; *** p < 0.001.HEK.293 cells are susceptible to infection by ChikV ::: ResultsHEK.293 cells were challenged with a multiplicity of infection (MOI) of 1 of the ChikV clone #4 to evaluate their susceptibility to the virus and their ability to produce viral progeny.", [["HEK", "ANATOMY", 111, 114], ["293 cells", "ANATOMY", 115, 124], ["ResultsHEK.293 cells", "ANATOMY", 167, 187], ["HEK", "CHEMICAL", 111, 114], ["infection", "DISEASE", 144, 153], ["infection", "DISEASE", 227, 236], ["HEK", "CELL", 111, 114], ["293 cells", "CELL", 115, 124], ["ResultsHEK.293 cells", "CELL", 167, 187], ["HEK", "CELL_LINE", 111, 114], ["293 cells", "CELL_LINE", 115, 124], ["ResultsHEK.293 cells", "CELL_LINE", 167, 187], ["infection", "PROBLEM", 144, 153], ["infection", "PROBLEM", 227, 236], ["the ChikV clone", "TREATMENT", 251, 266], ["the virus", "PROBLEM", 306, 315], ["infection", "OBSERVATION", 144, 153], ["infection", "OBSERVATION", 227, 236]]], ["Susceptibility to ChikV was next determined by mean of immunofluorescence detection of E1 envelope glycoprotein (Figure 1A).", [["E1 envelope glycoprotein", "GENE_OR_GENE_PRODUCT", 87, 111], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 113, 122], ["ChikV", "DNA", 18, 23], ["E1 envelope glycoprotein", "PROTEIN", 87, 111], ["Figure 1A", "PROTEIN", 113, 122], ["ChikV", "PROBLEM", 18, 23], ["immunofluorescence detection", "TEST", 55, 83], ["E1 envelope glycoprotein", "TREATMENT", 87, 111]]], ["Figure 1B shows the percentage of ChikV-infected cells during the time course of infection.", [["cells", "ANATOMY", 49, 54], ["infection", "DISEASE", 81, 90], ["ChikV", "GENE_OR_GENE_PRODUCT", 34, 39], ["cells", "CELL", 49, 54], ["ChikV-infected cells", "CELL_TYPE", 34, 54], ["Figure 1B", "TEST", 0, 9], ["ChikV", "PROBLEM", 34, 39], ["infected cells", "PROBLEM", 40, 54], ["infection", "PROBLEM", 81, 90], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["ChikV", "OBSERVATION", 34, 39], ["infected cells", "OBSERVATION", 40, 54], ["infection", "OBSERVATION", 81, 90]]], ["At MOI = 1, ChikV antigen E1 was detected on few percentage of cells (1.6% +/- 0.65) as early as 8 hours after infection.", [["cells", "ANATOMY", 63, 68], ["infection", "DISEASE", 111, 120], ["ChikV antigen E1", "GENE_OR_GENE_PRODUCT", 12, 28], ["cells", "CELL", 63, 68], ["ChikV antigen E1", "PROTEIN", 12, 28], ["MOI", "TEST", 3, 6], ["ChikV antigen E1", "TEST", 12, 28], ["cells", "TEST", 63, 68], ["infection", "PROBLEM", 111, 120], ["infection", "OBSERVATION", 111, 120]]], ["About 35% (+/-11%) of the cells were replicating the virus within the first 24 h and about 84% (+/-12%) of the cells were ChikV positive 48 hours post infection.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 111, 116], ["infection", "DISEASE", 151, 160], ["cells", "CELL", 26, 31], ["cells", "CELL", 111, 116], ["the cells", "PROBLEM", 22, 31], ["the virus", "PROBLEM", 49, 58], ["the cells", "PROBLEM", 107, 116], ["ChikV positive", "PROBLEM", 122, 136], ["infection", "PROBLEM", 151, 160], ["infection", "OBSERVATION", 151, 160]]], ["Release of ChikV particles in culture supernatant was monitored by quantification of viral RNA using qRT-PCR (Figure 1C).", [["supernatant", "ANATOMY", 38, 49], ["ChikV", "GENE_OR_GENE_PRODUCT", 11, 16], ["viral RNA", "RNA", 85, 94], ["ChikV particles", "PROBLEM", 11, 26], ["culture supernatant", "TEST", 30, 49], ["viral RNA", "PROBLEM", 85, 94], ["qRT", "TEST", 101, 104], ["PCR", "TEST", 105, 108], ["ChikV particles", "OBSERVATION", 11, 26], ["viral RNA", "OBSERVATION", 85, 94]]], ["At 48 h post infection, almost 1.2 \u00d7 1010/ml viral RNA copies were detected from the cell culture supernatant.", [["cell culture supernatant", "ANATOMY", 85, 109], ["infection", "DISEASE", 13, 22], ["cell", "CELL", 85, 89], ["viral RNA copies", "RNA", 45, 61], ["infection", "PROBLEM", 13, 22], ["viral RNA copies", "TEST", 45, 61], ["the cell culture", "TEST", 81, 97], ["infection", "OBSERVATION", 13, 22]]], ["These data confirm that HEK.293 cells are susceptible to ChikV and efficiently replicate the virus, as previously reported [20,21].Chikungunya virus induces autophagy in HEK.293 cells ::: ResultsTwo forms of LC3 have been reported in the literature.", [["HEK", "ANATOMY", 24, 27], ["293 cells", "ANATOMY", 28, 37], ["HEK", "ANATOMY", 170, 173], ["293 cells", "ANATOMY", 174, 183], ["Chikungunya", "DISEASE", 131, 142], ["HEK", "CELL", 24, 27], ["293 cells", "CELL", 28, 37], ["ChikV", "GENE_OR_GENE_PRODUCT", 57, 62], ["Chikungunya virus", "ORGANISM", 131, 148], ["HEK", "CELL", 170, 173], ["293 cells", "CELL", 174, 183], ["LC3", "GENE_OR_GENE_PRODUCT", 208, 211], ["HEK", "CELL_LINE", 24, 27], ["293 cells", "CELL_LINE", 28, 37], ["HEK", "CELL_LINE", 170, 173], ["293 cells", "CELL_LINE", 174, 183], ["LC3", "PROTEIN", 208, 211], ["Chikungunya virus", "SPECIES", 131, 148], ["Chikungunya virus", "SPECIES", 131, 148], ["These data", "TEST", 0, 10], ["ChikV", "PROBLEM", 57, 62], ["the virus", "PROBLEM", 89, 98], ["Chikungunya virus", "PROBLEM", 131, 148], ["LC3", "TEST", 208, 211], ["virus", "OBSERVATION", 93, 98]]], ["In absence of autophagy, LC3 adopts a diffuse cytoplasmic localization pattern.", [["cytoplasmic", "ANATOMY", 46, 57], ["LC3", "GENE_OR_GENE_PRODUCT", 25, 28], ["cytoplasmic", "ORGANISM_SUBSTANCE", 46, 57], ["LC3", "PROTEIN", 25, 28], ["autophagy", "PROBLEM", 14, 23], ["a diffuse cytoplasmic localization pattern", "PROBLEM", 36, 78], ["autophagy", "OBSERVATION", 14, 23], ["diffuse", "OBSERVATION_MODIFIER", 38, 45], ["cytoplasmic localization pattern", "OBSERVATION", 46, 78]]], ["When autophagy is stimulated, LC3 is conjugated to phosphatidylethanolamine, which participates in the formation of autophagosomes and remains on the autophagosomes membranes [22].", [["autophagosomes", "ANATOMY", 116, 130], ["autophagosomes membranes", "ANATOMY", 150, 174], ["phosphatidylethanolamine", "CHEMICAL", 51, 75], ["phosphatidylethanolamine", "CHEMICAL", 51, 75], ["LC3", "GENE_OR_GENE_PRODUCT", 30, 33], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 51, 75], ["autophagosomes", "CELLULAR_COMPONENT", 116, 130], ["autophagosomes membranes", "CELLULAR_COMPONENT", 150, 174], ["LC3", "PROTEIN", 30, 33], ["phosphatidylethanolamine", "TREATMENT", 51, 75], ["autophagosomes", "OBSERVATION", 116, 130]]], ["Therefore, modification of LC3 distribution from a diffuse to a punctate staining has been suggested to be a hallmark of autophagy.", [["LC3", "GENE_OR_GENE_PRODUCT", 27, 30], ["LC3", "PROTEIN", 27, 30], ["modification of LC3 distribution", "PROBLEM", 11, 43], ["a diffuse to a punctate staining", "PROBLEM", 49, 81], ["LC3 distribution", "OBSERVATION", 27, 43], ["diffuse", "OBSERVATION_MODIFIER", 51, 58], ["punctate", "OBSERVATION_MODIFIER", 64, 72], ["staining", "OBSERVATION", 73, 81], ["suggested to be", "UNCERTAINTY", 91, 106], ["autophagy", "OBSERVATION", 121, 130]]], ["To decipher the relationship between ChikV and autophagy, we performed fluorescence microscopy experiments in order to follow the LC3 distribution during the time course of ChikV infection.", [["infection", "DISEASE", 179, 188], ["ChikV", "GENE_OR_GENE_PRODUCT", 37, 42], ["LC3", "GENE_OR_GENE_PRODUCT", 130, 133], ["ChikV", "GENE_OR_GENE_PRODUCT", 173, 178], ["ChikV", "PROTEIN", 37, 42], ["LC3", "PROTEIN", 130, 133], ["ChikV", "SPECIES", 173, 178], ["ChikV", "PROBLEM", 37, 42], ["fluorescence microscopy experiments", "TEST", 71, 106], ["ChikV infection", "PROBLEM", 173, 188], ["ChikV", "OBSERVATION_MODIFIER", 173, 178], ["infection", "OBSERVATION", 179, 188]]], ["To this end, we generated from HEK.293 cells a stable cell line that expresses the fusion protein of green fluorescent protein (GFP) and LC3.", [["HEK", "ANATOMY", 31, 34], ["293 cells", "ANATOMY", 35, 44], ["cell line", "ANATOMY", 54, 63], ["HEK", "CELL", 31, 34], ["293 cells", "CELL", 35, 44], ["cell line", "CELL", 54, 63], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 101, 126], ["GFP", "GENE_OR_GENE_PRODUCT", 128, 131], ["LC3", "GENE_OR_GENE_PRODUCT", 137, 140], ["HEK", "CELL_LINE", 31, 34], ["293 cells", "CELL_LINE", 35, 44], ["fusion protein", "PROTEIN", 83, 97], ["green fluorescent protein", "PROTEIN", 101, 126], ["GFP", "PROTEIN", 128, 131], ["LC3", "PROTEIN", 137, 140], ["a stable cell line", "TREATMENT", 45, 63], ["the fusion protein", "TEST", 79, 97], ["green fluorescent protein", "TEST", 101, 126], ["stable", "OBSERVATION_MODIFIER", 47, 53], ["cell line", "OBSERVATION", 54, 63]]], ["In uninfected cells (Ct), GFP-LC3 showed a diffuse localization throughout the cytoplasm (Figure 2A).", [["cells", "ANATOMY", 14, 19], ["cytoplasm", "ANATOMY", 79, 88], ["cells", "CELL", 14, 19], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["LC3", "GENE_OR_GENE_PRODUCT", 30, 33], ["cytoplasm", "ORGANISM_SUBSTANCE", 79, 88], ["uninfected cells", "CELL_TYPE", 3, 19], ["GFP", "PROTEIN", 26, 29], ["LC3", "PROTEIN", 30, 33], ["Ct)", "TEST", 21, 24], ["GFP", "TEST", 26, 29], ["a diffuse localization throughout the cytoplasm", "PROBLEM", 41, 88], ["uninfected cells", "OBSERVATION", 3, 19], ["diffuse", "OBSERVATION_MODIFIER", 43, 50]]], ["During the time course of ChikV infection, GFP-LC3 adopts a punctate staining (number of GFP-LC3 dots per cell in Control: 2.3 +/-1.2; 16 h post infection: 25.9+/-4.9; 48 h post infection: 38.2 +/- 2.8).", [["cell", "ANATOMY", 106, 110], ["infection", "DISEASE", 32, 41], ["infection", "DISEASE", 145, 154], ["infection", "DISEASE", 178, 187], ["ChikV", "CANCER", 26, 31], ["GFP-LC3", "GENE_OR_GENE_PRODUCT", 43, 50], ["GFP", "GENE_OR_GENE_PRODUCT", 89, 92], ["LC3", "GENE_OR_GENE_PRODUCT", 93, 96], ["GFP", "PROTEIN", 43, 46], ["LC3", "PROTEIN", 47, 50], ["GFP", "PROTEIN", 89, 92], ["LC3 dots", "PROTEIN", 93, 101], ["ChikV", "SPECIES", 26, 31], ["ChikV infection", "PROBLEM", 26, 41], ["GFP", "TEST", 43, 46], ["a punctate staining", "PROBLEM", 58, 77], ["GFP", "TEST", 89, 92], ["infection", "PROBLEM", 145, 154], ["infection", "TEST", 178, 187], ["ChikV", "OBSERVATION", 26, 31], ["punctate", "OBSERVATION_MODIFIER", 60, 68]]], ["We showed that both the number of GFP-LC3-HEK.293 cells with punctate GFP-LC3 staining (Figure 2B) and the number of GFP-LC3 dots per cell (Figure 2C) were highly increased.", [["HEK", "ANATOMY", 42, 45], ["293 cells", "ANATOMY", 46, 55], ["punctate", "ANATOMY", 61, 69], ["cell", "ANATOMY", 134, 138], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["LC3", "GENE_OR_GENE_PRODUCT", 38, 41], ["293 cells", "CELL", 46, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 70, 73], ["LC3", "GENE_OR_GENE_PRODUCT", 74, 77], ["GFP", "GENE_OR_GENE_PRODUCT", 117, 120], ["LC3", "GENE_OR_GENE_PRODUCT", 121, 124], ["cell", "CELL", 134, 138], ["GFP", "PROTEIN", 34, 37], ["LC3", "PROTEIN", 38, 41], ["HEK", "PROTEIN", 42, 45], ["293 cells", "CELL_LINE", 46, 55], ["LC3", "PROTEIN", 74, 77], ["Figure 2B", "PROTEIN", 88, 97], ["GFP", "PROTEIN", 117, 120], ["LC3 dots", "PROTEIN", 121, 129], ["GFP", "TEST", 34, 37], ["punctate GFP", "TEST", 61, 73], ["LC3 staining", "TEST", 74, 86], ["GFP", "TEST", 117, 120], ["punctate", "OBSERVATION_MODIFIER", 61, 69], ["GFP", "OBSERVATION", 70, 73], ["LC3 staining", "OBSERVATION", 74, 86], ["increased", "OBSERVATION_MODIFIER", 163, 172]]], ["These results indicate that ChikV infection generates a redistribution of LC3 and stimulates autophagy.ChikV infection stimulates autophagosome formation in HEK.293 cells ::: ResultsTo confirm that ChikV infection triggers an autophagic process in target cells, we performed an ultrastructure analysis of ChikV-infected HEK.293 cells using transmission electron microscopy (TEM).", [["autophagosome", "ANATOMY", 130, 143], ["HEK", "ANATOMY", 157, 160], ["293 cells", "ANATOMY", 161, 170], ["cells", "ANATOMY", 255, 260], ["HEK", "ANATOMY", 320, 323], ["293 cells", "ANATOMY", 324, 333], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 204, 213], ["ChikV", "GENE_OR_GENE_PRODUCT", 28, 33], ["LC3", "GENE_OR_GENE_PRODUCT", 74, 77], ["ChikV", "GENE_OR_GENE_PRODUCT", 103, 108], ["autophagosome", "CELLULAR_COMPONENT", 130, 143], ["HEK", "CELL", 157, 160], ["293 cells", "CELL", 161, 170], ["ChikV", "GENE_OR_GENE_PRODUCT", 198, 203], ["cells", "CELL", 255, 260], ["ChikV", "GENE_OR_GENE_PRODUCT", 305, 310], ["HEK", "CELL", 320, 323], ["293 cells", "CELL", 324, 333], ["LC3", "PROTEIN", 74, 77], ["HEK", "CELL_LINE", 157, 160], ["293 cells", "CELL_LINE", 161, 170], ["target cells", "CELL_TYPE", 248, 260], ["ChikV-infected HEK", "CELL_LINE", 305, 323], ["293 cells", "CELL_LINE", 324, 333], ["ChikV", "SPECIES", 198, 203], ["ChikV infection", "PROBLEM", 28, 43], ["a redistribution of LC3", "PROBLEM", 54, 77], ["ChikV infection", "PROBLEM", 103, 118], ["ChikV infection", "PROBLEM", 198, 213], ["an autophagic process in target cells", "PROBLEM", 223, 260], ["an ultrastructure analysis", "TEST", 275, 301], ["ChikV", "PROBLEM", 305, 310], ["transmission electron microscopy", "TEST", 340, 372], ["ChikV", "OBSERVATION_MODIFIER", 28, 33], ["infection", "OBSERVATION", 34, 43], ["redistribution", "OBSERVATION_MODIFIER", 56, 70], ["LC3", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 109, 118], ["ChikV", "OBSERVATION_MODIFIER", 198, 203], ["infection", "OBSERVATION", 204, 213], ["autophagic process", "OBSERVATION", 226, 244]]], ["The cells were challenged with a high infectious dose of ChikV (MOI = 5) to increase the number of infected cells in the culture and favor the visualization of ChikV-positive cells and processed for electron microscopy.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 108, 113], ["ChikV-positive cells", "ANATOMY", 160, 180], ["ChikV", "CHEMICAL", 57, 62], ["cells", "CELL", 4, 9], ["cells", "CELL", 108, 113], ["ChikV", "GENE_OR_GENE_PRODUCT", 160, 165], ["cells", "CELL", 175, 180], ["infected cells", "CELL_TYPE", 99, 113], ["ChikV-positive cells", "CELL_LINE", 160, 180], ["ChikV (MOI", "TREATMENT", 57, 67], ["infected cells", "PROBLEM", 99, 113], ["the culture", "TEST", 117, 128], ["the visualization", "TEST", 139, 156], ["ChikV-positive cells", "PROBLEM", 160, 180], ["electron microscopy", "TEST", 199, 218], ["infected cells", "OBSERVATION", 99, 113], ["positive cells", "OBSERVATION", 166, 180]]], ["In these cells, we observed numerous membrane-bound vacuoles characteristic of autophagosomes (Figure 3A and 3B) that were not present when the HEK.293 cells were mock infected (data not shown).", [["cells", "ANATOMY", 9, 14], ["membrane", "ANATOMY", 37, 45], ["vacuoles", "ANATOMY", 52, 60], ["autophagosomes", "ANATOMY", 79, 93], ["HEK", "ANATOMY", 144, 147], ["293 cells", "ANATOMY", 148, 157], ["cells", "CELL", 9, 14], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["vacuoles", "CELLULAR_COMPONENT", 52, 60], ["autophagosomes", "CELLULAR_COMPONENT", 79, 93], ["HEK", "CELL", 144, 147], ["293 cells", "CELL", 148, 157], ["HEK", "CELL_LINE", 144, 147], ["293 cells", "CELL_LINE", 148, 157], ["numerous", "OBSERVATION_MODIFIER", 28, 36], ["membrane", "OBSERVATION_MODIFIER", 37, 45], ["bound vacuoles", "OBSERVATION", 46, 60]]], ["Therefore, this observation confirms that ChikV infection stimulates autophagosome formation in HEK.293 cells.", [["autophagosome", "ANATOMY", 69, 82], ["HEK", "ANATOMY", 96, 99], ["293 cells", "ANATOMY", 100, 109], ["infection", "DISEASE", 48, 57], ["ChikV", "GENE_OR_GENE_PRODUCT", 42, 47], ["autophagosome", "CELLULAR_COMPONENT", 69, 82], ["HEK", "CELL", 96, 99], ["293 cells", "CELL", 100, 109], ["HEK", "CELL_LINE", 96, 99], ["293 cells", "CELL_LINE", 100, 109], ["this observation", "TEST", 11, 27], ["ChikV infection", "PROBLEM", 42, 57], ["ChikV", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57]]], ["Interestingly, a proportion of virions were observed within the lumen of double-membrane-vesicles (Figure 3C) and we observed a significant proportion of cells that contained assembled bona fide viral particles.", [["virions", "ANATOMY", 31, 38], ["lumen", "ANATOMY", 64, 69], ["double-membrane-vesicles", "ANATOMY", 73, 97], ["cells", "ANATOMY", 154, 159], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 69], ["membrane-vesicles", "CELLULAR_COMPONENT", 80, 97], ["cells", "CELL", 154, 159], ["virions", "PROBLEM", 31, 38], ["a significant proportion of cells", "PROBLEM", 126, 159], ["virions", "OBSERVATION", 31, 38], ["lumen", "ANATOMY_MODIFIER", 64, 69], ["membrane", "ANATOMY_MODIFIER", 80, 88], ["vesicles", "ANATOMY", 89, 97], ["bona fide", "OBSERVATION", 185, 194], ["viral particles", "OBSERVATION", 195, 210]]], ["The colocalisation of viral particles in these structures suggests that they may interfere with the viral life cycle.Impairment of autophagy reduces ChikV replication ::: ResultsTo determine whether the autophagic process induced during ChikV infection was a host antiviral response or a proviral replication mechanism, we tested the effect of 3-Methyladenine (3-MA) on ChikV replication.", [["infection", "DISEASE", 243, 252], ["3-Methyladenine", "CHEMICAL", 344, 359], ["3-MA", "CHEMICAL", 361, 365], ["3-Methyladenine", "CHEMICAL", 344, 359], ["3-MA", "CHEMICAL", 361, 365], ["ChikV", "GENE_OR_GENE_PRODUCT", 237, 242], ["3-Methyladenine", "SIMPLE_CHEMICAL", 344, 359], ["3-MA", "SIMPLE_CHEMICAL", 361, 365], ["ChikV", "SIMPLE_CHEMICAL", 370, 375], ["ChikV", "SPECIES", 237, 242], ["The colocalisation of viral particles", "PROBLEM", 0, 37], ["the viral life cycle", "TREATMENT", 96, 116], ["Impairment of autophagy", "PROBLEM", 117, 140], ["the autophagic process", "PROBLEM", 199, 221], ["ChikV infection", "PROBLEM", 237, 252], ["a proviral replication mechanism", "TREATMENT", 286, 318], ["Methyladenine", "TREATMENT", 346, 359], ["ChikV replication", "TREATMENT", 370, 387], ["viral particles", "OBSERVATION", 22, 37]]], ["3-MA is a widely used selective inhibitor of autophagy which blocks the formation of autophagosomes and inhibits intracellular protein degradation without affecting protein synthesis [23].", [["autophagosomes", "ANATOMY", 85, 99], ["intracellular", "ANATOMY", 113, 126], ["3-MA", "CHEMICAL", 0, 4], ["3-MA", "CHEMICAL", 0, 4], ["3-MA", "SIMPLE_CHEMICAL", 0, 4], ["autophagosomes", "CELLULAR_COMPONENT", 85, 99], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 126], ["selective inhibitor of autophagy", "TREATMENT", 22, 54], ["autophagosomes", "PROBLEM", 85, 99], ["intracellular protein degradation", "PROBLEM", 113, 146], ["affecting protein synthesis", "PROBLEM", 155, 182], ["intracellular protein degradation", "OBSERVATION", 113, 146]]], ["Pre-treatment with 3-MA 2 hours before the infection with ChikV (MOI = 1) resulted in a significant reduction in the number of ChikV infected cells as shown by immunofluorescence microscopy (Figure 4A and 4B).", [["cells", "ANATOMY", 142, 147], ["3-MA", "CHEMICAL", 19, 23], ["infection", "DISEASE", 43, 52], ["3-MA", "CHEMICAL", 19, 23], ["3-MA", "GENE_OR_GENE_PRODUCT", 19, 23], ["cells", "CELL", 142, 147], ["ChikV infected cells", "CELL_TYPE", 127, 147], ["the infection", "PROBLEM", 39, 52], ["ChikV (MOI", "TREATMENT", 58, 68], ["a significant reduction", "PROBLEM", 86, 109], ["ChikV infected cells", "PROBLEM", 127, 147], ["immunofluorescence microscopy", "TEST", 160, 189], ["infection", "OBSERVATION", 43, 52], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["reduction", "OBSERVATION_MODIFIER", 100, 109], ["ChikV infected cells", "OBSERVATION", 127, 147]]], ["ChikV viral RNA release in culture supernatant was also significantly reduced (Figure 4C).", [["supernatant", "ANATOMY", 35, 46], ["ChikV", "GENE_OR_GENE_PRODUCT", 0, 5], ["ChikV viral RNA", "RNA", 0, 15], ["ChikV", "SPECIES", 0, 5], ["ChikV viral RNA release", "TEST", 0, 23], ["culture supernatant", "TEST", 27, 46]]], ["Furthermore, Western Blot analysis showed a limited expression of viral envelope and capsid proteins in infected cells pre-incubated with 3-MA (Figure 4D).", [["cells", "ANATOMY", 113, 118], ["3-MA", "CHEMICAL", 138, 142], ["3-MA", "CHEMICAL", 138, 142], ["cells", "CELL", 113, 118], ["3-MA", "SIMPLE_CHEMICAL", 138, 142], ["viral envelope and capsid proteins", "PROTEIN", 66, 100], ["infected cells", "CELL_TYPE", 104, 118], ["Blot analysis", "TEST", 21, 34], ["viral envelope", "PROBLEM", 66, 80], ["capsid proteins in infected cells", "PROBLEM", 85, 118], ["viral envelope", "OBSERVATION", 66, 80], ["infected cells", "OBSERVATION", 104, 118]]], ["This finding suggests that the autophagic machinery may not have an antiviral role during ChikV infection and instead may favor ChikV replication.Impairment of autophagy reduces ChikV replication ::: ResultsTo confirm the observation observed with pharmacological inhibitors, we used a target-specific RNA interference approach which will disrupt the autophagosomal machinery.", [["autophagosomal", "ANATOMY", 351, 365], ["infection", "DISEASE", 96, 105], ["ChikV", "GENE_OR_GENE_PRODUCT", 90, 95], ["ChikV", "GENE_OR_GENE_PRODUCT", 128, 133], ["autophagosomal", "CELLULAR_COMPONENT", 351, 365], ["ChikV", "SPECIES", 90, 95], ["ChikV infection", "PROBLEM", 90, 105], ["ChikV replication", "PROBLEM", 128, 145], ["Impairment of autophagy", "PROBLEM", 146, 169], ["the observation", "TEST", 218, 233], ["pharmacological inhibitors", "TREATMENT", 248, 274], ["a target-specific RNA interference approach", "TREATMENT", 284, 327], ["antiviral", "OBSERVATION", 68, 77]]], ["Cells were transfected with siRNA to knock down beclin-1 gene expression.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["beclin-1", "GENE_OR_GENE_PRODUCT", 48, 56], ["beclin", "PROTEIN", 48, 54], ["siRNA", "TREATMENT", 28, 33], ["beclin", "TEST", 48, 54]]], ["As shown in Figure 4E, cells transfected with specific siRNA reducing cellular Beclin-1 expression poorly supported ChikV replication unlike the unrelated siRNA-treated cells.", [["cells", "ANATOMY", 23, 28], ["cellular", "ANATOMY", 70, 78], ["cells", "ANATOMY", 169, 174], ["cells", "CELL", 23, 28], ["cellular", "CELL", 70, 78], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 79, 87], ["ChikV", "GENE_OR_GENE_PRODUCT", 116, 121], ["cells", "CELL", 169, 174], ["Beclin", "PROTEIN", 79, 85], ["treated cells", "CELL_LINE", 161, 174], ["specific siRNA", "TREATMENT", 46, 60], ["cellular Beclin", "TREATMENT", 70, 85], ["ChikV replication", "TREATMENT", 116, 133], ["the unrelated siRNA-treated cells", "PROBLEM", 141, 174]]], ["These results further demonstrate that autophagy is required for effective ChikV replication and enhances an intracellular step of the virus life cycle that remains to be elucidated.Induction of autophagy enhances viral growth ::: ResultsTo further determine the role of autophagy in viral replication, we investigated the effect of autophagy induction on viral protein expression.", [["intracellular", "ANATOMY", 109, 122], ["ChikV", "GENE_OR_GENE_PRODUCT", 75, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 122], ["autophagy", "PROBLEM", 39, 48], ["effective ChikV replication", "TREATMENT", 65, 92], ["an intracellular step of the virus life cycle", "TREATMENT", 106, 151], ["viral replication", "TREATMENT", 284, 301], ["autophagy induction", "TREATMENT", 333, 352], ["viral protein expression", "TREATMENT", 356, 380], ["viral replication", "OBSERVATION", 284, 301], ["viral protein expression", "OBSERVATION", 356, 380]]], ["Cells were treated with the pharmacological reagent Rapamycin, which has been shown to induce autophagy through inhibition of the mTOR pathway.", [["Cells", "ANATOMY", 0, 5], ["Rapamycin", "CHEMICAL", 52, 61], ["Rapamycin", "CHEMICAL", 52, 61], ["Cells", "CELL", 0, 5], ["Rapamycin", "SIMPLE_CHEMICAL", 52, 61], ["mTOR", "GENE_OR_GENE_PRODUCT", 130, 134], ["mTOR", "PROTEIN", 130, 134], ["the pharmacological reagent Rapamycin", "TREATMENT", 24, 61], ["the mTOR pathway", "TREATMENT", 126, 142]]], ["We observed that pre-treatment with Rapamycin 2 hours before infection with ChikV significantly increased the number of infected cells detected by immunofluorescence detection of E1 glycoprotein (Figure 5A and 5B).", [["cells", "ANATOMY", 129, 134], ["Rapamycin", "CHEMICAL", 36, 45], ["infection", "DISEASE", 61, 70], ["ChikV", "CHEMICAL", 76, 81], ["Rapamycin", "CHEMICAL", 36, 45], ["Rapamycin", "SIMPLE_CHEMICAL", 36, 45], ["ChikV", "SIMPLE_CHEMICAL", 76, 81], ["cells", "CELL", 129, 134], ["E1 glycoprotein", "GENE_OR_GENE_PRODUCT", 179, 194], ["infected cells", "CELL_TYPE", 120, 134], ["E1 glycoprotein", "PROTEIN", 179, 194], ["Figure 5A and 5B", "PROTEIN", 196, 212], ["Rapamycin", "TREATMENT", 36, 45], ["infection", "PROBLEM", 61, 70], ["ChikV", "PROBLEM", 76, 81], ["infected cells", "PROBLEM", 120, 134], ["immunofluorescence detection", "TEST", 147, 175], ["infected cells", "OBSERVATION", 120, 134]]], ["Levels of ChikV viral RNA detected in the cell culture supernatant were also increased when cells were treated with Rapamycin (Figure 5C).", [["cell culture supernatant", "ANATOMY", 42, 66], ["cells", "ANATOMY", 92, 97], ["Rapamycin", "CHEMICAL", 116, 125], ["Rapamycin", "CHEMICAL", 116, 125], ["ChikV", "GENE_OR_GENE_PRODUCT", 10, 15], ["cell", "CELL", 42, 46], ["cells", "CELL", 92, 97], ["Rapamycin", "SIMPLE_CHEMICAL", 116, 125], ["ChikV viral RNA", "RNA", 10, 25], ["Levels", "TEST", 0, 6], ["ChikV viral RNA", "PROBLEM", 10, 25], ["the cell culture supernatant", "TEST", 38, 66], ["Rapamycin (Figure 5C", "TREATMENT", 116, 136], ["ChikV", "OBSERVATION", 10, 15], ["viral RNA", "OBSERVATION", 16, 25], ["increased", "OBSERVATION_MODIFIER", 77, 86]]], ["Furthermore, Western Blot analysis showed that expression of E1 and E2 envelope glycoproteins and capsid protein is enhanced in cells exposed to the drug before viral challenge (Figure 5D).", [["cells", "ANATOMY", 128, 133], ["E1", "GENE_OR_GENE_PRODUCT", 61, 63], ["E2 envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 68, 93], ["cells", "CELL", 128, 133], ["E1 and E2 envelope glycoproteins", "PROTEIN", 61, 93], ["capsid protein", "PROTEIN", 98, 112], ["Blot analysis", "TEST", 21, 34], ["E1 and E2 envelope glycoproteins", "TREATMENT", 61, 93], ["capsid protein", "PROBLEM", 98, 112], ["viral challenge", "TREATMENT", 161, 176], ["capsid protein", "OBSERVATION", 98, 112]]], ["Although we can not totally rule out off-target effects of drugs on processes distinct from autophagy required for viral replication, these results further suggest that the autophagic process enhances viral replication and that it is critical for an intracellular step of the virus life cycle.DiscussionIn addition to the proteasomal degradation, autophagy represents a major catabolic pathway allowing the turn-over of cytoplasmic constituents in eukaryotic cells.", [["intracellular", "ANATOMY", 250, 263], ["cytoplasmic", "ANATOMY", 420, 431], ["cells", "ANATOMY", 459, 464], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 263], ["cytoplasmic", "ORGANISM_SUBSTANCE", 420, 431], ["cells", "CELL", 459, 464], ["eukaryotic cells", "CELL_TYPE", 448, 464], ["drugs", "TREATMENT", 59, 64], ["autophagy", "PROBLEM", 92, 101], ["viral replication", "TREATMENT", 115, 132], ["the autophagic process", "PROBLEM", 169, 191], ["viral replication", "TREATMENT", 201, 218], ["the proteasomal degradation", "PROBLEM", 318, 345], ["autophagy", "PROBLEM", 347, 356], ["a major catabolic pathway", "PROBLEM", 368, 393], ["eukaryotic cells", "OBSERVATION", 448, 464]]], ["Besides this house-keeping role, autophagy is now considered as a central component of the host immune antimicrobial response against intracellular pathogens.", [["intracellular", "ANATOMY", 134, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["intracellular pathogens", "PROBLEM", 134, 157], ["pathogens", "OBSERVATION", 148, 157]]], ["Indeed, certain pathogens, like bacteria, parasites and virus, have been shown to be targeted for autophagic degradation.", [["autophagic", "ANATOMY", 98, 108], ["certain pathogens", "PROBLEM", 8, 25], ["bacteria", "PROBLEM", 32, 40], ["parasites", "PROBLEM", 42, 51], ["virus", "PROBLEM", 56, 61], ["autophagic degradation", "PROBLEM", 98, 120], ["bacteria", "OBSERVATION_MODIFIER", 32, 40], ["autophagic degradation", "OBSERVATION", 98, 120]]], ["Therefore some intracellular pathogens have evolved to counteract host autophagy.", [["intracellular", "ANATOMY", 15, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["some intracellular pathogens", "PROBLEM", 10, 38], ["intracellular", "OBSERVATION_MODIFIER", 15, 28], ["pathogens", "OBSERVATION", 29, 38]]], ["Three main types of interaction have been described in the literature between autophagy and viruses.", [["main", "OBSERVATION_MODIFIER", 6, 10], ["interaction", "OBSERVATION", 20, 31], ["viruses", "OBSERVATION", 92, 99]]], ["(1) Autophagy may have a protective role by limiting virus replication.", [["virus replication", "TREATMENT", 53, 70]]], ["It has been shown for tobacco mosaic virus, Sindbis virus and parvovirus B19 [9-11].", [["tobacco mosaic virus", "DISEASE", 22, 42], ["Sindbis virus", "DISEASE", 44, 57], ["parvovirus B19", "DISEASE", 62, 76], ["tobacco mosaic virus", "ORGANISM", 22, 42], ["Sindbis virus", "ORGANISM", 44, 57], ["parvovirus B19", "ORGANISM", 62, 76], ["tobacco mosaic virus", "SPECIES", 22, 42], ["Sindbis virus", "SPECIES", 44, 57], ["parvovirus B19", "SPECIES", 62, 76], ["tobacco mosaic virus", "SPECIES", 22, 42], ["Sindbis virus", "SPECIES", 44, 57], ["parvovirus B19", "SPECIES", 62, 76], ["tobacco mosaic virus", "PROBLEM", 22, 42], ["Sindbis virus", "PROBLEM", 44, 57], ["parvovirus B19", "TEST", 62, 76], ["mosaic virus", "OBSERVATION", 30, 42], ["Sindbis virus", "OBSERVATION", 44, 57]]], ["(2) Autophagic machinery may be disrupted by some viruses.", [["some viruses", "PROBLEM", 45, 57], ["may be", "UNCERTAINTY", 25, 31], ["some", "OBSERVATION_MODIFIER", 45, 49], ["viruses", "OBSERVATION", 50, 57]]], ["This is the case for herpes simplex virus (HSV-1) which encodes the ICP34.5 protein implicated in autophagy inhibition [24].", [["herpes simplex virus", "DISEASE", 21, 41], ["herpes simplex virus", "ORGANISM", 21, 41], ["HSV-1", "ORGANISM", 43, 48], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 68, 75], ["ICP34.5 protein", "PROTEIN", 68, 83], ["herpes simplex virus", "SPECIES", 21, 41], ["HSV-1", "SPECIES", 43, 48], ["herpes simplex virus", "SPECIES", 21, 41], ["HSV-1", "SPECIES", 43, 48], ["herpes simplex virus", "PROBLEM", 21, 41], ["HSV", "TEST", 43, 46]]], ["(3) Autophagy may have a promoting role for the replication of some viruses.", [["some viruses", "PROBLEM", 63, 75], ["viruses", "OBSERVATION", 68, 75]]], ["Indeed, the autophagic vesicles are thought to be used as scaffold for intracellular membrane-associated replication factories of RNA viruses [25].", [["autophagic vesicles", "ANATOMY", 12, 31], ["intracellular membrane", "ANATOMY", 71, 93], ["autophagic vesicles", "CELLULAR_COMPONENT", 12, 31], ["intracellular membrane", "CELLULAR_COMPONENT", 71, 93], ["the autophagic vesicles", "PROBLEM", 8, 31], ["intracellular membrane", "PROBLEM", 71, 93], ["RNA viruses", "PROBLEM", 130, 141], ["autophagic vesicles", "OBSERVATION", 12, 31], ["RNA viruses", "OBSERVATION", 130, 141]]], ["This has been described for coronaviruses, picornaviruses, murine hepatitis virus, equine arterivirus, coxsackievirus and dengue virus [12-15].DiscussionThe present study explores the role of the autophagic machinery in ChikV-infected cells by monitoring the presence of double-membrane vesicles and the distribution of LC3.", [["autophagic", "ANATOMY", 196, 206], ["cells", "ANATOMY", 235, 240], ["membrane vesicles", "ANATOMY", 278, 295], ["murine hepatitis virus", "DISEASE", 59, 81], ["equine arterivirus, coxsackievirus and dengue virus", "DISEASE", 83, 134], ["coronaviruses", "ORGANISM", 28, 41], ["murine hepatitis virus", "ORGANISM", 59, 81], ["equine arterivirus", "ORGANISM", 83, 101], ["coxsackievirus", "ORGANISM", 103, 117], ["dengue virus", "ORGANISM", 122, 134], ["ChikV", "GENE_OR_GENE_PRODUCT", 220, 225], ["cells", "CELL", 235, 240], ["membrane vesicles", "CELLULAR_COMPONENT", 278, 295], ["LC3", "GENE_OR_GENE_PRODUCT", 320, 323], ["ChikV-infected cells", "CELL_LINE", 220, 240], ["LC3", "PROTEIN", 320, 323], ["murine", "SPECIES", 59, 65], ["hepatitis virus", "SPECIES", 66, 81], ["equine", "SPECIES", 83, 89], ["coxsackievirus and dengue virus", "SPECIES", 103, 134], ["murine hepatitis virus", "SPECIES", 59, 81], ["equine arterivirus", "SPECIES", 83, 101], ["dengue virus", "SPECIES", 122, 134], ["coronaviruses", "PROBLEM", 28, 41], ["picornaviruses", "PROBLEM", 43, 57], ["murine hepatitis virus", "PROBLEM", 59, 81], ["equine arterivirus", "PROBLEM", 83, 101], ["coxsackievirus", "PROBLEM", 103, 117], ["dengue virus", "PROBLEM", 122, 134], ["The present study", "TEST", 153, 170], ["ChikV-infected cells", "TREATMENT", 220, 240], ["double-membrane vesicles", "TREATMENT", 271, 295], ["infected cells", "OBSERVATION", 226, 240], ["double", "OBSERVATION", 271, 277], ["membrane vesicles", "OBSERVATION", 278, 295], ["LC3", "OBSERVATION", 320, 323]]], ["We demonstrate the effects of perturbing the autophagy pathway using pharmacological drugs or RNA interference on viral replication.", [["the autophagy pathway", "TREATMENT", 41, 62], ["pharmacological drugs", "TREATMENT", 69, 90], ["RNA interference", "PROBLEM", 94, 110], ["viral replication", "TREATMENT", 114, 131]]], ["Using these strategies, we provide the first evidence that cellular autophagy is promoted in ChikV-infected cells and that this process enhances ChikV replication.DiscussionTo understand whether autophagy plays a role in ChikV infection, we assessed the localization of a GFP-LC3 marker in uninfected or ChikV-infected HEK.293 cells by fluorescence microscopy experiments.", [["cellular", "ANATOMY", 59, 67], ["cells", "ANATOMY", 108, 113], ["HEK", "ANATOMY", 319, 322], ["293 cells", "ANATOMY", 323, 332], ["infection", "DISEASE", 227, 236], ["cellular", "CELL", 59, 67], ["ChikV", "GENE_OR_GENE_PRODUCT", 93, 98], ["cells", "CELL", 108, 113], ["ChikV", "GENE_OR_GENE_PRODUCT", 145, 150], ["ChikV", "GENE_OR_GENE_PRODUCT", 221, 226], ["GFP", "GENE_OR_GENE_PRODUCT", 272, 275], ["LC3", "GENE_OR_GENE_PRODUCT", 276, 279], ["ChikV", "GENE_OR_GENE_PRODUCT", 304, 309], ["HEK", "CELL", 319, 322], ["293 cells", "CELL", 323, 332], ["ChikV-infected cells", "CELL_LINE", 93, 113], ["GFP", "PROTEIN", 272, 275], ["LC3", "PROTEIN", 276, 279], ["ChikV-infected HEK", "CELL_LINE", 304, 322], ["293 cells", "CELL_LINE", 323, 332], ["ChikV", "SPECIES", 221, 226], ["these strategies", "TREATMENT", 6, 22], ["cellular autophagy", "PROBLEM", 59, 77], ["ChikV-infected cells", "PROBLEM", 93, 113], ["ChikV replication", "TREATMENT", 145, 162], ["ChikV infection", "PROBLEM", 221, 236], ["a GFP", "TEST", 270, 275], ["ChikV", "PROBLEM", 304, 309], ["fluorescence microscopy experiments", "TEST", 336, 371], ["cellular autophagy", "OBSERVATION", 59, 77], ["infected cells", "OBSERVATION", 99, 113], ["ChikV replication", "OBSERVATION", 145, 162]]], ["ChikV infection triggered an increase both in the number of autophagic cells and in the number of GFP-LC3 dots per cell.", [["autophagic cells", "ANATOMY", 60, 76], ["cell", "ANATOMY", 115, 119], ["infection", "DISEASE", 6, 15], ["ChikV", "GENE_OR_GENE_PRODUCT", 0, 5], ["autophagic cells", "CELL", 60, 76], ["GFP", "GENE_OR_GENE_PRODUCT", 98, 101], ["LC3", "GENE_OR_GENE_PRODUCT", 102, 105], ["cell", "CELL", 115, 119], ["autophagic cells", "CELL_TYPE", 60, 76], ["GFP", "PROTEIN", 98, 101], ["LC3 dots", "PROTEIN", 102, 110], ["ChikV infection", "PROBLEM", 0, 15], ["autophagic cells", "PROBLEM", 60, 76], ["infection", "OBSERVATION", 6, 15], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["both", "OBSERVATION_MODIFIER", 38, 42], ["autophagic cells", "OBSERVATION", 60, 76], ["LC3 dots", "OBSERVATION", 102, 110]]], ["Of note, accumulation of autophagosomes can be du to an increase in the autophagosomes formation or a decrease of their degradation, which results to the blockade of the fusion with lysosomes.", [["autophagosomes", "ANATOMY", 25, 39], ["autophagosomes", "ANATOMY", 72, 86], ["lysosomes", "ANATOMY", 182, 191], ["autophagosomes", "CELLULAR_COMPONENT", 25, 39], ["autophagosomes", "CELLULAR_COMPONENT", 72, 86], ["lysosomes", "CELLULAR_COMPONENT", 182, 191], ["autophagosomes", "PROBLEM", 25, 39], ["the autophagosomes formation", "PROBLEM", 68, 96], ["their degradation", "PROBLEM", 114, 131], ["autophagosomes", "OBSERVATION", 25, 39], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["autophagosomes formation", "OBSERVATION", 72, 96], ["decrease", "OBSERVATION_MODIFIER", 102, 110], ["fusion", "OBSERVATION", 170, 176]]], ["The early induction of autophagy, within 2 hours post infection, is in favour of the first hypothesis, nevertheless we can not exclude that ChikV could also have a role in the late phases of autophagosomes maturation.", [["autophagosomes", "ANATOMY", 191, 205], ["infection", "DISEASE", 54, 63], ["ChikV", "GENE_OR_GENE_PRODUCT", 140, 145], ["autophagosomes", "CELLULAR_COMPONENT", 191, 205], ["ChikV", "PROTEIN", 140, 145], ["infection", "PROBLEM", 54, 63], ["ChikV", "PROBLEM", 140, 145], ["autophagosomes maturation", "PROBLEM", 191, 216], ["early", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 54, 63], ["ChikV", "OBSERVATION", 140, 145], ["late phases", "OBSERVATION_MODIFIER", 176, 187], ["autophagosomes maturation", "OBSERVATION", 191, 216]]], ["In the present study, we did not answer this question, which remains to be elucidated.DiscussionTo confirm our results, we performed an ultrastructure analysis by Transmission Electronic Microscopy and visualized in the cytoplasm of ChikV-infected cells numerous vacuoles with features of autophagosomes.", [["cytoplasm", "ANATOMY", 220, 229], ["cells", "ANATOMY", 248, 253], ["vacuoles", "ANATOMY", 263, 271], ["autophagosomes", "ANATOMY", 289, 303], ["cytoplasm", "ORGANISM_SUBSTANCE", 220, 229], ["ChikV", "GENE_OR_GENE_PRODUCT", 233, 238], ["cells", "CELL", 248, 253], ["vacuoles", "CELLULAR_COMPONENT", 263, 271], ["autophagosomes", "CELLULAR_COMPONENT", 289, 303], ["ChikV-infected cells", "CELL_TYPE", 233, 253], ["the present study", "TEST", 3, 20], ["an ultrastructure analysis", "TEST", 133, 159], ["Electronic Microscopy", "TEST", 176, 197], ["ChikV", "PROBLEM", 233, 238], ["infected cells", "PROBLEM", 239, 253], ["autophagosomes", "PROBLEM", 289, 303], ["ChikV", "OBSERVATION", 233, 238], ["infected cells", "OBSERVATION", 239, 253]]], ["Furthermore, virions are localized in the lumen of those structures, consistent with the hypothesis that ChikV may recruit autophagosomes into virus factories to generate a scaffold for replication complex.", [["virions", "ANATOMY", 13, 20], ["lumen", "ANATOMY", 42, 47], ["autophagosomes", "ANATOMY", 123, 137], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 47], ["ChikV", "GENE_OR_GENE_PRODUCT", 105, 110], ["autophagosomes", "CELLULAR_COMPONENT", 123, 137], ["ChikV", "PROTEIN", 105, 110], ["replication complex", "PROTEIN", 186, 205], ["virions", "TREATMENT", 13, 20], ["the hypothesis", "PROBLEM", 85, 99], ["ChikV", "PROBLEM", 105, 110], ["autophagosomes into virus factories", "PROBLEM", 123, 158], ["a scaffold for replication complex", "TREATMENT", 171, 205], ["virions", "OBSERVATION", 13, 20], ["lumen", "ANATOMY_MODIFIER", 42, 47], ["consistent with", "UNCERTAINTY", 69, 84], ["ChikV", "OBSERVATION", 105, 110]]], ["This hypothesis need to be further investigated.", [["This hypothesis", "PROBLEM", 0, 15]]], ["The next step of the study was to investigate the impact of the autophagic process triggering in ChikV replication.", [["ChikV", "GENE_OR_GENE_PRODUCT", 97, 102], ["the study", "TEST", 17, 26], ["the autophagic process", "PROBLEM", 60, 82], ["ChikV replication", "TREATMENT", 97, 114], ["autophagic process", "OBSERVATION", 64, 82], ["ChikV replication", "OBSERVATION", 97, 114]]], ["For this purpose, we blocked the autophagic process by two ways: a pharmacological inhibition, using a common inhibitor, 3-Methyladenine, and a genetic inhibition, using RNA interference against the transcript of the protein Beclin 1.", [["3-Methyladenine", "CHEMICAL", 121, 136], ["3-Methyladenine", "CHEMICAL", 121, 136], ["3-Methyladenine", "SIMPLE_CHEMICAL", 121, 136], ["Beclin 1", "GENE_OR_GENE_PRODUCT", 225, 233], ["protein Beclin 1", "PROTEIN", 217, 233], ["a pharmacological inhibition", "TREATMENT", 65, 93], ["a common inhibitor", "TREATMENT", 101, 119], ["Methyladenine", "TREATMENT", 123, 136], ["a genetic inhibition", "TREATMENT", 142, 162], ["RNA interference", "TREATMENT", 170, 186], ["the protein Beclin", "TREATMENT", 213, 231], ["autophagic process", "OBSERVATION", 33, 51]]], ["We identified that ChikV replication is dramatically decreased by both approaches, attesting that the autophagic machinery is needed for ChikV replication.", [["ChikV", "GENE_OR_GENE_PRODUCT", 19, 24], ["ChikV", "GENE_OR_GENE_PRODUCT", 137, 142], ["ChikV replication", "TREATMENT", 19, 36], ["the autophagic machinery", "TREATMENT", 98, 122], ["ChikV replication", "TREATMENT", 137, 154], ["ChikV replication", "OBSERVATION", 19, 36], ["dramatically", "OBSERVATION_MODIFIER", 40, 52], ["decreased", "OBSERVATION_MODIFIER", 53, 62]]], ["Both the intracellular infection and extracellular RNA viral load were assessed and were found to be affected, suggesting that the autophagic machinery is needed to promote virus replication inside the cell and not only for the release of new ChikV progeny virions outside the cell.", [["intracellular", "ANATOMY", 9, 22], ["extracellular", "ANATOMY", 37, 50], ["cell", "ANATOMY", 202, 206], ["virions", "ANATOMY", 257, 264], ["cell", "ANATOMY", 277, 281], ["infection", "DISEASE", 23, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["cell", "CELL", 202, 206], ["ChikV", "GENE_OR_GENE_PRODUCT", 243, 248], ["cell", "CELL", 277, 281], ["the intracellular infection", "PROBLEM", 5, 32], ["extracellular RNA viral load", "TEST", 37, 65], ["the autophagic machinery", "PROBLEM", 127, 151], ["virus replication", "TREATMENT", 173, 190], ["intracellular", "OBSERVATION_MODIFIER", 9, 22], ["infection", "OBSERVATION", 23, 32], ["extracellular RNA", "OBSERVATION", 37, 54], ["viral load", "OBSERVATION", 55, 65], ["new", "OBSERVATION_MODIFIER", 239, 242], ["ChikV", "OBSERVATION", 243, 248]]], ["Of note, the partial blockade of both infection and replication suggests that autophagy contributes but is not strictly necessary for ChikV replication.", [["infection", "DISEASE", 38, 47], ["ChikV", "GENE_OR_GENE_PRODUCT", 134, 139], ["the partial blockade", "TREATMENT", 9, 29], ["both infection", "PROBLEM", 33, 47], ["autophagy", "PROBLEM", 78, 87], ["ChikV replication", "TREATMENT", 134, 151], ["both", "OBSERVATION_MODIFIER", 33, 37], ["infection", "OBSERVATION", 38, 47]]], ["We next used an autophagic inducer, Rapamycin, to decipher the impact of a stimulation of the autophagic process on ChikV replication.", [["autophagic", "ANATOMY", 16, 26], ["Rapamycin", "CHEMICAL", 36, 45], ["Rapamycin", "CHEMICAL", 36, 45], ["Rapamycin", "SIMPLE_CHEMICAL", 36, 45], ["ChikV", "GENE_OR_GENE_PRODUCT", 116, 121], ["an autophagic inducer", "TREATMENT", 13, 34], ["Rapamycin", "TREATMENT", 36, 45], ["a stimulation", "TREATMENT", 73, 86], ["ChikV replication", "TREATMENT", 116, 133]]], ["After treatment with Rapamycin, cells were much more permissive or sensitive to ChikV infection, suggesting that autophagy is a promoting factor for ChikV replication.DiscussionOur previous study provided evidence that completion of the apoptotic process is an important element for efficient virus propagation [18].", [["cells", "ANATOMY", 32, 37], ["Rapamycin", "CHEMICAL", 21, 30], ["infection", "DISEASE", 86, 95], ["Rapamycin", "CHEMICAL", 21, 30], ["Rapamycin", "SIMPLE_CHEMICAL", 21, 30], ["cells", "CELL", 32, 37], ["ChikV", "GENE_OR_GENE_PRODUCT", 80, 85], ["ChikV", "GENE_OR_GENE_PRODUCT", 149, 154], ["ChikV", "SPECIES", 80, 85], ["treatment", "TREATMENT", 6, 15], ["Rapamycin", "TREATMENT", 21, 30], ["cells", "TREATMENT", 32, 37], ["ChikV infection", "PROBLEM", 80, 95], ["autophagy", "PROBLEM", 113, 122], ["ChikV replication", "TREATMENT", 149, 166], ["previous study", "TEST", 181, 195], ["the apoptotic process", "TREATMENT", 233, 254], ["efficient virus propagation", "PROBLEM", 283, 310], ["ChikV", "OBSERVATION", 80, 85]]], ["Furthermore, ChikV-induced apoptosis possibly leads to the persistence of the virus in macrophages, and hence shielded from the immune system.", [["macrophages", "ANATOMY", 87, 98], ["immune system", "ANATOMY", 128, 141], ["ChikV", "CHEMICAL", 13, 18], ["ChikV", "GENE_OR_GENE_PRODUCT", 13, 18], ["macrophages", "CELL", 87, 98], ["ChikV", "PROTEIN", 13, 18], ["macrophages", "CELL_TYPE", 87, 98], ["ChikV-induced apoptosis", "PROBLEM", 13, 36], ["the virus in macrophages", "PROBLEM", 74, 98], ["ChikV", "OBSERVATION", 13, 18], ["virus", "OBSERVATION", 78, 83]]], ["On the way to decipher the mechanisms either controlling viral infection or, on the contrary, promoting viral spreading and pathogenicity, it seems that this virus has evolved to control both the apoptotic and the autophagic process.", [["viral infection", "DISEASE", 57, 72], ["viral infection", "PROBLEM", 57, 72], ["promoting viral spreading", "PROBLEM", 94, 119], ["pathogenicity", "PROBLEM", 124, 137], ["this virus", "PROBLEM", 153, 163], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["viral spreading", "OBSERVATION", 104, 119], ["autophagic process", "OBSERVATION", 214, 232]]], ["ChikV seems to be more than opportunistic and can exploit the classic cellular immune response.", [["cellular", "ANATOMY", 70, 78], ["ChikV", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 70, 78], ["ChikV", "PROBLEM", 0, 5], ["cellular immune response", "OBSERVATION", 70, 94]]], ["From a therapeutic standpoint, available drugs controlling autophagy could be used to limit ChikV spreading.Nonstandard abbreviationsChikV: Chikungunya Virus; LC3: light chain 3; GFP-LC3: LC3 fused to GFP; 3-MA: 3-methyladenine; Rapa: Rapamycin.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsMD designed research; MD, GLPY, PKT, BG and JJH performed research; MD, LB and PG and MCJB analysed data; MD wrote the paper.", [["3-methyladenine", "CHEMICAL", 212, 227], ["Rapa", "CHEMICAL", 229, 233], ["Rapamycin", "CHEMICAL", 235, 244], ["PG", "CHEMICAL", 423, 425], ["3-MA", "CHEMICAL", 206, 210], ["3-methyladenine", "CHEMICAL", 212, 227], ["Rapa", "CHEMICAL", 229, 233], ["Rapamycin", "CHEMICAL", 235, 244], ["ChikV", "GENE_OR_GENE_PRODUCT", 92, 97], ["Chikungunya Virus", "ORGANISM", 140, 157], ["LC3: light chain 3", "GENE_OR_GENE_PRODUCT", 159, 177], ["GFP-LC3", "GENE_OR_GENE_PRODUCT", 179, 186], ["LC3", "GENE_OR_GENE_PRODUCT", 188, 191], ["GFP", "GENE_OR_GENE_PRODUCT", 201, 204], ["3-MA", "SIMPLE_CHEMICAL", 206, 210], ["3-methyladenine", "SIMPLE_CHEMICAL", 212, 227], ["Rapa", "SIMPLE_CHEMICAL", 229, 233], ["Rapamycin", "SIMPLE_CHEMICAL", 235, 244], ["LC3: light chain 3", "PROTEIN", 159, 177], ["GFP", "PROTEIN", 179, 182], ["LC3", "PROTEIN", 183, 186], ["LC3", "PROTEIN", 188, 191], ["GFP", "PROTEIN", 201, 204], ["Chikungunya Virus", "SPECIES", 140, 157], ["available drugs", "TREATMENT", 31, 46], ["autophagy", "TREATMENT", 59, 68], ["ChikV spreading", "PROBLEM", 92, 107], ["Chikungunya Virus", "PROBLEM", 140, 157], ["light chain", "TEST", 164, 175], ["GFP", "TEST", 179, 182], ["GFP", "TEST", 201, 204], ["methyladenine", "TREATMENT", 214, 227], ["Rapamycin", "TREATMENT", 235, 244], ["BG", "TEST", 381, 383]]]]}